<SEC-DOCUMENT>0001387131-18-000776.txt : 20180223
<SEC-HEADER>0001387131-18-000776.hdr.sgml : 20180223
<ACCEPTANCE-DATETIME>20180223170043
ACCESSION NUMBER:		0001387131-18-000776
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180223
DATE AS OF CHANGE:		20180223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		18637473

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>txmd-10k_123117.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>

<HEAD>
    <TITLE>txmd-10k_123117.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.9 -->
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <div align="LEFT" style="font-family: Times New Roman, Times, Serif;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 4pt solid; width: 100%; font: 1pt Times New Roman, Times, Serif;">
            <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
        </div>
    </div>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 14pt;"><b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;">&nbsp;<b>Washington, DC 20549</B></FONT></P>

<P STYLE="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;"></FONT></P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
&nbsp;</FONT></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt;"><b>Form 10-K</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: left; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#x2612;</b></font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif;">
            <td style="text-align: left; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>For the fiscal year ended December 31, 2017</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Commission File Number 001-00100</B></FONT></P>

<P STYLE="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;"></FONT></P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</font>
    </p>
     <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 24pt;">&nbsp; <b>TherapeuticsMD, Inc.</b></font>
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 35%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif">    </p>

    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp; <i>(Exact Name of Registrant as Specified in Its Charter)</i>&nbsp; &nbsp; &nbsp;</font>
    </p>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif;">
            <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;&nbsp;<b>Nevada</b></font>
            </td>
            <td style="width: 34%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>87-0233535</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif;">
            <td style="text-align: center; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>(State or Other Jurisdiction of Incorporation or Organization)</i> &nbsp; &nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>(I.R.S. Employer Identification No.)</i></font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<b>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>6800 Broken Sound Parkway NW&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Third Floor</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Boca Raton, Florida 33487</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>(561) 961-1900</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>(Address, including zip code, and telephone number,</i>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>including area code, of Principal Executive Offices)</i>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Securities registered pursuant to Section 12(b) of the Act:</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; width: 40%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Title of Each Class</b></font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 40%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Name of Each Exchange on Which Registered</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common Stock, par value $0.001 per share</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Nasdaq Stock Market LLC</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Securities registered pursuant to Section 12(g) of the Act: </b>None.</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#x2612;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#x2610;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#x2610;&nbsp;&nbsp;&nbsp;No &#x2612;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes &#x2612;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#x2610;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes &#x2612;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#x2610;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#x2019;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. &#x2612;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; &#x201C;smaller reporting company&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act. (Check one):</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/9.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 40%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Large accelerated filer &#x2612;</font>
            </td>
            <td style="width: 40%; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;Accelerated filer &#x2610;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;Non-accelerated filer &#x2610;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Smaller reporting company &#x2610;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Do not check if a smaller reporting company)</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Emerging growth Company &#x2610;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x25A1;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#x2610;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#x2612;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The aggregate market value of common stock held by non-affiliates of the registrant (169,430,175 shares) based on the closing price of the registrant&#x2019;s common stock as reported on NYSE American on June 30, 2017, which was the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, was $892,897,022.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of February 20, 2018, there were outstanding 216,439,483 shares of the registrant&#x2019;s common stock, par value $0.001 per share.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Documents Incorporated by Reference</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Portions of the registrant&#x2019;s definitive Proxy Statement for its 2018 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10- K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <div align="LEFT" style="font-family: Times New Roman, Times, Serif;">
        <div style="border-bottom: Black 4pt solid; border-top: Black 1pt solid; width: 100%; font: 1pt Times New Roman, Times, Serif;">
            <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
        </div>
    </div>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt/10.2pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Options:  NewSection; Sequence:  1; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC.</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>ANNUAL REPORT ON FORM 10-K</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Fiscal Year Ended December 31, 2017</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>TABLE OF CONTENTS&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 10%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 85%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">PART I</font>
            </td>
            <td style="width: 5%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka001">
                        <font style="font-size: 10pt;">Item 1.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka001">
                        <font style="font-size: 10pt;"><i>Business</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka002">
                        <font style="font-size: 10pt;">Item 1A.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka002">
                        <font style="font-size: 10pt;"><i>Risk Factors</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">25</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka003">
                        <font style="font-size: 10pt;">Item 1B.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka003">
                        <font style="font-size: 10pt;"><i>Unresolved Staff Comments</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">46</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka004">
                        <font style="font-size: 10pt;">Item 2.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka004">
                        <font style="font-size: 10pt;"><i>Properties</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">46</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka005">
                        <font style="font-size: 10pt;">Item 3.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka005">
                        <font style="font-size: 10pt;"><i>Legal Proceedings</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">47</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka006">
                        <font style="font-size: 10pt;">Item 4.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka006">
                        <font style="font-size: 10pt;"><i>Mine Safety Disclosures</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">47</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka007">
                        <font style="font-size: 10pt;">PART II</font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka008">
                        <font style="font-size: 10pt;">Item 5.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka008">
                        <font style="font-size: 10pt;"><i>Market for the Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">47</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka009">
                        <font style="font-size: 10pt;">Item 6.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka009">
                        <font style="font-size: 10pt;"><i>Selected Financial Data</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">49</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka010">
                        <font style="font-size: 10pt;">Item 7.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka010">
                        <font style="font-size: 10pt;"><i>Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">50</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka011">
                        <font style="font-size: 10pt;">Item 7A.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka011">
                        <font style="font-size: 10pt;"><i>Quantitative and Qualitative Disclosures about Market Risk</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">66</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka012">
                        <font style="font-size: 10pt;">Item 8.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka012">
                        <font style="font-size: 10pt;"><i>Financial Statements and Supplementary Data</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">66</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka013">
                        <font style="font-size: 10pt;">Item 9.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka013">
                        <font style="font-size: 10pt;"><i>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">67</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka014">
                        <font style="font-size: 10pt;">Item 9A.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka014">
                        <font style="font-size: 10pt;"><i>Controls and Procedures</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">67</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka015">
                        <font style="font-size: 10pt;">Item 9B.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka015">
                        <font style="font-size: 10pt;"><i>Other Information</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka016">
                        <font style="font-size: 10pt;">PART III</font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka017">
                        <font style="font-size: 10pt;">Item 10.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka017">
                        <font style="font-size: 10pt;"><i>Directors, Executive Officers and Corporate Governance</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka018">
                        <font style="font-size: 10pt;">Item 11.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka018">
                        <font style="font-size: 10pt;"><i>Executive Compensation</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka019">
                        <font style="font-size: 10pt;">Item 12.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka019">
                        <font style="font-size: 10pt;"><i>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka020">
                        <font style="font-size: 10pt;">Item 13.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka020">
                        <font style="font-size: 10pt;"><i>Certain Relationships and Related Transactions, and Director Independence</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka021">
                        <font style="font-size: 10pt;">Item 14.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka021">
                        <font style="font-size: 10pt;"><i>Principal Accounting Fees and Services</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">70</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka022">
                        <font style="font-size: 10pt;">PART IV</font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka023">
                        <font style="font-size: 10pt;">Item 15.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka023">
                        <font style="font-size: 10pt;"><i>Exhibits, Financial Statement Schedules</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">71</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka024">
                        <font style="font-size: 10pt;">Item 16.</font>
                    </a>
                </font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">
                    <a href="#txmd10ka024">
                        <font style="font-size: 10pt;"><i>Form 10-K Summary</i></font>
                    </a>
                </font>
            </td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">73</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">vitaMedMD<sup>&#xAE;</sup>, TherapeuticsMD<sup>&#xAE;</sup>, and BocaGreenMD<sup>&#xAE;</sup> are registered trademarks of our company. This Annual Report also contains trademarks and trade names of other companies.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">This Annual Report includes market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government agency sources, filings of public companies in our industry, and internal company surveys. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the foregoing industry and market data to be reliable at the date of the report, this information could prove to be inaccurate as a result of a variety of matters.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  2; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Statement Regarding Forward-Looking Information</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. For example, statements regarding our operations, financial position, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales are all forward-looking statements. These statements may be found in the items of this Annual Report entitled &#x201C;Business&#x201D; and &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201D; as well as in this Annual Report generally. These statements are generally accompanied by words such as &#x201C;intend,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;potential(ly),&#x201D; &#x201C;continue,&#x201D; &#x201C;forecast,&#x201D; &#x201C;predict,&#x201D; &#x201C;plan,&#x201D; &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; or the negative of such terms or other comparable terminology.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have based these forward-looking statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date hereof, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, research and product development uncertainties, regulatory policies and approval requirements, competition from other businesses, market and general economic factors, and the other risks discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated financial statements and notes thereto included in this Annual Report.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have identified some of the important factors that could cause future events to differ from our current expectations and they are described in this Annual Report in the section entitled &#x201C;Risk Factors&#x201D; that you should review carefully. Please consider our forward-looking statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  3; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>PART I</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 1.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i><a name="txmd10ka001"></a>Business</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Overview</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Our Company</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side-effect profile compared with competing products. With our SYMBODA&#x2122; technology, we are developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have submitted two new drug applications, or NDAs, to the U.S. Food and Drug Administration, or FDA. In December 2017, we submitted our NDA for TX-001HR, our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe vasomotor symptoms, or VMS, due to menopause in menopausal women with an intact uterus. In November 2017, we re-submitted our NDA for TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy, or VVA, in menopausal women with vaginal linings that do not receive enough estrogen. The NDA for our TX-004HR drug candidate has a Prescription Drug User Fee Act, or PDUFA, target action date for the completion of the FDA&#x2019;s review of May 29, 2018 and, if approved on that date, the drug candidate could be launched as early as the third quarter of 2018. If the NDA for TX-001HR is accepted by the FDA, it could be approved as soon as the fourth quarter of 2018 and launched in 2019. We intend to leverage and grow our current marketing and sales organization to commercialize our advanced hormone therapy drug candidates in the United States assuming the successful completion of the FDA regulatory process. We believe that our national sales force has developed strong relationships in the OB/GYN market to sell our current prescription prenatal vitamin products and that by delivering additional products through the same sales channel we can leverage our already deployed assets.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Throughout this Annual Report, the terms &#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D; &#x201C;TherapeuticsMD,&#x201D; or &#x201C;our company&#x201D; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Hormone Therapy Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The menopause hormone therapy market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies. On November 27, 2013, the Drug Quality and Security Act of 2013, or the DQSA, became law and the FDA was given additional oversight over compounding pharmacies. We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products, typically referred to as bioidenticals when produced and sold by compounding pharmacies, are not easily measured or monitored. We estimate the sales of non-FDA approved compounded bioidentical hormone therapy combinations of estradiol and progesterone products by compounding pharmacies approximate $1.5 billion per year. According to PHAST<sup>TM</sup> Prescription from Symphony Health IVD, or Symphony Heath Solutions, the market for FDA-approved hormone therapy products for the treatment of menopause symptoms or prevention of osteoporosis approximated $4.7 billion based on 2017 sales. Our phase 3 clinical trials were intended to establish an indication of the safety and efficacy of our hormone therapy drug candidates at specific dosage levels. We intend our hormone therapy drug candidates, if approved, to provide hormone therapies with well characterized safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved compounded bioidentical market. This is based on our belief that our drug candidates will offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone dose, lower patient cost as a result of insurance coverage, and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Options:  NewSection; Value:  1; Sequence:  4; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->1
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Pipeline of our Hormone Therapy Drug Candidates</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-001HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-001HR is our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate for the treatment of moderate to severe VMS due to menopause, including hot flashes, night sweats and sleep disturbances in menopausal women with an intact uterus. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product. According to Symphony Health Solutions, sales of FDA-approved combinations of estrogen and progestins were approximately $588 million and sales of estradiol and progesterone on a stand-alone basis were approximately $952 million and approximately $404 million, respectively, in the United States for the 12 months ended December 31, 2017. In December 2016, we announced positive top-line results from the recently completed REPLENISH Trial, our phase 3 clinical trial of TX-001HR, and on December 28, 2017 we submitted an NDA for TX-001HR with the FDA. Assuming that the NDA is accepted 74 days thereafter and an FDA review period of ten months from the receipt date to the PDUFA date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2018.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-002HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. In July 2014, we suspended enrollment and in October 2014 we stopped the SPRY Trial, our phase 3 clinical trial for TX-002HR, to update the phase 3 protocol based on discussions with the FDA. Our Investigational New Drug Application, or IND, related to TX-002HR is currently in inactive status. We have currently suspended further development of this drug candidate to prioritize our leading drug candidates.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-003HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-003HR is a natural estradiol formulation. This hormone therapy drug candidate is bioidentical to the hormones that naturally occur in a woman&#x2019;s body. We currently do not have plans to further develop this hormone therapy drug candidate. Our IND related to TX-003HR is currently inactive.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-004HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-004HR is our applicator-free vaginal estradiol softgel drug candidate for the treatment of dyspareunia, a symptom of VVA in menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. According to Symphony Health Solutions, sales of FDA-approved products for VVA treatment were approximately $1.8 million in the United States for the 12 months ended December 31, 2017. In December 2015, we announced positive top-line results from the REJOICE Trial, our phase 3 clinical trial of TX-004HR. In November 2017, we re-submitted our NDA for TX-004HR. The NDA has a PDUFA target action date for the completion of the FDA&#x2019;s review of May 29, 2018, and, if approved on that date, the drug candidate could be launched as early as the third quarter of 2018.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Preclinical Development</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Based upon leveraging our SYMBODA<sup>TM</sup> hormone technology, we have four preclinical projects that include development of a progesterone-alone and combination estradiol and progesterone products in a topical cream form, which we refer to as TX-005HR and TX-006HR, respectively, and transdermal patch form, which we refer to as TX-007HR and TX-008HR, respectively. We completed a proof-of-concept preclinical study of TX-005HR in 32 rats. The study used four groups of eight female ovariectomized rats, each of whom were treated with subcutaneous injections of estradiol for eight days. On day four of treatment, they were also dosed with a placebo, subcutaneous injections of progesterone or a similar dose of TX-005HR topical progesterone cream. The results, presented at North American Menopause Society, or NAMS, meeting in October 2015, showed that the progesterone in TX-005HR penetrated the skin and opposed the effect of subcutaneous estradiol on the endometrium. In the fourth quarter of 2016, we submitted an IND application for TX-006HR, our combination estradiol and progesterone drug candidate in a topical cream form, and intend to commence phase 1 clinical trials of this drug candidate as early as 2018. We may in the future engage with a financing partner to advance our topical cream and transdermal patch projects. We have recently conducted rat bioavailability studies on several novel, oral formulations of progesterone. We are currently adapting this formulation for the inclusion of estradiol and have embarked on its development as TX-009HR. In addition to menopausal treatments, we are also evaluating various other indications for our hormone technology, including contraception and premature ovarian failure.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  5; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->2
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Current Products</i></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As we continue the clinical development of our hormone therapy drug candidates, we continue to manufacture and distribute our prescription product lines, consisting of prenatal vitamins under our vitaMedMD<sup>&#xAE; </sup>brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD<sup>&#xAE; </sup>Prena1 name. All of our prenatal vitamins are gluten-, sugar-, and lactose-free. A prenatal vitamin option that is both vegan and kosher is also available for women with special dietary needs. We believe our product attributes result in greater consumer acceptance and satisfaction than competitive products while offering the highest quality and patented ingredients. As of January 1, 2017, we decided to focus on selling our prescription vitamins and ceased manufacturing and distributing our over-the-counter, or OTC, product lines, except for Iron 21/7 which we ceased manufacturing and distributing in October 2017. The sales of discontinued products have declined steadily over time resulting in immaterial sales.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Industry and Market</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Health Care and Pharmaceutical Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">According to the EvaluatePharma&#xAE; World Preview 2017, Outlook to 2022 report, despite the global pharmaceutical industry facing pricing and market access concerns, worldwide prescription drug sales are expected to reach approximately $1.1 trillion by 2022, which would represent a compound annual growth rate of approximately 6.5% between 2017 and 2022. New drug approvals in 2016 dropped to 27 (consisting of new molecular entities and biologics), down 50%, as compared to the record high of 56 approvals in 2015. A positive drug approval trend was observed in the first months of 2017 with 21 novel drugs already approved as compared to 15 drugs approved up to May 2016, suggesting that the decline in approvals in 2016 was mostly due to timing of approvals rather than more structural dynamics. There were 51 new drugs (consisting of new molecular entities and biologics) approved by FDA in 2014.&nbsp; The value of these drugs continues to be high, and with U.S. five years post-launch sales of the new drugs approved in 2016, 2015 and 2014 forecast to be over $14 billion, $30 billion, $23 billion, respectively.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Women&#x2019;s Health Care Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">According to the BBC Research report &#x201C;Therapeutics for Women&#x2019;s Health: Technologies and Global Markets,&#x201D; menopause, post-menopause osteoporosis, endometriosis, breast cancer and polycystic ovary syndrome (PCOS) are the most common issues within women&#x2019;s health and the U.S. women&#x2019;s health therapeutics market will grow from nearly $19.5 billion in 2015 to $25.3 billion by 2020, rising at compound annual growth rate of 5.4%. According to the GBI Research (a provider of industry-leading business intelligence solutions on a global basis) report &#x201C;Women&#x2019;s Health Therapeutic Market through 2018,&#x201D; the women&#x2019;s health therapeutics market is one of the most attractive markets in the global pharmaceutical industry. Hormone therapy, gynecological disorders, and musculoskeletal disorders in women are the prime areas of focus in the women&#x2019;s health therapeutics market.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Hormone Therapy Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Menopause is the spontaneous and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. It is defined as the final menstrual period and is confirmed when a woman has not had her period for 12 consecutive months. Hormone therapy is the most effective treatment in the United States and Canada for relief of menopausal symptoms according to NAMS. These symptoms are caused by the reduced levels of circulating estrogen as ovarian production shuts down. The symptoms include hot flashes, night sweats, sleep disturbances, and vaginal dryness. According to Symphony Health Solutions, prescriptions for FDA-approved hormone therapy products for the treatment of menopause symptoms or prevention of osteoporosis generated total U.S. sales of over $4.7 billion on over 30 million prescriptions for the 12 months ended December 31, 2017, of which prescriptions for oral hormone therapy accounted for approximately $2.0 billion in U.S. sales on 20 million prescriptions over the same time period.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Prescriptions for menopausal hormone therapy in the United States dropped significantly following the Women&#x2019;s Health Initiative, or WHI, study in 2002, which found that subjects using conjugated equine estrogens plus the synthetic progestin medroxyprogesterone acetate had, among other things, a greater incidence of coronary heart disease, breast cancer, stroke, and pulmonary embolism. A number of additional studies regarding the benefits and risks of hormone therapy have been conducted over the last decade since the WHI results were first published. In general, recommendations for hormone therapy use are to be judged on an individual basis, and the FDA recommends that women with moderate to severe menopausal symptoms who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->3
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">There were approximately 41.7 million women in the United States between the ages of 45 and 64 in 2010, projected to increase slightly by 2.8% to 42.9 million in 2015 and to approximately 44.3 million in 2040, according to the 2010 National Census population figures. These women are the target market for hormone therapy to treat menopausal related symptoms.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Hormone Therapy Products</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Estrogen (with or without a progestin) is the most effective treatment of VMS and VVA due to menopause according to NAMS. According to Symphony Health Solutions, total U.S. sales of FDA-approved oral, transdermal, and suppository estrogen (with and without a progestin) hormone therapy products were approximately $4.0 billion for the 12 months ended December 31, 2017. The three primary hormone therapy products are estrogen, progestin, and combination of estrogen and progestin, which are produced in a variety of forms, including oral tablets or capsules, skin patches, gels, emulsion, or vaginal suppositories and creams.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Estrogen-Only Therapies</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Estrogen therapies are used to treat VMS due to menopause that are a direct result of the decline in estrogen levels associated with ovarian shutdown at menopause. Estrogen therapy has been used to manage these symptoms for more than 50 years. Estrogen is a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol, a natural ovarian produced estrogen. Based upon the age demographic for all women receiving prescriptions for estrogen therapy and the average age range during which women experience VMS, we believe that estrogen is primarily used for the treatment of VMS, but also is prescribed for the prevention of osteoporosis.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Estrogen-only therapy, or ET, is used primarily in women who have had a hysterectomy and/or have undergone surgical menopause, as those women do not require a progestin to protect the uterine endometrium. Approximately 433,000 women undergo a hysterectomy each year in the United States according to the United States Centers for Disease Control and Prevention. ET is also used for the treatment of VVA, which has a variety of indications, including dyspareunia (painful intercourse), vaginal dryness, vaginal itching and irritation, painful urination, and other symptoms.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">ET is also approved for the prevention of osteoporosis. Multiple studies conducted on various estrogen compositions, including studies published in the Journal of the American Medical Association in 2002, Osteoporosis International in 2000, The Lancet in 2002, Maturitas in 2008, and Climacteric in 2005, suggested efficacy based on increases in bone mineral density. Epidemiological and some fracture prevention studies, such as the study published in the New England Journal of Medicine in 1980, also have suggested a decrease in bone fractures as a result of ET.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">According to Symphony Health Solutions, total FDA-approved ET only U.S. sales amounted to $2.8 billion, of which $1.8 billion was specifically used for the treatment of VVA, for the 12 months ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Progestin-Only Therapies</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Progestins include the naturally occurring hormone progesterone and a number of synthetic progestin compounds that have progestational activity. These agents are used for a variety of indications and conditions, but most often, progestins are used either alone or in combination with an estrogen for hormonal contraception and to prevent endometrial hyperplasia from unopposed estrogen in hormone therapy. Progestins alone are also used to treat women with secondary amenorrhea in order to create withdrawal bleeding in these women who have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis. Progesterone has also been used to prevent threatened or recurrent pregnancy loss and for the prevention of preterm birth. Progestins have also been used in fertility treatments. Progestins have also been used as a palliative measure for metastatic endometrial carcinoma and in the treatment of renal and breast carcinoma.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Estrogen/Progestin Combination Products</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Progestins are used in combination with estrogen in menopausal women with uteruses to avoid an increase in the incidence of endometrial hyperplasia, which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence of uterine, or endometrial, cancer. Studies have shown that, after one year, the incidence of endometrial hyperplasia is less than 1% in women taking estrogen/progestin combinations, in contrast to up to 20% in women taking estrogen alone. In accordance with FDA recommendations, doctors typically recommend that a menopausal or post-menopausal woman who has a uterus take estrogen plus a progestin, either as a combination drug or as two separate drugs. Symphony Health Solutions estimates that sales of FDA-approved combinations of estrogen and progestins were approximately $588 million and the sales of estradiol and progesterone on a stand-alone basis were approximately $952 million and approximately $404 million, respectively, in the United States for the 12 months ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  7; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->4
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Limitations of Existing Estrogen/Progestin Therapies</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The most commonly prescribed progestin is a synthetic progestin (medroxyprogesterone acetate), which can cause some women to experience painful vaginal bleeding, breast tenderness, and bloating and may reduce cardio-protective benefits potentially associated with estrogen therapy by limiting the estrogen&#x2019;s ability to raise high-density lipoprotein cholesterol, or good cholesterol, and low-density lipoprotein, or bad cholesterol. A widely prescribed naturally occurring progesterone is known as Prometrium<sup>&#xAE; </sup>(progesterone USP). The brand is marketed by AbbVie Inc., and generic versions have been available since 2012. Natural progesterone is used in combination with estrogen for hormone therapy; however, we believe there are currently no FDA-approved hormone therapy combination products with natural progesterone.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Prenatal Vitamin Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">According to the Centers for Disease Control and Prevention, there are approximately four million births per year in the U.S. Of women giving birth in the U.S., the U.S. Department of Health and Human Services reports that approximately 73% received early prenatal care in the first trimester, while 6% began prenatal care in the third trimester or did not receive any prenatal care. Most doctors encourage taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health organizations as helpful for a healthy pregnancy outcome.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">There are hundreds of prenatal vitamins available, with both prescription and OTC choices. According to Symphony Health Solutions, during the 12 months ended December 31, 2017, approximately 6.2 million prescriptions for prenatal vitamins were issued in the United States resulting in total sales of approximately $379 million, with sales between branded and generic products split nearly evenly.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our Business Model</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a women&#x2019;s health care company focused on creating and commercializing products exclusively for women, including products specifically for pregnancy, childbirth, nursing, pre-menopause, and menopause. We have utilized our current product lines as the foundation of our business platform. If approved and commercialized, our hormone therapy drug candidates will allow us to enter the $4.7 billion market for FDA-approved hormone therapy products for the treatment of menopause symptoms or prevention of osteoporosis, based on 2017 total U.S. sales of the hormone therapy market, according to Symphony Health Solutions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our current product line is marketed and sold by a direct national sales force that calls on health care providers in the OB/GYN market space. We market our prescription prenatal vitamins under our vitaMedMD brand name and authorized generic formulations of our prescription prenatal vitamin products under our BocaGreenMD Prena1 brand name. We believe that our vitaMedMD brand name has become a recognized name for high quality women&#x2019;s health care, while our BocaGreenMD products provide physicians, women, and payors with a lower Wholesale Acquisition Cost (WAC) alternative for prenatal vitamins. We intend to leverage our existing relationships and distribution system to introduce our hormone therapy drug candidates, if approved, which we believe will enable us to provide a comprehensive line of women&#x2019;s health care products all under one brand. As of January 1, 2017, we decided to focus on selling our prescription vitamins and ceased manufacturing and distributing our OTC product lines, except for Iron 21/7 which we ceased manufacturing and distributing in October 2017. The sales of discontinued products have declined steadily over time resulting in immaterial sales.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our sales model focuses on the &#x201C;4Ps&#x201D;: patient, provider, pharmacist, and payor. We market and sell our current products primarily through a direct national sales force of approximately 50 full-time professionals that calls on health care providers in the OB/GYN market space. In addition, our products allow health care providers to offer an alternative to patients to meet their individual nutritional and financial requirements related to co-payment and cost-of-care considerations and help patients realize cost savings over competing products. We also believe that our combination of branded and authorized generic lines offers physicians, women, and payors cost-effective alternatives for top-quality care. We supply our prescription products to consumers through retail pharmacies nationwide. Our fully staffed customer care center uses current customer relationship management software to respond to health care providers, pharmacies, and consumers via incoming and outgoing telephone calls, e-mails, and live-chat. As of January 1, 2017, we stopped selling our products through our websites directly to consumers.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->5
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As health care becomes increasingly consumer driven, patients are seeking more information, control, and convenience, which places additional time and financial pressures on physicians, and as a result, physicians are looking for improved ways to provide better service to their patients. A recent study by IMS Health Inc. concluded that physicians desire fewer but more encompassing relationships with companies that can provide more valuable information, deliver more relevant services, and better respond to specific needs of their practice and patients. Our goal is to meet this challenge by focusing on the opportunities in women&#x2019;s health, specifically the OB/GYN market, to provide a better customer experience for physician, payor, pharmacist, and patient through the following means:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe we will offer physicians a comprehensive product line of women&#x2019;s health care products, including our hormone therapy drug candidates, if approved.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our hormone therapy drug candidates are designed to use the lowest effective dose for the shortest duration.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe the attributes of our dietary supplements will result in greater consumer acceptance and satisfaction than competitive products while offering the highest quality products incorporating patented ingredients, such as Quatrefolic<sup>&#xAE;</sup>, FOLMAX&#xAE;, FePlus&#xAE;, and pur-DHA&#x2122;. All of our prenatal vitamins are gluten-, sugar-, and lactose-free.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We strive to improve our existing products and develop new products to generate additional revenue through our existing sales channels.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe health care providers are able to offer alternatives to patients that meet the patient&#x2019;s individual nutritional and financial requirements and help patients realize cost savings over competing products.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Improved patient education, a high level of patient compliance, and reduced cost of products all result in lower cost of care for payors and improved outcomes for patients.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our Growth Strategy</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a women&#x2019;s health care company with a corporate culture designed to foster innovation in the development and commercialization of products that address the needs of patients, pharmacists, payers and providers in the twenty-first century.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe that building a culture of innovation around patient needs and opportunities, rather than focusing on specific drugs, will enable us to effectively develop and commercialize our products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Exclusive Focus on Women&#x2019;s Health Issues</i>. We have steadily developed relationships with many of the largest OB/GYN practices in the country through the sales of our line of prenatal vitamins. We believe that our singular focus on women&#x2019;s health issues will enable us to continue to build long-term relationships with women as they move through their life cycles of family planning through menopause.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Focus on Hormone Therapy Products</i>. We plan to continue our focus on the development, clinical trials, and commercialization of hormone therapy products designed to (1) alleviate the symptoms of, and reduce the health effects resulting from, menopause-related hormone deficiencies, including hot flashes and vaginal dryness, and (2) demonstrate equivalent clinical efficacy at lower doses, enabling an enhanced side effect profile compared with competing products. We believe there is a large unmet need in this segment of the market.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Penetrate Compounding Market with FDA-approved Products</i>. As we are not aware of any current FDA-approved hormone therapy combination products that are bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries, we believe that our hormone therapy drug candidate for combined estradiol and progesterone, if approved by the FDA, will provide a safer and more effective alternative to non-FDA approved compounded bioidentical hormone therapy products, at a lower price to patients since most insurance companies do not provide coverage for non-FDA approved compounded products. We intend to work with independent and community based pharmacies that currently compound bioidentical hormone therapy products to help them transition their patients to our hormone therapy products, if approved. We launched the BIO-IGNITE&#x2122; program, an outreach program to quantify the number of compounded bio-identical estradiol and progesterone prescriptions currently dispensed by the 3,000-3,500 high-volume compounding pharmacies and qualify their interests in dispensing our hormone therapy product candidates, if approved.&nbsp; As part of the BIO-IGNITE&#x2122; program, we intend to work with compounding pharmacies to identify the number of compounded estradiol and progesterone prescriptions that are directly substitutable by the two potential doses of TX-001HR, if approved, and to enter into agreements with such pharmacies to dispense our hormone therapy products in lieu of compounding, if approved.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Multi-Channel Marketing Emphasis</i>. We plan to continue our emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that are receptive to the data and savings we provide. We believe this will effectively position us for the launch of our hormone therapy products, if approved.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, proliferation of digital technology has dramatically increased the amount of information to available to patients and providers putting more power in their hands. We believe this makes patient/provider engagement and experience a more important lever for life sciences companies and that providing patients and providers with important information whenever and however they want it, on a real-time basis, is a critical piece of serving this market.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  9; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->6
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Multiple Sales Partners</i>. We plan to continue to pursue multiple sales partners, including large chain pharmacies, independent community pharmacies, mail order and compounding and specialty pharmacies. We believe providing a higher level of customer care through unique programs targeted at each of these sales partners can produce better outcomes and value for the patient, provider and payer.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Geographical Expansion</i>. We currently plan to expand our geographic market and sales team to approximately 150 professionals as we commercialize our TX-001HR and TX-004HR product candidates, if approved.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Sales and Marketing</b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Although our direct national sales force is similar to that of a traditional pharmaceutical company in that sales representatives call on OB/GYN practices to provide education and sampling, we believe our sales representatives are more customer-centric in their sales approach by offering physicians more than just differences in our products from the competition; they are also able to offer physicians opportunities to assist their patients in obtaining products in a cost-effective manner.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our national rollout strategy has been to focus first on the largest metropolitan areas in the United States. In order to accelerate the sales ramp-up in a new territory, we employ a national sales/large practice sales effort to identify key practices in new or expanding markets. Concurrent with our provider sales effort, we work with commercial insurance payors for partnerships in which the payor can support the prescription and/or recommendation of our products for the benefit of the patient, physician, and payor, with an end result of providing better outcomes for all three constituents.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At the forefront of our sales approach is the philosophy that the physician should recommend or prescribe products based only on what is best for the patient. In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having an assortment of high-quality product options that can be recommended or prescribed by both the physician and payor is the foundation of providing valuable options to the patient.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe our sales force has developed strong relationships in the OB/GYN market to sell our current products. We have also established relationships with some of the largest OB/GYN practices in their respective markets. By delivering additional products through the same sales channel, we believe we can leverage our already deployed assets to increase our sales and achieve profitability. We intend to leverage and grow our current marketing and sales organization to commercialize our drug candidates in the United States assuming the successful completion of the FDA regulatory process. In addition, we may partner with licensors or other strategic partners to commercialize our drug candidates outside of the OB/GYN market or in non-U.S. markets.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Online Commerce</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A vast majority of our OTC product sales were completed online. As of January 1, 2017, we decided to focus on selling our prescription vitamins and ceased manufacturing and distributing our OTC product lines, except for Iron 21/7 which we ceased manufacturing and distributing in October 2017. The sales of discontinued products have declined steadily over time resulting in immaterial sales. As a result, as of January 1, 2017, we stopped selling our products through our websites directly to consumers.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Sales Concentration</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">See Note 11 to the consolidated financial statements included in this Annual Report for a discussion of the concentration of sales of our prescription prenatal vitamin products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Commercialization</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We cannot market or promote a new product until a marketing application has been approved by the FDA. On November 29, 2017, we resubmitted the NDA for TX-004HR with the&nbsp;FDA. The&nbsp;FDA&nbsp;has acknowledged that the resubmission is a complete, class 2 response to the complete response letter, or CRL, that we received on&nbsp;May 5, 2017&nbsp;for TX-004HR. The PDUFA target action date for the completion of the&nbsp;FDA&#x2019;s&nbsp;review of the NDA for TX-004HR is&nbsp;May 29, 2018.</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We submitted the NDA for TX-001HR with the FDA on December 28, 2017. Assuming that the NDA is accepted 74 days thereafter and an FDA review period of ten months from the receipt date to the PDUFA date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2018.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  10; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->7
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe that it will be possible for us to access the United States market through a specialty sales force. Subject to receiving marketing authorization in the United States, we expect to commence commercialization via our then-in-place sales and marketing organization. If approved, we plan to launch TX-004HR in the third quarter of 2018 and TX-001HR in 2019.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our Current Product Lines</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We offer a wide range of products targeted for women&#x2019;s health specifically associated with pregnancy, child birth, nursing, and post-child birth. As we continue the clinical development of our hormone therapy drug candidates, we continue to manufacture and distribute our prescription prenatal vitamins product lines under our vitaMedMD<sup>&#xAE; </sup>brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD<sup>&#xAE; </sup>Prena1 name. As of January 1, 2017, we decided to focus on selling our prescription vitamins and ceased manufacturing and distributing our OTC product lines, except for Iron 21/7 which we ceased manufacturing and distributing in October 2017. The sales of discontinued products have declined steadily over time resulting in immaterial sales.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">For the years ended December 31, 2017, 2016, and 2015, approximately 99.9%, 99.8%, and 99.5%, respectively, of our consolidated revenue was generated by our prenatal vitamin products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In March 2012, we launched our first prescription prenatal vitamin, vitaMedMD Plus Rx, with subsequent launches of our second prescription prenatal vitamin, vitaMedMD One Rx, in April 2012 and our third prescription prenatal vitamin, vitaMedMD RediChew&#x2122; Rx, in May 2012. In the fourth quarter of 2012, we launched our BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were authorized generic formulations of our vitaMedMD-branded prescription prenatal vitamins. In the first quarter of 2014, we introduced a new prescription prenatal vitamin product under our branded vitaMedMD name as vitaPearl and under our authorized generic Prena1 name as Prena1 Pearl, which features a unique, proprietary combination of FOLMAX&#x2122;, FePlus&#x2122;, and pur-DHA&#x2122;. In January 2016, we launched vitaTrue. Our current product line is detailed below.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaTrue<sup>TM</sup></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaTrue<sup>TM </sup></i>is our newest prescription prenatal vitamin and is targeted at health-conscious consumers. <i>vitaTrue<sup>TM</sup></i> is the first and only vegan and kosher prenatal vitamin with 40% more folic acid than the leading prescription prenatal vitamin. <i>vitaTrue<sup>TM</sup></i> contains a complete multivitamin with 16 essential vitamins and minerals and 300 mg of plant based docosahexaenoic acid, or DHA. vitaTrue is fish, gluten, lactose, and sugar free.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaPearl&#x2122;</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaPearl </i>is our leading prescription prenatal vitamin and is a complete prenatal vitamin in one tiny pearl. <i>vitaPearl</i> provides 40% more folic acid than the leading prescription prenatal vitamin. <i>vitaPearl</i> delivers 14 key vitamins and minerals plus 200 mg of DHA, providing comprehensive support for a woman and her body whether she is planning a pregnancy, pregnant, or nursing.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaMedMD One Rx Prenatal Multivitamin</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaMedMD One Rx</i> is a prescription product with a single-dose daily multivitamin that provides 14 vitamins and minerals, Quatrefolic<sup>&#xAE;</sup>, and 200 mg of plant-based DHA.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaMedMD RediChew&#xAE; Rx Prenatal Multivitamin</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>vitaMedMD RediChew&#xAE; Rx</i> is a prescription, easy-to-chew, small, vanilla-flavored chewable tablet containing Folmax<i>&#xAE;</i>, vitamin D3, vitamin B2, vitamin B6, and vitamin B12. We believe <i>vitaMedMD RediChew Rx</i> is an excellent option for women who have difficulty swallowing tablets or softgels, or are experiencing nausea and morning sickness.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>BocaGreenMD Prena1 True</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>BocaGreenMD Prena1 True</i> is an authorized generic of <i>vitaTrue<sup>TM</sup></i>, the first vegan and kosher prenatal vitamin.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>BocaGreenMD Prena1 Pearl</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>BocaGreenMD Prena1 Pearl</i> is an authorized generic of <i>vitaPearl</i>, a complete prescription prenatal vitamin in one tiny pearl.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>BocaGreenMD Prena1 Chew</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  11; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->8
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>BocaGreenMD Prena1 Chew</i> is an authorized generic of <i>vitaMedMD RediChew Rx</i>, a prescription, single daily easy-to-chew, vanilla-flavored, chewable tablet.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Products discontinued: <i>vitaMedMD Plus (Prenatal Women&#x2019;s Multivitamin + DHA&#x2122;)</i>, <i>vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD Menopause Relief with Lifenol<sup>&#xAE;</sup> Plus Bone Support, vitaMedMD Vitamin D3 50,000 IU, and vitaMedMD Iron 21/7.</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our Hormone Therapy Drug Candidates</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have submitted two NDAs with the FDA for our hormone therapy drug candidates. In December 2017, we submitted the NDA for TX-001HR, our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of VMS due to menopause in menopausal women with an intact uterus. In November 2017, we re-submitted our NDA for TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of VVA in menopausal women with vaginal linings that do not receive enough estrogen. The NDA for our TX-004HR drug candidate has a PDUFA target action date of May 29, 2018, and if approved on that date, the drug candidate could be launched as early as the third quarter of 2018. If the NDA for our TX-001HR drug candidate is accepted by the FDA, it could be approved as soon as the fourth quarter of 2018 and launched in 2019.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-001HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-001HR is our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate for the treatment of moderate to severe VMS due to menopause, including hot flashes, night sweats and sleep disturbances for menopausal women with an intact uterus. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We previously conducted a pharmacokinetics, or PK, study of TX-001HR to demonstrate that our drug candidate is bioequivalent to the reference listed drug based on the criterion that the 90% confidence interval on the test-to-reference ratio is contained entirely within the interval 80% to 125%. The study compared our combined capsule TX-001HR of 2 mg estradiol and 200 mg of progesterone to 2 mg of Estrace<sup>&#xAE;</sup> and 200 mg of Prometrium<sup>&#xAE;</sup>.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The study compared the mean plasma concentrations for free estradiol between TX-001HR and Estrace<sup>&#xAE;</sup> in 62 female test subjects. When the results of a single dose-fed study were compared over 48 hours by the test drug versus reference drug, the ratio was 0.93 with the standard deviation within the subject being 0.409 for an upper 95% confidence bound of -0.089. The maximum plasma concentration levels of free estradiol showed that the drug -versus -reference drug ratio was 0.88 with the standard deviation within the subject being 0.344 for an upper 95% confidence bound of -0.040 over 48 hours.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The study also compared the mean plasma concentrations for progesterone between TX-001HR and Prometrium<sup>&#xAE;</sup> in 62 female test subjects. When the results were compared over 48 hours of the test that the drug-versus-reference drug, the ratio was 1.05 with the standard deviation within the subject being 0.956 for an upper 95% confidence bound of -0.542. The maximum plasma concentration levels of progesterone showed drug versus reference drug ratio as 1.16 with the standard deviation within the subject being 1.179 for an upper 95% confidence bound of -0.785 over 48 hours.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On September 5, 2013, we began enrollment in the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, phase 3 clinical trial of TX-001HR in menopausal women with an intact uterus. The trial was designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe VMS due to menopause and the endometrial safety of TX-001HR. Patients were assigned to one of five arms, four active and one placebo, and received study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia was an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe VMS was the mean change of frequency and severity of moderate to severe VMS at weeks four and 12 compared to placebo, as measured by the number and severity of hot flashes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flashes at screening were included in the VMS analysis, while all subjects were included in the endometrial hyperplasia analysis. The secondary endpoints included reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. The trial evaluated 1,835 patients between 40 and 65 years old at 111 sites. On December 5, 2016, we announced positive topline data for the REPLENISH Trial.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The REPLENISH Trial evaluated four doses of TX-001HR and placebo; the doses studied were:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 1 mg/progesterone 100 mg (n = 416) </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  12; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->9
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 48px; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 0.5 mg/progesterone 100 mg (n = 423) </font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 48px; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 0.5 mg/progesterone 50 mg (n = 421) </font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 48px; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 0.25 mg/progesterone 50 mg (n = 424) </font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 48px; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Placebo (n = 151) </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The REPLENISH Trial results demonstrated:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; &nbsp;&nbsp;&nbsp;&nbsp;TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both achieved all four of the co-primary efficacy endpoints and the primary safety endpoint.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; &nbsp;&nbsp;&nbsp;&nbsp;TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both demonstrated a statistically significant and clinically meaningful reduction from baseline in both the frequency and severity of hot flashes compared to placebo.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; &nbsp;&nbsp;&nbsp;&nbsp;TX-001HR estradiol 0.5 mg/progesterone 50 mg and TX-001HR estradiol 0.25 mg/progesterone 50 mg were not statistically significant at all of the co-primary efficacy endpoints. The estradiol 0.25 mg/progesterone 50 mg dose was included in the clinical trial as a non-effective dose to meet the recommendation of the FDA guidance to identify the lowest effective dose.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; &nbsp;&nbsp;&nbsp;&nbsp;The incidence of consensus endometrial hyperplasia or malignancy was 0 percent across all four TX-001HR doses, meeting the recommendations established by the FDA&#x2019;s draft guidance.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As outlined in the FDA guidance, the co-primary efficacy endpoints in the REPLENISH Trial were the change from baseline in the number and severity of hot flashes at weeks four and 12 as compared to placebo. The primary safety endpoint was the incidence of endometrial hyperplasia with up to 12 months of treatment. General safety was also evaluated.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The results of the REPLENISH Trial are summarized in the table below (p-values of &lt; 0.05 meet FDA guidance and support evidence of efficacy):</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; border-right: Black 1pt solid; border-top: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="6">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 5pt; padding-right: 5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="6">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Replenish Trial Co-Primary Efficacy Endpoints: Mean Change in Frequency and Severity of Hot Flashes Per Week Versus Placebo at Weeks 4 and 12, VMS-MITT Population</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; width: 36%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; width: 12%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; width: 12%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; width: 12%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; width: 12%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; width: 16%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Estradiol/Progesterone</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1 mg/100 mg</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.5 mg/100 mg</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.5 mg/50 mg</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.25 mg/50 mg</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Placebo</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; font-family: Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(n = 141)</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(n = 149)</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(n = 147)</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(n = 154)</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(n = 135)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="background-color: white; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Frequency</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 4 P-value versus placebo</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.013</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.141</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.001</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="background-color: #cceeff; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 12 P-value versus placebo</font>
            </td>
            <td style="background-color: #cceeff; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="background-color: #cceeff; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="background-color: #cceeff; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.002</font>
            </td>
            <td style="background-color: #cceeff; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="background-color: #cceeff; border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="background-color: white; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Severity</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="background-color: white; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="background-color: white; border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; font-family: Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 4 P-value versus placebo</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.031</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.005</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.401</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.100</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 12 P-value versus placebo</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.018</font>
            </td>
            <td style="padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.096</font>
            </td>
            <td style="border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-left: Black 1pt solid; border-top: black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-top: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-top: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-top: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-top: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-right: Black 1pt solid; border-top: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="background-color: white; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="6">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Replenish Trial Primary Safety Endpoint: Incidence of Consensus Endometrial Hyperplasia or Malignancy up to 12 months, Endometrial Safety Population&#x166;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-left: 4.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Endometrial Hyperplasia</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0% (0/280)</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0% (0/303)</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0% (0/306)</font>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0% (0/274)</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: Black 1pt solid; padding-left: 4.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0% (0/92)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;
            <font style="font-size: 10pt;">MITT = Modified intent to treat</font>
        </font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x166;Per FDA, consensus hyperplasia refers to the concurrence of two of the three pathologists be accepted as the final diagnosis</font>
    </p>
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  13; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->10
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We submitted the NDA for TX-001HR with the FDA on December 28, 2017. Assuming that the NDA is accepted 74 days thereafter and an FDA review period of ten months from the receipt date to the PDUFA target action date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2018.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Symphony Health Solutions estimates that sales of FDA-approved combinations of estrogen and progestins were approximately $588 million and the sales of estradiol and progesterone on a stand-alone basis were approximately $952 million and approximately $404 million, respectively, in the United States for the 12 months ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-002HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board, or IRB, approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we suspended enrollment and in October 2014 we stopped the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. Our IND related to TX-002HR is currently in inactive status. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it. We have currently suspended further development of this drug candidate to prioritize our leading drug candidates.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-003HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-003HR is a natural estradiol formulation. This hormone therapy drug candidate is bioidentical to the hormones that naturally occur in a woman&#x2019;s body. We currently do not have plans to further develop this hormone therapy drug candidate. Our IND related to TX-003HR is currently inactive.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-004HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-004HR is our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of VVA in menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. We initiated the REJOICE Trial, a randomized, multicenter, double-blind, placebo-controlled phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of three doses &#x2013; 25 mcg, 10 mcg and 4 mcg (compared to placebo) &#x2013; of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On November 10, 2015, the FDA held a scientific workshop on labeling &#x201C;lower&#x201D; dose estrogen-alone products for symptoms of VVA to provide an opportunity for the FDA to obtain input from experts on several topics related to the product label of lower dose estrogen-alone products approved solely for the treatment of moderate to severe symptoms of VVA due to menopause. According to the FDA, lower-dose estrogen products means products that contain less than the 0.625 mg of conjugated estrogens used in the WHI study and estradiol products containing 0.0375 mg and below. Discussion topics at the workshop included the relevance of the boxed warnings based on data from the WHI to the lower dose estrogen-alone products; certain members in the scientific/medical community have questioned whether the boxed warnings section in the labeling, which is currently required to be included on all estrogen products, is applicable in whole or in part to these lower-dose estrogen products. The boxed warnings include: (1) an increased risk of endometrial cancer in women with a uterus who uses unopposed estrogens, (2) estrogen therapy with or without progestins should not be used for the prevention of cardiovascular disease or dementia, (3) an increased risk of stroke and deep vein thrombosis (DVT) in women treated with estrogen-alone, (4) an increased risk of probable dementia in postmenopausal women 65 years of age and older treated with estrogen-alone, (5) an increased risk of invasive breast cancer in women treated with estrogen plus progestin, and (6) to use the lowest effective dose for the shortest duration. It is unknown at this time what, if any, changes the FDA may propose with respect to the boxed warnings on lower dose estrogen-alone products for symptoms of VVA or whether such label changes would be applicable to TX-004HR, if approved.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 7, 2015, we announced positive top-line results from the REJOICE Trial. The pre-specified four co-primary efficacy endpoints were the changes from baseline to week 12 versus placebo in the percentage of vaginal superficial cells, percentage of vaginal parabasal cells, vaginal pH and severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA. The trial enrolled 764 menopausal women (40 to 75 years old) experiencing moderate to severe dyspareunia at approximately 89 sites across the United States and Canada. Trial participants were randomized to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg (n=191) doses or placebo (n=192) for a total of 12 weeks, all administered once daily for two weeks and then twice weekly (approximately three to four days apart) for ten weeks.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following table sets forth the statistical significance of the REJOICE Trial results for the four pre-specified co-primary efficacy endpoints, based on mean changes from baseline to week 12 compared to placebo.&nbsp; Based on our analyses of the REJOICE Trial data, statistical significance of the results for the co-primary endpoint of severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA has improved for all three doses from the results originally reported.</font>
    </p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>25 mcg</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>10 mcg</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>4 mcg</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 68%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Superficial Cells</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Parabasal Cells</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Vaginal pH</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; font: 10pt Times New Roman, Times, Serif;">
            <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Severity of Dyspareunia</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P = 0.0149</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  14; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->11
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The 25 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level. The FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial.</font>
    </p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Statistical improvement over placebo was also observed for all three doses at the first assessment at week two and sustained through week 12 (see table below).</font>
    </p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center; font-weight: bold;">25 mcg</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center; font-weight: bold;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center; font-weight: bold;">10 mcg</td>
            <td style="padding-bottom: 1pt; text-align: center; font-weight: bold;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>4 mcg</b></font>
            </td>
            <td style="padding-bottom: 1pt; text-align: center; font-weight: bold;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 68%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 2</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 8%; text-align: right;">P = 0.0105</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 8%; text-align: right;">P = 0.0019</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 8%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P = 0.026</font>
            </td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 6</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: right;">P &lt; 0.0001</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">P = 0.0009</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P = 0.0069</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 8</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: right;">P &lt; 0.0001</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">P &lt; 0.0001</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P = 0.0003</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Week 12</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: right;">P &lt; 0.0001</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">P &lt; 0.0001</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P = 0.0149</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Vaginal dryness was a prespecified key secondary endpoint. The 25 mcg and 10 mcg doses of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoint of vaginal dryness. The 4 mcg dose of TX-004HR demonstrated statistically significant results at the p = 0.0014 level compared to placebo (see table below).</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>25 mcg</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>10 mcg</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>4 mcg</b></font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 44%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Severity of Vaginal Dryness </font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 16%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 16%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 16%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">P&nbsp;=&nbsp;0.0014</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The pharmacokinetic data for all three doses demonstrated negligible to very low systemic absorption of 17 beta estradiol, estrone and estrone conjugated, supporting the previous phase 1 trial data. TX-004HR was well tolerated, and there were no clinically significant differences compared to placebo-treated participants with respect to adverse events. There were no drug-related serious adverse events reported.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We submitted the NDA for TX-004HR with the FDA on July 7, 2016. The FDA determined that the NDA was sufficiently complete to permit a substantive review and accepted the NDA for filing with the PDUFA target action date for the completion of the FDA&#x2019;s review of May 7, 2017. The NDA submission was supported by the complete TX-004HR clinical program, including positive results of the phase 3 REJOICE Trial. The NDA submission included all three doses of TX-004HR (4 mcg, 10 mcg and 25 mcg) that were evaluated in the REJOICE Trial.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On May 5, 2017, we received a CRL from the FDA regarding the NDA for TX-004HR. In the CRL, the only approvability concern raised by the FDA was the lack of long-term safety data for TX-004HR beyond the 12 weeks studied in the phase 3 REJOICE Trial. The CRL did not identify any issues related to the efficacy of TX-004HR and did not identify any approvability issues related to chemistry, manufacturing and controls.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  15; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->12
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On June 14, 2017, we participated in a Type A Post-Action Meeting with the Division of Bone, Reproductive, and Urologic Products (DBRUP) of the FDA to discuss the CRL. At the meeting, we presented information that we believed could address concerns raised by the FDA in the CRL and positively affect the status of the NDA for TX-004HR. On July 5, 2017, we received the official minutes of the meeting from the FDA, which provided the FDA&#x2019;s response to the information presented at the Type A meeting. Per the FDA&#x2019;s request, we formally submitted the information presented at the Type A meeting for consideration related to the NDA for TX-004HR.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On August 3, 2017, we received a formal General Advice Letter from the FDA stating that an initial review of this information has been completed and requesting that we submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18, 2017. On September 14, 2017, we submitted the additional endometrial safety information that was requested by the FDA in the General Advice Letter to the NDA for TX-004HR. The submission included a comprehensive, systematic review of the medical literature on the use of vaginal estrogen products and the risk of endometrial hyperplasia or cancer, including the safety data from the recently published Women&#x2019;s Health Initiative Observational Study, or WHI Study, of vaginal estrogen use in postmenopausal women and information on the relevance of the first uterine pass effect for low-dose vaginal estrogen products. The WHI Study demonstrated no significant difference in the risk of invasive breast cancer, stroke, colorectal cancer, endometrial cancer and venous thromboembolism in vaginal estrogen users versus non-users. The WHI Study also shows that, among women with an intact uterus, there was a decreased risk of cardiovascular disease, hip fracture and all-cause mortality in vaginal estrogen users versus non-users. The WHI Study evaluated over 4,000 women who used vaginal estrogens for a median duration of two to three years.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On November 3, 2017, we participated in an in-person meeting with DBRUP. At the meeting, DBRUP agreed to the resubmission of the NDA for the 4 mcg and 10 mcg doses of TX-004HR without the need for an additional pre-approval study.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On November 29, 2017, we resubmitted the NDA for the 4 mcg and 10 mcg doses of TX-004HR with the&nbsp;FDA. We have committed to conduct a post-approval observational study. The&nbsp;FDA&nbsp;has acknowledged that the resubmission is a complete, class 2 response to the CRL received on&nbsp;May 5, 2017&nbsp;for TX-004HR. The PDUFA target action date for the completion of the&nbsp;FDA&#x2019;s&nbsp;review is&nbsp;May 29, 2018. If approved, the 4 mcg formulation of TX-004HR would represent a lower effective dose than the currently available VVA therapies approved by the FDA.</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">According to Symphony Health Solutions, the total FDA-approved market for VVA treatment was approximately $1.8 billion in U.S. sales for the 12 months ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, we had 18 issued patents, which included 13 utility patents that relate to our combination progesterone and estradiol formulations, three utility patents and one design patent that relate to TX-004HR, which establish an important intellectual property foundation for TX-004HR, one utility patent that relates to a pipeline transdermal patch technology, and one utility patent that relates to our OPERA<sup>&#xAE;</sup> information technology platform.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Preclinical Development</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Based upon leveraging our SYMBODA<sup>TM</sup> hormone technology, we have four preclinical projects that include development of a progesterone-alone and combination estradiol and progesterone products in a topical cream form, which we refer to as TX-005HR and TX-006HR, respectively, and transdermal patch form, which we refer to as TX-007HR and TX-008HR, respectively. We completed a proof-of-concept preclinical study of TX-005HR in 32 rats. The study used four groups of eight female ovariectomized rats, each of whom were treated with subcutaneous injections of estradiol for eight days. On day four of treatment, they were also dosed with a placebo, subcutaneous injections of progesterone or a similar dose of TX-005HR topical progesterone cream. The results, presented at North American Menopause Society, or NAMS, meeting in October 2015, showed that the progesterone in TX-005HR penetrated the skin and opposed the effect of subcutaneous estradiol on the endometrium. In the fourth quarter of 2016, we submitted an IND application for TX-006HR, our combination estradiol and progesterone drug candidate in a topical cream form, and intend to commence phase 1 clinical trials of this drug candidate as early as 2018. We may in the future engage with a financing partner to advance our topical cream and transdermal patch projects. We have recently conducted rat bioavailability studies on several novel, oral formulations of progesterone. We are currently adapting this formulation for the inclusion of estradiol and have embarked on its development as TX-009HR. In addition to menopausal treatments, we are also evaluating various other indications for our hormone technology, including contraception and premature ovarian failure.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Competition</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Pharmaceutical Industry</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The pharmaceutical industry is subject to intense competition and is characterized by extensive research efforts and rapid technological change. Competition in our industry occurs in a variety of areas, including developing and bringing new products to market before others, developing new technologies to improve existing products, developing new products to provide the same benefits as existing products at lower cost, and developing new products to provide benefits superior to those of existing products. Most major pharmaceutical companies, as well as numerous specialty pharmaceutical companies, sell products in the women&#x2019;s health sector of the pharmaceutical industry, which is comprised of products designed for post-pubescent females and is generally considered very fragmented. There are many companies focused on the women&#x2019;s health sector of the pharmaceutical industry that have significantly greater financial and other resources than we do, including generic manufacturers, drug compounding pharmacies, and large pharmaceutical companies. In addition, academic and other research institutions could be engaged in research and development efforts for the indications targeted by our products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  16; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->13
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Hormone Therapy Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The menopause hormone therapy market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies. On November 27, 2013, the DQSA became law and the FDA was given additional oversight over compounding pharmacies. In January 2018, the FDA announced the release of its 2018 Compounding Priorities Plan, which lays out how the agency will implement certain key provisions of the DQSA and other provisions of the law relevant to compounders over the course of the coming year. This plan confirms the FDA&#x2019;s renewed commitment to compounding oversight and education outreach to health care professionals, all of which, we believe, will help discourage prescribing of compounded bio-identical hormones and encourage compounding pharmacies to collaborate with us.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe, FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products, typically referred to as &#x201C;bioidenticals&#x201D; when produced and sold by compounding pharmacies, are not easily measured or monitored. Our phase 3 clinical trials are intended to establish an indication of the safety and efficacy of our hormone therapy drug candidates at specific dosage levels. We intend our hormone therapy drug candidates, if approved by the FDA, to provide hormone therapies with well characterized safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved compounded bioidentical market. This aim is based on our belief that our drug candidates will offer advantages in terms of demonstrated safety and efficacy consistency in the hormone dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-001HR is our combination estradiol and progesterone drug candidate for the treatment of moderate to severe VMS due to menopause. The combination of estradiol and progesterone for the treatment of moderate to severe VMS due to menopause for menopausal women with an intact uterus is comprised of two components: the FDA-approved drug market and the non-FDA-approved compounded drug market. Symphony Health Solutions estimates that sales of FDA-approved combinations of estrogen and progestins were approximately $588 million and the sales of estradiol and progesterone on a stand-alone basis were approximately $952 million and approximately $404 million, respectively, in the United States for the 12 months ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The largest competitors in the FDA-approved market are Pfizer (PREMPRO), Breckenridge (generic estradiol) and Noven (CombiPatch), with sales of PREMPRO constituting a majority of such sales. None of the current FDA-approved drugs for the treatment of moderate to severe VMS due to menopause is bioidentical to both the estradiol and progesterone produced by the ovaries. Based on various reports, including data recently presented at the NAMS Annual Meeting, &#x201C;Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones for Menopausal Women: It&#x2019;s Not What You Think,&#x201D; by JoAnn V. Pinkerton, et al., we estimate that U.S. sales of non-FDA-approved compounded combination estradiol and progesterone products approximate $1.5 billion per year. The market for non-FDA-approved compounded hormone therapy products is generally considered very fragmented because the products are prepared and sold by individual compounding pharmacies. We believe that TX-001HR, if approved by the FDA, would represent the first time a combination product of estradiol and progesterone that is bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-004HR is our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of VVA in menopausal women with vaginal linings that do not receive enough estrogen. According to Symphony Health Solutions, the FDA-approved U.S. market for treatment of VVA in menopausal women was approximately $1.8 billion for the 12 months ended December 31, 2017. Approximately $1.5 billion of such sales were by three products currently on the market: Pfizer (PREMARIN cream), Allergan (ESTRACE cream) and Vagifem and its generics. We believe that TX-004HR, if approved by the FDA, will be at least as effective as the existing treatments for VVA because of an early onset of action with less systemic exposure and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. Generics for Vagifem were introduced to the market in 2017, taking significant share from Vagifem only. Generics for Estrace were approved by the FDA and are anticipated to enter the market in 2018. Also, a new product&#x2013; AMAG (Intrarosa insert) &#x2013; was approved by the FDA for the treatment of dyspareunia in November 2016 and was licensed for commercialization in early 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  17; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->14
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Prenatal Vitamin Market</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The prenatal vitamin market is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed as either OTC products or prescription products, with many companies marketing their products through both channels. According to Symphony Health Solutions, during the 12 months ended December 31, 2017, approximately 6.2 million prescriptions for prenatal vitamins were issued in the United States resulting in total sales of approximately $379 million.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Seasonality</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The specialty pharmaceutical industry is not subject to seasonal sales fluctuation.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Products in Development</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our market objective is to develop an entire suite of products that are condition-specific and geared to the women&#x2019;s health sector. Our focus is to introduce products in which we use proprietary or patented molecules or ingredients that will differentiate our products from the competition. We currently have numerous products in development, including our hormone therapy drug candidates as described above.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Manufacturing of Our Products; Availability of and Dependence Upon Suppliers; Raw Materials for Our Products</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have sourced and qualified third-party contract manufacturing organizations, or CMOs, for the commercial supply of our hormone therapy drug candidates that have expertise in the manufacture of soft gel capsules. The regulations for manufacturing of approved drug products are significantly more stringent than the standards for manufacturing supplements or drug product for clinical trials. Our CMOs are responsible for the manufacture of our products in accordance with our specifications and applicable regulatory requirements.&nbsp; We have entered into long-term supply agreements with Catalent Pharma Solutions, LLC, or Catalent, for the commercial supply of our TX-001HR and TX- 004HR hormone therapy drug candidates, if approved. Under the terms of the agreements, we will be obligated to purchase certain minimum annual amounts of each product once we commence commercial sales of such product following regulatory approval of Catalent as a manufacturer of the product. We may terminate the agreement for a particular drug candidate in the event that we cease pursuit of regulatory approval for such drug candidate for certain specified reasons. If we are unable to obtain sufficient quantities of drug candidates or receive raw materials in a timely manner, we could be required to delay our manufacturing and seek alternative manufacturers, which would be costly and time-consuming. The hormone therapy drug candidates used in our recently completed phase 3 clinical trials for TX-001HR and TX-004HR were manufactured by a different CMO.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have a multi-faceted risk management approach to ensure continuous supply from our qualified CMOs for the commercial supply of our hormone therapy products. This approach includes oversight of the manufacturing processes, regular GMP audits, a review of their business continuity plans, management of finished product inventory and safety stock, and second sourcing as appropriate.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have also sourced and qualified manufacturers of the active pharmaceutical ingredient, or APIs, to be used in our drug candidates, if approved. We follow a risk management approach for our API manufacturer similar to that followed for the commercial supply of the finished drug product.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We use third-party manufacturers to manufacture and package our vitamin and supplement products, as well as meet applicable contract and regulatory requirements.&nbsp; We currently obtain approximately 100% of our vitaMedMD and BocaGreen products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand manufacturer specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages, bars, and functional foods in the dietary supplement category. As a result, we are dependent on Lang and its subcontractors for the manufacture of most of our vitamin and supplement products. &nbsp;In addition to manufacturing, Lang also provides a variety of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory review, and packaging production. &nbsp;We believe that Lang maintains multiple supply and purchasing relationships throughout the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have experienced no difficulties in obtaining the vitamin and supplement products we need in the amounts we require and do not anticipate those issues in the future. &nbsp;We believe the terms of our agreements with Lang are competitive with other suppliers and manufacturers. At present, we believe our relationship with Lang is excellent, and we intend to continue to use Lang as our third-party manufacturer for most of our vitamins and supplements.&nbsp; Although we anticipate continuing our relationship with Lang, we believe that we could obtain similar terms with other suppliers to provide the same services in the event our relationship with Lang terminates. Accordingly, we do not believe that such termination would have a material adverse effect on our business.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  18; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->15
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Quality Control for our Products</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our products are required to be manufactured in accordance with the FDA&#x2019;s current Good Manufacturing Practice, or cGMPs.&nbsp; To approve an NDA, the FDA must assure that the proposed manufacturing facilities for our drug candidates are in compliance with the FDA&#x2019;s cGMP regulations, which may include an FDA Pre-Approval Inspection Process, or PAI. Our third-party suppliers and manufacturers are responsible for continued compliance with cGMP requirements. We have executed Quality Agreements that delineate the responsibilities of each company in the quality assurance process. To comply with these drug commercialization standards, we have personnel with pharmaceutical development, manufacturing, and quality assurance experience who are responsible for the relationships with our suppliers. We have contracted with Catalent, an established manufacturer of softgel drug products, to manufacture the commercial supply for both our TX-001HR and TX-004HR hormone therapy drug candidates. Although Catalent has received FDA Form 483 observations from FDA inspections in the past, we are not aware of any open FDA investigations into its manufacturing processes at the facilities that would be used to manufacture our products, if approved. We anticipate that as part of the PAI of our NDA for TX-004HR (or TX-001HR) the FDA may inspect Catalent&#x2019;s facilities.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The CMO that manufactured the hormone therapy drug candidates used in our recently completed phase 3 clinical trials for TX-001HR and TX-004HR was inspected by the FDA, which issued it a FDA Form 483 listing various observations, some of which pertained to the clinical supply of our TX-001HR and TX-004HR drug candidates. The CMO has submitted its written response to the Form 483 observations to the FDA, which we believe will satisfactorily address the FDA&#x2019;s observations with respect to the clinical supply of our TX-001HR and TX-004HR drug candidates. We do not believe that the observations made by the FDA with respect to the CMO will have a material adverse effect on the FDA&#x2019;s review of our NDA for TX-004HR or the timing of our anticipated submission of an NDA for TX-001HR. We believe the inspection was not conducted as part of the FDA&#x2019;s review of our NDA for TX-004HR. As noted above, we have contracted with a different CMO, Catalent, to provide the commercial supply of our TX-001HR and TX- 004HR hormone therapy drug candidates.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our quality assurance team establishes controls that are designed to document the manufacturing process and ensure that our contract manufacturers meet product specifications and that our finished products contain the correct ingredients, purity, strength, and composition in compliance with FDA regulations. Our contractors test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards (when applicable), including quantitative and qualitative assay and microbial and heavy metal contamination (as appropriate).</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Distribution of our Products</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the third quarter of 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies. In addition to third-party logistics providers, we use some of the same national and regional distributors as other pharmaceutical companies, including Cardinal, McKesson, AmerisourceBergen, H.D. Smith, and Smith Drug. Wholesaler product inventory is monitored daily and sales out is monitored weekly. National and regional retail pharmacies are also an area of focus to make sure our products are purchased and dispensed properly.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Customer Service</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our goal is 100% customer satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal, we maintain a fully-staffed customer care center that uses current customer relationship management software to respond to health care providers, pharmacies, and consumers. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships and facilitate repeat visits and purchases. We also facilitate repeat customer orders through our auto-ship feature.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our representatives receive regular training so that they can effectively and efficiently field questions from current and prospective customers and are also trained not to answer questions that should be directed to a customer&#x2019;s physician. Having a quality customer care center allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead generation, and customer retention.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our Return Policy</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We sell our prescription products through third-party logistics providers, wholesale distributors, and retail pharmacy distributors, all of whom may return a product within six months prior to and twelve months after the expiration date of the product. Once customers buy a prescription product from the pharmacy, the product may not be returned.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  19; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->16
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our Quality Guarantee</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We proudly stand behind the quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products. Under our quality guarantee, we:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">ensure the potency and quality of our vitamin products; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">help health care providers and payors by delivering information on patient compliance and satisfaction.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We value frequent communication with and feedback from our customers in order to continue to improve our offerings and services.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Research and Development</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our product development programs are concentrated in the area of advanced hormone therapy pharmaceutical products. We engage in programs to provide alternatives to the FDA and non-FDA-approved compounded bioidentical market for hormone therapy. Our programs seek to bring new products to market in unique delivery systems or formats that enhance the effectiveness, safety, and reliability of existing hormone therapy alternatives.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We intend for our hormone therapy drug candidates, if approved, to provide an alternative to the non-FDA-approved compounded bioidentical market based on our belief that our drug candidates will offer advantages in terms of proven safety, efficacy, and stability, lower patient cost as a result of insurance coverage, and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our research and development expenses were approximately $33.9 million in 2017, $53.9 million in 2016, and $72.0 million in 2015.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Intellectual Property</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our success depends, in part, on our ability to obtain patents, maintain trade secret protection, and operate without infringing the proprietary rights of others. Our intellectual property portfolio is one of the means by which we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect our products and to maintain our competitive position. We are diligently seeking ways to protect our intellectual property through various legal mechanisms in relevant jurisdictions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="background-color: white; font-family: Times New Roman, Times, Serif; font-size: 10pt;">We also have numerous pending foreign and domestic patent applications. As of December 31, 2017, we had 18 issued domestic, or U.S., patents and 13 issued foreign patents, including:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">13 domestic and three foreign utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us. The domestic utility patents will expire in 2032. In addition, we have pending patent applications with respect to our combination progesterone and estradiol product candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">three domestic and 10 foreign patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate. These patents establish an important intellectual property foundation for TX-004HR and are owned by us. These domestic patents will expire in 2033 or 2032. In addition, we have pending patent applications related to our applicator-free vaginal estradiol softgel product candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">one domestic utility patent that relates to a pipeline transdermal patch technology, which is owned by us and will expire in 2032. We have pending patent applications with respect to this technology in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South Africa; and</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">one utility patent that relates to our OPERA<sup>&#xAE;</sup> information-technology platform, which is owned by us and is a domestic patent that will expire in 2029.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, we had filed 46 nonprovisional and 33 provisional patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our technology or our hormone therapy drug candidates, including issued patents, and 123 international patent applications with respect to our technology or our hormone therapy drug candidates, including Patent Cooperation Treaty (PCT) and national stage filings.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We hold multiple U.S. trademark registrations and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all of the areas in which it is used. Federally registered trademarks have a perpetual life so long as they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  20; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->17
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We intend to actively protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively prosecute, enforce, and defend our patents, trademarks, and proprietary technology. The loss, by expiration or otherwise, of any one patent may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive and time consuming, even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully challenged, that a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to account for patent rights of third parties.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">OPERA is our patented information technology platform used in our business. We believe the deployment of OPERA and the further development and deployment of related technology creates a sustainable competitive advantage in clinical development and product improvement.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As we continue to develop proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that will enable us to gain patent protection for these products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">While we seek broad coverage under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement claims. In addition, patents expire and we cannot provide any assurance that any patents will be issued from our pending application or that any potentially issued patents will adequately protect our intellectual property.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Government Regulation</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In the United States, the FDA regulates pharmaceuticals, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including federal and state consumer protection laws, laws protecting the privacy of health-related information, and laws prohibiting unfair and deceptive acts and trade practices.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Pharmaceutical Regulation</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The process required by the FDA before a new drug product may be marketed in the United States generally involves the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">completion of or reference to extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA&#x2019;s Good Laboratory Practice, or GLP, regulations;</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">submission to the FDA of an IND application under which the holder may begin conducting human clinical trials, provided that the FDA does not object; the IND must be updated annually;</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication; and</font>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">submission to the FDA of an NDA after completion of all pivotal clinical trials.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">An IND application is a request for authorization from the FDA to administer an investigational drug product to humans. We have submitted five INDs for our hormone therapy drug candidates. The INDs for TX-002HR and TX-003HR are currently on inactive status. The INDs for TX-004HR, TX-001HR, and TX-006HR remain active.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in the clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site&#x2019;s IRB before the trials may be initiated, and the IRB must monitor the study until completed and re-assess and approve the study at least annually. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Clinical trials are usually conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety, characterize pharmacokinetics, and assist in finding the potential dosing range. After phase 1, the drug is administered to small populations of patients (phase 2) to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess dosing and safety. Phase 3 clinical trials are usually multi-center, double-blind controlled trials in hundreds or even thousands of subjects at various sites to assess the safety and effectiveness of the drug.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  21; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->18
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the course of a clinical trial, we are required to inform the FDA and the IRB about adverse events associated with our drug candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group reviews unblinded data from clinical trials and provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climates.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls and proposed labeling, among other things.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Once the NDA submission has been accepted for filing, the FDA&#x2019;s goal is to review standard applications within ten months of filing or 12 months of receipt for a new molecular entity. However, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities in which the drug product will be formulated and its active pharmaceutical ingredient, or API, will be produced, it may issue an approval letter or, instead, a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could also approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include phase 4 clinical trials and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">After regulatory approval of a drug product is obtained, we would be required to comply with a number of post-approval requirements. As a holder of an approved NDA, we would be required to report, among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of our products. Also, quality control and manufacturing procedures must continue to conform to cGMP after approval to ensure and preserve the long-term stability of the drug product. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. For example, Catalent, the CMO that we have contracted with for the commercial supply of our TX-001HR and TX-004HR hormone therapy drug candidates, if approved, was issued a Form FDA-483 in 2016 with respect to its softgel manufacturing plant that will be used for the manufacture of the commercial supply of TX-001HR and TX- 004HR, if approved.&nbsp; The corrective actions identified in Catalent&#x2019;s response to the Form FDA 483 have been completed and we are not aware of any open FDA investigations into Catalent&#x2019;s manufacturing processes at this facility.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our drug candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could delay or prevent regulatory approval of our products under development.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  22; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->19
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our hormone therapy drug candidates may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored to the medical needs of an individual patient. The medications created by the compounding pharmacy are theoretically &#x201C;new drugs&#x201D; that would otherwise be subject to the new drug approval requirements of the FDCA.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">However, for approximately 50 years, the FDA left regulation of compounding pharmacies to the states. In 1992, in response to various safety concerns, the FDA issued a Compliance Policy Guide, which announced that the &#x201C;FDA may, in the exercise of its enforcement discretion, initiate federal enforcement actions...when the scope and nature of a pharmacy&#x2019;s activities raises the kinds of concerns normally associated with a manufacturer and...results in significant violations of the new drug, adulteration, or misbranding provisions of the Act.&#x201D; Thereafter, Congress enacted the Food and Drug Administration Modernization Act of 1997, or FDAMA, which sought to clarify FDA&#x2019;s regulatory authority over compounding pharmacies. FDAMA exempted &#x201C;compounded drugs&#x201D; from the FDA&#x2019;s standard drug approval requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from advertising or promoting particular compounded drugs. In 2002, though, the Supreme Court declared this provision of FDAMA to be unconstitutional under the First Amendment, effectively re-instating the pre-FDAMA regime. Shortly thereafter, the FDA issued its 2002 Compliance Policy Guide 460.200, which states that the FDA will exercise enforcement discretion to exclude compounded drugs from the new drug approval requirements except where compounding pharmacies act more akin to traditional drug manufacturers.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">To further clarify the FDA&#x2019;s jurisdiction, Congress enacted and the President signed into law the DQSA, which among other things, formalized the relationship between the FDA and compounding pharmacies by exempting compounding pharmacy products from the FDA approval requirements and the requirement to label products with adequate directions for use, but not the exemption from cGMP requirements. To qualify for this exemption, a compounding pharmacy must register with the FDA as an &#x201C;outsourcing facility,&#x201D; subject to FDA inspection and other requirements. The FDA does not exercise the same authority to regulate compounding pharmacies as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report adverse events associated with compounded drugs, while commercial drug manufacturers are subject to stringent regulatory reporting requirements.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>505(b)(2) Application</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We submitted two NDAs for our hormone therapy drug candidates, TX-004HR and TX-001HR, assuming that the clinical data justify submission, under section 505(b)(2) of the FDCA, or Section 505(b)(2). Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon published literature and the FDA&#x2019;s findings of safety and effectiveness based on certain pre-clinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which a referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As part of our NDA submission, we intend to certify that all of the patents for approved products referenced in the NDA for each of the hormone therapy drug candidates as listed in the FDA&#x2019;s Orange Book have expired and that we will not be compelled to certify that any patent is invalid, unenforceable, or will not be infringed by the new products. If, in fact, this assessment is incorrect, it can have a serious and significant adverse effect on our ability to obtain FDA approval or market our new products. If we are compelled to certify that a patent is invalid, unenforceable, or not infringed, then the holder of that patent can initiate a patent infringement suit against us and the FDA is precluded from approving our product for 30 months or until a court decision or settlement finding that the patent is invalid, unenforceable or not infringed, whichever is earlier.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Marketing Exclusivity</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A Section 505(b)(2) NDA applicant may be eligible for its own regulatory exclusivity period, such as a three-year exclusivity. The first approved Section 505(b)(2) NDA applicant for a particular condition, or change to a marketed product, such as a new extended release formulation for a previously approved product, may be granted three-year Hatch-Waxman exclusivity if one or more clinical studies, other than bioavailability or bioequivalence studies, was essential to the approval of the application and was conducted or sponsored by the applicant. Should this occur, the FDA would be precluded from making effective any other application for the same condition of use or for a change to the marketing product that was granted exclusivity until after that three-year exclusivity period has run. Additional exclusivities may also apply.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  23; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->20
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Additionally, the Section 505(b)(2) NDA applicant may have relevant patents in the Orange Book, and if it does, it can initiate patent infringement litigation against those applicants that challenge such patents, which could result in a 30-month stay delaying those applicants.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Dietary Supplement Regulation</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our currently marketed products are regulated as dietary supplements. The processing, formulation, safety, manufacturing, packaging, labeling, advertising, and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Generally, our nutritional product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that appear to have beneficial impact based upon scientific literature and input from physicians; however, we are generally prohibited from making disease treatment and prevention claims in the promotion of our products that use these formulations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Dietary Supplement Health and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United States prior to October 15, 1994 may be used in dietary supplements without notifying the FDA. &#x201C;New&#x201D; dietary ingredients (<i>i.e.</i>, dietary ingredients that were &#x201C;not marketed in the United States before October 15, 1994&#x201D;) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been &#x201C;present in the food supply as an article used for food&#x201D; without being &#x201C;chemically altered.&#x201D; A new dietary ingredient notification must provide the FDA evidence of a &#x201C;history of use or other evidence of safety&#x201D; establishing that use of the dietary ingredient &#x201C;will reasonably be expected to be safe.&#x201D; A new dietary ingredient notification must be submitted to the FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification of new dietary ingredients. FDA guidance is not mandatory and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA&#x2019;s &#x201C;current thinking&#x201D; on the topic discussed in the guidance, including its position on enforcement. The draft guidance on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such action would have material adverse impact on our business and growth prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The FDA or other agencies could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based in part on such reports, the FDA has issued public warnings to consumers to stop using certain third party dietary supplement products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The FDCA permits &#x201C;statements of nutritional support&#x201D; to be included in labeling for dietary supplements without premarket approval. Such statements must be submitted to the FDA within 30 days of marketing. Such statements may describe how a particular dietary ingredient affects the structure, function, or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function, or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat, or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific evidence substantiating that the statement is truthful and not misleading. If the FDA determines that a particular statement of nutritional support is an unacceptable drug claim, conventional food claim, or an unauthorized version of a &#x201C;health claim,&#x201D; or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading, we would be prevented from using the claim.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, DSHEA provides that so-called &#x201C;third-party literature,&#x201D; such as a reprint of a peer-reviewed scientific publication linking a particular dietary ingredient with health benefits, may be used &#x201C;in connection with the sale of a dietary supplement to consumers&#x201D; without the literature being subject to regulation as labeling. The literature: (1) must not be false or misleading; (2) may not &#x201C;promote&#x201D; a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject our product to regulatory action as an illegal drug.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  24; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->21
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In June 2007, pursuant to the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing, packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA is conducting inspections of dietary supplement manufacturers pursuant to these requirements. The failure of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility &#x201C;adulterated,&#x201D; and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 2, 2011, the manufacturing of dietary ingredients contained in dietary supplements are subject to similar or even more burdensome manufacturing requirements, which has the potential to increase the costs of dietary ingredients and subject suppliers of such ingredients to more rigorous inspections and enforcement. The FSMA also requires importers of food, including dietary supplements and dietary ingredients, to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The FDA has broad authority to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and regulatory powers include the FDA&#x2019;s ability to order mandatory recalls, administratively detain domestic products, require certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The FTC exercises jurisdiction over the advertising of dietary supplements and cosmetics. In recent years, the FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and &#x201C;free&#x201D; offers.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are also subject to regulation under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65 in the state of California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought against non-compliant parties and can result in substantial costs and fines.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Other U.S. Health Care Laws and Compliance Requirements</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are also subject to additional health care regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state health care laws and regulations include the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The federal health care anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal health care programs, such as Medicare and Medicaid.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The federal False Claims Act imposes criminal and civil penalties, and authorizes civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment involving federally funded programs that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money with respect to a federal program.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  25; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->22
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The federal false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with any mater within the jurisdiction of the federal government, including the delivery of or payment for health care benefits, items, or services.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Efforts to ensure that our business arrangements with third parties comply with applicable health care laws and regulations could be costly. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other health care laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party payor programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians, providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government funded health care programs.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, or by other federal, state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we generally consider favorable, such as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The growth and demand for eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers. These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business. There is currently great uncertainty in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and libel and personal privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example, tax authorities in a number of states, as well as a Congressional advisory commission, are currently reviewing the appropriate tax treatment of companies engaged in online commerce and new state tax regulations may subject us to additional state sales and income taxes. New legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently apply to our business, or a change in application of existing laws and regulations to the Internet and commercial online services could result in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Employees</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, we had 173 full time employees, six of whom are executive officers. Additionally, from time to time, we hire temporary contract employees. None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts. We have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  26; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->23
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Our History</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On October 3, 2011, we changed our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD pursuant to which (1) all outstanding membership units of VitaMed were exchanged for shares of our common stock, (2) all outstanding VitaMed options and warrants were exchanged and converted into options and warrants to purchase shares of our common stock, and (3) VitaMed became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMed would become the sole focus of our company and services previously performed relative to the licensing agreement discussed in the following paragraph were discontinued.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We were incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff&#x2019;s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a &#x201C;shell company&#x201D; under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America&#x2019;s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America&#x2019;s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America&#x2019;s Minority Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011, we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum Health Network for commissions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Available Information</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a Nevada corporation. We maintain our principal executive offices at 6800 Broken Sound Parkway NW, Third Floor, Boca Raton, Florida 33487. Our telephone number is (561) 961-1900. We maintain websites at <i>www.therapeuticsmd.com</i>, <i>www.vitamedmdrx.com</i>, and <i>www.bocagreenmd.com</i>. The information contained on our websites or that can be accessed through our websites is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings required by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The public may read and copy any materials we file with, or furnish to, the SEC at the SEC&#x2019;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site (<i>www.sec.gov</i>) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  27; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->24
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Risk Factors</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify; font-family: Times New Roman, Times, Serif;">
            <td style="width: 0in; font-family: Times New Roman, Times, Serif;"></td>
            <td style="width: 1in; text-align: left; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 1A.</b></font>
            </td>
            <td style="text-align: justify; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;
                    <font style="line-height: 106%;"><b><i><a name="txmd10ka002"></a>Risk Factors</i></b></font>
                </font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with all of the information included in this Annual Report before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Risks Related to Our Business</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have incurred recurring net losses, including net losses of approximately $77 million, $90 million, and $85 million for the years ended December 31, 2017, 2016, and 2015, respectively. As of December 31, 2017, we had an accumulated deficit of approximately $387 million. We have generated limited revenue and have funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We may incur substantial additional losses over the next few years as a result of our research, development, clinical trial and commercialization activities. As a result, we may never achieve or maintain profitability, even if we successfully commercialize our hormone therapy drug candidates. If we continue to incur substantial losses and are unable to secure additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, refinance then-existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We currently derive all of our revenue from sales of our women&#x2019;s health care products, and our failure to maintain or increase sales of these products could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In 2017, we derived virtually all of our revenue from sales of women&#x2019;s health care products, including prenatal and women&#x2019;s multi-vitamins and iron supplements. Sales of our vitamin products varied from 2010 through 2017. We cannot assure you that we will be able to sustain such sales or that such sales will grow. In addition to other risks described herein, our ability to maintain or increase existing product sales is subject to a number of risks and uncertainties, including the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the presence of new or existing competing products, including generic copies of our prescription prenatal vitamin products that are not our authorized generic products;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">any supply or distribution problems arising with any of our manufacturing and distribution strategic partners;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">changed or increased regulatory restrictions or regulatory actions by the FDA;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">changes in health care laws and policy, including changes in requirements for rebates, reimbursement, and coverage by federal health care programs;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the impact or efficacy of any price increases we may implement in the future;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">changes to our labels and labeling, including new safety warnings or changes to our boxed warning, that further restrict how we market and sell our products; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">acceptance of our products as safe and effective by physicians and patients.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If revenue from sales of our existing prescription prenatal vitamins does not continue or increase, we may be required to reduce our operating expenses or to seek to raise additional funds, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects, or we may not be able to commercialize our hormone therapy drug candidates or commence or continue clinical trials to seek approval for any other products we may choose to develop in the future.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  28; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->25
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If our products or drug candidates do not have the effects intended or cause undesirable side effects, our business may suffer.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Although many of the ingredients in our current dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption, they also contain innovative ingredients or combinations of ingredients. While we believe that all of these products and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions, such as the potential effect of high doses of folic acid masking pernicious anemia. In addition, these products may not have the effect intended if they are not taken in accordance with certain instructions, which include certain dietary restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and prospects could be harmed significantly.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our future success will depend in large part on our ability to commercialize our hormone therapy drug candidates designed to alleviate symptoms of and reduce the health risks resulting from menopause, including VMS and VVA.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our future success will depend in large part on our ability to successfully develop and commercialize our hormone therapy drug candidates designed to alleviate the symptoms of and reduce the health risks resulting from menopause, including hot flashes and dyspareunia. We have submitted IND applications for six hormone therapy drug candidates, which the FDA has allowed to proceed, and which permit us to conduct clinical testing on these proposed products. In December 2015, we completed a phase 3 clinical trial of our TX-004HR drug candidate and in December 2016 we completed a phase 3 clinical trial for our TX-001HR drug candidate. We have submitted NDAs for both drug candidates. In the fourth quarter of 2016 we submitted an IND application for our TX-006HR drug candidate and intend to commence phase 1 clinical trials of this drug candidate as early as 2018. In July 2014, we suspended enrollment in the phase 3 clinical trial for our TX-002HR drug candidate and in October 2014 we stopped the trial and are considering whether to update the phase 3 protocol based on discussions with the FDA. We have currently suspended further development of this drug candidate to prioritize our leading drug candidates and the IND application for this drug candidate is currently inactive. We have no current plans to conduct clinical trials for our TX-003HR drug candidate and the IND application for this drug candidate is currently inactive. Drug development is a necessarily uncertain undertaking. We may not be able to complete the development of our drug candidates, the results of the clinical trials may not be sufficient to support an NDA for any of our drug candidates, and even if we believe the results of our clinical trials are sufficient to support any NDA that we submit, the FDA may disagree and may not approve our NDA. In addition, even if the FDA approves one or more of our NDAs, it may do so with restrictions on the intended uses that may make commercialization of the product or products financially untenable. The failure to commercialize or obtain necessary approval for any one or more of these products could substantially harm our prospects and our business.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We may not be able to complete the development and commercialization of our hormone therapy drug candidates if we fail to obtain additional financing.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We need substantial amounts of cash to complete the clinical development and commercialization of our hormone therapy drug candidates. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected on these programs. We do not currently have any committed external source of funds. We may attempt to raise additional capital from the issuance of equity or debt securities, collaborations with third parties, licensing of rights to our products, or other means, or a combination of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from our day-to-day activities, which may adversely affect our ability to conduct our day-to-day operations. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to take one or more of the following actions:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">significantly delay, scale back, or discontinue our product development and commercialization efforts;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">seek collaborators for our hormone therapy drug candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be the case; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">license, potentially on unfavorable terms, our rights to our hormone therapy drug candidates that we otherwise would seek to develop or commercialize ourselves.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms that may not be favorable to us.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  29; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->26
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing discovery, development, and commercialization efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We have no experience as a company in bringing a drug to regulatory approval.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have never obtained regulatory approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept the NDA for our TX-001HR drug candidate for substantive review or may conclude, after review of our data, that one or more of our NDAs are insufficient to obtain regulatory approval of any of our hormone therapy drug candidates. We have begun to conduct validation and scale up of the manufacturing processes for TX-001HR, our proposed combination estradiol and progesterone drug candidate, and TX-004HR, our proposed applicator-free vaginal estradiol softgel drug candidate. The FDA may also require that we conduct additional clinical or manufacturing validation studies, which may be costly and time-consuming, and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA required studies, approval of any NDA that we submit may be significantly delayed, possibly for years, or may require us to expend more resources than we have available or can secure. Any delay or inability in obtaining regulatory approvals would delay or prevent us from commercializing our hormone therapy drug candidates, generating revenue from these proposed products, and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA we submit. If any of these outcomes occur, we may be forced to abandon our planned NDAs for one or more of our hormone therapy drug candidates, which would materially adversely affect our business and could potentially cause us to cease operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We have completed our phase 3 clinical trials of TX-001HR for the treatment of moderate to severe VMS due to menopause in menopausal women with an intact uterus and TX-004HR for the treatment of moderate to severe dyspareunia in menopausal women with VVA. Although we have discussed our clinical development plans for each drug candidate with the FDA, the agency may ultimately determine that our phase 3 clinical trials for one or both candidates are not sufficient for regulatory approval. If we are required to conduct additional clinical trials or non-clinical studies, our development of TX-001HR or TX-004HR, as applicable, will be more time-consuming and costly than we presently anticipate, which could have a material adverse effect on our business, results of operations and financial condition.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 5, 2016, we announced positive top-line results from the REPLENISH Trial, our phase 3 clinical trial to evaluate the safety and efficacy of TX-001HR, an investigational bio-identical hormone therapy combination of 17&#xDF;-estradiol and progesterone in a single, oral softgel, for the treatment of moderate to severe VMS due to menopause in menopausal women with an intact uterus.&nbsp; The REPLENISH Trial evaluated four doses of TX-001HR and placebo in 1,835 menopausal women between 40 and 65 years old. The doses studied were: 17&#xDF;-estradiol 1 mg/progesterone 100 mg; 17&#xDF;-estradiol 0.5 mg/progesterone 100 mg; 17&#xDF;-estradiol 0.5 mg/progesterone 50 mg; and 17&#xDF;-estradiol 0.25 mg/progesterone 50 mg (n = 424).&nbsp; The REPLENISH Trial results demonstrated that TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both achieved all four of the co-primary efficacy endpoints and the primary safety endpoint and demonstrated a statistically significant and clinically meaningful reduction from baseline in both the frequency and severity of hot flashes compared to placebo.&nbsp; TX-001HR estradiol 0.5 mg/progesterone 50 mg and TX-001HR estradiol 0.25 mg/progesterone 50 mg were not statistically significant at all of the co-primary efficacy endpoints; the estradiol 0.25 mg/progesterone 50 mg dose was included in the clinical trial as a non-effective dose to meet the recommendation of the FDA guidance to identify the lowest effective dose. The incidence of consensus endometrial hyperplasia or malignancy was 0 percent across all four TX-001HR doses, meeting the recommendations established by the FDA&#x2019;s draft guidance.&nbsp; Based on the results of the REPLENISH Trial, we currently intend to seek regulatory approval for the estradiol 1 mg/progesterone 100 mg and estradiol 0.5 mg/progesterone 100 mg doses of TX-001HR for the treatment of moderate to severe VMS due to menopause in menopausal women with an intact uterus in the U.S.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 7, 2015, we announced positive top-line results from the REJOICE Trial, our phase 3 clinical trial to evaluate the safety and efficacy of three doses&#x2014;25 mcg, 10 mcg and 4 mcg (compared to placebo)&#x2014;of TX-004HR for the treatment of moderate to severe dyspareunia in menopausal women with VVA. Both the 25 mcg dose and the 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary efficacy endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p&nbsp;&lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level.&nbsp; As discussed below, where an NDA is supported by a single clinical trial, as is the case with TX-004HR, the FDA has taken the position initially that the results of our trial would have to achieve statistical significance at the 0.01 level or better. Statistical significance at the 0.0149 level may not be sufficient to satisfy this requirement.&nbsp; If the FDA continues to maintain this position, we may have to either conduct an additional trial or eliminate the 4 mcg dose formulation from the TX-004HR NDA.&nbsp; The elimination of this low dose from our product line could adversely affect our sales of TX-004HR, if approved.&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  30; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->27
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We cannot assure you that the FDA will approve all or any doses of TX-001HR or TX-004HR for commercialization. The FDA may not agree with one or more aspects of our clinical trial designs, including the duration of the trials, clinical endpoints, controls, dose ranges, collection of safety data, level of statistical significance, or adequacy of our non-clinical studies.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our TX-001HR or TX-004HR hormone therapy drug candidates are currently undergoing stability testing.&nbsp; The FDA will review the period of time that our drug candidates are stable, which will dictate the amount of time post-manufacturing that the products may be used by patients, if approved. If our hormone therapy drug candidates fail to remain stable or the period of time that they remain stable is too short, it could limit the commercial viability of our products, which could materially adversely impact our business, results of operations and financial condition.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, prior to approval of an NDA, the FDA may audit one or more of the sites where the applicable phase 3 clinical trial was conducted to ensure the integrity of the data, inspect our clinical records in our corporate offices, and will inspect the facilities of our third party contract manufacturers where the applicable drug candidate will be manufactured commercially, if approved and where the drug was manufactured for clinical trials. If one or more site audits reveals anomalies, or if the manufacturing facilities do not pass inspection, full consideration of the NDA by the FDA could be delayed, or the FDA may require us to undertake further clinical or non-clinical trials or could require our contract manufacturers to improve or change their processes, any of which would delay or prevent commercialization of the applicable drug candidate and could materially adversely impact our business, results of operations and financial condition.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Clinical trials are lengthy and expensive with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results</i>.</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. For example, we suspended enrollment in and subsequently stopped the SPRY trial for our progesterone alone drug candidate in order to update the phase 3 protocol based on discussions with the FDA. Failure can occur at any time during the clinical trial process as a result of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Prior to approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled clinical trials. In some situations, the FDA approves drugs on the basis of a single well-controlled clinical trial. We believe we may be required to conduct only a single phase 3 clinical trial of each of TX-001HR, our proposed combination estradiol and progesterone drug candidate, TX-002HR, our progesterone alone drug candidate, and TX-004HR, our applicator-free vaginal estradiol softgel drug candidate. However, in connection with our TX-004HR drug candidate, the FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher numerical level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial. If clinical trials for any of our hormone therapy drug candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve that drug and we would not be able to commercialize it, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our dependence upon third parties for the manufacture and supply of our existing women&#x2019;s health care products and our hormone therapy drug candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products.&nbsp;</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We do not currently have, nor do we plan to build, the infrastructure or capability to internally manufacture our existing women&#x2019;s health care products or our hormone therapy drug candidates. We have relied, and will continue to rely, on third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory requirements.&nbsp; We have entered into long-term supply agreements with Catalent for the commercial supply of our TX-001HR and TX-004HR hormone therapy drug candidates. Under the terms of the agreements, we will be obligated to purchase certain minimum annual amounts of each product once we commence commercial sales of such product following regulatory approval of Catalent as a manufacturer of the product.&nbsp; We depend on Lang, a full-service, private label and corporate brand manufacturer, to supply approximately 100% of our vitaMedMD and BocaGreen products.&nbsp; We do not have long-term contracts for the commercial supply of our existing women&#x2019;s health care products, however, in certain circumstances, including our failure to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by Lang that it cannot use in another product category that it then sells.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  31; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->28
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Regulatory requirements could pose barriers to the manufacture of our existing women&#x2019;s health care products and our hormone therapy drug candidates. Our third-party manufacturers are required to comply with cGMP regulations. As a result, the facilities used by any of our current or future manufacturers must be approved by the FDA. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are responsible for manufacturing even though that manufacturing is conducted by a third-party CMO. All of our existing products are, and our hormone therapy drug candidates, if approved, will be manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. The CMO that will manufacture our hormone therapy drug candidates, if approved, has previously been inspected by the FDA and received Form 483 observations with respect to its softgel manufacturing plant that will be used for the manufacture of the commercial supply of TX-001HR and TX-004HR, if approved.&nbsp; As part of the PAI of our NDA for TX-004HR, the FDA inspected Catalent&#x2019;s manufacturing facilities that would be used to manufacture the product; we anticipate that as part of the PAI of our NDA for TX-001HR, the FDA may again inspect Catalent&#x2019;s manufacturing facilities that would be used to manufacture that product. If this inspection results in Form 483 observations, the approval of our NDA could be delayed significantly. The CMO that manufactured the hormone therapy drug candidates used in our recently completed phase 3 clinical trials for TX-001HR and TX-004HR was recently inspected by the FDA, which issued it a Form FDA-483 listing various observations, some of which pertained to the clinical supply of our TX-001HR and TX-004HR drug candidates. The CMO has submitted its written response to the Form 483 observations to the FDA, however, neither we nor the CMO has been informed by the FDA as to whether the CMO&#x2019;s response addresses and remediates these observations in a manner satisfactory to the FDA. If this CMO is not able to address and remediate the FDA&#x2019;s observations pertaining to the clinical supply of our TX-001HR and TX-004HR drug candidates in a manner satisfactory to the FDA, it could have a material adverse effect on the FDA&#x2019;s review of our NDA for TX-004HR or the timing of our anticipated submission of an NDA for TX-001HR.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for the commercial manufacture of our existing products or our hormone therapy drug candidates, we may need to find alternative manufacturing facilities, which would result in disruptions of our sales and significant delays of up to several years in obtaining approval for our hormone therapy drug candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMP regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have a material adverse impact on our business, financial condition, results of operations, and prospects. Finally, we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed products or otherwise do not satisfactorily perform according to the terms of their agreements with us.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We also do not have long-term contracts for the supply of the API used in our hormone therapy drug candidates.&nbsp; If any supplier of the API or other products used in our hormone therapy drug candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of an agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the supply of our hormone therapy drug candidates, which could impair our ability to supply our hormone therapy drug candidates at the levels required for commercialization and prevent or delay their successful commercialization.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Future legislation, or the absence of such legislation, regulations, and policies adopted by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials for our hormone therapy drug candidates.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The FDA has established regulations, guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities. Any change in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols or clinical trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion of the clinical trials for our hormone therapy drug candidates.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, the FDA&#x2019;s policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our drug candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example, in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt to any such changes, our business, prospects, and ability to achieve or sustain profitability could be adversely affected.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  32; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->29
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Even if we obtain regulatory approval for our hormone therapy drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Even if we obtain regulatory approval for one or more of our hormone therapy drug candidates in the United States, the FDA may still impose significant restrictions on a product&#x2019;s indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for our hormone therapy drug candidates, if approved, may include restrictions on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. If approved, our hormone therapy drug candidates will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#x2019;s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once approved, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA&#x2019;s cGMPs regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The distribution of product samples to physicians must comply with the requirements of the Prescription Drug Marketing Act. Sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, and similar state laws. We would also be required under the Sunshine provision of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act or ACA, to report annually to the Centers for Medicare &#38; Medicaid Services on payments that we make to physicians and teaching hospitals and ownerships interests in the company held by physicians. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration and to low income patients of certain hospitals, additional laws and requirements apply. Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">conduct an investigation into our practices and any alleged violation of law;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">issue warning letters or untitled letters asserting that we are in violation of the law;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">seek an injunction or impose civil or criminal penalties or monetary fines;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">suspend or withdraw regulatory approval;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">require that we suspend or terminate any ongoing clinical trials;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  33; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->30
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">refuse to approve pending applications or supplements to applications filed by us;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">exclude us from providing our products to those participating in government health care programs, such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>The commercial success of our existing products and our hormone therapy drug candidates that we develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payors.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Physicians may not prescribe our products, including any of our hormone therapy drug candidates, if approved by the appropriate regulatory authorities for marketing and sale, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our hormone therapy drug candidates, by physicians, patients, and payors, will depend on a number of factors, many of which are beyond our control, including the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the clinical indications for which our hormone therapy drug candidates are approved, if at all;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">acceptance by physicians and payors of each product as a safe and effective treatment;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the cost of treatment in relation to alternative treatments, including numerous generic drug products;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the relative convenience and ease of administration of our products in the treatment of the symptoms for which they are intended;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the availability and efficacy of competitive drugs;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the effectiveness of our sales force and marketing efforts;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the availability of coverage and adequate reimbursement by third parties, such as insurance companies and other health care payors, or by government health care programs, including Medicare and Medicaid;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">limitations or warnings contained in a product&#x2019;s FDA-approved labeling; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">prevalence and severity of adverse side effects.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Even if the medical community accepts that our products are safe and efficacious for their approved indications, physicians may not immediately be receptive to the use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. We cannot assure you that any labeling approved by the FDA will permit us to promote our products as being superior to competing products. If our products, including, in particular our hormone therapy drug candidates, if approved, do not achieve an adequate level of acceptance by physicians and payors, we may not generate sufficient or any revenue from these products and we may not become profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our products, including our hormone therapy drug candidates if approved, face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Development and awareness of our brand will depend largely upon our success in increasing our customer base. The dietary supplement and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our products, including any hormone therapy drug candidates that may be approved, face intense competition, including from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. A non-hormonal product, Brisdelle, produced by Noven Pharmaceuticals, was approved by the FDA for treatment of VMS in June 2013. Many of these companies have greater financial and other resources, such as larger research and development staffs and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly and may be more effective in selling and marketing their products. They also may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. As a result, our competitors may succeed in commercializing products before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. If we are unable to economically promote or maintain our brand, our business, results of operations and financial condition could be severely harmed. In addition, our efforts to provide an alternative to the non-FDA-approved compound bioidentical market for estradiol and progesterone products sold by compounding pharmacies may not be successful.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  34; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->31
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Market acceptance and sales of our products, including any hormone therapy drug candidates, will depend on coverage and reimbursement policies and may be affected by health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which products they will pay for and establish reimbursement levels. Third-party payors generally do not cover OTC products, and coverage for vitamins and dietary supplements varies. We cannot be sure that coverage and reimbursement will be available for our products, including any hormone therapy drug candidates, if approved, or whether the amount of such coverage and reimbursement, if any, will be sufficient to enable us to successfully compete with other products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Specifically, in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain others by establishing a new Part D to the Medicare program. However, unlike traditional Medicare&#x2014;which provides coverage for outpatient drugs&#x2014;coverage under Part D is provided by private insurers operating under contract with CMS. In addition, this legislation provided authority for limiting the number of certain outpatient drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including our hormone therapy drug candidates, if approved, and could significantly harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar reduction in payments from private payors.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In March 2010, the Affordable Care Act became law in the United States. The goal of ACA is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. Among other measures, ACA increased rebates on manufacturers for certain covered drug products reimbursed by state Medicaid programs. While we cannot predict the full effect that the Affordable Care Act will have on federal reimbursement policies in general or on our business specifically, the ACA may result in downward pressure on drug reimbursement, which could negatively affect market acceptance of our products. In addition, we cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have on us if they are adopted. If the ACA or parts of it are repealed, it is unclear what impact that would have on drug reimbursements or coverage and it is equally unclear what programs, if any, Congress might enact to replace the repealed portions of the ACA.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The availability of generic products at lower prices than branded products may also substantially reduce the likelihood of reimbursement for branded products, such as our hormone therapy drug candidates, if approved. We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative proposals. If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Failure to obtain regulatory approval outside the U.S. will prevent us from marketing our drug candidates in non- U.S. markets.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We may attempt to market certain of our drug candidates in non-U.S. markets. In order to market our drug candidates in the European Union and many other non-U.S. jurisdictions, we must obtain separate regulatory approvals. We have had limited interactions with non-U.S. regulatory authorities, the approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval or clearance. Approval or clearance by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by other regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval or clearance. If we pursue non-U.S. regulatory approvals, we may not obtain them on a timely basis, if at all. If we pursue non-U.S. regulatory approvals, our failure to receive necessary approvals to commercialize our drug candidates in a given market could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  35; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->32
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, if we seek and obtain approval to market our drug candidates in one or more non-U.S. markets, we will be subject to rules and regulations in those markets relating to our product. In some countries, particularly countries of the European Union, each of which has developed its own rules and regulations, pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our drug candidates to other available products. If reimbursement of our drug candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to generate revenues and achieve or sustain profitability with respect to any given market, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Future legislation or regulations may adversely affect reimbursement from government programs</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reductions, triggering the legislation&#x2019;s automatic reduction of several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Bipartisan Budget Act of 2015, signed into law on November 2, 2015, increased the rebates that generic drug manufacturers are obligated to pay under the Medicaid program by applying an inflation-based rebate formula to generic drugs that previously only applied to brand name drugs. If we ever obtain regulatory approval and commercialization of any of our drug candidates, these new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. On December 13, 2016, President Obama signed into law the 21st Century Cures Act, which, among other things, may increase the types of clinical trial designs that would be acceptable to support an NDA. It is unclear, at this time, how these provisions will be implemented or whether they would have any effect on our company.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates may be. If the ACA or parts of it are repealed, it is unclear what impact that would have on drug reimbursements or coverage and it is equally unclear what programs, if any, Congress and the Trump Administration might enact and sign into law to replace the repealed portions of the ACA.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We face an inherent risk of product liability claims as a result of the marketing of our current products and the clinical testing of our hormone therapy drug candidates despite obtaining appropriate informed consents from our clinical trial participants. Additionally, in light of the history of product liability claims related to other hormone replacement therapy products, we will face an even greater risk if we obtain FDA approval and commercialize our hormone therapy drug candidates in the United States or other additional jurisdictions or if we engage in the clinical testing of proposed new products or commercialize any additional products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failures to warn of dangers inherent in the product, negligence, strict liability, or breaches of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our existing products or hormone therapy drug candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, product liability claims may result in any of the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the inability to commercialize our products or hormone therapy drug candidates;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial is completed;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">labeling, marketing, or promotional restrictions;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">product recalls or withdrawals;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  36; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->33
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">decreased demand for our products or products that we may develop in the future;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">loss of revenue;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">injury to our reputation;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">initiation of investigations by regulators;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">costs to defend the related litigation;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">a diversion of management&#x2019;s time and our resources;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">substantial monetary awards to trial participants or patients;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">exhaustion of any available insurance and our capital resources; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">a decline in our stock price.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Although we maintain general liability insurance of up to $10 million in the aggregate and clinical trial liability insurance of $10 million in the aggregate for our hormone therapy drug candidates, this insurance may not fully cover potential liabilities. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our business may be affected by unfavorable publicity or lack of consumer acceptance.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are highly dependent upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our particular products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by our consumers as less than favorable or that may question earlier favorable research or publicity could have a material adverse effect on our ability to generate revenue. Adverse publicity in the form of published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates consumption of our product or any other similar product with illness or other adverse effects, or that questions the benefits of our product or a similar product, or that claims that such products do not have the effect intended could have a material adverse effect on our business, reputation, financial condition, or results of operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If we use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials. In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the United States govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors) comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future. We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws, we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, and may adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We are subject to extensive and costly government regulation.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The products we currently market, including the vitamins, and the pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare &#38; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products under various regulatory provisions. If any drug products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  37; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->34
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling products. Our failure to comply with these regulations could result in, by way of example, significant fines, criminal and civil liability, product seizures, recalls, withdrawals, withdrawals of approvals, and exclusion and debarment from government programs. Any of these actions, including the inability of our hormone therapy drug candidates to obtain and maintain regulatory approval, could have a materially adverse effect on our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We are subject to additional federal and state laws and regulations relating to our business, and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are subject to additional health care regulation and enforcement by the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the federal health care program Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order, or recommendation of, any good or service for which payment may be made under government health care programs such as the Medicare and Medicaid programs;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government health care programs that are false or fraudulent;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">federal criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating to health care matters; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Further, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity can now be found guilty of fraud or false claims under ACA without actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations, and financial condition.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The ACA also imposes new reporting requirements on device and pharmaceutical manufacturers to make annual public disclosures of payments to certain health care providers and physician ownership of their stock by health care providers. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &#x201C;knowing failures&#x201D;), for all payments, transfers of value, or ownership or investment interests that are not reported. Manufacturers were required to begin data collection on August 1, 2013 and were required to report such data to CMS by March 31, 2014.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians for marketing. Some states, such as California, Massachusetts and Vermont, mandate implementation of corporate compliance programs, along with the tracking and reporting of gifts, compensation, and other remuneration to physicians.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  38; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->35
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The scope and enforcement of these laws is uncertain and subject to change in the current environment of health care reform, especially in light of the lack of applicable precedent and regulations. We cannot predict the impact on our business of any changes in these laws. Federal or state regulatory authorities may challenge our current or future activities under these laws. Any such challenge could have a material adverse effect on our reputation, business, results of operations, and financial condition. Any state or federal regulatory review of us, regardless of the outcome, would be costly and time-consuming.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our ability to compete in the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial, scientific, and medical personnel. In order to induce valuable employees to remain with us, we have, among other things, provided stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams may terminate their employment with us on short notice. We do not have employment agreements with a number of our key employees. As a result, most employees are employed on an at-will basis, which means that any of these employees could leave our employment at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Any failure to adequately expand a direct sales force will impede our growth.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We expect to be substantially dependent on a direct sales force to attract new business and to manage customer relationships. We plan to expand our direct sales force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our success in recruiting, training, and retaining sufficient direct sales personnel. New and future hires may not become as productive as expected, and we may be unable to hire sufficient numbers of qualified individuals in the future in the markets in which we do business. If we are unable to hire and develop sufficient numbers of productive sales personnel our business prospects could suffer.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other pharmaceutical companies with which we compete for qualified personnel may have greater financial and other resources, different risk profiles, and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality personnel, our ability to commercialize drug candidates may be limited.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our success is tied to our distribution channels.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We sell our prescription prenatal vitamin products to wholesale distributors and retail pharmacy distributors. During the year ended December 31, 2017, four customers each generated more than 10% of our total revenues; revenue generated from these four customers combined accounted for approximately 59% of our total revenue during the year ended December 31, 2017. Our business would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially favorable terms to us.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>A failure to maintain optimal inventory levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our ability to maintain optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances, our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials, if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products in the future, each of which could have a material adverse effect on our business, financial condition, results of operations, and cash flows.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Delays in clinical trials are common for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We may experience delays in future clinical trials for our drug candidates. Clinical trials might not begin on time; may be interrupted, delayed, suspended, or terminated once commenced; might need to be redesigned; might not enroll a sufficient number of patients; or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in obtaining regulatory approval to commence a trial;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  39; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->36
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">imposition of a clinical hold following an inspection of clinical trial operations or trial sites by the FDA or other regulatory authorities;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">imposition of a clinical hold because of safety or efficacy concerns by the DSMB, FDA, or IRB, or us;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 48px; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in obtaining required IRB approval at each site;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in identifying, recruiting, and training suitable clinical investigators;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in recruiting suitable patients to participate in a trial;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">clinical sites dropping out of a trial to the detriment of enrollment;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">time required to add new sites;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in obtaining sufficient supplies of clinical trial materials, including suitable API; or</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays resulting from negative or equivocal findings of DSMB for a trial.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Any of these delays in completing future clinical trials could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenue from our drug candidates subject to the trial.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We may be required to suspend or discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our drug candidates.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Clinical trials may be suspended or terminated at any time for a number of reasons. A clinical trial may be suspended or terminated by us, our collaborators, the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An IRB may also suspend or terminate our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe the clinical trials are not being conducted in accordance with applicable regulatory requirements or present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any proposed product that we develop, the commercial prospects of such proposed product will be harmed and our ability to generate product revenue from any of these proposed products will be delayed or eliminated. Any of these occurrences may harm our business, financial condition, results of operations, and prospects significantly.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We rely on third parties to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our hormone therapy drug candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We do not have the resources to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our on-going clinical programs for our hormone therapy drug candidates, as well as for the execution of clinical studies. Although we control only certain aspects of our CROs&#x2019; activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We cannot assure you that the CROs will conduct the research properly or in a timely manner, or that the results will be reproducible. We and our CROs are required to comply with the FDA&#x2019;s cGCPs, which are regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of our hormone therapy drug candidates to a statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply with these regulations or recruit a sufficient number of patients, we may be required to repeat clinical trials, which would delay the regulatory approval process.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  40; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->37
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, we do not employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our hormone therapy drug candidates that we seek to develop. As a result, our financial results and the commercial prospects for our hormone therapy drug candidates that we seek to develop could be harmed, our costs could increase, and our ability to generate revenue could be delayed or end.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We typically engage one or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources and expertise in an attempt to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation of clinical trial data for submission with an NDA for each of our hormone therapy drug candidates. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially affect our ability to meet our desired clinical development timelines and can increase our costs significantly. Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operations, or prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our ability to utilize net operating loss carryforwards may be limited.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, we had federal net operating loss carryforwards, or NOLs, of approximately $338.6 million. Subject to applicable limitations, these NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce our future federal income taxes otherwise payable.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Section 382 of the Internal Revenue Code of 1986, as amended, imposes limitations on a corporation&#x2019;s ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percent over a three-year period. In the event that an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under Section 382 as a result of events in the past or the issuance of shares of our common stock in the future. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under Section 382.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent and imposing new restrictions on the use of NOLs. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018. We must assess whether our valuation allowance analyses with respect to our NOLs are affected by various aspects of the Tax Act. Furthermore, the Tax Act limits the NOL carryover deduction in a taxable year to the lesser of the NOL carryforward or 80 percent of the taxpayer&#x2019;s taxable income (before taking into account any deduction on account of such NOLs), which may restrict our ability to offset future taxable income with NOLs and increase our future federal income taxes otherwise payable.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  41; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->38
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Since we have recorded provisional amounts related to certain portions of the Tax Act, any corresponding determination of the need for or change in a valuation allowance or otherwise is also provisional.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our business may be impacted by new or changing tax laws or regulations and actions by federal, state, and/or local agencies, or how judicial authorities apply tax laws.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In connection with the products we sell and intend to sell, we calculate, collect, and remit various federal, state, and local taxes, surcharges and regulatory fees (&#x201C;tax&#x201D; or &#x201C;taxes&#x201D;) to numerous federal, state and local governmental authorities. In addition, we incur and pay state and local taxes and fees on purchases of goods and services used in our business.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. In many cases, the application of tax laws (including the recently enacted Tax Act) is uncertain and subject to differing interpretations, especially when evaluated against new technologies and services.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In the event that we have incorrectly described, disclosed, calculated, assessed, or remitted amounts that were due to governmental authorities, we could be subject to additional taxes, fines, penalties, or other adverse actions, which could materially impact our business, results of operations, and financial condition.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our success depends on how efficiently we respond to changing consumer preferences and demand.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our success depends, in part, on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a timely or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact our inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings depends upon a number of factors, including our ability to achieve the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">accurately anticipate customer needs;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">innovate and develop new products;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">successfully commercialize new products in a timely manner;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">competitively price our products in the market;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">procure and maintain products in sufficient volumes and in a timely manner; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">differentiate our product offerings from those of our competitors.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If we do not introduce new products, make enhancements to existing products, or maintain the appropriate inventory levels to meet customers&#x2019; demand in a timely manner, our business, results of operations, and financial condition could be materially and adversely affected.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We may initiate product recalls or withdrawals, or may be subject to regulatory enforcement actions that could negatively affect our business.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We may be subject to product recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall, withdrawal, or seizure of any of our products could materially and adversely affect consumer confidence in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products would require significant management attention, would likely result in substantial and unexpected expenditures, and could materially and adversely affect our business, financial condition, and results of operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, we had 173 full time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial, sales and marketing, and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional drug candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our hormone therapy drug candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth in our organization.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  42; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->39
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We may not be able to maintain effective and efficient information systems or properly safeguard our information systems.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our operations are dependent on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing information systems or the implementation of new systems could cause disruptions in our business operations, including violations of patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse consequences.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, information security risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health, business, or financial information. Despite our layered security controls, experienced computer programmers and hackers may be able to penetrate our information systems and misappropriate or compromise sensitive patient or personnel information or proprietary or confidential information, create system disruptions or cause shutdowns. They also may be able to develop and deploy viruses, worms and other malicious software programs that disable our systems or otherwise exploit any security vulnerabilities. Outside parties may also attempt to fraudulently induce employees to take actions, including the release of confidential or sensitive information or to make fraudulent payments, through illegal electronic spamming, phishing or other tactics.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A failure in or breach of our information systems as a result of cyber-attacks or other tactics could disrupt our business, result in the release or misuse of protected health information, or PHI, confidential or proprietary business information or financial loss, damage our reputation, increase our administrative expenses, and expose us to additional risk of liability to federal or state governments or individuals. Although we believe that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of existing or potential customers and disruption of our operations. In addition, breaches of our security measures and the unauthorized dissemination of patient healthcare and other sensitive information, proprietary or confidential information about us or other third-parties could expose such persons&#x2019; private information to the risk of financial or medical identity theft or expose us or such persons to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our brand and reputation or otherwise harm our business. Any of these disruptions or breaches of security could have a material adverse effect on our business, financial condition, and results of operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our employees and business partners may not appropriately secure and protect confidential information in their possession. </i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Each of our employees and business partners is responsible for the security of the information in our systems or under our control and to ensure that private and financial information is kept confidential. Should an employee or business partner not follow appropriate security measures, including those related to cyber threats or attacks or other tactics, as well as our privacy and security policies and procedures, the improper release of personal information, including PHI, or confidential business or financial information, or misappropriation of assets could result. The release of such information or misappropriation of assets could have a material adverse effect on our business, financial condition, and results of operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  43; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->40
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Risks Related to our Intellectual Property </i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Another party could develop hormone therapy products and obtain FDA regulatory exclusivity in the United States before we do, potentially preventing our ability to commercialize our hormone therapy drug candidates and other products in development.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We plan to seek to obtain market exclusivity for our hormone therapy drug candidates and any other drug candidates we develop in the future. To the extent that patent protection is not available or has expired, FDA marketing exclusivity may be the only available form of exclusivity available for these proposed products. Marketing exclusivity can delay the submission or the approval of certain marketing applications. Potentially competitive products may also be seeking marketing exclusivity and may be in various stages of development, including some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted, nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It is possible that competing products may obtain FDA approval with marketing exclusivity before we do, which could delay our ability to submit a marketing application or obtain necessary regulatory approvals, result in lost market opportunities with respect to our hormone therapy drug candidates, and materially adversely affect our business, financial condition, and results of operations.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy drug candidates and other products are not adequate, we may not be able to compete effectively in our market.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to maintain adequate protection of other intellectual property for our hormone therapy drug candidates and other products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the United States, such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">These risks include the possibility of the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the patent applications that we have filed may fail to result in issued patents in the United States or in foreign countries;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">patents issued or licensed to us or our partners may be challenged or discovered to have been issued on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid or unenforceable;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the scope of any patent protection may be too narrow to exclude competitors from developing or designing around these patents;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">we or our licensors were not the first to make the inventions covered by each of our issued patents and pending patent applications;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">we or our licensors may not have been the first inventors to file patent applications for these technologies in the United States or were not the first to file patent applications directed to these technologies abroad;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">we may fail to comply with procedural, documentary, fee payment, and other similar provisions during the patent application process, which can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  44; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->41
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">future drug candidates may not be patentable;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">others may claim rights or ownership with regard to patents and other proprietary rights that we hold or license;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">delays in development, testing, clinical trials, and regulatory review may reduce the period of time during which we could market our drug candidates under patent protection; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">we may fail to timely apply for patents on our technologies or products.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">While we apply for patents covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas of product development. These entities&#x2019; applications, patents, and other intellectual property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our hormone therapy drug candidates. In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope of the claims.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If we, our licensors, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our hormone therapy drug candidates or future drug candidates, if approved, may be threatened, we could lose our competitive advantage, and the competition we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, mechanisms exist in much of the world permitting some form of challenge by generic drug marketers to our patents prior to, or immediately following, the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &#x201C;at risk&#x201D; launches to challenge relevant patent rights.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our business also may rely on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached, it could adversely impact our business.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If we are sued for infringing intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or commercializing our drug candidates.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our commercial success depends, in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S. issued patents and pending applications that exist in the areas of hormone therapy, including compounds, formulations, treatment methods, and synthetic processes, which may be applied towards the synthesis of hormones. Patent applications are confidential when filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products or drug candidates. Therefore, we cannot ever know with certainty the nature or existence of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market our drug candidates as planned or that we or our licensors&#x2019; and partners&#x2019; patents will not be opposed or litigated by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of any of our drug candidates, the holders of any such patent may be able to block our ability to develop and commercialize the applicable drug candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have a material adverse effect on our business.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">There is a substantial amount of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we infringe its patents or other proprietary rights, we could face a number of risks that could adversely affect our business, financial condition, results of operations, and prospects, including the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">infringement and other intellectual property claims, which would be costly and time-consuming to defend, whether or not we are ultimately successful, which in turn could delay the regulatory approval process, consume our capital, and divert management&#x2019;s attention from our business;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  45; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->42
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">substantial damages for past infringement, which we may have to pay if a court determines that our products or technologies infringe a competitor&#x2019;s patent or other proprietary rights;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">a court prohibiting us from selling or licensing our technologies or future products unless the third party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">if a license is available from a third party, we may have to pay substantial royalties or lump sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license; or</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">redesigning our products so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are party from time to time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating to our drug candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our partners to curtail or cease the development of some or all of our drug candidates, which could adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have submitted, and intend to submit, NDAs for our hormone therapy drug candidates, assuming that the clinical data justify submission, under Section 505(b)(2), which was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. To the extent that a Section 505(b)(2) NDA relies on clinical trials conducted for a previously approved drug product or the FDA&#x2019;s prior findings of safety and effectiveness for a previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications in its Section 505(b)(2) NDA with respect to any patents for the approved product on which the application relies that are listed in the FDA&#x2019;s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. Specifically, the applicant must certify for each listed patent that (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is not sought until after patent expiration; or (iv) the listed patent is invalid, unenforceable or will not be infringed by the proposed new product. A certification that the new product will not infringe the previously approved product&#x2019;s listed patent or that such patent is invalid or unenforceable is known as a Paragraph IV certification.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If the Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2) NDA for 30 months beginning on the date the patent holder receives notice, or until a court deems the patent unenforceable, invalid or not infringed, whichever is earlier. The court also has the ability to shorten or lengthen the 30 month period if either party is found not to be reasonably cooperating in expediting the litigation. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its product only to be subject to significant delay and patent litigation before its product may be commercialized. Alternatively, if the NDA or relevant patent holder does not file a patent infringement lawsuit within the specified 45 day period, the FDA may approve the Section 505(b)(2) application at any time.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If we cannot certify that all of the patents listed in the Orange Book for the approved products referenced in the NDAs for each of our hormone therapy drug candidates have expired, we will be compelled to include a Paragraph IV certification in the NDA for such drug candidate. Our inability to certify that all of the patents listed in the FDA&#x2019;s Orange Book for approved products referenced in the NDAs for each of our hormone therapy drug candidates could have significant adverse effects on the timing for obtaining approval of our hormone therapy drug candidates.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  46; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->43
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the United States or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If we are unable to protect the confidentiality of certain information, the value of our products and technology could be materially adversely affected.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We also rely on trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees, independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming, and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets, know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties with whom we have obligations of confidentiality.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As is common in the pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property rights, which could adversely affect our business, financial condition, results of operations, and prospects.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Risks Related to Ownership of Our Common Stock</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>The market price of our common stock may be highly volatile, and you could lose all or part of your investment.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The trading price of our common stock on Nasdaq is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">any delay in filing our NDAs for our hormone therapy drug candidates and any adverse development or perceived adverse development with respect to the FDA&#x2019;s review of the NDAs, including the FDA&#x2019;s issuance of a &#x201C;refusal to file&#x201D; letter or a request for additional information;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">changes in laws or regulations applicable to our products or proposed products, including clinical trial requirements for approvals;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">unanticipated serious safety concerns related to the use of our hormone therapy drug candidates;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">a decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">any delay of our phase 3 clinical trials for our hormone therapy drug candidates;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  47; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->44
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font-family: Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">adverse results or delays in clinical trials;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the inability to obtain adequate clinical supply for our hormone therapy drug candidates or the inability to do so at acceptable prices;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">adverse regulatory decisions;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the introduction of new products or technologies offered by us or our competitors;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the effectiveness of our or our potential strategic partners&#x2019; commercialization efforts;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">developments concerning our sources of manufacturing supply and any commercialization strategic partners;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the inability to effectively manage our growth;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">actual or anticipated variations in quarterly operating results;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the failure to meet or exceed the estimates and projections of the investment community;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the overall performance of the U.S. equity markets and general political and economic conditions;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">additions or departures of key scientific or management personnel;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">adverse market reaction to any indebtedness we may incur or securities we may issue in the future;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">sales of our common stock by us or our stockholders in the future;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">significant lawsuits, including patent or stockholder litigation;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">changes in the market valuations of similar companies;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">the trading volume of our common stock;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">increases in our common stock available for sale upon expiration of lock-up agreements;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">effects of natural or man-made catastrophic events or other business interruptions; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">other events or factors, many of which are beyond our control.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, the stock market in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, our executive officers, directors, holders of 5% or more of our stock, and their affiliates beneficially owned approximately 73% of our common stock on an as converted basis. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  48; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->45
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required annually to deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us with an attestation report on the effectiveness of internal control over financial reporting for future periods as required by Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will be limited to the value of their stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Some provisions of our charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Provisions in our articles of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult to remove our current management. These provisions in our articles of incorporation and bylaws include the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">authorizing the issuance of &#x201C;blank check&#x201D; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and thwart a takeover attempt;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">prohibiting cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="line-height: 106%; font-family: Times New Roman, Times, Serif; font-size: 10pt;">advance notice provisions in connection with stockholder proposals that may prevent or hinder any attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, we are subject to Nevada&#x2019;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits an &#x201C;interested stockholder&#x201D; from entering into a &#x201C;combination&#x201D; with a company, unless certain conditions are met. An &#x201C;interested stockholder&#x201D; is a person who, together with affiliates and associates, beneficially owns (or within the prior two years, did beneficially own) 10% or more of the corporation&#x2019;s capital stock entitled to vote.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 1B.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka003"></a>Unresolved Staff Comments</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">None.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 2.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka004"></a>Properties</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our corporate headquarters is located in Boca Raton, Florida, where we lease 33,124 square feet of office space pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and was subsequently amended on February 18, 2015, April 26, 2016 and October 4, 2016 to lease additional administrative space. The lease expires on October 31, 2021. The primary functions performed at this location are executive, administrative, accounting, treasury, marketing, and human resources. We believe that our current facility is in good working order and is capable of supporting our operations for the foreseeable future.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Value:  1; Sequence:  49; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->46
            <!-- Field: /Sequence -->
            &nbsp;</p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka005"></a>Item 3.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Legal Proceedings</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">From time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding that we believe would have a material effect on our business or financial condition.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka006"></a>Item 4.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Mine Safety Disclosures</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">Not applicable.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka007"></a>PART II</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka008"></a>Item 5.</b></font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Market for the Registrant&#x2019;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&nbsp;</b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><b>Market Information on Common Stock</b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Since October 9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol &#x201C;TXMD.&#x201D; From April 23, 2013 to October 6, 2017, our common stock was listed on the NYSE American under the symbol &#x201C;TXMD.&#x201D; Prior to that time, our common stock was quoted on the OTCQB. The following table sets forth for the periods indicated the high and low sales prices of our common stock on the NYSE American or Nasdaq, as applicable.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">High</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Low</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify; font-weight: bold;">2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 64%; text-align: justify;">Fourth Quarter</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">6.97</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">4.34</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Third Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">7.01</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">4.54</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Second Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">8.30</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.50</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">First Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">7.32</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">5.38</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify; font-weight: bold;">2016</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Fourth Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">7.48</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">4.39</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Third Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">8.72</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.18</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Second Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">9.29</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.20</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">First Quarter</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">10.17</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">5.69</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On February 20, 2018, there were approximately 208 record holders and as of February 9, 2018, there were approximately 20,119 beneficial owners of our common stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Dividends</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Historically, we have not paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as well as other factors deemed relevant by our board of directors.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Performance Graph </b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following line graph compares cumulative total shareholder return for the five years ended December 31, 2017 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, 2012 and includes reinvestment of dividends. Measurement points are at the last trading day of the fiscal years ended December 31, 2012, 2013, 2014, 2015, 2016 and 2017. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  50; Options:  NewSection; Value:  47; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->47
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: red; margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><img alt="(LINE GRAPH)" src="txmd10k001.jpg">&nbsp;</font>
    </p>
    <p style="color: red; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following line graph compares cumulative total shareholder return for the period beginning when our common stock became listed on the NYSE American exchange (April 23, 2013) and ended December 31, 2017 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on April 23, 2013 and includes reinvestment of dividends. Measurement points are April 23, 2013 and the last trading day of the fiscal years ended December 31, 2017, 2016, 2015, 2014 and 2013 and each of the following quarters ended therein beginning with the quarter ended June 30, 2013. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: red; margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><img alt="(LINE GRAPH)" src="txmd10k002.jpg">&nbsp;</b></font>
    </p>
    <p style="color: red; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  51; Value:  47; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->48
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The performance graphs shall not be deemed &#x201C;filed&#x201D; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange Act or the Securities Act.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka009"></a>Item 6.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Selected Financial Data</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following table sets forth selected consolidated financial and other data as of and for the periods indicated. You should read the following information together with the more detailed information contained in &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; and our consolidated financial statements and the related notes included elsewhere in this Annual Report. The consolidated statements of operations for the years ended December 31, 2017, 2016, and 2015 and the consolidated balance sheet data as of December 31, 2017 and 2016 are derived from our audited consolidated financial statements included in this Annual Report. The consolidated statements of operations for the years ended December 31, 2014 and 2013, and the consolidated balance sheet data as of December 31, 2015, 2014, and 2013, are derived from our audited consolidated financial statements not included in this Annual Report.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b>&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>(in thousands, except per share data)</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 8.65; text-indent: -8.65;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="18">Year Ended December 31,</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 8.65; text-indent: -8.65;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2014</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2013</td>
            <td style="padding-bottom: 1pt; font-weight: bold;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 8.65; text-indent: -8.65;">&nbsp;</td>
            <td>&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td colspan="2">&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65; font-weight: bold;">Consolidated Statements of Operations Data:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; width: 35%; text-align: left; text-indent: -8.65;">Revenue, net</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">16,778</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">19,356</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">20,143</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">15,026</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">8,776</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 8.65; text-align: left; text-indent: -8.65;">Cost of goods sold</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">2,637</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">4,185</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">4,506</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">3,672</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">1,960</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 8.65; text-align: left; text-indent: -8.65;">Gross profit</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">14,141</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">15,171</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">15,637</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">11,354</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">6,816</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Operating expenses:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Sales, general, and administration</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">57,703</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">51,348</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">28,721</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">22,124</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">19,015</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Research and development</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">33,853</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">53,943</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">72,043</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">43,219</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">13,551</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 8.65; text-align: left; text-indent: -8.65;">Depreciation and amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">213</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">133</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">63</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">52</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">58</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 8.65; text-align: left; text-indent: -8.65;">Total operating expense</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">91,769</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">105,424</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">100,827</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">65,395</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">32,624</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Operating loss</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(77,628</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(90,253</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(85,190</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(54,041</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(25,808</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 8.65; text-align: left; text-indent: -8.65;">Other income (expense), net</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">703</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">378</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">113</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(176</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(2,611</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 8.65; text-align: left; text-indent: -8.65;">Net loss</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(76,925</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(89,875</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(85,077</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(54,217</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(28,419</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Net loss per share, basic and diluted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.37</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.46</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.49</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.36</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.22</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Weighted average number of common&nbsp;shares outstanding, basic and diluted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">205,523</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">196,088</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">173,174</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">149,727</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">127,570</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-indent: -8.65;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65; font-weight: bold;">Consolidated Balance Sheet Data (at end of period)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Total assets</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">143,230</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">142,472</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">73,729</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">59,079</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">62,016</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Total liabilities</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">13,321</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">14,983</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">10,666</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">10,690</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">7,318</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Total stockholders&#x2019; equity</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">129,909</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">127,489</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">63,063</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">48,389</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">54,698</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65; font-weight: bold;">Other Data:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Capital expenditures (for the period)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">827</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">1,241</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">584</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">617</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">480</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 8.65; text-align: left; text-indent: -8.65;">Working capital (at the end of period)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">126,233</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">124,428</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">60,014</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">45,545</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">52,085</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  52; Value:  47; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->49
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka010"></a>Item 7.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><i>You should read the following discussion and analysis in conjunction with the information set forth under &#x201C;Selected Financial Data&#x201D; and our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See &#x201C;Statement Regarding Forward-Looking Information.&#x201D; Our actual results may differ materially from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties described under &#x201C;Risk Factors&#x201D; elsewhere in this Annual Report.</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Company Overview</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. With our SYMBODA&#x2122; technology, we are developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Research and Development &#x2013; Overview</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have submitted two new drug applications, or NDAs, with the U.S. Food and Drug Administration, or FDA, for our hormone therapy drug candidates. In December 2017, we submitted the NDA for TX-001HR, our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of vasomotor symptoms, or VMS, due to menopause in menopausal women with an intact uterus. In November 2017, we re-submitted our NDA for TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy, or VVA, in menopausal women with vaginal linings that do not receive enough estrogen. The NDA for our TX-004HR drug candidate has a Prescription Drug User Fee Act, or PDUFA, target action date for the completion of the FDA&#x2019;s review of May 29, 2018, and if approved on that date, the drug candidate could be launched as early as the third quarter of 2018. If the NDA for our TX-001HR drug candidate is accepted by the FDA, it could be approved as soon as the fourth quarter of 2018 and launched in 2019.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>TX-001HR</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-001HR is our bio-identical hormone therapy combination of 17&#xDF;- estradiol and progesterone in a single, oral softgel drug candidate for the treatment of moderate to severe VMS due to menopause, including hot flashes, night sweats and sleep disturbances in menopausal women with an intact uterus. The hormone therapy drug candidate is bioidentical to, or having the same chemical and molecular structure as, the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We previously conducted a pharmacokinetics, or PK, study of TX-001HR to demonstrate that our drug candidate is bioequivalent to the reference listed drug based on the criterion that the 90% confidence interval on the test-to-reference ratio is contained entirely within the interval 80% to 125%. The study compared our combined capsule TX-001HR of 2 mg estradiol and 200 mg of progesterone to 2 mg of Estrace<sup>&#xAE;</sup> and 200 mg of Prometrium<sup>&#xAE;</sup>.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The study compared the mean plasma concentrations for free estradiol between TX-001HR and Estrace<sup>&#xAE;</sup> in 62 female test subjects. When the results of a single dose-fed study were compared over 48 hours by the test drug versus reference drug, the ratio was 0.93 with the standard deviation within the subject being 0.409 for an upper 95% confidence bound of -0.089. The maximum plasma concentration levels of free estradiol showed that the drug -versus -reference drug ratio was 0.88 with the standard deviation within the subject being 0.344 for an upper 95% confidence bound of -0.040 over 48 hours.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The study also compared the mean plasma concentrations for progesterone between TX-001HR and Prometrium<sup>&#xAE;</sup> in 62 female test subjects. When the results were compared over 48 hours of the test that the drug-versus-reference drug, the ratio was 1.05 with the standard deviation within the subject being 0.956 for an upper 95% confidence bound of -0.542. The maximum plasma concentration levels of progesterone showed drug versus reference drug ratio as 1.16 with the standard deviation within the subject being 1.179 for an upper 95% confidence bound of -0.785 over 48 hours.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  53; Value:  47; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->50
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On September 5, 2013, we began enrollment in the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, phase 3 clinical trial of TX-001HR in menopausal women with an intact uterus. The trial was designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe VMS due to menopause and the endometrial safety of TX-001HR. Patients were assigned to one of five arms, four active and one placebo, and received study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia was an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe VMS was the mean change of frequency and severity of moderate to severe VMS at weeks four and 12 compared to placebo, as measured by the number and severity of hot flashes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flashes at screening were included in the VMS analysis, while all subjects were included in the endometrial hyperplasia analysis. The secondary endpoints included reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. The trial evaluated 1,835 patients between 40 and 65 years old at 111 sites. On December 5, 2016, we announced positive topline data for the REPLENISH Trial.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The REPLENISH Trial evaluated four doses of TX-001HR and placebo; the doses studied were:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 1 mg/progesterone 100 mg (n = 416) </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 0.5 mg/progesterone 100 mg (n = 423) </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 0.5 mg/progesterone 50 mg (n = 421) </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">17&#xDF;-estradiol 0.25 mg/progesterone 50 mg (n = 424) </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Placebo (n = 151) </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The REPLENISH Trial results demonstrated:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both achieved all four of the co-primary efficacy endpoints and the primary safety endpoint.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both demonstrated a statistically significant and clinically meaningful reduction from baseline in both the frequency and severity of hot flashes compared to placebo.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; TX-001HR estradiol 0.5 mg/progesterone 50 mg and TX-001HR estradiol 0.25 mg/progesterone 50 mg were not statistically significant at all of the co-primary efficacy endpoints. The estradiol 0.25 mg/progesterone 50 mg dose was included in the clinical trial as a non-effective dose to meet the recommendation of the FDA guidance to identify the lowest effective dose.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF; The incidence of consensus endometrial hyperplasia or malignancy was 0 percent across all four TX-001HR doses, meeting the recommendations established by the FDA&#x2019;s draft guidance.</font>
    </p>
    <p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As outlined in the FDA guidance, the co-primary efficacy endpoints in the REPLENISH Trial were the change from baseline in the number and severity of hot flashes at weeks four and 12 as compared to placebo. The primary safety endpoint was the incidence of endometrial hyperplasia with up to 12 months of treatment. General safety was also evaluated.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  54; Value:  47; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->51
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The results of the REPLENISH Trial are summarized in the table below (p-values of &lt; 0.05 meet FDA guidance and support evidence of efficacy):</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="border-left: black 1pt solid; border-right: black 1pt solid; border-top: black 1pt solid; padding-left: 5pt; padding-right: 5pt; padding-top: 10pt; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Replenish Trial Co-Primary Efficacy Endpoints: Mean Change in Frequency and Severity of Hot Flashes Per Week Versus Placebo at Weeks 4 and 12, VMS-MITT Population</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt; width: 36%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; width: 16%; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Estradiol/Progesterone</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">1 mg/100 mg</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.5 mg/100 mg</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.5 mg/50 mg</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.25 mg/50 mg</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">Placebo</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 141)</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 149)</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 147)</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">(n = 154)</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">(n = 135)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Frequency</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 4 P-value versus placebo</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.013</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.141</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.001</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 12 P-value versus placebo</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0.002</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Severity</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 4 P-value versus placebo</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.031</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.005</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.401</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.100</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Week 12 P-value versus placebo</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">&lt;0.001</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.018</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">0.096</font>
            </td>
            <td style="border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">&#x2014;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; border-top: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-top: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-right: black 1pt solid; border-top: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-left: black 1pt solid; border-right: black 1pt solid; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Replenish Trial Primary Safety Endpoint: Incidence of Consensus Endometrial Hyperplasia or Malignancy up to 12 months, Endometrial Safety Population&#x166;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top;">
            <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt;">
                <font style="font-size: 10pt;">Endometrial Hyperplasia</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/280)</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/303)</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/306)</font>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/274)</font>
            </td>
            <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center;">
                <font style="font-size: 10pt;">0% (0/92)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">MITT = Modified intent to treat</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#x166;Per FDA, consensus hyperplasia refers to the concurrence of two of the three pathologists be accepted as the final diagnosis</p>
    <p style="margin: 0pt 31.55pt 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We submitted the NDA for TX-001HR with the FDA on December 28, 2017. Assuming that the NDA is accepted 74 days thereafter and an FDA review period of ten months from the receipt date to the PDUFA target action date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2018.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-002HR</i></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board, or IRB, approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we suspended enrollment and in October 2014 we stopped the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. Our IND related to TX-002HR is currently in inactive status. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it. We have currently suspended further development of this drug candidate to prioritize our leading drug candidates.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-003HR</i></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-003HR is a natural estradiol formulation. This hormone therapy drug candidate is bioidentical to the hormones that naturally occur in a woman&#x2019;s body. We currently do not have plans to further develop this hormone therapy drug candidate. Our IND related to TX-003HR is currently inactive.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-004HR</i></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-004HR is our applicator free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of VVA in menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, and it will have an added advantage of being a more simple, easier to use dosage form versus traditional VVA treatments. We initiated the REJOICE Trial, a randomized, multicenter, double-blind, placebo-controlled phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of three doses &#x2013; 25 mcg, 10 mcg and 4 mcg (compared to placebo) &#x2013; of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  55; Options:  NewSection; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->52
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On November 10, 2015, the FDA held a scientific workshop on labeling &#x201C;lower&#x201D; dose estrogen-alone products for symptoms of VVA to provide an opportunity for the FDA to obtain input from experts on several topics related to the product label of lower dose estrogen-alone products approved solely for the treatment of moderate to severe symptoms of VVA due to menopause. According to the FDA, lower-dose estrogen products means products that contain less than the 0.625 mg of conjugated estrogens used in the WHI study and estradiol products containing 0.0375 mg and below. Discussion topics at the workshop included the relevance of the boxed warnings based on data from the WHI to the lower dose estrogen-alone products; certain members in the scientific/medical community have questioned whether the boxed warnings section in the labeling, which is currently required to be included on all estrogen products, is applicable in whole or in part to these lower-dose estrogen products. The boxed warnings include: (1) an increased risk of endometrial cancer in women with a uterus who uses unopposed estrogens, (2) estrogen therapy with or without progestins should not be used for the prevention of cardiovascular disease or dementia, (3) an increased risk of stroke and deep vein thrombosis (DVT) in women treated with estrogen-alone, (4) an increased risk of probable dementia in post-menopausal women 65 years of age and older treated with estrogen-alone, (5) an increased risk of invasive breast cancer in women treated with estrogen plus progestin, and (6) to use the lowest effective dose for the shortest duration. It is unknown at this time what, if any, changes the FDA may propose with respect to the boxed warnings on lower dose estrogen-alone products for symptoms of VVA or whether such label changes would be applicable to TX-004HR, if approved.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On December 7, 2015, we announced positive top-line results from the REJOICE Trial. The pre-specified four co-primary efficacy endpoints were the changes from baseline to week 12 versus placebo in the percentage of vaginal superficial cells, percentage of vaginal parabasal cells, vaginal pH and severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA. The trial enrolled 764 menopausal women (40 to 75 years old) experiencing moderate to severe dyspareunia at approximately 89 sites across the United States and Canada. Trial participants were randomized to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg (n=191) doses or placebo (n=192) for a total of 12 weeks, all administered once daily for two weeks and then twice weekly (approximately three to four days apart) for ten weeks.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The following table sets forth the statistical significance of the REJOICE Trial results for the four pre-specified co-primary efficacy endpoints, based on mean changes from baseline to week 12 compared to placebo.&nbsp; Based on our analyses of the REJOICE Trial data, statistical significance of the results for the co-primary endpoint of severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA has improved for all three doses from the results originally reported.</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;"><b>25 mcg</b></font>
            </td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;"><b>10 mcg</b></font>
            </td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;"><b>4 mcg</b></font>
            </td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff;">
            <td style="padding-left: 8.8pt; width: 67%; vertical-align: top; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Superficial Cells</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 8%; vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 8%; vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="width: 8%; vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="width: 1%; vertical-align: bottom; text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="background-color: white;">
            <td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Parabasal Cells</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff;">
            <td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Vaginal pH</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="background-color: white;">
            <td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Severity of Dyspareunia</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: right;">
                <font style="font-size: 10pt;">P = 0.0149</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The 25 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level. The FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial.</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">Statistical improvement over placebo was also observed for all three doses at the first assessment at week two and sustained through week 12 (see table below).</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 43%;">&nbsp;</td>
            <td style="width: 4%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 9%; text-align: center;">
                <font style="font-size: 10pt;"><b>25 mcg</b></font>
            </td>
            <td style="width: 9%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 9%; text-align: center;">
                <font style="font-size: 10pt;"><b>10 mcg</b></font>
            </td>
            <td style="width: 9%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 9%; text-align: center;">
                <font style="font-size: 10pt;"><b>4 mcg</b></font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff;">
            <td style="padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Week 2</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.0105</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.0019</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.026&nbsp;&nbsp;</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white;">
            <td style="padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Week 6</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.0009</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.0069</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff;">
            <td style="padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Week 8</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.0003</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white;">
            <td style="padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt;">
                <font style="font-size: 10pt;">Week 12</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P &lt; 0.0001</font>
            </td>
            <td>&nbsp;</td>
            <td style="padding-left: 8.8pt; text-align: center;">
                <font style="font-size: 10pt;">P = 0.0149</font>
            </td>
            <td>&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Vaginal dryness was a prespecified key secondary endpoint. The 25 mcg and 10 mcg doses of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoint of vaginal dryness. The 4 mcg dose of TX-004HR demonstrated statistically significant results at the p = 0.0014 level compared to placebo (see table below).</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2">
                <font style="font-size: 10pt;"><b>25 mcg</b></font>
            </td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2">
                <font style="font-size: 10pt;"><b>10 mcg</b></font>
            </td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2">
                <font style="font-size: 10pt;"><b>4 mcg</b></font>
            </td>
        </tr>
        <tr style="background-color: #cceeff;">
            <td style="padding-left: 8.8pt; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Severity of Vaginal Dryness </font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;">P&nbsp;&lt;&nbsp;0.0001</font>
            </td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;">P&nbsp;=&nbsp;0.0014</font>
            </td>
        </tr>
        <tr style="background-color: white;">
            <td style="width: 44%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 16%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 16%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 16%;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The pharmacokinetic data for all three doses demonstrated negligible to very low systemic absorption of 17 beta estradiol, estrone and estrone conjugated, supporting the previous phase 1 trial data. TX-004HR was well tolerated, and there were no clinically significant differences compared to placebo-treated participants with respect to adverse events. There were no drug-related serious adverse events reported.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  56; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->53
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">We submitted the NDA for TX-004HR with the FDA on July 7, 2016. The FDA determined that the NDA was sufficiently complete to permit a substantive review and accepted the NDA for filing with the PDUFA target action date for the completion of the FDA&#x2019;s review of May 7, 2017. The NDA submission was supported by the complete TX-004HR clinical program, including positive results of the phase 3 REJOICE Trial. The NDA submission included all three doses of TX-004HR (4 mcg, 10 mcg and 25 mcg) that were evaluated in the REJOICE Trial.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On May 5, 2017, we received a CRL from the FDA regarding the NDA for TX-004HR. In the CRL, the only approvability concern raised by the FDA was the lack of long-term safety data for TX-004HR beyond the 12 weeks studied in the phase 3 REJOICE Trial. The CRL did not identify any issues related to the efficacy of TX-004HR and did not identify any approvability issues related to chemistry, manufacturing and controls.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On June 14, 2017, we participated in a Type A Post-Action Meeting with the Division of Bone, Reproductive, and Urologic Products (DBRUP) of the FDA to discuss the CRL. At the meeting, we presented information that we believed could address concerns raised by the FDA in the CRL. On July 5, 2017, we received the official minutes of the meeting from the FDA, which provided the FDA&#x2019;s response to the information presented at the Type A meeting. Per the FDA&#x2019;s request, we formally submitted the information presented at the Type A meeting for consideration related to the NDA for TX-004HR.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On August 3, 2017, we received a formal General Advice Letter from the FDA stating that an initial review of this information has been completed and requesting that we submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18, 2017. On September 14, 2017, we submitted the additional endometrial safety information that was requested by the FDA in the General Advice Letter to the NDA for TX-004HR. The submission included a comprehensive, systematic review of the medical literature on the use of vaginal estrogen products and the risk of endometrial hyperplasia or cancer, including the safety data from the recently published Women&#x2019;s Health Initiative Observational Study, or WHI Study, of vaginal estrogen use in post-menopausal women and information on the relevance of the first uterine pass effect for low-dose vaginal estrogen products. The WHI Study demonstrated no significant difference in the risk of invasive breast cancer, stroke, colorectal cancer, endometrial cancer and venous thromboembolism in vaginal estrogen users versus non-users. The WHI Study also shows that, among women with an intact uterus, there was a decreased risk of cardiovascular disease, hip fracture and all-cause mortality in vaginal estrogen users versus non-users. The WHI Study evaluated over 4,000 women who used vaginal estrogens for a median duration of two to three years.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On November 3, 2017, we participated in an in-person meeting with DBRUP. At the meeting, DBRUP agreed to the resubmission of the NDA for the 4 mcg and 10 mcg doses of TX-004HR without the need for an additional pre-approval study.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On November 29, 2017, we resubmitted the NDA for the 4 mcg and 10 mcg doses of TX-004HR with the&nbsp;FDA. We have committed to conduct a post-approval observational study. The&nbsp;FDA&nbsp;has acknowledged that the resubmission is a complete, class 2 response to the CRL received on&nbsp;May 5, 2017&nbsp;for TX-004HR. The PDUFA target action date for the completion of the&nbsp;FDA&#x2019;s&nbsp;review is&nbsp;May 29, 2018. If approved, the 4 mcg formulation of TX-004HR would represent a lower effective dose than the currently available VVA therapies approved by the FDA.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Research and Development Expenses</b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A significant portion of our operating expenses to date have been incurred in research and development activities. Research and development expenses relate primarily to the discovery and development of our drug products. Our business model is dependent upon our company continuing to conduct a significant amount of research and development. &#x201C;Other research and development&#x201D; costs in the table below consist of products costs incurred prior to IND approval from the FDA as well as other clinical and regulatory consulting costs. Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, investigative sites, and consultants that conduct our clinical trials and a substantial portion of our preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls capabilities, and acquiring clinical trial materials; and costs associated with other research activities and regulatory approvals.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  57; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->54
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We make payments to the CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future research and development activities were $0, $228,933 and $1,138,073, at December 31, 2017, 2016 and December 31, 2015, respectively.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following table indicates our research and development expense by project for the periods indicated:</p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 61%; text-align: justify;">TX-001HR</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">19,381</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">31,857</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">33,227</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">TX-002HR</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">23</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">TX-004HR</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">8,043</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">9,248</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">19,574</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">Other research and development</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">6,429</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">12,838</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">19,219</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">Total research and development</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">33,853</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">53,943</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">72,043</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development expenditures will continue to be incurred as we continue development of our drug candidates and advance the development of our proprietary pipeline of novel drug candidates. We expect to incur ongoing research and development costs as we develop our drug pipeline, continue stability testing and validation on our drug candidates, prepare regulatory submissions and work with regulatory authorities on existing submissions.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2017 and since the project&#x2019;s inception in February 2013, we have incurred approximately $19,381,000 and $115,397,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2017 and since the project&#x2019;s inception in April 2013, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2017 and since the project&#x2019;s inception in August 2014, we have incurred approximately $8,043,000 and $40,849,000, respectively, in research and development costs with respect to TX-004HR, our vaginal estradiol softgel drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The costs of clinical trials may vary significantly over the life of a project owing to factors that include, but are not limited to, the following: per patient trial costs; the number of patients that participate in the trials; the number of sites included in the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients; the amount of time required to recruit patients for the trial; the duration of patient follow-up; and the efficacy and safety profile of the drug candidate. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory testing, regulatory submission and response work.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  58; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->55
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Results of Operations</b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><i>Comparison of Years Ended December 31, 2017, 2016, and 2015:</i></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Year ended December 31, 2017 compared with year ended December 31, 2016</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Years Ended December 31,</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2017</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2016</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">Change</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">
                <font style="font-size: 10pt;">(000s)</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 61%; text-align: justify;">
                <font style="font-size: 10pt;">Revenue</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">16,778</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">19,356</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">(2,578</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Cost of goods sold</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">2,637</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">4,185</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(1,548</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">
                <font style="font-size: 10pt;">Operating expenses</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">91,769</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">105,424</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">(13,655</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify;">Operating loss</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(77,628</font>
            </td>
            <td>
                <font style="font-size: 10pt;">)</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(90,253</font>
            </td>
            <td>
                <font style="font-size: 10pt;">)</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">12,625</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Other income</font>
            </td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">703</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">378</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">325</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">
                <font style="font-size: 10pt;">Net loss</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">(76,925</font>
            </td>
            <td style="padding-bottom: 2pt;">
                <font style="font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">(89,875</font>
            </td>
            <td style="padding-bottom: 2pt;">
                <font style="font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">12,950</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Revenue</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Revenue for the year ended December 31, 2017 decreased by approximately $2,578,000, or 13%, to approximately $16,778,000, compared with approximately $19,356,000 for the year ended December 31, 2016. This decrease was attributable to a decrease in the average net revenue per unit of our products, primarily related to higher coupons in 2017 due to implementation of a new point of sale coupon system, partially offset by a slight increase in the number of units sold.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Cost of Goods Sold</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Cost of goods sold decreased by approximately $1,548,000, or 37%, to approximately $2,637,000 for the year ended December 31, 2017, compared with approximately $4,185,000 for the year ended December 31, 2016 primarily related to lower distribution costs. Our gross margins was 84% for the year ended December 31, 2017 as compared to 78% for the year ended December 31, 2016. The increase in gross margin percentage was primarily attributable to the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors which, among other things, lowered the cost to package, prepare and deliver our products to customers.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Expenses</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our principal operating costs included the following items as a percentage of total operating expenses.</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 54%; text-align: left;">Human resource related costs</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">27</td>
            <td style="width: 1%; text-align: left;">%</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">23</td>
            <td style="width: 1%; text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Sales and marketing costs, excluding human resource costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">22</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">12</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Product research and development costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">37</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">51</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Professional fees and consulting costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Other operating expenses</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">8</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">9</td>
            <td style="text-align: left;">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  59; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->56
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Operating expenses decreased by approximately $13,655,000, or 13%, to approximately $91,769,000 for the year ended December 31, 2017, compared with approximately $105,424,000 for the year ended December 31, 2016, as a result of the following items:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Years Ended December 31,</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2017</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2016</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">Change</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">
                <font style="font-size: 10pt;">(000s)</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 61%; text-align: justify;">
                <font style="font-size: 10pt;">Research and development costs</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">33,853</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">53,943</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">(20,090</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Human resource related costs</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">24,720</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">24,599</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">121</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Sales and marketing, excluding human resource costs</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">19,614</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">12,753</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">6,861</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Professional and consulting costs</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">5,859</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">5,301</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">558</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">
                <font style="font-size: 10pt;">Other operating expenses</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">7,723</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">8,828</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">(1,105</font>
            </td>
            <td style="padding-bottom: 1pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">
                <font style="font-size: 10pt;">Total operating expenses</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">91,769</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">105,424</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">(13,655</font>
            </td>
            <td style="padding-bottom: 2pt;">
                <font style="font-size: 10pt;">)&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development costs for the year ended December 31, 2017 decreased by approximately $20,090,000, or 37%, to approximately $33,853,000, primarily as a result of a decrease in costs related to our phase 3 clinical trials of TX-001HR and TX-004HR, partially offset by scale-up and manufacturing activities for our phase 3 clinical trials of TX-001HR and TX-004HR and costs related to regulatory submission related to TX-001HR. Research and development costs in 2017 included approximately a $2,400,000 in NDA submission fees related to TX-001HR and a write-off of approximately $1,000,000 of prepaid manufacturing costs. Research and developments costs during the year ended December 31, 2017 included the following research and development projects:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2017 and since the project&#x2019;s inception in February 2013, we have incurred approximately $19,381,000 and $115,397,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2017 and since the project&#x2019;s inception in April 2013, we have incurred approximately $0 and 2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2017 and since the project&#x2019;s inception in August 2014, we have incurred approximately $8,043,000 and $40,849,000, respectively, in research and development costs with respect to TX-004HR, our vaginal estradiol softgel drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business.&#x201D; For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; &#x201C;Item 1. Business &#x2014; Products in Development&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation.&#x201D; Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Human resource related costs, including salaries and benefits, increased by approximately $121,000, or 0.5%, to approximately $24,720,000 for the year ended December 31, 2017, compared with approximately $24,599,000 for the year ended December 31, 2016, primarily as a result of an increase of approximately $5,750,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our hormone therapy drug candidates, partially offset by a decrease in non-cash compensation expense included in this category of approximately $5,629,000 related to employee stock option amortization during 2017 as compared to 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Sales and marketing costs increased by approximately $6,861,000, or 54%, to approximately $19,614,000 for the year ended December 31, 2017, compared with approximately $12,753,000 for the year ended December 31, 2016, primarily as a result of increased expenses in the first half of 2017 associated with sales and marketing efforts to support commercialization of our hormone therapy drug candidates, which were curtailed in the third quarter of 2017 due to the status of the NDA for TX-004HR, higher costs related to outsourced sales personnel and their related expenses which started in the fourth quarter of 2016, together with an increase in employee incentives.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Professional and consulting costs increased by approximately $558,000, or 11%, for the year ended December 31, 2017, to approximately $5,859,000 compared with approximately $5,301,000 for the year December 31, 2016, primarily as a result of result of increased legal and other professional expenses, partially offset by a decrease in consulting and accounting expenses.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  60; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->57
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">All other costs decreased by approximately $1,105,000, or 13%, to approximately $7,723,000 for the year ended December 31, 2017, compared with approximately $8,828,000 for the year ended December 31, 2016, primarily as a result of a decrease in write-off of accounts receivable balances of approximately $2,200,000, which occurred in 2016, partially offset by an increase in rent, information technology, insurance, and other office expenses in 2017.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Loss</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the foregoing, our operating loss decreased approximately $12,625,000, or 14%, to approximately $77,628,000 for the year ended December 31, 2017, compared with approximately $90,253,000 for the year ended December 31, 2016, primarily as a result of decreased research and development expenses, non-cash compensation expense and other expenses, partially offset by increased sales and marketing expenses associated with sales and marketing efforts to support commercialization of our hormone therapy drug candidates and higher personnel costs.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Other Income </i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Other non-operating income increased by approximately $325,000, or 86%, to approximately $703,000 for the year ended December 31, 2017 compared with approximately $378,000 for the comparable period in 2016, primarily as a result of increased interest income.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Net Loss</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the net effects of the foregoing, net loss decreased approximately $12,950,000, or 14%, to approximately $76,925,000 for the year ended December 31, 2017, compared with approximately $89,875,000 for the year ended December 31, 2016. Net loss per share of common stock, basic and diluted, was ($0.37) for the year ended December 31, 2017, compared with ($0.46) per share of common stock for the year ended December 31, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Year ended December 31, 2016 compared with year ended December 31, 2015</u></i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Years Ended December 31,</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2016</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2015</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">Change</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">
                <font style="font-size: 10pt;">(000s)</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 61%; text-align: justify;">
                <font style="font-size: 10pt;">Revenue</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">19,356</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">20,143</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">(787</font>
            </td>
            <td style="width: 1%;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Cost of goods sold</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">4,185</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">4,506</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(321</font>
            </td>
            <td>)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: justify;">
                <font style="font-size: 10pt;">Operating expenses</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">105,424</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">100,827</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">4,597</font>
            </td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: justify;">Operating loss</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(90,253</font>
            </td>
            <td>
                <font style="font-size: 10pt;">)</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(85,190</font>
            </td>
            <td>
                <font style="font-size: 10pt;">)</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">(5,063</font>
            </td>
            <td>
                <font style="font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Other income</font>
            </td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">378</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">113</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">265</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">
                <font style="font-size: 10pt;">Net loss</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">(89,875</font>
            </td>
            <td style="padding-bottom: 2pt;">
                <font style="font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">(85,077</font>
            </td>
            <td style="padding-bottom: 2pt;">
                <font style="font-size: 10pt;">)</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; text-align: right;">
                <font style="font-size: 10pt;">(4,798</font>
            </td>
            <td style="padding-bottom: 2pt;">
                <font style="font-size: 10pt;">)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Revenue</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Revenue for the year ended December 31, 2016 decreased by approximately $787,000, or 4%, to approximately $19,356,000, compared with approximately $20,143,000 for the year ended December 31, 2015. This decrease was primarily attributable to a decrease in the average net revenue per unit of our products primarily related to higher estimates related to discounts and returns in 2016, and the reversal of the deferred revenue balance in the first quarter of 2015 related to products sold through wholesale distributors until the right of return no longer existed, partially offset by an increase in the number of units sold.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Cost of Goods Sold</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Cost of goods sold decreased by approximately $321,000, or 7%, to approximately $4,185,000 for the year ended December 31, 2016, compared with approximately $4,506,000 for the year ended December 31, 2015 primarily related to lower distribution costs and more favorable product mix of our products sold, partially offset by the reversal of the deferred balance in the first quarter of 2015 related to products sold through wholesale distributors until the right of return no longer existed. Our gross margins of 78% for the year ended December 31, 2016 remained unchanged from the year ended December 31, 2015.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  61; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->58
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Expenses</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our principal operating costs included the following items as a percentage of total operating expenses.</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 74%; text-align: justify;">Human resource related costs</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">23</td>
            <td style="width: 1%; text-align: left;">%</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">15</td>
            <td style="width: 1%; text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Sales and marketing costs, excluding human resource costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">12</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Product research and development costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">51</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">71</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Professional fees and consulting costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Other operating expenses</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">9</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4</td>
            <td style="text-align: left;">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Operating expenses increased by approximately $4,597,000, or 5%, to approximately $105,424,000 for the year ended December 31, 2016, compared with approximately $100,827,000 for year ended December 31, 2015, as a result of the following items:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">
                <font style="font-size: 10pt;">Years Ended December 31,</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2016</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">2015</font>
            </td>
            <td style="text-align: center;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">
                <font style="font-size: 10pt;">Change</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">
                <font style="font-size: 10pt;">(000s)</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 61%; text-align: justify;">
                <font style="font-size: 10pt;">Research and development costs</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">53,943</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">72,043</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="width: 10%; text-align: right;">
                <font style="font-size: 10pt;">(18,100</font>
            </td>
            <td style="width: 1%;">
                <font style="font-size: 10pt;">)</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Human resource related costs</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">24,599</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">14,966</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">9,633</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Sales and marketing, excluding human resource costs</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">12,753</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">5,920</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">6,833</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Professional and consulting costs</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">5,301</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">3,649</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-size: 10pt;">1,652</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Other operating expenses</font>
            </td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">8,828</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">4,249</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: right;">
                <font style="font-size: 10pt;">4,579</font>
            </td>
            <td>&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Total operating expenses</font>
            </td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 2.25pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: black 2.25pt double; text-align: right;">
                <font style="font-size: 10pt;">105,424</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 2.25pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: black 2.25pt double; text-align: right;">
                <font style="font-size: 10pt;">100,827</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: black 2.25pt double;">
                <font style="font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: black 2.25pt double; text-align: right;">
                <font style="font-size: 10pt;">4,597</font>
            </td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development costs for the year ended December 31, 2016 decreased by approximately $18,100,000, or 25%, to approximately $53,943,000, primarily as a result of a decrease in costs related to our phase 3 clinical trials of TX-001HR and TX-004HR, partially offset by scale-up and manufacturing activities for our phase 3 clinical trials of TX-001HR and TX-004HR and costs related to regulatory submission related to TX-004HR. Research and developments costs during the year ended December 31, 2016 included the following research and development projects:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2016 and since the project&#x2019;s inception in February 2013, we have incurred approximately $31,857,000 and $96,016,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2016 and since the project&#x2019;s inception in April 2013, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2016 and since the project&#x2019;s inception in August 2014, we have incurred approximately $9,248,000 and $32,806,000, respectively, in research and development costs with respect to TX-004HR, our vaginal estradiol softgel drug candidate.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business.&#x201D; For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; &#x201C;Item 1. Business &#x2014; Products in Development&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation.&#x201D; Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  62; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->59
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Human resource related costs, including salaries and benefits, increased by approximately $9,633,000, or 64%, to approximately $24,599,000 for the year ended December 31, 2016, compared with approximately $14,966,000 for the year ended December 31, 2015, primarily as a result of an increase of approximately $3,492,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our hormone therapy drug candidates and an increase in non-cash compensation expense included in this category of approximately $6,141,000 related to employee stock option amortization during 2016 as compared to 2015.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Sales and marketing costs increased approximately $6,833,000 for the year ended December 31, 2016, or 115%, to approximately $12,753,000, compared with approximately $5,920,000 for the year ended December 31, 2015, primarily as a result of increased expenses associated with sales and marketing efforts to support commercialization of our hormone therapy drug candidates coupled with an increase in employee incentives.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Professional and consulting costs increased approximately $1,652,000 for the year ended December 31, 2016, or 45%, to approximately $5,301,000 compared with approximately $3,649,000 for the year December 31, 2015, primarily as a result of increased legal, consulting, accounting expenses.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">All other costs increased approximately $4,579,000, or 108%, to approximately $8,828,000 for the year ended December 31, 2016, compared with approximately $4,249,000 for the year ended December 31, 2015, primarily as a result of a write-off of accounts receivable balances of approximately $2,200,000, increased insurance, rent, information technology and other office expenses.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Operating Loss</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the foregoing, our operating loss increased approximately $5,063,000, or 6%, to approximately $90,253,000 for the year ended December 31, 2016, compared with approximately $85,190,000 for the year ended December 31, 2015, primarily as a result of increased personnel costs, sales and marketing expenses to support commercialization of our hormone therapy drug candidates, coupled with a write-off of accounts receivable balances mentioned above and an increase in non-cash compensation expense, professional fees and other operating expenses as well a decrease in revenue, partially offset by a decrease in research and development costs.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Other Income </i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Other non-operating income increased by approximately $265,000, or 235%, to approximately $378,000 for the year ended December 31, 2016 compared with approximately $113,000 for the comparable period in 2015, primarily as a result of increased interest income.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Net Loss</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the net effects of the foregoing, net loss increased approximately $4,798,000, or 6%, to approximately $89,875,000 for the year ended December 31, 2016, compared with approximately $85,077,000 for the year ended December 31, 2015. Net loss per share of common stock, basic and diluted, was ($0.46) for the year ended December 31, 2016, compared with ($0.49) per share of common stock for the year ended December 31, 2015.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Liquidity and Capital Resources</b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities. For the three-year period ending December 31, 2017, we received approximately $294,811,000 in net proceeds from the issuance of shares of our common stock. As of December 31, 2017, we had a cash balance of approximately $127,136,000, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of 12,400,000 shares of our common stock at a price of $5.55 per share. The net proceeds to us from the offering were approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued 12,400,000 shares of our common stock. We intend to use a majority of the net proceeds from this offering to fund pre-commercialization and commercialization activities for our TX-004HR and TX-001HR drug candidates. We currently intend to fund the next phase of our pre-commercialization and commercialization expenses for our TX-004HR and TX-001HR drug candidates through debt financing and are currently engaged in discussions to secure debt financing commitments. If we are successful in obtaining these commitments, we currently anticipate we would begin to draw on them following approval of either TX-004HR or TX-001HR.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  63; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->60
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For the fiscal year ended December 31, 2017, our days sales outstanding, or DSO, was 97 days compared to 92 days for the year ended December 31, 2016. The increase in our DSO as of December 31, 2017 was partially related to implementation of a new point of sale coupon system which lowered our revenues, as well as to the timing of payments received from our customers subsequent to December 31, 2017. We anticipate that our DSO will fluctuate in the future based upon a variety of factors, including longer payment terms associated with the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors, as compared to the terms previously provided to our retail pharmacy distributors, changes in the healthcare industry and specific terms that may be extended in connection with the launch of our hormone therapy drug candidates, if approved.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We believe that our existing cash will allow us to fund our operating plan through at least the next 12 months from the date of this Annual Report. &nbsp;However, if the commercialization of our hormone therapy drug candidates is delayed, our existing cash may be insufficient to satisfy our liquidity requirements until we are able to commercialize our hormone therapy drug candidates. &nbsp;If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing and other pre-commercialization efforts and&nbsp;we may seek to sell additional equity or debt securities or obtain a credit facility. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products. Additionally, we may have to grant licenses on terms that may not be favorable to us.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We need substantial amounts of cash to complete the clinical development of and commercialize of our hormone therapy drug candidates. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Summary of (Uses) and Sources of Cash</b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">Year Ended December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 61%; text-align: left;">Net cash flows used in operating activities</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(76,155,614</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(69,142,333</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(79,044,199</td>
            <td style="width: 1%; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Net cash flows used in investing activities</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(827,108</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(1,255,456</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(584,361</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Net cash flows provided by financing activities</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">72,584,249</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">137,225,535</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">92,973,228</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Activities</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The principal use of cash in&nbsp;operating activities for the year ended December 31, 2017 was to fund our current expenses primarily related to supporting clinical development, scale-up and manufacturing activities and future commercial activities, adjusted for non-cash items. The increase of approximately $7,013,000 in cash used in operating activities for the year ended December 31, 2017 in comparison to the year ended December 31, 2016 was primarily due to changes in the components of working capital and lower non-cash compensation expense, as well as a decrease in net loss.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The decrease of approximately $9,902,000 in cash used in operating activities for the year ended December 31, 2016 in comparison to the year ended December 31, 2015 was due primarily to an increase in our net loss adjusted for non-cash compensation expense and changes in the components of working capital.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Investing Activities</i></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The decrease of approximately $428,000 in cash used in investing activities for the year ended December 31, 2017 compared with the year ended December 31, 2016 was primarily due to a decrease in patent costs and costs relating to the purchase of fixed assets.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The increase of approximately $671,000 in cash used in investing activities for the year ended December 31, 2016 compared with the year ended December 31, 2015 was primarily due to an increase in patent costs and the increase in costs relating to the purchase of fixed assets.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  64; Value:  52; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->61
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Financing Activities</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Financing activities represent the principal source of our cash flow. Our financing activities for the year ended December 31, 2017 provided net cash of approximately $72,584,000. The cash provided by financing activities during the year ended December 31, 2017 included approximately $68,573,000 in proceeds from sale of our common stock and approximately $4,011,000 in proceeds from the exercise of options and warrants.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of 12,400,000 shares of our common stock at a price of $5.55 per share. The net proceeds to us from the offering were approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued 12,400,000 shares of our common stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our financing activities for the year ended December 31, 2016 provided net cash of approximately $137,226,000. The cash provided by financing activities during the year ended December 31, 2016 included approximately $134,864,000 in proceeds from sale of our common stock and approximately $2,362,000 in proceeds from the exercise of options and warrants.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On January 6, 2016, we entered into an underwriting agreement with Goldman, Sachs &#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or Underwriters, relating to an underwritten public offering of 15,151,515 shares of our common stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of common stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of our common stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our financing activities for the year ended December 31, 2015 provided net cash of approximately $92,973,000. The cash provided by financing activities included approximately $91,375,000 in proceeds from sale of our common stock and approximately $1,598,000 in proceeds from the exercise of options and warrants.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus &#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of our common stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of our common stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32,257,000, after deducting underwriting discounts and commissions and other estimated offering expense payable by us. The offering closed on July 15, 2015 and we issued 4,423,077 shares of our common stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of our common stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of our common stock, which option was exercised in full. The net proceeds to us from the offering were approximately $59,118,000, after deducting underwriting discounts and commissions and other estimated offering expense payable by us. The offering closed February 17, 2015 and we issued 15,617,282 shares of our common stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Critical Accounting Policies and New Accounting Pronouncements</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Critical Accounting Policies</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. We consider an accounting estimate to be critical if:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">it requires assumptions to be made that were uncertain at the time the estimate was made, and</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">changes in the estimate or different estimates that could have been selected could have a material impact on our results of operations or financial condition.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">We base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation of trends in the industry, information provided by our customers, and information available from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following accounting policies and estimates as those that we believe are most critical to our financial condition and results of operations and that require our most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense and income taxes.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  65; Options:  NewSection; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->62
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Revenue Recognition. </i>We recognize revenue on arrangements in accordance with ASC 605, <em>Revenue Recognition</em>. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><em><u>&nbsp;</u></em></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><em>Prescription Products</em></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0px; line-height: normal; text-align: justify; text-indent: 0.5in; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns.</p>
    <p style="text-align: justify; text-indent: 0.5in;">Revenue related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.&nbsp; Our prescription products currently have a shelf life of 24 months from the date of manufacture.</p>
    <p style="text-align: justify; text-indent: 0.5in;">Prior to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were known or determinable and there was no right of return with respect to such product.&nbsp; On September 1, 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and mitigate exposure to any one retail pharmacy.&nbsp; Beginning on September 1, 2016, all of our prescription products are distributed under the wholesale distributor model described above.</p>
    <p style="text-align: justify; text-indent: 0.5in;">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.&nbsp; We record distributor fees based on amounts stated in contracts and estimate chargebacks based on the number of units sold each period.
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Research and Development Expenses. </i>Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $0 and $228,933 at December 31, 2017 and 2016, respectively, all of which was included in other current assets on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses include professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Share-Based Compensation. </i>We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, <i>Compensation-Stock Compensation</i>, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with two other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  66; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->63
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Equity instruments (&#x201C;instruments&#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity - Based Payments to Non-Employees</i>, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505. We recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We adopted ASU 2016-09, effective January 1, 2017, electing to account for forfeitures when they occur. Prior to that, we estimated the forfeiture rate based on our historical experience of forfeitures.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Income Taxes. </i>We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2017 and 2016, we had no tax positions relating to open tax returns that were considered to be uncertain. Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2013 are subject to review.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine the tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded tax assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore, our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which is reflected in our provision for income taxes and recorded tax assets and liabilities.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and
Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited
to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, effective January 1, 2018. Consequently, we have
recorded a decrease related to deferred tax assets and deferred tax liabilities of approximately $49,500,000 and approximately
$2,800,000, respectively, with a corresponding net adjustment to the valuation allowance of approximately $46,700,000 for the
year ended December 31, 2017. The Tax Act modifies Section 162(m) of the Internal Revenue Code of 1986, as amended, or the IRC,
by (1) expanding which employees are considered covered employees by including the chief financial officer, (2) providing that
if an individual is a covered employee for a taxable year beginning after December 31, 2016, the individual remains a covered
employee for all future years, and (3) removing the exceptions for compensation stemming from contracts entered into on or before
November 2, 2017, unless such contracts were materially modified on or after the date. Compensation agreements entered into and
share-based payment awards granted after this date will be subject to the revised terms of IRC Section 162(m). In December 2017,
the SEC staff issued Staff Accounting Bulletin No. 118,&nbsp;<I>Income Tax Accounting Implications of the Tax Cuts and Jobs Act&nbsp;</I>(SAB
118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment
date. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are
expected over the next 12 months, we consider the accounting for share-based compensation arrangements under the Tax Act to be
incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax positions. We must assess whether
our valuation allowance analyses are affected by various aspects of the Tax Act. Since, as discussed herein, we have recorded
provisional amounts related to certain portions of the Tax Act, any corresponding determination of the need for or change in a
valuation allowance is also provisional.</FONT></P>

<P STYLE="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Segment Reporting. </i>We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>New Accounting Pronouncements</i>
            <font style="color: #252525;">. In May 2017, the Financial Accounting Standards Board, or FASB, issued an Accounting Standards Update, or ASU, 2017-09 that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We adopted this guidance and it did not have an impact on our consolidated financial statements.</font>
        </font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  67; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->64
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted with retrospective application. We adopted this guidance and it did not have an impact on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In March 2016, the FASB issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&nbsp;ASU&nbsp;2016-09&nbsp;effective January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to the accounting for our operating lease.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We have performed a review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step model of the new standard to our contracts as well as compared the results to our current accounting practices. We are currently in the process of drafting disclosures required by the new standard. At this point of our analysis, we do not believe that the adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures related to contracts with customers.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Off-Balance Sheet Arrangements</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, 2016, and 2015, we had no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  68; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->65
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our drug candidates, use of such drug candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of December 31, 2017, 2016, and 2015.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by GAAP, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Effects of Inflation</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">For each of the fiscal years ended December 31, 2017, 2016, and 2015, our business and operations have not been materially affected by inflation.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Contractual Obligations</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A summary of contractual obligations as of December 31, 2017 is as follows:</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1px;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">&nbsp;</td>
            <td style="padding-bottom: 1px;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="8">Payments Due By Period</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1px; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Total</td>
            <td style="padding-bottom: 1px; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;">Less than
                <br> 1 Year</td>
            <td style="padding-bottom: 1px; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">1-3 Years</td>
            <td style="padding-bottom: 1px; font-weight: bold;">&nbsp;</td>
            <td style="padding-bottom: 1px; font-weight: bold;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="2">4-5 Years</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 3px; width: 51%; text-align: left;">Operating Lease Obligations</td>
            <td style="padding-bottom: 3px; width: 1%;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; width: 1%; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; width: 10%; text-align: right;">4,101,506</td>
            <td style="padding-bottom: 3px; width: 1%; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; width: 1%;">$</td>
            <td style="border-bottom: Black 2pt double; width: 10%; text-align: right;">951,194</td>
            <td style="padding-bottom: 3px; width: 1%;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; width: 1%; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; width: 10%; text-align: right;">2,207,185</td>
            <td style="padding-bottom: 3px; width: 1%; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 3px; width: 1%;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; width: 1%; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; width: 10%; text-align: right;">943,127</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Legal Proceedings</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Employment Agreements</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have entered into&nbsp;employment&nbsp;agreements&nbsp;with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Seasonality</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The specialty pharmaceutical industry component of women&#x2019;s health is not subject to seasonal sales fluctuation.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka011"></a>Item 7A.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Quantitative and Qualitative Disclosures about Market Risk</i></b></font>
            </td>
        </tr>
    </table>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">We had a cash balance of approximately $127,136,000 as of December 31, 2017
            <font style="color: #252525;">. </font>We hold certain portions of our cash balances in overnight money market placements all of which are fully available to us to support our cash flow requirements. The primary objective of our investment policy is to preserve principal and maintain proper liquidity to meet operating needs
            <font style="color: #252525;">. </font>Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment
            <font style="color: #252525;">. </font>Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates
            <font style="color: #252525;">. </font>To minimize this risk, we intend to maintain a portfolio that may include cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates
            <font style="color: #252525;">. </font>Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka012"></a>Item 8.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Financial Statements and Supplementary Data</i></b></font>
            </td>
        </tr>
    </table>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">Reference is made to the financial statements, the notes thereto, and the reports thereon, commencing on page F-1 of this Annual Report, which financial statements, notes, and reports are incorporated herein by reference.</font>
    </p>
    <p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  69; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->66
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka013"></a>Item 9.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">None.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka014"></a>Item 9A.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Controls and Procedures</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>&nbsp;</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><i>Evaluation of Disclosure Controls and Procedures</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2017, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Changes in Internal Control over Financial Reporting</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">There was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Inherent Limitations on Effectiveness of Controls</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Management&#x2019;s Annual Report on Internal Control over Financial Reporting</i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  70; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->67
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2017. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#x2014;Integrated Framework (2013). Management&#x2019;s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Based on management&#x2019;s assessment, we believe that our internal controls over financial reporting were effective as of December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The effectiveness of our internal control over financial reporting as of December 31, 2017 has been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated in their Report of Independent Registered Certified Public Accounting Firm on Internal Control Over Financial Reporting as of December 31, 2017, which appears below.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  71; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->68
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt/14pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt/14pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt/14pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Board of Directors and Shareholders
            <br> TherapeuticsMD, Inc.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><strong>O</strong></font><strong>pinion on internal control over financial reporting</strong></p>
    <p style="text-align: justify; page-break-after: avoid;">We have audited the internal control over financial reporting of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the &#x201C;Company&#x201D;) as of December 31, 2017, based on criteria established in the 2013 <em>Internal Control&#x2014;Integrated Framework</em> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201C;COSO&#x201D;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in the 2013 <em>Internal Control&#x2014;Integrated Framework</em> issued by COSO.</p>
    <p style="text-align: justify;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201C;PCAOB&#x201D;), the consolidated financial statements of the Company as of and for the year ended December 31, 2017, and our report dated February 23, 2018 expressed an unqualified opinion on those financial statements.</p>
    <p style="text-align: justify;"><strong><font style="font-size: 10pt;">Basis for opinion</font></strong></p>
    <p style="text-align: justify;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#x2019;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
    <p style="text-align: justify;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
    <p style="text-align: justify;">
        <font style="font-size: 10pt;"><strong>Definition and limitations of internal control over financial reporting</strong></font>
    </p>
    <p style="text-align: justify;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</p>
    <p style="text-align: justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
    <p style="text-align: justify;">&nbsp;/s/ GRANT THORNTON LLP</p>
    <p style="text-align: justify;">Fort Lauderdale, Florida</p>
    <p>&nbsp;February 23, 2018</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  72; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->69
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka015"></a>Item 9B.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Other Information</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">None.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka016"></a>PART III</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka017"></a>Item 10.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Directors, Executive Officers, and Corporate Governance</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">The information required by this Item relating to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2018 Annual Meeting of Stockholders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka018"></a>Item 11.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Executive Compensation</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2018 Annual Meeting of Stockholders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka019"></a>Item 12.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2018 Annual Meeting of Stockholders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka020"></a>Item 13.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Certain Relationships and Related Transactions, and Director Independence</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the Exchange Act for our 2018 Annual Meeting of Stockholders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10ka021"></a>Item 14.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Principal Accounting Fees and Services</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2018 Annual Meeting of Stockholders.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page;  ; Sequence:  73; Value:  62; -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->70
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmd10ka022"></a>PART IV </b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0px;">&nbsp;</td>
            <td style="width: 96px;">
                <font style="font-size: 10pt;"><b><a name="txmd10ka023"></a>Item 15.</b></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><b><i>Exhibits, Financial Statement Schedules</i></b></font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0px;"></td>
            <td style="width: 48px;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><b>Financial Statements and Financial Statements Schedules</b></font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">&nbsp;</td>
            <td style="width: 48px;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Financial Statements are listed in the Index to Consolidated Financial Statements on page F-1 of this Annual Report. &nbsp; &nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">No financial statement schedules are included because such schedules are not applicable, are not required, or because required information is included in the consolidated financial statements or notes thereto.</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: justify;">
            <td style="width: 0px;"></td>
            <td style="width: 48px; text-align: left;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><b>Exhibits</b></font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 5%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 7%;">
                <font style="font-size: 10pt;"><b>Exhibit</b></font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 18%;">
                <font style="font-size: 10pt;"><b>Date</b></font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 68%;">
                <font style="font-size: 10pt;"><b>Description</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">2.1</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">July 6, 2009</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#x2019;s Minority Health Network, Inc., and the Major Shareholders<sup>(1)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">2.2</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">June 11, 2010</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc.<sup>(2)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">2.3</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">October 25, 2007</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization<sup>(3)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">2.4</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">July 18, 2011</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC<sup>(4)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">3.1</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">July 20, 2010</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">Articles of Conversion of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm">3.2</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">July 20, 2010</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115002352/ex3-1.htm">3.3</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115002352/ex3-1.htm">Composite Amended and Restated Articles of Incorporation of the Company, as amended<sup>(6)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">3.4</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">Bylaws of AMHN, Inc.<sup>(7)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">3.5</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">December 17, 2015</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">First Amendment to Bylaws of the Company<sup>(8)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">4.1</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">Form of Certificate of Common Stock<sup>(9)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">10.1</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">Form of Common Stock Purchase Warrant <sup>(10)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">10.2*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">Form of Non-Qualified Stock Option Agreement <sup>(10)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">10.3*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">Amended and Restated 2012 Stock Incentive Plan<sup>(11)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">10.4*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">2009 Long Term Incentive Compensation Plan, as amended<sup>(12)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002306/ex10_7.htm">10.5</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">October 23, 2011</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002306/ex10_7.htm">Common Stock Purchase Warrant to Lang Naturals, Inc.<sup>(13)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">10.6</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 24, 2012</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">Form of Common Stock Purchase Warrant<sup>(14)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112002558/ex-10_26.htm">10.7</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">April 17, 2012</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112002558/ex-10_26.htm">Master Services Agreement between the Company and Sancilio and Company, Inc.<sup>(15)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713116004361/ex10-9.htm">10.8</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">May 17, 2012</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713116004361/ex10-9.htm">Consulting Agreement between the Company and Sancilio and Company, Inc.<sup>(16)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112003118/ex4-1.htm">10.9</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">September 26, 2012</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112003118/ex4-1.htm">Form of Securities Purchase Agreement <sup>(17)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112003625/ex10-28.htm">10.10*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">November 8, 2012</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112003625/ex10-28.htm">Form of Employment Agreement<sup>(18)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">10.11</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">January 31, 2013</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">Common Stock Purchase Warrant, issued to Plato &#38; Associates, LLC<sup>(19)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-32.htm">10.12</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">May 7, 2013</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-32.htm">Consulting Agreement between the Company and Sancilio and Company, Inc. <sup>(20)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-31.htm">10.13*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">May 8, 2013</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-31.htm">Agreement to Forfeit Non-Qualified Stock Options between the Company and Robert G. Finizio<sup>(22)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113002760/ex10-33.htm">10.14</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">May 16, 2013</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113002760/ex10-33.htm">Lease between the Company and 6800 Broken Sound LLC<sup>(23)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115000875/ex10-36.htm">10.15</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 18, 2015</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115000875/ex10-36.htm">First Amendment to Lease between the Company and 6800 Broken Sound, LLC<sup>(24)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713116005278/ex10-1.htm">10.16</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">April 26, 2016</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713116005278/ex10-1.htm">Second Amendment to Lease between the Company and 6800 Broken Sound, LLC<sup>(25)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713116007716/ex10-1.htm">10.17</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">October 4, 2016</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713116007716/ex10-1.htm">Third Amendment to Lease between the Company and 6800 Broken Sound, LLC<sup>(26)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-1.htm">10.18*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">December 17, 2015</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-1.htm">Employment Agreement between the Company and Brian Bernick<sup>(8)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-2.htm">10.19*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">December 17, 2015</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-2.htm">Employment Agreement between the Company and Michael Donegan<sup>(8)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-3.htm">10.20*</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">December 17, 2015</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-3.htm">Employment Agreement between the Company and Mitchel Krassan<sup>(8)</sup></a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex21-1.htm">21.1&#x2020;</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex21-1.htm">Subsidiaries of the Company</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex23-1.htm">23.1&#x2020;</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex23-1.htm">Consent of Grant Thornton, LLP</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
    </table>
    <!-- Field: Page;  ; Sequence:  74; Options:  NewSection; Value:  71; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->71
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 5%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 7%;">
                <font style="font-size: 10pt;"><b>Exhibit</b></font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 18%;">
                <font style="font-size: 10pt;"><b>Date</b></font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 68%;">
                <font style="font-size: 10pt;"><b>Description</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex31-1.htm">31.1&#x2020;</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex31-2.htm">31.2&#x2020;</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex32-1.htm">32.1&#x2020;</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex32-1.htm">Certification pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex32-2.htm">32.2&#x2020;</a></font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;"><a href="ex32-2.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">101.INS&#x2020;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">XBRL Instance Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">101.SCH&#x2020;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">XBRL Taxonomy Extension Schema Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">101.CAL&#x2020;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">101.DEF&#x2020;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">XBRL Taxonomy Extension Definition Linkbase Instance Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">101.LAB&#x2020;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">XBRL Taxonomy Extension Label Linkbase Instance Document</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">101.PRE&#x2020;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">n/a&nbsp;</font>
            </td>
            <td>&nbsp;</td>
            <td>
                <font style="font-size: 10pt;">XBRL Taxonomy Extension Presentation Linkbase Instance Document&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 4%; text-align: justify;">
                <font style="font-size: 10pt;">*</font>
            </td>
            <td style="width: 96%; text-align: justify;">
                <font style="font-size: 10pt;">Indicates a contract with management or compensatory plan or arrangement.</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">&#x2020;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed herewith.</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(1)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(2)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(3)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission on May 1, 2008 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(4)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(5)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2010 filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(6)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2015 filed with the Commission on August 7, 2015 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(7)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(8)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on December 22, 2015 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(9)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby by reference (SEC File No. 333-186189).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(10)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(11)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(12)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Registration Statement on Form S-8 filed with the Commission on October 15, 2013 and incorporated herein by reference (SEC File No. 333-191730).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(13)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on October 24, 2011 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(14)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(15)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2012 filed with the Commission on August 9, 2012 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(16)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-K for the year ended December 31, 2015, filed with the Commission on February 26, 2016 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(17)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 8-K filed with the Commission on October 2, 2012 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(18)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2012 filed with the Commission on November 13, 2012 and incorporated herein by reference (SEC File No. 000-16731).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(19)</sup></font>
            </td>
            <td style="text-align: justify;">
                <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein by reference (SEC File No. 000-16731).</p>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(20)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2013 filed with the Commission on May 10, 2013 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  75; Value:  71; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->72
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 4%; text-align: justify;">
                <font style="font-size: 10pt;"><sup>(21)</sup></font>
            </td>
            <td style="width: 96%; text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2013 filed with the Commission on August 7, 2013 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(22)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-K for the year ended December 31, 2014 filed with the Commission on March 12, 2015 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(23)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2016 filed with the Commission on May 5, 2016 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><sup>(24)</sup></font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2016 filed with the Commission on November 5, 2016 and incorporated herein by reference (SEC File No. 001-00100).</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;"><b><i><a name="txmd10ka024"></a>Item 16.&nbsp;Form 10-K Summary</i></b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
    </table>
    <!-- Field: Page;  ; Sequence:  76; Value:  71; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->73
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>SIGNATURES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 60%; text-align: justify;">
                <font style="font-size: 10pt;">Date: February 23, 2018</font>
            </td>
            <td style="width: 40%; text-align: justify;">
                <font style="font-size: 10pt;"><b>THERAPEUTICSMD, INC.</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Chief Executive Officer</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.</p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 12%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 9%; text-align: center;">
                <font style="font-size: 10pt;"><b>Signature</b></font>
            </td>
            <td style="width: 12%; text-align: center;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 16%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 10%; text-align: center;">
                <font style="font-size: 10pt;"><b>Capacity</b></font>
            </td>
            <td style="width: 16%; text-align: center;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 9%; text-align: center;">&nbsp;</td>
            <td style="border-bottom: black 1pt solid; width: 5%; text-align: center;">
                <font style="font-size: 10pt;"><b>Date</b></font>
            </td>
            <td style="width: 9%; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Chief Executive Officer, Director</font>
                <br>
                <font style="font-size: 10pt;">(Principal Executive Officer)</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Robert G. Finizio</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ John C.K. Milligan, IV</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">President, Secretary, Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">John C.K. Milligan, IV</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
            <td>&nbsp;</td>
            <td colspan="3" rowspan="2">
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer, Treasurer&nbsp;</p>
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</p>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Tommy G. Thompson</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Chairman</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Tommy G. Thompson </font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Brian Bernick </i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Brian Bernick </font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ J. Martin Carroll</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">&nbsp;J. Martin Carroll</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td style="vertical-align: top;">&nbsp;</td>
            <td style="vertical-align: top;" colspan="3">&nbsp;</td>
            <td style="vertical-align: top;">&nbsp;</td>
            <td colspan="3">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="border-bottom: black 1pt solid; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Cooper C. Collins</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">&nbsp;Cooper C. Collins</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td style="vertical-align: top;">&nbsp;</td>
            <td style="vertical-align: top;" colspan="3">&nbsp;</td>
            <td style="vertical-align: top;">&nbsp;</td>
            <td colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Robert V. LaPenta, Jr.</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Robert V. LaPenta, Jr </font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Jules Musing</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Jules Musing</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Angus C. Russell</i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Angus C. Russell</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="vertical-align: bottom; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3">&nbsp;</td>
        </tr>
        <tr>
            <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center;" colspan="3">
                <font style="font-size: 10pt;"><i>/s/ Nicholas Segal </i></font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <font style="font-size: 10pt;">Director</font>
            </td>
            <td>&nbsp;</td>
            <td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2">
                <p style="margin-bottom: 0; margin-top: 0;">
                    <font style="font-size: 10pt;">February 23, 2018</font>
                </p>
                <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: center;" colspan="3">
                <font style="font-size: 10pt;">Nicholas Segal</font>
            </td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  77; Value:  71; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; ;  ; Type:  Arabic; Name:  PageNo; -->74
            <!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>INDEX TO FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 92%;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center;">
                <font style="font-size: 10pt;">Page</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="font-size: 10pt;">Report of Independent Registered Public Accounting Firm</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">F-2 </font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <a href="#txmd10kb001">
                    <font style="font-size: 10pt;">Consolidated Balance Sheets as of December 31, 2017 and 2016</font>
                </a>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">F-3</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <a href="#txmd10kb002">
                    <font style="font-size: 10pt;">Consolidated Statements of Operations for the years ended December 31, 2017, 2016 and 2015</font>
                </a>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">F-4</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <a href="#txmd10kb003">
                    <font style="font-size: 10pt;">Consolidated Statements of Stockholders&#x2019; Equity for the years ended December 31, 2017, 2016 and 2015</font>
                </a>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">F-5</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <a href="#txmd10kb004">
                    <font style="font-size: 10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016 and 2015</font>
                </a>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">F-6</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <a href="#txmd10kb005">
                    <font style="font-size: 10pt;">Notes to Consolidated Financial Statements</font>
                </a>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">F-7</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page;  ; Sequence:  78; Options:  NewSection; Value:  1; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->1
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">Board of Directors and Shareholders</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">TherapeuticsMD, Inc.</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Opinion on the financial statements</b></p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We have audited the accompanying consolidated balance sheets of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the &#x201C;Company&#x201D;) as of December 31, 2017 and 2016, the related consolidated statements of operations, stockholders&#x2019; equity, and cash flows for each of the three years in the period ended December 31, 2017, and the related notes (collectively referred to as the &#x201C;financial statements&#x201D;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201C;PCAOB&#x201D;), the Company&#x2019;s internal control over financial reporting as of December 31, 2017, based on criteria established in the 2013 <i>Internal Control&#x2014;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201C;COSO&#x201D;), and our report dated February 23, 2018 expressed an unqualified opinion.</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Basis for opinion</b></p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">/s/ GRANT THORNTON LLP</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">We have served as the Company&#x2019;s auditor since 2015.</p>
    <p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Fort Lauderdale, Florida</p>
    <p style="margin: 0 0 14.2pt; font: 10pt/normal Times New Roman, Times, Serif;">February 23, 2018</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  79; -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
            <tr>
                <td style="text-align: center; width: 100%">F-
                    <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->2
                    <!-- Field: /Sequence -->
                    &nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <table cellpadding="0" cellspacing="0" style="width: 100%">
            <tr>
                <td style="text-align: center; width: 100%">&nbsp;</td>
            </tr>
        </table>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmd10kb001"></a>CONSOLIDATED BALANCE SHEETS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: center;" colspan="8">ASSETS</td>
            <td>&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Current Assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; width: 74%; text-indent: -0.125in;">Cash</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">127,135,628</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">131,534,101</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Accounts receivable, net of allowance for doubtful accounts of $380,580 and $376,374, respectively</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,328,802</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,500,699</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-indent: -0.125in;">Inventory</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,485,358</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,076,321</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Other current assets</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">6,604,284</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">2,299,052</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Total current assets</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">139,554,072</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">139,410,173</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Fixed assets, net</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">437,055</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">516,839</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Other Assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Intangible assets, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,099,747</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,405,972</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Security deposit</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">139,036</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">139,036</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Total other assets</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">3,238,783</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">2,545,008</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in;">Total assets</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">143,229,910</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">142,472,020</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: center;" colspan="8">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Current Liabilities:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Accounts payable</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">4,097,600</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">7,358,514</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Other current liabilities</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">9,223,595</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">7,624,085</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Total current liabilities</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">13,321,195</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">14,982,599</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Commitments and Contingencies - See Note 12</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Stockholders&#x2019; Equity:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Common stock - par value $0.001; 350,000,000 shares authorized: 216,429,642 and 196,688,222 issued and outstanding, respectively</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">216,430</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">196,688</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Additional paid-in capital</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">516,351,405</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">436,995,052</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Accumulated deficit</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(386,659,120</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(309,702,319</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Total stockholders&#x2019; equity</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">129,908,715</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">127,489,421</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in;">Total liabilities and stockholders&#x2019; equity</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">143,229,910</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">142,472,020</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  80; Options:  NewSection; Value:  3; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->3
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmd10kb002"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">Year Ended December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: center; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: center; text-indent: -0.125in;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">&nbsp;</td>
            <td style="text-align: center;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; width: 61%; text-align: left; text-indent: -0.125in;">Revenues, net</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">16,777,713</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">19,356,450</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">20,142,898</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Cost of goods sold</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">2,636,943</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">4,185,708</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">4,506,673</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Gross profit</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">14,140,770</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">15,170,742</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">15,636,225</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Operating expenses:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Sales, general, and administrative</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">57,703,370</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">51,348,414</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">28,721,236</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Research and development</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">33,852,993</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">53,943,477</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">72,042,774</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Depreciation and amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">213,117</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">132,451</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">62,400</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Total operating expenses</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">91,769,480</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">105,424,342</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">100,826,410</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Operating loss</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(77,628,710</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(90,253,600</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(85,190,185</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Other income</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Miscellaneous income</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">695,631</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">367,317</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">95,719</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Accreted interest</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">7,699</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">10,824</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">17,442</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Total other income</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">703,330</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">378,141</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">113,161</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Loss before income taxes</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(76,925,380</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(89,875,459</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(85,077,024</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Provision for income taxes</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Net loss</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(76,925,380</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(89,875,459</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(85,077,024</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Loss per share, basic and diluted:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Net loss per share, basic and diluted</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(0.37</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(0.46</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(0.49</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Weighted average number of common shares outstanding, basic and diluted</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">205,523,288</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">196,088,196</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">173,174,229</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <!-- Field: Page; Sequence:  81; Value:  4; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->4
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmd10kb003"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#x2019; EQUITY</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>FOR THE YEARS ENDED DECEMBER 31, 2017, 2016 AND 2015</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: center; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Common Stock</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">Additional
                <br> Paid in</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="text-align: center;" colspan="2">Accumulated</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;" colspan="2">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: center; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Shares</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Amount</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Capital</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Deficit</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Total</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; width: 35%; text-indent: -0.125in; font-weight: bold;">Balance, January 1, 2015</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">156,097,019</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">156,097</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">182,982,846</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(134,749,836</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">48,389,107</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Shares issued in offerings, net of cost</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">20,040,359</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">20,040</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,354,609</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,374,649</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Shares issued for exercise of options, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">612,981</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">613</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,231,966</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,232,579</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Shares issued for exercise of warrants, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,177,682</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,178</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">364,822</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">366,000</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Share-based compensation</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6,777,835</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6,777,835</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Net loss</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(85,077,024</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(85,077,024</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold;">Balance, December 31, 2015</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">177,928,041</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">177,928</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">282,712,078</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(219,826,860</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">63,063,146</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Shares issued in offerings, net of cost</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">17,424,242</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">17,424</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">134,846,051</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">134,863,475</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Shares issued for exercise of warrants, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">722,744</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">723</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,372,277</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,373,000</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Shares issued for exercise of options, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">613,195</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">613</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">988,447</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">989,060</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Share-based compensation</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">17,076,199</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">17,076,199</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Net loss</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(89,875,459</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(89,875,459</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold;">Balance, December 31, 2016</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">196,688,222</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">196,688</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">436,995,052</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(309,702,319</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">127,489,421</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Shares issued in offerings, net of cost</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">12,400,000</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">12,400</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">68,560,235</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">68,572,635</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Shares issued for exercise of warrants, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">7,238,874</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">7,239</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,791,760</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,798,999</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Shares issued for exercise of options, net</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">102,546</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">103</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">212,512</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">212,615</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Share-based compensation</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6,760,425</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6,760,425</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">Adoption of ASU 2016-09</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">31,421</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(31,421</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in;">Net loss</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(76,925,380</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(76,925,380</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold;">Balance, December 31, 2017</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">216,429,642</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">216,430</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">516,351,405</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(386,659,120</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">129,908,715</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center;">&nbsp;</p>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <!-- Field: Page; Sequence:  82; Value:  4; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->5
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><a name="txmd10kb004"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
    <p style="margin: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: center; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">Year Ended December, 31,</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: center; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt; text-align: center;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font-weight: bold;">CASH FLOWS FROM OPERATING ACTIVITIES</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; width: 61%; text-align: left; text-indent: -0.125in;">Net loss</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(76,925,380</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(89,875,459</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">(85,077,024</td>
            <td style="width: 1%; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Adjustments to reconcile net loss to net cash used in operating activities:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.5in; text-indent: -0.125in;">Depreciation</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">141,601</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">77,906</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">29,959</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.5in; text-align: left; text-indent: -0.125in;">Amortization of intangible assets</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">71,516</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">54,545</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">32,441</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.5in; text-align: left; text-indent: -0.125in;">Provision for doubtful accounts</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,206</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,524,909</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">22,157</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.5in; text-align: left; text-indent: -0.125in;">Share-based compensation</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">6,889,323</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">17,411,021</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">7,189,699</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.5in; text-align: left; text-indent: -0.125in;">Changes in operating assets and liabilities:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.625in; text-align: left; text-indent: -0.125in;">Accounts receivable</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">167,691</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(3,975,893</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(917,656</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.625in; text-indent: -0.125in;">Inventory</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(409,037</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(386,168</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">491,960</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.625in; text-align: left; text-indent: -0.125in;">Other current assets</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(4,434,130</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">709,907</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(773,532</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.625in; text-align: left; text-indent: -0.125in;">Other assets</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(17,442</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.625in; text-align: left; text-indent: -0.125in;">Accounts payable</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(3,260,914</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,232,340</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(3,200,955</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.625in; text-align: left; text-indent: -0.125in;">Deferred revenue</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(522,613</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.625in; text-align: left; text-indent: -0.125in;">Other current liabilities</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">1,599,510</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">84,559</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">3,698,887</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.625in; text-align: left; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Net cash used in operating activities</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(76,155,614</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(69,142,333</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(79,044,119</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font-weight: bold;">CASH FLOWS FROM INVESTING ACTIVITIES</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Patent costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(765,291</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(845,266</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(419,104</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Purchase of fixed assets</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(61,817</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(396,154</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(165,257</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Payment of security deposit</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(14,036</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Net cash used in investing activities</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(827,108</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(1,255,456</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(584,361</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in; font-weight: bold;">CASH FLOWS FROM FINANCING ACTIVITIES</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in;">Proceeds from sale of common stock, net of costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">68,572,635</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">134,863,475</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,374,649</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.375in; text-indent: -0.125in;">Proceeds from exercise of options</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">212,615</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">989,060</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,232,579</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-indent: -0.125in;">Proceeds from exercise of warrants</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">3,798,999</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">1,373,000</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">366,000</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-indent: -0.125in;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in;">Net cash provided by financing activities</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">72,584,249</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">137,225,535</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">92,973,228</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-indent: -0.125in;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in;">(Decrease) increase in cash</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(4,398,473</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">66,827,746</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">13,344,748</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in;">Cash, beginning of period</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">131,534,101</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">64,706,355</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">51,361,607</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; padding-left: 0.25in; text-indent: -0.125in;">Cash, end of period</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">127,135,628</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">131,534,101</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">64,706,355</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center;">&nbsp;</p>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0;">&nbsp;</p>
    <!-- Field: Page; Sequence:  83; Value:  4; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->6
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="txmd10kb005"></a>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 1 &#x2013; THE COMPANY</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201C;our company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; or &#x201C;us.&#x201D;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Nature of Business</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. With our SYMBODA&#x2122; technology, we are developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements, which we ceased manufacturing in October 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 2 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Principles of Consolidation</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Cash</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &#x201C;FDIC&#x201D;) insured limits of $250,000 per bank. We have never experienced any losses related to these funds.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Trade Accounts Receivable and Allowance for Doubtful Accounts</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts.
            <font style="color: #252525;">To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be </font>required. At December 31, 2017, four different customers represented 27%, 23%, 22% and 11%, respectively, of our gross accounts receivable. At December 31, 2016, two different customers represented 28% and 20%, respectively, of our gross accounts receivable.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the third quarter of 2016, we wrote-off accounts receivable balances of approximately $2,200,000 related to two retail pharmacy distributors. Both pharmacies are relatively small owner-managed pharmacies and share a similar amount of collection risk. Among the factors that contributed to our decision to write-off these balances were our inability to collect the outstanding balances and the lack of a continuing communication and business relationship with these parties following the centralization of the distribution channel for both our retail pharmacy distributors and wholesale distributors, effective September 1, 2016.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Inventories</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Inventories represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or net realizable value using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  84; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->7
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Pre-Launch Inventory</u></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Fixed Assets</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Intangible Assets</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i>Intangibles - Goodwill and Other</i>, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2017, we had 18 issued patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Impairment of Long-Lived Assets</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">significant declines in an asset&#x2019;s market price;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">significant deterioration in an asset&#x2019;s physical condition;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">significant changes in the nature or extent of an asset&#x2019;s use or operation;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">significant adverse changes in the business climate that could impact an asset&#x2019;s value, including adverse actions or assessments by regulators;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#x2019;s use; and</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &#x201C;income approach&#x201D; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2017, 2016, and 2015.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  85; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->8
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We perform impairment tests for intangible assets with indefinite useful lives annually, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There was no impairment of indefinite lived intangible assets during the years ended December 31, 2017, 2016, and 2015.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Fair Value of Financial Instruments</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 5%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Level 1</b></font>
            </td>
            <td style="width: 87%; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">unadjusted quoted prices in active markets for identical assets or liabilities;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 5%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Level 2</b></font>
            </td>
            <td style="width: 87%; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 5%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Level 3</b></font>
            </td>
            <td style="width: 87%; font-size: 10pt;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">unobservable inputs for the asset or liability.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At December 31, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31, 2017, 2016, and 2015.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Income Taxes</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2017 and 2016, we had no tax positions relating to open tax returns that were considered to be uncertain.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2013 are subject to review.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  86; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->9
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Share-Based Compensation</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, <i>Compensation-Stock Compensation</i>, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Equity instruments (&#x201C;instruments&#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity - Based Payments to Non-Employees</i>, or ASC 505<i>. </i>ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Revenue Recognition</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We recognize revenue on arrangements in accordance with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product lines, except for Iron 21/7, which we ceased manufacturing in October 2017. The revenue that is generated by us from major customers is all generated from sales of our prescription prenatal vitamin products, which is disclosed in Note 11. There are no major customers for our OTC prenatal vitamin or other products.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Over-the-Counter Products</u></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product lines, except for Iron 21/7, which we ceased manufacturing in October 2017.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  87; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->10
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Prescription Products</u></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Revenue related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Prior to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription products are distributed under the wholesale distributor model described above.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated in contracts and estimate chargebacks based on the number of units sold each period.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Segment Reporting</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Shipping and Handling Costs</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Advertising Costs</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We expense advertising costs when incurred. Advertising costs were $448,288, $752,611, and $792,574 during the years ended December 31, 2017, 2016, and 2015, respectively.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Research and Development Expenses</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $0 and $228,933 at December 31, 2017 and 2016, respectively, all of which was included in other current assets on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration, or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses include professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  88; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->11
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Earnings Per Share</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31,</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2017</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2016</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2015</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 25%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Stock options</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 12%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">23,365,225</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 12%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">21,767,854</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 12%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">20,725,325</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Warrants</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3,115,905</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">12,060,071</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">12,722,431</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">26,481,130</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">33,827,925</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">33,447,756</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><u>Concentration of Credit Risk and other Risks and Uncertainties</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Use of Estimates</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Recently Issued Accounting Pronouncements</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In May 2017, the FASB issued ASU 2017-09, which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We adopted this guidance and it did not have an impact on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted with retrospective application. We adopted this guidance and it did not have an impact on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In March 2016, the FASB issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&nbsp;ASU&nbsp;2016-09&nbsp;effective January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated financial statements.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  89; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->12
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to the accounting for our operating lease.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We have performed a review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step model of the new standard to our contracts as well as compared the results to our current accounting practices. We are currently in the process of drafting disclosures required by the new standard. At this point of our analysis, we do not believe that the adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures related to contracts with customers.</font>
    </p>
    <p style="color: #252525; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 3 &#x2013; INVENTORY</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Inventory consists of the following:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">
                <font style="font: 10pt Times New Roman, Times, Serif;">December 31,</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2017</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2016</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 40%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Finished product</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 12%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,485,358</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="width: 12%; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,062,285</font>
            </td>
            <td style="width: 1%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Raw material</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2014;</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">14,036</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TOTAL INVENTORY</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,485,358</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</font>
            </td>
            <td style="border-bottom: Black 2pt double; border-top: Black 1pt solid; text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,076,321</font>
            </td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 4 &#x2013; OTHER CURRENT ASSETS</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other current assets consist of the following:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 40%; text-align: left;">Prepaid sales and marketing costs</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">5,335,936</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">&#x2014;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Prepaid insurance</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">680,243</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">628,039</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Prepaid manufacturing costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">991,809</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Prepaid consulting</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">128,898</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Other prepaid costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">523,694</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">405,960</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Prepaid vendor deposits</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">64,411</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">44,311</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: left;">Prepaid research and development costs</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">100,035</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-align: left;">TOTAL OTHER CURRENT ASSETS</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">6,604,284</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">2,299,052</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  90; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->13
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 5 &#x2013; FIXED ASSETS, NET</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fixed assets, net consist of the following:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 50%; text-align: left;">Accounting system</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">301,096</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">301,096</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>Equipment</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">273,536</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">215,182</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Computer hardware</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">80,211</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">80,211</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Furniture and fixtures</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">116,542</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">113,079</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: left;">Leasehold improvements</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">37,888</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">37,888</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">809,273</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">747,456</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: left;">Accumulated depreciation</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(372,218</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(230,617</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-align: left;">&nbsp;TOTAL FIXED ASSETS, NET</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">437,055</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">516,839</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">Depreciation expense for the years ended December 31, 2017, 2016, and 2015 was $141,601, $77,906, and $29,959, respectively.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 6 &#x2013; INTANGIBLE ASSETS, NET</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2017 and 2016:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">December 31, 2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Gross
                <br> Carrying
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Accumulated
                <br> Amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Net
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted-
                <br> Average
                <br> Remaining
                <br> Amortization
                <br> Period (yrs.)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: left;">Amortizable intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; width: 40%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">OPERA<sup>&#xAE;</sup> software patent</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">31,951</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">(8,487</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">23,464</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">11.75</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left;">Development costs of corporate website</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,743</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(91,743</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left;">Approved hormone therapy drug candidate patents</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,293,614</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(171,911</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,121,703</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">15</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.125in; text-align: left;">Hormone therapy drug candidate patents (pending)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,721,305</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,721,305</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Non-amortizable intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left;">Multiple trademarks</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">233,275</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">233,275</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">indefinite</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.25in;">TOTAL</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">3,371,888</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(272,141</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">)</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">3,099,747</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">December 31, 2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Gross
                <br> Carrying
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Accumulated
                <br> Amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Net
                <br> Amount</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted-
                <br> Average
                <br> Remaining
                <br> Amortization
                <br> Period (yrs.)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: left;">Amortizable intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; width: 40%; text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">OPERA<sup>&#xAE;</sup> software patent</font>
            </td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">31,951</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">(6,490</td>
            <td style="width: 1%; text-align: left;">)</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">25,461</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">12.75</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left;">Development costs of corporate website</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">91,743</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(91,743</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left;">Approved hormone therapy drug candidate patents</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,093,452</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(102,393</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">991,059</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">16</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left;">Hormone therapy drug candidate patents (pending)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,203,987</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,203,987</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">n/a</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Non-amortizable intangible assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left;">Multiple trademarks for vitamins/supplements</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">185,465</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">185,465</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">indefinite</font>
            </td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.5in;">Total</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">2,606,598</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(200,626</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">)</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">2,405,972</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized.
            <font style="background-color: white;">During the years ended December 31, 2017 and 2016, there was no impairment recognized related to intangible assets.</font>
        </font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  91; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->14
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="background-color: white; font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have numerous pending foreign and domestic patent applications. As of December 31, 2017, we had 18 issued domestic, or U.S., patents and 13 issued foreign patents, including:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">13 domestic and three foreign utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us. The domestic utility patents will expire in 2032. In addition, we have pending patent applications with respect to our combination progesterone and estradiol product candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">three domestic and 10 foreign patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate. These patents establish an important intellectual property foundation for TX-004HR and are owned by us. These domestic patents will expire in 2033 or 2032. In addition, we have pending patent applications related to our applicator-free vaginal estradiol softgel product candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">one domestic utility patent that relates to a pipeline transdermal patch technology, which is owned by us and will expire in 2032. We have pending patent applications with respect to this technology in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South Africa; and</font>
            </td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x25CF;</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">one utility patent that relates to our OPERA<sup>&#xAE;</sup> information-technology platform, which is owned by us and is a domestic patent that will expire in 2029.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="background-color: white; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Amortization expense was $71,516, $54,545, and $32,441 for the years ended December 31, 2017, 2016, and 2015, respectively. Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Year Ending
                <br> December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Estimated
                <br> Amortization</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 20%; text-align: left;">2018</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 15%; text-align: right;">76,777</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2019</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">76,777</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2020</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">76,777</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2021</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">76,777</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2022</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">76,777</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Thereafter</font>
            </td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">761,282</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 7&#x2013; OTHER CURRENT LIABILITIES</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other current liabilities consist of the following:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 50%; text-align: left;">Accrued clinical trial costs</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">366,933</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">1,281,080</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Accrued payroll, bonuses and commission costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4,240,379</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,531,440</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Accrued compensated absences</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">945,457</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">665,561</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Accrued legal and accounting expense</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">600,350</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">176,518</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Accrued sales and marketing costs</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">420,162</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">665,773</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Other accrued expenses</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">602,916</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">224,865</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Allowance for wholesale distributor fees</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">172,973</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">76,510</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Accrued royalties</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">114,480</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">26,507</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Allowance for coupons and returns</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,432,846</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">794,816</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: left;">Accrued rent</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">327,099</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">181,015</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2.5pt; padding-left: 0.125in; text-align: left;">TOTAL OTHER CURRENT LIABILITIES</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">9,223,595</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2.5pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">7,624,085</td>
            <td style="padding-bottom: 2.5pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  92; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->15
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 8 &#x2013; STOCKHOLDERS&#x2019; EQUITY</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Preferred Stock</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At December 31, 2017, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Common Stock</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At December 31, 2017, we had 350,000,000 shares of Common Stock authorized for issuance, of which 216,429,642 shares of our Common Stock were issued and outstanding.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Issuances During 2017</u></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of 12,400,000 shares of our Common Stock at a price of $5.55 per share. The net proceeds to us from the offering were approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued 12,400,000 shares of Common Stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2017, certain individuals exercised stock options to purchase 102,546 shares of Common Stock for $212,615 in cash.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Issuances During 2016</u></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On January 6, 2016, we entered into an underwriting agreement with Goldman Sachs &#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of our Common Stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2016, certain individuals exercised stock options to purchase 525,362 shares of Common Stock for $989,060 in cash. Also during the same period, stock options to purchase 127,109 shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 87,833 shares of Common Stock were issued.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Issuances During 2015</u></i></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus &#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32,257,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July 15, 2015 and we issued 4,423,077 shares of our Common Stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59,118,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2015, certain individuals exercised stock options to purchase 612,867 shares of Common Stock for $1,232,579 in cash. Also during the same period, stock options to purchase 417 shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 114 shares of Common Stock were issued.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  93; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->16
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Warrants to Purchase Common Stock</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, we had warrants outstanding to purchase an aggregate of 3,115,905 shares of our Common Stock with a weighted-average contractual remaining life of 1.8 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in a weighted average exercise price of $2.58 per share.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2017, we granted warrants to purchase 125,000 shares of Common Stock to outside consultants at an exercise price of $6.83 per share. The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 63.24%; risk free rate of 1.47%; and dividend yield of 0%. The grant date fair value of the warrants was $3.67 per share. The warrants vest ratably over a 12-month period and have an expiration date of March 15, 2022.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2016, we granted warrants to purchase 245,000 shares of Common Stock to outside consultants at the weighted average price of $7.90 per share. These warrants vest and have expiration dates as follows: warrants to purchase 75,000 shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares of Common Stock vest ratably over a 24-month period and have an expiration date of April 21, 2021, and warrants to purchase 120,000 shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an exercise price of $6.35 vesting ratably over a 12-month period, with an expiration date of April 6, 2020. We recorded share-based compensation expense related to warrants previously issued of $313,271, $936,974 and $139,142 for the years ended December 31, 2017, 2016, and 2015, respectively, in the accompanying consolidated financial statements. At December 31, 2017, total unrecognized estimated compensation expense related to the unvested portion of these warrants was approximately $128,000 which is expected to be recognized over a weighted-average period of 0.2 years.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Summary of our Warrant activity during the year ended December 31, 2017:</i></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Number of
                <br> Shares Under Warrants</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted
                <br> Average
                <br> Exercise Price</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted
                <br> Average
                <br> Remaining
                <br> Contractual
                <br> Life in Years</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Aggregate
                <br> Intrinsic
                <br> Value</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 48%;">Balance at December 31, 2016</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">12,060,071</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">2.08</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 10%; text-align: right;">1.0</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 10%; text-align: right;">45,063,867</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in;">Granted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">125,000</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.83</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in;">Exercised</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(9,066,666</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">1.98</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">48,535,969</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in;">Expired</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(2,500</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">2.64</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in;">Cancelled/Forfeited</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>Balance at December 31, 2017</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">3,115,905</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">2.58</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.8</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">11,348,273</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Vested and Exercisable at December 31, 2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,792,983</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">2.64</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.8</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">1,141,836</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>Unvested at December 31, 2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">322,922</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">2.57</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2.0</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">10,206,436</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The aggregate intrinsic value of warrants exercised during 2016 and 2015, was $3,988,343 and $7,282,404, respectively.&nbsp; The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2017, 2016 and 2015 are set forth in the table below.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 35%;">Weighted average exercise price</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">6.83</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">7.90</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">6.35</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>Weighted average grant date fair value</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.67</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">4.78</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.27</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Risk-free interest rate</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.47</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.04-1.28</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.02</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>Volatility</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">63.24</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">74.10-74.15</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">60.59</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Term (in years)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Dividend yield</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.00</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.00</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.00</td>
            <td style="text-align: left;">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the instrument. The estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the instrument as we have insufficient historical information regarding our stock options to provide a basis for estimate. The expected volatility of warrants was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  94; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->17
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1.</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013. These shares were exercised in 2017 and are included in the warrant exercise details below;</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px; text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">2.</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the years ended December 31, 2017, 2016, and 2015, we recorded $0, $77,026, and $154,068, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. As of December 31, 2017 this warrant was fully amortized. These shares were exercised in 2017 and are included in the warrant exercise details below; and</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">&nbsp;</td>
        </tr>
    </table>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 48px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 24px;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">3.</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">283,334 shares will vest upon the receipt by us, prior to the warrant expiration date of April 30,2018, of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that receipt of such an approval may occur in the near future.</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain new drug approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. During the years ended December 31, 2017, 2016, and 2015, we recorded $128,898, $257,796, and $257,796, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements. As of December 31, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized. This warrant was fully exercised, of which 800,000 shares were exercised in 2017 and 500,000 shares were exercised in 2016.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Warrant exercises</u></i></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999 in cash. In addition, during the year ended December 31, 2017, certain individuals exercised warrants to purchase 6,590,000 shares of Common Stock pursuant to the warrants&#x2019; cashless exercise provisions, wherein 4,762,208 shares of Common Stock were issued.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2016, certain individuals exercised warrants to purchase 722,744 shares of Common Stock for $1,373,000 in cash.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  95; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->18
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Options to Purchase Common Stock of the Company</u></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of December 31, 2017, there were non-qualified stock options to purchase 18,575,084 shares of Common Stock outstanding under the 2009 Plan. As of December 31, 2017, there were 2,173,878 shares available to be issued under 2009 Plan.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of December 31, 2017, there were non-qualified stock options to purchase 4,790,141 shares of Common Stock outstanding under the 2012 Plan. As of December 31, 2017, there were 5,128,333 shares available to be issued under 2012 Plan.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2017, 2016, and 2015 are set forth in the table below.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 35%; text-align: justify;">Weighted average exercise price</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">6.60</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">6.22</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">8.14</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>Weighted average grant date fair value</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.82</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.94</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">4.45</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Risk-free interest rate</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.84-2.05</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.13-1.90</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1.47-1.67</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Volatility</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">61.56-64.25</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">70.26-73.34</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">58.78-62.94</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Term (in years)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.5-6.25</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.5-6.25</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.27-6.25</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Dividend yield</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.00</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.00</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">0.00</td>
            <td style="text-align: left;">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards as we have insufficient historical information regarding our stock options to provide a basis for estimate. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to us with respect to industry, stage of life cycle, market capitalization, and financial leverage. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  96; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->19
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2017 is as follows:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Number of
                <br> Shares Under
                <br> Options</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted
                <br> Average
                <br> Exercise Price</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted
                <br> Average
                <br> Remaining
                <br> Contractual
                <br> Life in Years</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Aggregate
                <br> Intrinsic
                <br> Value</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 40%; text-align: justify;">Balance at December 31, 2016</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">21,767,854</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">3.56</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">5.8</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">60,495,730</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: justify;">Granted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">2,271,500</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.60</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: justify;">Exercised</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(102,546</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">2.07</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">452,287</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: justify;">Expired</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(108,375</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">7.64</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: justify;">Cancelled/Forfeited</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(463,208</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.28</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: justify;">Balance at December 31, 2017</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">23,365,225</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.78</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.13</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">64,664,821</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: justify;">Vested and Exercisable at December 31, 2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">19,770,142</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3.27</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4.47</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">63,895,512</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: justify;">Unvested at December 31, 2017</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">3,595,083</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">6.60</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">8.79</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">769,309</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At December 31, 2017, our outstanding options had exercise prices ranging from $0.10 to $8.92 per share. The aggregate intrinsic value of options exercised during 2016 and 2015, was $3,828,358 and $3,186,371, respectively. Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2017, 2016, and 2015 was approximately $6,447,154, $16,139,225, and $6,621,658, respectively, and it is based on awards vested. At December 31, 2017, total unrecognized estimated compensation expense related to unvested options was approximately $10,596,000, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.1 years. No tax benefit was realized due to a continued pattern of operating losses.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 9 &#x2013; INCOME TAXES</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">For financial reporting purposes, income before taxes includes the following components:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; width: 45%; text-align: left;">United States</td>
            <td style="padding-bottom: 1pt; width: 1%;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">$</td>
            <td style="border-bottom: Black 1pt solid; width: 12%; text-align: right;">(76,925,380</td>
            <td style="padding-bottom: 1pt; width: 1%; text-align: left;">)</td>
            <td style="padding-bottom: 1pt; width: 1%;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">$</td>
            <td style="border-bottom: Black 1pt solid; width: 12%; text-align: right;">(89,875,459</td>
            <td style="padding-bottom: 1pt; width: 1%; text-align: left;">)</td>
            <td style="padding-bottom: 1pt; width: 1%;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">$</td>
            <td style="border-bottom: Black 1pt solid; width: 12%; text-align: right;">(85,077,024</td>
            <td style="padding-bottom: 1pt; width: 1%; text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt;">Total</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(76,925,380</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(89,875,459</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">(85,077,024</td>
            <td style="padding-bottom: 2pt; text-align: left;">)</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="background-color: white; font-family: Times New Roman, Times, Serif; font-size: 10pt;">For the years ended December 31, 2017, 2016, and 2015, there was no provision for income taxes, current or deferred. </font>
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">At December 31, 2017, we had a federal net operating loss carry forward of approximately $338,613,987 available to offset future taxable income through 2037. The federal carryforwards will begin to expire in 2031.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 55%; text-align: left;">Federal statutory tax rate</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">34.0</td>
            <td style="width: 1%; text-align: left;">%</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">34.0</td>
            <td style="width: 1%; text-align: left;">%</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 12%; text-align: right;">34.0</td>
            <td style="width: 1%; text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">State tax rate, net of federal tax benefit</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.0</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">5.4</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">4.73</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Adjustment in valuation allowances</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">22.6</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(40.3</td>
            <td style="text-align: left;">)%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(38.97</td>
            <td style="text-align: left;">)%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Federal income tax rate change</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">(60.8</td>
            <td style="text-align: left;">)%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">%</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&#x2014;</td>
            <td style="text-align: left;">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; text-align: left;">Permanent and other differences</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(0.8</td>
            <td style="padding-bottom: 1pt; text-align: left;">)%</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">0.9</td>
            <td style="padding-bottom: 1pt; text-align: left;">%</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">0.24</td>
            <td style="padding-bottom: 1pt; text-align: left;">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: left;">(Provision) benefit for income taxes</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left;">%</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left;">%</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left;">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  97; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->20
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2017, 2016, and 2015 are as follows:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2017</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2016</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="text-align: left;">Deferred Income Tax Assets:</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; width: 45%; text-align: left;">Net operating losses</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">99,596,321</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">111,730,450</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">79,499,633</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left;">R&#38;D Credit</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">186,347</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">186,347</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">186,347</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-left: 0.25in; text-align: left;">Total deferred income tax asset</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">99,782,668</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">111,916,797</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">79,685,980</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left;">Valuation allowance</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(99,782,668</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(111,916,797</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">(79,685,980</td>
            <td style="padding-bottom: 1pt; text-align: left;">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="padding-bottom: 2pt; text-align: left;">Deferred income tax assets, net</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on the Company&#x2019;s Balance Sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Unrecognized Tax Benefits</i></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of the period ended December 31, 2017, we have no unrecognized tax benefits.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, effective January 1, 2018. Consequently, we have recorded a decrease related to deferred tax assets and deferred tax liabilities of approximately $49,500,000 and approximately $2,800,000, respectively, with a corresponding net adjustment to the valuation allowance of approximately $46,700,000 for the year ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Act modifies Section 162(m) of the Internal Revenue Code of 1986, as amended, or the IRC, by (1) expanding which employees
are considered covered employees by including the chief financial officer, (2) providing that if an individual is a covered employee
for a taxable year beginning after December 31, 2016, the individual remains a covered employee for all future years, and (3)
removing the exceptions for compensation stemming from contracts entered into on or before November 2, 2017, unless such contracts
were materially modified on or after the date. Compensation agreements entered into and share-based payment awards granted after
this date will be subject to the revised terms of IRC Section 162(m). In December 2017, the SEC staff issued Staff Accounting
Bulletin No. 118,&nbsp;<I>Income Tax Accounting Implications of the Tax Cuts and Jobs Act&nbsp;</I>(SAB 118), which allows us
to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Since the Tax Act
was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12
months, we consider the accounting for share-based compensation arrangements under the Tax Act to be incomplete due to the forthcoming
guidance and our ongoing analysis of final year-end data and tax positions.</FONT></P>

<P STYLE="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We must assess whether our valuation allowance analyses
are affected by various aspects of the Tax Act. Since, as discussed herein, we have recorded provisional amounts related to certain
portions of the Tax Act, any corresponding determination of the need for or change in a valuation allowance is also provisional.</FONT></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 10 &#x2013; RELATED PARTIES</u></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of our company since July 2015. During the years ended December 31, 2017, 2016 and 2015, we were billed by Catalent approximately $3,646,000, $3,647,000 and $1,266,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of December 31, 2017 and December 31, 2016, there were amounts due to Catalent of approximately $523,000 and $57,000, respectively.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 11 - BUSINESS CONCENTRATIONS</u></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We purchase our products from several suppliers with approximately 100%, 98%, and 60% of our purchases supplied by one vendor for the years ended December 31, 2017, 2016 and 2015, respectively.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the years ended December 31, 2017, 2016 and 2015; four, three, and two customers each, respectively, generated more than 10% of our revenues. Revenue generated from four major customers combined accounted for approximately 59% of our revenue during the year ended December 31, 2017. Revenue generated from three major customers combined accounted for approximately 41% of our revenue during the year ended December 31, 2016. Revenue generated from two major customers combined accounted for approximately 67% of our recognized revenue during the year ended December 31, 2015.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  98; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->21
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the year ended December 31, 2017, AmerisourceBergen generated approximately $2,667,000 of our revenue; McKesson Corporation generated approximately $1,959,000 of our revenue; Cardinal Health generated approximately $2,559,000 of our revenue and Pharmacy Innovations PA generated approximately $2,715,000 of our revenue. During the year ended December 31, 2016, Woodstock Pharmaceutical and Compounding generated approximately $2,247,000 of our revenue; Medical Center Pharmacy generated approximately $3,700,000 of our revenue and Pharmacy Innovations PA generated approximately $2,040,000 of our revenue. During the year ended December 31, 2015, Woodstock Pharmaceutical and Compounding generated approximately $8,848,000 of our revenue and Due West Pharmacy generated approximately $4,843,000 of our revenue.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As a result of developments in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&#x2019; reliance on third party payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming longer than in prior years. As a result, during the third quarter of 2016, we centralized the distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies and minimize business risk exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution agreements with our retail pharmacy distributors to effectuate this centralization which were effective September 1, 2016.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 12 &#x2013; COMMITMENTS AND CONTINGENCIES</u></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Operating Lease</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The rental expense related to our current lease during the years ended December 31, 2017, 2016 and 2015 was $1,029,205, $709,483, and $446,099, respectively.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, future minimum rental payments on non-cancelable operating leases are as follows:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Years Ending December 31,</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="text-align: justify;" colspan="2">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 20%; text-align: left;">2018</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 15%; text-align: right;">951,194</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2019</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,094,116</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2020</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">1,113,069</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2021</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">943,127</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">2022</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
            <td style="padding-bottom: 1pt; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: left;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Total minimum lease payments</font>
            </td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
            <td style="padding-bottom: 2pt;">&nbsp;</td>
            <td style="border-bottom: Black 2pt double; text-align: left;">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right;">4,101,506</td>
            <td style="padding-bottom: 2pt; text-align: left;">&nbsp;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><u>Legal Proceedings</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Off-Balance Sheet Arrangements</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2017, 2016, and 2015, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  99; Value:  8; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->22
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&nbsp;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Employment Agreements</u></font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>NOTE 13 &#x2013; SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Summarized quarterly financial data for fiscal years 2017 and 2016 is as follows:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">2017 Quarters</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; font-style: italic;">(In thousands, except per share)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">1<sup>st</sup></td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2<sup>nd</sup></td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">3<sup>rd</sup></td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">4th</td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 30%;">Revenues</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">3,985</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">4,250</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">4,418</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">4,125</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Gross profit</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,326</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,568</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,717</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,530</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Net loss</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(21,156</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(19,677</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(14,665</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(21,427</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Loss per common share, basic and diluted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.11</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.10</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.07</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.10</td>
            <td style="text-align: left;">)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td>&nbsp;</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">2016 Quarters</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
        </tr>
        <tr style="vertical-align: bottom;">
            <td style="padding-bottom: 1pt; font-style: italic;">(In thousands, except per share)</td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">1<sup>st</sup></td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2<sup>nd</sup></td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">3<sup>rd</sup></td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
            <td style="padding-bottom: 1pt;">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">4th</td>
            <td style="padding-bottom: 1pt; text-align: left;"></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="width: 30%;">Revenues</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">4,930</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">4,403</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">5,536</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
            <td style="width: 1%;">&nbsp;</td>
            <td style="width: 1%; text-align: left;">$</td>
            <td style="width: 12%; text-align: right;">4,487</td>
            <td style="width: 1%; text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td style="text-align: left;">Gross profit</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,822</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,273</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">4,298</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">3,778</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Net loss</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(20,929</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(21,094</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(25,016</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(22,836</td>
            <td style="text-align: left;">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom;">
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
            <td style="text-align: right;">&nbsp;</td>
            <td style="text-align: left;">&nbsp;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom;">
            <td style="text-align: left;">Loss per common share, basic and diluted</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.11</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.11</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.13</td>
            <td style="text-align: left;">)</td>
            <td>&nbsp;</td>
            <td style="text-align: left;">$</td>
            <td style="text-align: right;">(0.12</td>
            <td style="text-align: left;">)</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  100; Options:  Last; -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%; text-align: center">F-
                    <!-- Field: Sequence;  ; Type:  Arabic; Name:  PageNo; -->23
                    <!-- Field: /Sequence -->
                </td>
                <td style="width: 33%; text-align: right">&nbsp;</td>
            </tr>
        </table>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ex21-1.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<HTML>

<HEAD>
    <TITLE></TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.0 -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="background-color: white; margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10k_123117.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="background-color: white; margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 21.1</b></p>
    <p style="background-color: white; margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="background-color: white; margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><u>Subsidiaries of the Company</u></b></p>
    <p style="background-color: white; margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: bottom;">
            <td style="width: 50%;">
                <font style="font-size: 10pt;"><b>Name</b></font>
            </td>
            <td style="width: 50%; text-align: center;">
                <font style="font-size: 10pt;"><b>State or Jurisdiction of Incorporation or Organization</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="font-size: 10pt;">VitaMedMD, LLC</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Delaware</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="font-size: 10pt;">BocagreenMD, Inc.</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Nevada</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td>
                <font style="font-size: 10pt;">VitaCare Prescription Services, Inc.</font>
            </td>
            <td style="text-align: center;">
                <font style="font-size: 10pt;">Florida</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  1; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->1
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex23-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10k_123117.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 23.1</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>&nbsp;</b></p>
    <p style="line-height: 14.0pt; text-align: justify;">We have issued our reports dated February 23, 2018, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of TherapeuticsMD, Inc. (a Nevada Corporation) on Form 10-K for the year ended December 31, 2017. We consent to the incorporation by reference of said reports in the Registration Statements of TherapeuticsMD, Inc. on Forms S-3 (File No. 333-207837, File No. 333-185156, and File No. 333-201171) and on Form S-8 (File No. 333-191730).</p>
    <p style="line-height: 14.0pt; text-align: justify;">&nbsp;/s/ GRANT THORNTON LLP</p>
    <p style="line-height: 14.0pt; text-align: justify;">Fort Lauderdale, Florida</p>
    <p style="line-height: 14.0pt; text-align: justify;">February 23, 2018</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  2; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->2
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10k_123117.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.1</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Robert G. Finizio, certify that:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 24px; text-align: justify;">&nbsp;</td>
            <td style="width: 24px; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(c)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(d)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(5)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 24px; text-align: justify;">&nbsp;</td>
            <td style="width: 24px; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 50%; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Executive Officer</p>
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Executive Officer)</p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  3; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->3
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-2.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10k_123117.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.2</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Daniel A. Cartwright, certify that:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 24px; text-align: justify;">&nbsp;</td>
            <td style="width: 24px; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(c)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(d)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 24px; text-align: justify;">
                <font style="font-size: 10pt;">(5)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 24px;">&nbsp;</td>
            <td style="width: 24px; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 50%; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer</p>
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  4; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->4
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10k_123117.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 32.1</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In connection with the annual report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 50%; text-align: justify;">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 50%; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Chief Executive Officer </font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">(Principal Executive Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  5; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->5
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-2.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10k_123117.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 32.2</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In connection with the annual report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 50%; text-align: justify;">
                <font style="font-size: 10pt;">February 23, 2018</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 50%; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Chief Financial Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: justify;">&nbsp;</td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">(Principal Financial and Accounting Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; Options:  NewSection; Value:  6; -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type:  Arabic; Name:  PageNo; -->6
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>txmd-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\Clients\TherapeuticsMD\XBRL\20171231\txmd_123117.xfr; Date: 2018%2D02%2D23T16:57:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80280002 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20171231">
    <link:schemaRef xlink:href="txmd-20171231.xsd" xlink:type="simple" />
    <xbrli:context id="From2017-01-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_Patents1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_Patents2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-05to2016-01-06_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-05</xbrli:startDate>
        <xbrli:endDate>2016-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-01-06_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-11to2016-01-12_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-11</xbrli:startDate>
        <xbrli:endDate>2016-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-01to2012-05-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember_custom_IndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:IndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember_custom_IndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:IndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-24to2017-09-25_custom_JPMorganSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:JPMorganSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-24</xbrli:startDate>
        <xbrli:endDate>2017-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-25_custom_JPMorganSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:JPMorganSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-27to2017-09-28_custom_JPMorganSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:JPMorganSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-27</xbrli:startDate>
        <xbrli:endDate>2017-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:ThreeCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:PharmacyInnovationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_AmerisourceBergenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:AmerisourceBergenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CardinalHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CardinalHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_McKessonCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:McKessonCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_WoodstockPharmaceuticalAndCompoundingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:WoodstockPharmaceuticalAndCompoundingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_MedicalCenterPharmacyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MedicalCenterPharmacyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DueWestPharmacyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:DueWestPharmacyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FourCustomersMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FourCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">txmd:FourCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:PharmacyInnovationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-30to2016-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-30</xbrli:startDate>
        <xbrli:endDate>2016-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_CustomerConcentrationRisk1Member_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_CustomerConcentrationRisk2Member_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk1Member_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk2Member_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk3Member_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk4Member_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_Patents3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_Patents4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_DeferredTaxAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">txmd:DeferredTaxAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_DeferredTaxLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">txmd:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_WoodstockPharmaceuticalAndCompoundingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:WoodstockPharmaceuticalAndCompoundingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-02-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>txmd:Number</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2017-01-01to2017-12-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2017-01-01to2017-12-31">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2017-01-01to2017-12-31">10-K</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2017-01-01to2017-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-01-01to2017-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityVoluntaryFilers contextRef="From2017-01-01to2017-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2017-01-01to2017-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2017-01-01to2017-12-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-01-01to2017-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2017-01-01to2017-12-31">2017</dei:DocumentFiscalYearFocus>
    <dei:TradingSymbol contextRef="From2017-01-01to2017-12-31">TXMD</dei:TradingSymbol>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2017-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2016-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">228933</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1485358</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1062285</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">14036</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1485358</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1076321</us-gaap:InventoryNet>
    <txmd:PrepaidManufacturingCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">991809</txmd:PrepaidManufacturingCostsCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">680243</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">628039</us-gaap:PrepaidInsurance>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">100035</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">128898</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidVendorDepositsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">64411</txmd:PrepaidVendorDepositsCurrent>
    <txmd:PrepaidVendorDepositsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">44311</txmd:PrepaidVendorDepositsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">523694</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">405960</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">6604284</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2299052</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">809273</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">747456</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_EquipmentMember" unitRef="USD" decimals="0">273536</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">116542</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_EquipmentMember" unitRef="USD" decimals="0">215182</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">113079</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">372218</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">230617</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">437055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">516839</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">141601</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">77906</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">29959</us-gaap:Depreciation>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1293614</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2017-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1721305</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1093452</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1203987</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">272141</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">200626</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">8487</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">171911</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">6490</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">102393</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">23464</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1121703</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1721305</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">25461</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">991059</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">1203987</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2017-01-01to2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P11Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2017-01-01to2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2016-01-01to2016-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P12Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2016-01-01to2016-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P16Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2017-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">233275</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2016-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">185465</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2017-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">233275</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2016-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">185465</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3371888</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2606598</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3099747</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2405972</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">71516</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">54545</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">32441</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2017-01-01to2017-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31" unitRef="N" decimals="INF">18</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="N" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31_custom_Patents1Member" unitRef="N" decimals="INF">13</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31_us-gaap_PatentsMember" unitRef="N" decimals="INF">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31_custom_Patents2Member" unitRef="N" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31_custom_Patents3Member" unitRef="N" decimals="INF">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2017-12-31_custom_Patents4Member" unitRef="N" decimals="INF">3</txmd:NumberOfIssuedPatents>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">5335936</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">366933</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1281080</txmd:AccruedClinicalTrialCostsCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">4240379</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">3531440</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">945457</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">665561</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">600350</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">176518</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">420162</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">665773</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">602916</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">224865</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">172973</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76510</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">114480</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">26507</us-gaap:AccruedRoyaltiesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1432846</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">794816</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">327099</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">181015</us-gaap:AccruedRentCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">9223595</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">7624085</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">26481130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">33827925</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">23365225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3115905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12060071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">21767854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">33447756</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">20725325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12722431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.6156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.7026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.5878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.6425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.7334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.6294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">21767854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">23365225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">18575084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">4790141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">2271500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">102546</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">102546</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">613195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">612981</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">19770142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">3595083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.60</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P5Y1M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">60495730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">64664821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">452287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">3828358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">3186371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">63895512</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">769309</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">216429642</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">196688222</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">216429642</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">196688222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">196688222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">216429642</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">177928041</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">212615</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">989060</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1232579</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">103</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">613</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">613</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">212512</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">988447</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1231966</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">1232579</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-11to2016-01-12_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">17424242</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-09-27to2017-09-28_custom_JPMorganSecuritiesLLCMember" unitRef="Shares" decimals="INF">12400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">12400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">17424242</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20040359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">4423077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">15617282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="AsOf2016-01-06_custom_GoldmanSachsMember" unitRef="USDPShares" decimals="INF">8.25</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2017-09-25_custom_JPMorganSecuritiesLLCMember" unitRef="USDPShares" decimals="INF">5.55</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-07-09_custom_StifelUnderwritersMember" unitRef="USDPShares" decimals="INF">7.80</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USDPShares" decimals="INF">4.05</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">68572635</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">134863475</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">91374649</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">17424</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">20040</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">68560235</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">134846051</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">91354609</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">2272727</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">576923</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">2037036</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">6.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-05-31_custom_Warrant1Member" unitRef="USDPShares" decimals="INF">2.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member" unitRef="Shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2016-01-01to2016-12-31_custom_OutsideConsultant2Member" unitRef="Shares" decimals="INF">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Shares" decimals="INF">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" unitRef="Shares" decimals="INF">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">6889323</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">17411021</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">313271</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">936974</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">128898</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">257796</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="USD" decimals="0">405066</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="USD" decimals="0">77026</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">7189699</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">139142</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="USD" decimals="0">154068</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">257796</us-gaap:ShareBasedCompensation>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member">2022-03-15</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2016-01-01to2016-12-31_custom_OutsideConsultant2Member">2021-01-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember">2021-04-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">2021-04-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">2021-01-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember">2020-04-06</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2016-01-01to2016-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_custom_NonQualified2012StockIncentivePlanMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member_us-gaap_ShareBasedCompensationAwardTrancheOneMember">2016-04-21</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.6324</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0.4471</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.4584</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.0147</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0.0074</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.0141</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2017-01-01to2017-12-31_custom_OutsideConsultant2Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">128000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="USD" decimals="0">1532228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="USD" decimals="0">405066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="USD" decimals="0">462196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">850000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Shares" decimals="INF">1300000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">833000</txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-05-01to2013-05-11_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">2173878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">5128333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">6447154</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">16139225</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">6621658</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">10596000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2017-01-01to2017-12-31">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">3798999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1373000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="USD" decimals="0">3798999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="USD" decimals="0">1373000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">366000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7239</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">723</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1178</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3791760</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1372277</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">364822</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">366000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="Shares" decimals="INF">2476666</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember_custom_IndividualsMember" unitRef="Shares" decimals="INF">722744</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-12-31_custom_Warrant2Member" unitRef="Shares" decimals="INF">4762208</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7238874</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">722744</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1177682</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">945485</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-12-31_custom_Warrant2Member" unitRef="Shares" decimals="INF">232197</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-01-01to2017-12-31_custom_LongTermIncentiveCompensationPlan2009Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-01-01to2017-12-31_custom_NonQualified2012StockIncentivePlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">9066666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-01-01to2017-12-31_custom_Warrant1Member" unitRef="Shares" decimals="INF">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2016-01-01to2016-12-31_custom_Warrant1Member" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-01-01to2017-12-31_custom_Warrant2Member" unitRef="Shares" decimals="INF">6590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1255485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2015-01-01to2015-12-31_custom_Warrant2Member" unitRef="Shares" decimals="INF">310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">102546</txmd:NumberOfStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">523362</txmd:NumberOfStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">612867</txmd:NumberOfStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">127109</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">417</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">87833</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">114</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2017-01-01to2017-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">3646000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2016-01-01to2016-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">3647000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2015-01-01to2015-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">1266000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2017-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">523000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2016-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">57000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">1.00</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" unitRef="Pure" decimals="INF">.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember" unitRef="Pure" decimals="INF">.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FourCustomersMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_FourCustomersMember" unitRef="Pure" decimals="INF">.59</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-12-31_custom_CustomerConcentrationRisk1Member_us-gaap_AccountsReceivableMember" unitRef="Pure" decimals="INF">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-12-31_custom_CustomerConcentrationRisk2Member_us-gaap_AccountsReceivableMember" unitRef="Pure" decimals="INF">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk1Member_us-gaap_AccountsReceivableMember" unitRef="Pure" decimals="INF">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk2Member_us-gaap_AccountsReceivableMember" unitRef="Pure" decimals="INF">.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk3Member_us-gaap_AccountsReceivableMember" unitRef="Pure" decimals="INF">.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-01-01to2017-12-31_custom_CustomerConcentrationRisk4Member_us-gaap_AccountsReceivableMember" unitRef="Pure" decimals="INF">.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">16777713</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="-3">4125000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="-3">4487000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">19356450</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsMember" unitRef="USD" decimals="0">2715000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_AmerisourceBergenMember" unitRef="USD" decimals="0">2667000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CardinalHealthMember" unitRef="USD" decimals="0">2559000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_McKessonCorporationMember" unitRef="USD" decimals="0">1959000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_WoodstockPharmaceuticalAndCompoundingMember" unitRef="USD" decimals="0">2247000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_MedicalCenterPharmacyMember" unitRef="USD" decimals="0">3700000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_DueWestPharmacyMember" unitRef="USD" decimals="0">4843000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_PharmacyInnovationsMember" unitRef="USD" decimals="0">2040000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">20142898</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="-3">4930000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="-3">4403000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="-3">5536000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="-3">3985000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="-3">4250000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="-3">4418000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_WoodstockPharmaceuticalAndCompoundingMember" unitRef="USD" decimals="0">8848000</us-gaap:SalesRevenueNet>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">951194</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">4101506</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2017-01-01to2017-12-31">P63M</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">1029205</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">709843</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">446099</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseExpirationDate1 contextRef="From2016-04-30to2016-05-01">2021-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:Cash contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">127135628</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">131534101</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">64706355</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">51361607</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">4328802</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">4500699</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">139554072</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">139410173</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">139036</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">139036</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3238783</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2545008</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">143229910</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">142472020</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">4097600</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">7358514</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">13321195</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">14982599</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">216430</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">196688</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">516351405</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">436995052</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">-386659120</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">-309702319</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">129908715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">127489421</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">63063146</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">196688</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">216430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">177928</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">156097</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">436995052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">516351405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">282712078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">182982846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-309702319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-386659120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-219826860</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-134749836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">48389107</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">143229910</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">142472020</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">380580</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">376374</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <txmd:OptionExercisePrices contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.10</txmd:OptionExercisePrices>
    <txmd:OptionExercisePrices contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">8.92</txmd:OptionExercisePrices>
    <dei:DocumentPeriodEndDate contextRef="From2017-01-01to2017-12-31">2017-12-31</dei:DocumentPeriodEndDate>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-76925380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="-3">-21427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="-3">-22836000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-89875459</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85077024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-76925380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-89875459</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-85077024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="-3">-20929000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="-3">-21094000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="-3">-25016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="-3">-21156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="-3">-19677000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="-3">-14665000</us-gaap:NetIncomeLoss>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">4206</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2524909</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">22157</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-167691</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">3975893</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">917656</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">409037</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">386168</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-491960</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">4434130</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-709907</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">773532</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">17442</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-3260914</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">4232340</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-3200955</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-522613</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">1599510</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">84559</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">3698887</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-76155614</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-69142333</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-79044119</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">765291</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">845266</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">419104</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">61817</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">396154</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">165257</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-827108</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-1255456</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-584361</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">68572635</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">134863475</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="USD" decimals="0">134864000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-09-24to2017-09-25_custom_JPMorganSecuritiesLLCMember" unitRef="USD" decimals="0">68573000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">91374649</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="USD" decimals="0">32257000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USD" decimals="0">59118000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">212615</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">989060</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1232579</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">3798999</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1373000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">366000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">72584249</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">137225535</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">92973228</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-4398473</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">66827746</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">13344748</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">6760425</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">17076199</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">6777835</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6760425</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17076199</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6777835</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">7699</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">10824</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">17442</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:OtherNonoperatingIncome contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">695631</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">367317</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">95719</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-77628710</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-90253600</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85190185</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">91769480</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">105424342</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">100826410</us-gaap:OperatingExpenses>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">213117</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">132451</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">62400</us-gaap:DepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">33852993</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">53943477</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">72042774</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">57703370</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">51348414</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">28721236</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GrossProfit contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">14140770</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="-3">3530000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="-3">3778000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">15170742</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">15636225</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="-3">3822000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="-3">3273000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="-3">4298000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="-3">3326000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="-3">3568000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="-3">3717000</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsSold contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2636943</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">4185708</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">4506673</us-gaap:CostOfGoodsSold>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">703330</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">378141</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">113161</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-10-01to2017-12-31" unitRef="USDPShares" decimals="INF">-.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-10-01to2016-12-31" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" decimals="INF">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" decimals="INF">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-03-31" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-07-01to2016-09-30" unitRef="USDPShares" decimals="INF">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-03-31" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-04-01to2017-06-30" unitRef="USDPShares" decimals="INF">-.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-07-01to2017-09-30" unitRef="USDPShares" decimals="INF">-.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">205523288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">196088196</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">173174229</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-76925380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-89875459</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85077024</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2017-01-01to2017-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_us-gaap_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2017-01-01to2017-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_us-gaap_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AdvertisingExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">448288</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">752611</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">792574</us-gaap:AdvertisingExpense>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2017-01-01to2017-12-31_us-gaap_MinimumMember">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2017-01-01to2017-12-31_us-gaap_MaximumMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76777</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76777</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76777</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76777</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">76777</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">761282</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue contextRef="AsOf2016-12-31_custom_OutsideConsultant2Member" unitRef="USDPShares" decimals="INF">7.90</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.58</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.08</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue contextRef="AsOf2015-12-31_custom_OutsideConsultantMember" unitRef="USDPShares" decimals="INF">6.35</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">11348273</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">45063867</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.83</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">7.90</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">.0147</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0102</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0128</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">.6324</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.6059</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.7410</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.7415</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1 contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.83</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.98</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.64</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.64</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">48535969</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">3988343</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">7282404</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">1141836</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">10206436</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P1Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P9M18D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P2Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">108375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">463208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">7.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">8.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P4Y5M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P8Y9M14D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31_us-gaap_ScenarioForecastMember" unitRef="Pure" decimals="INF">.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2017-01-01to2017-12-31" unitRef="Pure" decimals="INF">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">0.0473</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2017-01-01to2017-12-31" unitRef="Pure" decimals="INF">.226</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">-0.403</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">-0.3897</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2017-01-01to2017-12-31" unitRef="Pure" decimals="INF">-.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">0.0024</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">99596321</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">111730450</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">79499633</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">99782668</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">111916797</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">79685980</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">99782668</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">111916797</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">79685980</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-12-31_us-gaap_InternalRevenueServiceIRSMember" unitRef="USD" decimals="0">338613987</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-76925380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-89875459</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85077024</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2017-01-01to2017-12-31_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">-76925380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2016-01-01to2016-12-31_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">-89875459</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2015-01-01to2015-12-31_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">-85077024</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Pure" decimals="INF">-.608</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1094116</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1113069</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">943127</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">2200000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2017-01-01to2017-12-31">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <us-gaap:NumberOfOperatingSegments contextRef="From2017-01-01to2017-12-31" unitRef="N" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1 contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">31000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1>
    <txmd:NumberOfSharesOfferedInUnderwritingAgreement contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">15151515</txmd:NumberOfSharesOfferedInUnderwritingAgreement>
    <txmd:NumberOfSharesOfferedInUnderwritingAgreement contextRef="From2017-09-24to2017-09-25_custom_JPMorganSecuritiesLLCMember" unitRef="Shares" decimals="INF">12400000</txmd:NumberOfSharesOfferedInUnderwritingAgreement>
    <txmd:NumberOfSharesOfferedInUnderwritingAgreement contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">3846154</txmd:NumberOfSharesOfferedInUnderwritingAgreement>
    <txmd:NumberOfSharesOfferedInUnderwritingAgreement contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">13580246</txmd:NumberOfSharesOfferedInUnderwritingAgreement>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">3115905</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember">P1Y9M18D</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">322922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrantsMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" unitRef="Shares" decimals="INF">283334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-46700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2017-01-01to2017-12-31_custom_DeferredTaxAssetMember" unitRef="USD" decimals="0">-49500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2017-01-01to2017-12-31_custom_DeferredTaxLiabilitiesMember" unitRef="USD" decimals="0">2800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:NatureOfOperations contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;1 &amp;#8211; THE COMPANY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD,&#13;Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware&#13;limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,&#13;Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare&#13;collectively are sometimes referred to as &amp;#8220;our company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our,&amp;#8221; or &amp;#8220;us.&amp;#8221;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Nature&#13;of Business&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are a women&amp;#8217;s health care company focused on creating and commercializing products targeted exclusively for women. Currently,&#13;we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our&#13;advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate&#13;the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis&#13;and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone&#13;or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile&#13;compared with competing products. With our SYMBODA&amp;#8482; technology, we are developing advanced hormone therapy pharmaceutical&#13;products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition,&#13;we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements,&#13;which we ceased manufacturing in October 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;2 &amp;#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Principles&#13;of Consolidation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed,&#13;BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &amp;#8220;FDIC&amp;#8221;)&#13;insured limits of $250,000 per bank. We have never experienced any losses related to these funds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Trade&#13;Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade&#13;accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts&#13;and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,&#13;historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than&#13;90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual&#13;credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts&#13;previously written off when received as an increase in the allowance for doubtful accounts. &lt;font style="color: #252525"&gt;To the&#13;extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be &lt;/font&gt;required.&#13;At December 31, 2017, four different customers represented 27%, 23%, 22% and 11%, respectively, of our gross accounts receivable.&#13;At December 31, 2016, two different customers represented 28% and 20%, respectively, of our gross accounts receivable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the third quarter of 2016, we wrote-off accounts receivable balances of approximately $2,200,000 related to two retail pharmacy&#13;distributors. Both pharmacies are relatively small owner-managed pharmacies and share a similar amount of collection risk. Among&#13;the factors that contributed to our decision to write-off these balances were our inability to collect the outstanding balances&#13;and the lack of a continuing communication and business relationship with these parties following the centralization of the distribution&#13;channel for both our retail pharmacy distributors and wholesale distributors, effective September 1, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories&#13;represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or&#13;net realizable value using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete&#13;or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product&#13;improvements rendering previous versions obsolete.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Pre-Launch&#13;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is&#13;probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit&#13;cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research&#13;and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fixed&#13;Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the&#13;useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line&#13;method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are&#13;depreciated over the shorter of their useful life or the term of the lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;capitalize software and software development costs incurred to create and acquire computer software for internal use, principally&#13;related to software coding and application development. We begin to capitalize software development costs when both the preliminary&#13;project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only&#13;external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized&#13;on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Intangible&#13;Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350,&#13;&lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside&#13;legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized&#13;patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off&#13;any capitalized patent costs at that time. As of December 31, 2017, we had 18 issued patents (See Note 6). We capitalize external&#13;costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized.&#13;We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not&#13;be recoverable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Impairment&#13;of Long-Lived Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events&#13;or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include,&#13;among others, the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    declines in an asset&amp;#8217;s market price;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    deterioration in an asset&amp;#8217;s physical condition;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    changes in the nature or extent of an asset&amp;#8217;s use or operation;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    adverse changes in the business climate that could impact an asset&amp;#8217;s value, including adverse actions or assessments&#13;    by regulators;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;accumulation&#13;    of costs significantly in excess of original expectations related to the acquisition or construction of an asset;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;current-period&#13;    operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated&#13;    with an asset&amp;#8217;s use; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;expectations&#13;    that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously&#13;    estimated useful life.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;If&#13;impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset&#13;or asset group&amp;#8217;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level&#13;for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination&#13;of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual&#13;disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values&#13;are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived&#13;from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization,&#13;including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production.&#13;If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&amp;#8217; fair&#13;value and respective carrying values. We determine the fair value of the assets using an &amp;#8220;income approach&amp;#8221; based upon&#13;a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant&#13;estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount&#13;rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information&#13;about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and&#13;changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.&#13;There was no impairment of long-lived assets to be held and used during the years ended December 31, 2017, 2016, and 2015.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;perform impairment tests for intangible assets with indefinite useful lives annually, or more frequently if events occur or circumstances&#13;change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test&#13;for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying&#13;amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There&#13;was no impairment of indefinite lived intangible assets during the years ended December 31, 2017, 2016, and 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair&#13;Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount&#13;of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity&#13;of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy&#13;as defined by ASC 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in&#13;active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and&#13;liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 87%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted&#13;    quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 87%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices&#13;    for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;    or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 87%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable&#13;    inputs for the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in&#13;connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31,&#13;2017, 2016, and 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Income&#13;Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated&#13;future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities&#13;and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable&#13;income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect&#13;on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded&#13;to reduce deferred tax assets to the amount that will more likely than not be realized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, we recognize the effect of uncertain income tax positions only if the positions&#13;are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized&#13;uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes&#13;in recognition or measurement are reflected in the period in which those changes in judgment occur.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31,&#13;2017 and 2016, we had no tax positions relating to open tax returns that were considered to be uncertain.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after&#13;2013 are subject to review.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based&#13;Compensation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs&#13;in the financial statements over the period during which employees are required to provide services. Share-based compensation&#13;arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and&#13;employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.&#13;We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,&#13;&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, to value options. Option valuation models require the input of assumptions, including&#13;the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected&#13;dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds&#13;whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which&#13;our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility&#13;of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available&#13;that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage.&#13;On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose&#13;stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical&#13;stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms&#13;of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid&#13;cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the&#13;input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based&#13;award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based&#13;awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment.&#13;As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different&#13;in the future.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Equity&#13;instruments (&amp;#8220;instruments&amp;#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,&#13;as required by ASC 505, &lt;i&gt;Equity - Based Payments to Non-Employees&lt;/i&gt;, or ASC 505&lt;i&gt;. &lt;/i&gt;ASC 505 defines the measurement date&#13;and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as&#13;defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The&#13;estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related&#13;to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement&#13;date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular&#13;grant as defined in ASC 505.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant&#13;date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis&#13;over the employee&amp;#8217;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures.&#13;If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly&#13;different from what we have recorded in the current period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue&#13;Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize revenue on arrangements in accordance with ASC 605, &lt;i&gt;Revenue Recognition&lt;/i&gt;. We recognize revenue only when the price&#13;is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably&#13;assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation&#13;and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers&#13;of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products&#13;pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing&#13;support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which we ceased manufacturing in October 2017. The revenue that is generated by us from major customers&#13;is all generated from sales of our prescription prenatal vitamin products, which is disclosed in Note 11. There are no major customers&#13;for our OTC prenatal vitamin or other products.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,&#13;when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if&#13;any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC&#13;customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit&#13;card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back&#13;return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC&#13;sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which we ceased manufacturing in October 2017.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy&#13;distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees,&#13;customer rebates, coupons and estimated returns.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped&#13;to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products&#13;sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.&#13;Our prescription products currently have a shelf life of 24 months from the date of manufacture.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prior&#13;to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the&#13;product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were&#13;known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the&#13;distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader&#13;population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription&#13;products are distributed under the wholesale distributor model described above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer&#13;loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry&#13;averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated&#13;in contracts and estimate chargebacks based on the number of units sold each period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment&#13;Reporting&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.&#13;Our business operations are managed by a single management team that reports to the President of our company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect&#13;to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one&#13;reportable operating segment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Shipping&#13;and Handling Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Advertising&#13;Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;expense advertising costs when incurred. Advertising costs were $448,288, $752,611, and $792,574 during the years ended December&#13;31, 2017, 2016, and 2015, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research&#13;and Development Expenses&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations,&#13;or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal&#13;R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance&#13;payments to be expensed in future research and development activities are capitalized, and were $0 and $228,933 at December 31,&#13;2017 and 2016, respectively, all of which was included in other current assets on the accompanying consolidated balance sheets.&#13;CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory&#13;consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses&#13;include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,&#13;or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and&#13;FDA submissions. Legal activities that were classified as R&amp;#38;D expenses include professional research and advice regarding&#13;R&amp;#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing,&#13;and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity&#13;expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance&#13;of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D&#13;activities when the activity has been performed or when the goods have been received rather than when the payment is made. We&#13;review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs&#13;applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such&#13;studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become&#13;known.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Earnings&#13;Per Share&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and&#13;disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common&#13;stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average&#13;number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the&#13;period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation&#13;of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table&#13;below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common&#13;stockholders for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;    of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 25%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,365,225&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,115,905&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,060,071&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,722,431&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,481,130&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,827,925&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,447,756&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Concentration&#13;of Credit Risk and other Risks and Uncertainties&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financial&#13;instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable.&#13;Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance&#13;provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Concentration&#13;of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail&#13;pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&amp;#8217;s financial condition, and&#13;collateral is not required.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Use&#13;of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#13;States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments&#13;that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities.&#13;We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical&#13;experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form&#13;the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&#13;Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently&#13;Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the FASB issued ASU 2017-09, which clarifies when changes to the terms or conditions of a share-based payment award&#13;must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the&#13;terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards&#13;without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will&#13;be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods&#13;within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We&#13;adopted this guidance and it did not have an impact on our consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity&#13;in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for&#13;public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years.&#13;Early adoption is permitted with retrospective application. We adopted this guidance and it did not have an impact on our consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2016, the FASB issued ASU 2016-09, Compensation &amp;#8211; Stock Compensation: Improvements to Employee Share-Based Payment&#13;Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both&#13;public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,&#13;as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years&#13;beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&amp;#160;ASU&amp;#160;2016-09&amp;#160;effective&#13;January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture&#13;rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of&#13;approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies&#13;in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full&#13;valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to&#13;recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained&#13;earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated&#13;financial statements.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets&#13;but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current&#13;real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting&#13;for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning&#13;after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process&#13;of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing&#13;to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to&#13;the accounting for our operating lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#8217;s core principle&#13;is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects&#13;the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies&#13;will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance&#13;obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating&#13;the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective&#13;date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for&#13;public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB&#13;issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting&#13;for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical&#13;expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We&#13;have performed a review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition&#13;resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step&#13;model of the new standard to our contracts as well as compared the results to our current accounting practices. We are currently&#13;in the process of drafting disclosures required by the new standard. At this point of our analysis, we do not believe that the&#13;adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures&#13;related to contracts with customers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Principles&#13;of Consolidation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed,&#13;BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &amp;#8220;FDIC&amp;#8221;)&#13;insured limits of $250,000 per bank. We have never experienced any losses related to these funds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Trade&#13;Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade&#13;accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts&#13;and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,&#13;historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than&#13;90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual&#13;credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts&#13;previously written off when received as an increase in the allowance for doubtful accounts. &lt;font style="color: #252525"&gt;To the&#13;extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be &lt;/font&gt;required.&#13;At December 31, 2017, four different customers represented 27%, 23%, 22% and 11%, respectively, of our gross accounts receivable.&#13;At December 31, 2016, two different customers represented 28% and 20%, respectively, of our gross accounts receivable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the third quarter of 2016, we wrote-off accounts receivable balances of approximately $2,200,000 related to two retail pharmacy&#13;distributors. Both pharmacies are relatively small owner-managed pharmacies and share a similar amount of collection risk. Among&#13;the factors that contributed to our decision to write-off these balances were our inability to collect the outstanding balances&#13;and the lack of a continuing communication and business relationship with these parties following the centralization of the distribution&#13;channel for both our retail pharmacy distributors and wholesale distributors, effective September 1, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories&#13;represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or&#13;net realizable value using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete&#13;or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product&#13;improvements rendering previous versions obsolete.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <txmd:PrelaunchInventoryPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Pre-Launch&#13;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is&#13;probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit&#13;cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research&#13;and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</txmd:PrelaunchInventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fixed&#13;Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the&#13;useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line&#13;method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are&#13;depreciated over the shorter of their useful life or the term of the lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;capitalize software and software development costs incurred to create and acquire computer software for internal use, principally&#13;related to software coding and application development. We begin to capitalize software development costs when both the preliminary&#13;project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only&#13;external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized&#13;on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Intangible&#13;Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350,&#13;&lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside&#13;legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized&#13;patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off&#13;any capitalized patent costs at that time. As of December 31, 2017, we had 18 issued patents (See Note 6). We capitalize external&#13;costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized.&#13;We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not&#13;be recoverable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Impairment&#13;of Long-Lived Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events&#13;or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include,&#13;among others, the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    declines in an asset&amp;#8217;s market price;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    deterioration in an asset&amp;#8217;s physical condition;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    changes in the nature or extent of an asset&amp;#8217;s use or operation;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant&#13;    adverse changes in the business climate that could impact an asset&amp;#8217;s value, including adverse actions or assessments&#13;    by regulators;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;accumulation&#13;    of costs significantly in excess of original expectations related to the acquisition or construction of an asset;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;current-period&#13;    operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated&#13;    with an asset&amp;#8217;s use; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;expectations&#13;    that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously&#13;    estimated useful life.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;If&#13;impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset&#13;or asset group&amp;#8217;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level&#13;for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination&#13;of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual&#13;disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values&#13;are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived&#13;from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization,&#13;including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production.&#13;If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&amp;#8217; fair&#13;value and respective carrying values. We determine the fair value of the assets using an &amp;#8220;income approach&amp;#8221; based upon&#13;a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant&#13;estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount&#13;rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information&#13;about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and&#13;changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.&#13;There was no impairment of long-lived assets to be held and used during the years ended December 31, 2017, 2016, and 2015.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;perform impairment tests for intangible assets with indefinite useful lives annually, or more frequently if events occur or circumstances&#13;change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test&#13;for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying&#13;amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There&#13;was no impairment of indefinite lived intangible assets during the years ended December 31, 2017, 2016, and 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair&#13;Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount&#13;of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity&#13;of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy&#13;as defined by ASC 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in&#13;active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and&#13;liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 87%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted&#13;    quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 87%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices&#13;    for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;    or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 87%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable&#13;    inputs for the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in&#13;connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31,&#13;2017, 2016, and 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Income&#13;Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated&#13;future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities&#13;and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable&#13;income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect&#13;on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded&#13;to reduce deferred tax assets to the amount that will more likely than not be realized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, we recognize the effect of uncertain income tax positions only if the positions&#13;are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized&#13;uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes&#13;in recognition or measurement are reflected in the period in which those changes in judgment occur.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31,&#13;2017 and 2016, we had no tax positions relating to open tax returns that were considered to be uncertain.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after&#13;2013 are subject to review.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based&#13;Compensation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs&#13;in the financial statements over the period during which employees are required to provide services. Share-based compensation&#13;arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and&#13;employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.&#13;We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,&#13;&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, to value options. Option valuation models require the input of assumptions, including&#13;the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected&#13;dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds&#13;whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which&#13;our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility&#13;of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available&#13;that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage.&#13;On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose&#13;stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical&#13;stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms&#13;of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid&#13;cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the&#13;input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based&#13;award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based&#13;awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment.&#13;As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different&#13;in the future.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Equity&#13;instruments (&amp;#8220;instruments&amp;#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,&#13;as required by ASC 505, &lt;i&gt;Equity - Based Payments to Non-Employees&lt;/i&gt;, or ASC 505&lt;i&gt;. &lt;/i&gt;ASC 505 defines the measurement date&#13;and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as&#13;defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The&#13;estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related&#13;to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement&#13;date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular&#13;grant as defined in ASC 505.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant&#13;date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis&#13;over the employee&amp;#8217;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures.&#13;If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly&#13;different from what we have recorded in the current period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue&#13;Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;recognize revenue on arrangements in accordance with ASC 605, &lt;i&gt;Revenue Recognition&lt;/i&gt;. We recognize revenue only when the price&#13;is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably&#13;assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation&#13;and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers&#13;of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products&#13;pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing&#13;support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which we ceased manufacturing in October 2017. The revenue that is generated by us from major customers&#13;is all generated from sales of our prescription prenatal vitamin products, which is disclosed in Note 11. There are no major customers&#13;for our OTC prenatal vitamin or other products.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <txmd:OverTheCounterProductsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,&#13;when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if&#13;any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC&#13;customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit&#13;card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back&#13;return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC&#13;sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product&#13;lines, except for Iron 21/7, which we ceased manufacturing in October 2017.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</txmd:OverTheCounterProductsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment&#13;Reporting&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.&#13;Our business operations are managed by a single management team that reports to the President of our company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect&#13;to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one&#13;reportable operating segment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Shipping&#13;and Handling Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Advertising&#13;Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;expense advertising costs when incurred. Advertising costs were $448,288, $752,611, and $792,574 during the years ended December&#13;31, 2017, 2016, and 2015, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research&#13;and Development Expenses&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations,&#13;or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal&#13;R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance&#13;payments to be expensed in future research and development activities are capitalized, and were $0 and $228,933 at December 31,&#13;2017 and 2016, respectively, all of which was included in other current assets on the accompanying consolidated balance sheets.&#13;CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory&#13;consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses&#13;include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,&#13;or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and&#13;FDA submissions. Legal activities that were classified as R&amp;#38;D expenses include professional research and advice regarding&#13;R&amp;#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing,&#13;and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity&#13;expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance&#13;of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D&#13;activities when the activity has been performed or when the goods have been received rather than when the payment is made. We&#13;review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs&#13;applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such&#13;studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become&#13;known.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Earnings&#13;Per Share&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and&#13;disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common&#13;stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average&#13;number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the&#13;period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation&#13;of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table&#13;below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common&#13;stockholders for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;    of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 25%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,365,225&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,115,905&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,060,071&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,722,431&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,481,130&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,827,925&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,447,756&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable&#13;to common stockholders for the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;    of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 25%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,365,225&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,115,905&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,060,071&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,722,431&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,481,130&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,827,925&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,447,756&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Concentration&#13;of Credit Risk and other Risks and Uncertainties&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financial&#13;instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable.&#13;Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance&#13;provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Concentration&#13;of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail&#13;pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&amp;#8217;s financial condition, and&#13;collateral is not required.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Use&#13;of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Our&#13;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#13;States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments&#13;that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities.&#13;We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical&#13;experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form&#13;the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&#13;Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently&#13;Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the FASB issued ASU 2017-09, which clarifies when changes to the terms or conditions of a share-based payment award&#13;must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the&#13;terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards&#13;without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will&#13;be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods&#13;within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We&#13;adopted this guidance and it did not have an impact on our consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity&#13;in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for&#13;public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years.&#13;Early adoption is permitted with retrospective application. We adopted this guidance and it did not have an impact on our consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2016, the FASB issued ASU 2016-09, Compensation &amp;#8211; Stock Compensation: Improvements to Employee Share-Based Payment&#13;Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both&#13;public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,&#13;as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years&#13;beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&amp;#160;ASU&amp;#160;2016-09&amp;#160;effective&#13;January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture&#13;rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of&#13;approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies&#13;in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full&#13;valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to&#13;recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained&#13;earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated&#13;financial statements.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets&#13;but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current&#13;real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting&#13;for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning&#13;after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process&#13;of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing&#13;to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to&#13;the accounting for our operating lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#8217;s core principle&#13;is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects&#13;the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies&#13;will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance&#13;obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating&#13;the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective&#13;date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for&#13;public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB&#13;issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting&#13;for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical&#13;expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We&#13;have performed a review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition&#13;resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step&#13;model of the new standard to our contracts as well as compared the results to our current accounting practices. We are currently&#13;in the process of drafting disclosures required by the new standard. At this point of our analysis, we do not believe that the&#13;adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures&#13;related to contracts with customers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;3 &amp;#8211; INVENTORY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    product&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,485,358&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,062,285&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,036&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,485,358&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,076,321&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    product&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,485,358&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,062,285&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,036&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,485,358&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,076,321&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;4 &amp;#8211; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5,335,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;680,243&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;628,039&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;991,809&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;128,898&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;523,694&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;405,960&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;64,411&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,311&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100,035&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,604,284&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,299,052&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current assets consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5,335,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;680,243&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;628,039&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;991,809&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;128,898&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;523,694&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;405,960&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;64,411&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,311&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;100,035&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,604,284&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,299,052&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;5 &amp;#8211; FIXED ASSETS, NET&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets, net consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;273,536&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;215,182&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;116,542&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;113,079&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;37,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;37,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;809,273&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;747,456&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(372,218&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(230,617&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;437,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;516,839&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&#13;expense for the years ended December 31, 2017, 2016, and 2015 was $141,601, $77,906, and $29,959, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets, net consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;273,536&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;215,182&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;116,542&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;113,079&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;37,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;37,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;809,273&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;747,456&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(372,218&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(230,617&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;437,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;516,839&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;6 &amp;#8211; INTANGIBLE ASSETS, NET&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets&#13;as of December 31, 2017 and 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13; Carrying&lt;br /&gt;&#13; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Net &lt;br /&gt; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted- &lt;br /&gt;&#13;Average &lt;br /&gt; Remaining &lt;br /&gt; Amortization&lt;br /&gt;&#13; Period (yrs.)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(8,487&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;23,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;11.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,293,614&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(171,911&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,121,703&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,721,305&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,721,305&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;233,275&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;233,275&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,371,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(272,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,099,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13; Carrying&lt;br /&gt;&#13; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Net &lt;br /&gt; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;&#13; Average &lt;br /&gt; Remaining &lt;br /&gt; Amortization&lt;br /&gt;&#13; Period (yrs.)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(6,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;25,461&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;12.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,093,452&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(102,393&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;991,059&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;185,465&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;185,465&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,606,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(200,626&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,405,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent&#13;is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated&#13;useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off&#13;any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. &lt;font style="background-color: white"&gt;During&#13;the years ended December 31, 2017 and 2016, there was no impairment recognized related to intangible assets.&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;We&#13;have numerous pending foreign and domestic patent applications. As of December 31, 2017, we had 18 issued domestic, or U.S., patents&#13;and 13 issued foreign patents, including:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13 domestic and&#13;    three foreign utility patents that relate to our combination progesterone and estradiol product candidates, which are owned&#13;    by us. The domestic utility patents will expire in 2032. In addition, we have pending patent applications with respect to&#13;    our combination progesterone and estradiol product candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel,&#13;    Japan, Mexico, Russia, South Africa, and South Korea;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;three domestic and&#13;    10 foreign patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate. These patents&#13;    establish an important intellectual property foundation for TX-004HR and are owned by us. These domestic patents will expire&#13;    in 2033 or 2032. In addition, we have pending patent applications related to our applicator-free vaginal estradiol softgel&#13;    product candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa,&#13;    and South Korea;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;one domestic utility&#13;    patent that relates to a pipeline transdermal patch technology, which is owned by us and will expire in 2032. We have pending&#13;    patent applications with respect to this technology in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South&#13;    Africa; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;one utility patent&#13;    that relates to our OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; information-technology platform, which is owned by us and is a domestic patent that&#13;    will expire in 2029.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Amortization&#13;expense was $71,516, $54,545, and $32,441 for the years ended December 31, 2017, 2016, and 2015, respectively. Estimated amortization&#13;expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Year Ending &lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Estimated &lt;br /&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;761,282&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <txmd:ScheduleOfIntangibleAssetsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets&#13;as of December 31, 2017 and 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13; Carrying&lt;br /&gt;&#13; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Net &lt;br /&gt; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted- &lt;br /&gt;&#13;Average &lt;br /&gt; Remaining &lt;br /&gt; Amortization&lt;br /&gt;&#13; Period (yrs.)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(8,487&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;23,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;11.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,293,614&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(171,911&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,121,703&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,721,305&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,721,305&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;233,275&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;233,275&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,371,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(272,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,099,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13; Carrying&lt;br /&gt;&#13; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Net &lt;br /&gt; Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;&#13; Average &lt;br /&gt; Remaining &lt;br /&gt; Amortization&lt;br /&gt;&#13; Period (yrs.)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(6,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;25,461&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;12.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,093,452&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(102,393&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;991,059&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,203,987&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;185,465&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;185,465&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,606,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(200,626&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,405,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</txmd:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated amortization&#13;expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Year Ending &lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Estimated &lt;br /&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,777&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;761,282&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;7&amp;#8211; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;366,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,281,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,240,379&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,531,440&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;945,457&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;665,561&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;600,350&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;176,518&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;420,162&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;665,773&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;602,916&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;224,865&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;172,973&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,510&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;114,480&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;26,507&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,432,846&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;794,816&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;327,099&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,223,595&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,624,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;current liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;366,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,281,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,240,379&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,531,440&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;945,457&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;665,561&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;600,350&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;176,518&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;420,162&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;665,773&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;602,916&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;224,865&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;172,973&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,510&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;114,480&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;26,507&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,432,846&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;794,816&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;327,099&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,223,595&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,624,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;8 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Preferred&#13;Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2017, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares&#13;of preferred stock were issued or outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Common&#13;Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2017, we had 350,000,000 shares of Common Stock authorized for issuance, of which 216,429,642 shares of our Common&#13;Stock were issued and outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances&#13;During 2017&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public&#13;offering of 12,400,000 shares of our Common Stock at a price of $5.55 per share. The net proceeds to us from the offering were&#13;approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017&#13;and we issued 12,400,000 shares of Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2017, certain individuals exercised stock options to purchase 102,546 shares of Common Stock for $212,615&#13;in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances&#13;During 2016&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 6, 2016, we entered into an underwriting agreement with Goldman Sachs &amp;#38; Co. and Cowen and Company, LLC, as the representatives&#13;of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common&#13;Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters&#13;a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full.&#13;The net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions&#13;and other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of&#13;our Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2016, certain individuals exercised stock options to purchase 525,362 shares of Common Stock for $989,060&#13;in cash. Also during the same period, stock options to purchase 127,109 shares of Common Stock were exercised pursuant to the&#13;options&amp;#8217; cashless exercise provisions, wherein 87,833 shares of Common Stock were issued.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances&#13;During 2015&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus &amp;#38; Company, Incorporated and Guggenheim Securities,&#13;LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering&#13;of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement,&#13;we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock,&#13;which option was exercised in full. The net proceeds to us from the offering were approximately $32,257,000, after deducting underwriting&#13;discounts and commissions and other estimated offering expenses payable by us. The offering closed on July 15, 2015 and we issued&#13;4,423,077 shares of our Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative&#13;of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common&#13;Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters&#13;a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full.&#13;The net proceeds from the offering were approximately $59,118,000, after deducting underwriting discounts and commissions and&#13;other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our&#13;Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2015, certain individuals exercised stock options to purchase 612,867 shares of Common Stock for $1,232,579&#13;in cash. Also during the same period, stock options to purchase 417 shares of Common Stock were exercised pursuant to the options&amp;#8217;&#13;cashless exercise provisions, wherein 114 shares of Common Stock were issued.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants&#13;to Purchase Common Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of December 31, 2017, we had warrants outstanding to purchase an aggregate of 3,115,905 shares of our Common Stock with a weighted-average&#13;contractual remaining life of 1.8 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in a weighted average&#13;exercise price of $2.58 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires&#13;the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the&#13;term of the warrant.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2017, we granted warrants to purchase 125,000 shares of Common Stock to outside consultants at an&#13;exercise price of $6.83 per share. The fair value for these warrants was determined by using the Black-Scholes Model on the date&#13;of the grant using a term of five years; volatility of 63.24%; risk free rate of 1.47%; and dividend yield of 0%. The grant date&#13;fair value of the warrants was $3.67 per share. The warrants vest ratably over a 12-month period and have an expiration date of&#13;March 15, 2022.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2016, we granted warrants to purchase 245,000 shares of Common Stock to outside consultants at the&#13;weighted average price of $7.90 per share. These warrants vest and have expiration dates as follows: warrants to purchase 75,000&#13;shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares&#13;of Common Stock vest ratably over a 24-month period and have an expiration date of April 21, 2021, and warrants to purchase 120,000&#13;shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an&#13;exercise price of $6.35 vesting ratably over a 12-month period, with an expiration date of April 6, 2020. We recorded share-based&#13;compensation expense related to warrants previously issued of $313,271, $936,974 and $139,142 for the years ended December 31,&#13;2017, 2016, and 2015, respectively, in the accompanying consolidated financial statements. At December 31, 2017, total unrecognized&#13;estimated compensation expense related to the unvested portion of these warrants was approximately $128,000 which is expected&#13;to be recognized over a weighted-average period of 0.2 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Summary&#13;of our Warrant activity during the year ended December 31, 2017:&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Number of&lt;br /&gt;&#13; Shares Under Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted &lt;br /&gt;&#13;Average&lt;br /&gt;&#13; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Aggregate &lt;br /&gt; Intrinsic&lt;br /&gt;&#13; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2016&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;12,060,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;45,063,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;125,000&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.83&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(9,066,666&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;48,535,969&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(2,500&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,115,905&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.58&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.8&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;11,348,273&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,792,983&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.8&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,141,836&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;322,922&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.57&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;10,206,436&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: normal; font-style: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"&gt;The&amp;#160;&lt;/font&gt;&lt;font style="font-weight: normal; font-style: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px"&gt;aggregate&#13;intrinsic value of warrants exercised during 2016 and 2015, was $3,988,343 and $7,282,404, respectively.&lt;/font&gt; The&#13;weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years&#13;ended December 31, 2017, 2016 and 2015 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; font: 10pt Times New Roman, Times, Serif"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.67&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.78&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.27&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.47&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.04-1.28&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.02&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;63.24&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;74.10-74.15&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;60.59&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period&#13;is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected&#13;to fluctuate each year during the term of the instrument. The estimated volatility is an average of the historical volatility&#13;of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is&#13;based on historical stock prices over a period equal to the term of the instrument as we have insufficient historical information&#13;regarding our stock options to provide a basis for estimate. The expected volatility of warrants was estimated based on a historical&#13;volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, market capitalization,&#13;and financial leverage.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used&#13;in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and&#13;Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and&#13;vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000&#13;shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As&#13;consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01&#13;per share that has vested or will vest, as applicable, as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares were&#13;    earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate&#13;    in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares&#13;    did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using&#13;    the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and&#13;    a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013. These shares were exercised&#13;    in 2017 and are included in the warrant exercise details below;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares vested&#13;    on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date&#13;    of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the&#13;    years ended December 31, 2017, 2016, and 2015, we recorded $0, $77,026, and $154,068, respectively, as non-cash compensation&#13;    in the accompanying consolidated financial statements related to this warrant. As of December 31, 2017 this warrant was fully&#13;    amortized. These shares were exercised in 2017 and are included in the warrant exercise details below; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;283,334 shares will vest upon the receipt by&#13;    us, prior to the warrant expiration date of April 30,2018, of any final FDA approval of a drug candidate that SCI helped us&#13;    design. It is anticipated that receipt of such an approval may occur in the near future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over&#13;approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services&#13;in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization&#13;efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing&#13;and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated&#13;therewith; (b) services in support of our efforts to successfully obtain new drug approval; and (c) other consulting services&#13;as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228&#13;on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of&#13;0.74%; and a dividend yield of 0%. During the years ended December 31, 2017, 2016, and 2015, we recorded $128,898, $257,796, and&#13;$257,796, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements.&#13;As of December 31, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized. This warrant was fully exercised, of which&#13;800,000 shares were exercised in 2017 and 500,000 shares were exercised in 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Warrant&#13;exercises&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999&#13;in cash. In addition, during the year ended December 31, 2017, certain individuals exercised warrants to purchase 6,590,000 shares&#13;of Common Stock pursuant to the warrants&amp;#8217; cashless exercise provisions, wherein 4,762,208 shares of Common Stock were issued.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2016, certain individuals exercised warrants to purchase 722,744 shares of Common Stock for $1,373,000&#13;in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common&#13;Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares&#13;of Common Stock were exercised pursuant to the warrants&amp;#8217; cashless exercise provisions, wherein 232,197 shares of Common&#13;Stock were issued.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Options&#13;to Purchase Common Stock of the Company&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,&#13;directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder&#13;value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009&#13;Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance&#13;units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder.&#13;Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options&#13;may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified&#13;expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the&#13;date the option is issued. As of December 31, 2017, there were non-qualified stock options to purchase 18,575,084 shares of Common&#13;Stock outstanding under the 2009 Plan. As of December 31, 2017, there were 2,173,878 shares available to be issued under 2009&#13;Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012&#13;Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain&#13;consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation&#13;rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described&#13;in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option&#13;grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior&#13;to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally&#13;ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder.&#13;As of December 31, 2017, there were non-qualified stock options to purchase 4,790,141 shares of Common Stock outstanding under&#13;the 2012 Plan. As of December 31, 2017, there were 5,128,333 shares available to be issued under 2012 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires&#13;the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life&#13;of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2017, 2016,&#13;and 2015 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.82&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.94&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.45&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.84-2.05&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.13-1.90&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.47-1.67&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;61.56-64.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;70.26-73.34&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;58.78-62.94&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period&#13;is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is&#13;expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility&#13;of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is&#13;based on historical stock prices over a period equal to the term of the awards as we have insufficient historical information&#13;regarding our stock options to provide a basis for estimate. The expected volatility of share options was estimated based on a&#13;historical volatility analysis of peers that were similar to us with respect to industry, stage of life cycle, market capitalization,&#13;and financial leverage. The average expected life is based on the contractual terms of the stock option using the simplified method.&#13;We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to&#13;pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common&#13;Stock and our estimates of expected volatility and the other relevant assumptions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2017 is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Number of&lt;br /&gt;&#13; Shares Under&lt;br /&gt;&#13; Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Aggregate &lt;br /&gt; Intrinsic&lt;br /&gt;&#13; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2016&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;60,495,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,271,500&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(102,546&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.07&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;452,287&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(108,375&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.64&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(463,208&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.28&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,365,225&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.78&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.13&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;64,664,821&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;19,770,142&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.27&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.47&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;63,895,512&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Unvested at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,595,083&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8.79&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;769,309&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2017, our outstanding options had exercise prices ranging from $0.10 to $8.92 per share. &lt;font style="font-weight: normal; font-style: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px"&gt;The&#13;aggregate intrinsic value of options exercised during 2016 and 2015, was $3,828,358 and $3,186,371,&#13;respectively.&lt;/font&gt;&lt;/font&gt; &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Share-based&#13;compensation expense related to options recognized in our results of operations for the years ended December 31, 2017, 2016,&#13;and 2015 was approximately $6,447,154, $16,139,225, and $6,621,658, respectively, and it is based on awards vested. At&#13;December 31, 2017, total unrecognized estimated compensation expense related to unvested options was approximately&#13;$10,596,000, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a&#13;weighted-average period of 2.1 years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <txmd:ScheduleOfWarrantRollForwardTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Summary&#13;of our Warrant activity during the year ended December 31, 2017:&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Number of&lt;br /&gt;&#13; Shares Under Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted &lt;br /&gt;&#13;Average&lt;br /&gt;&#13; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Aggregate &lt;br /&gt; Intrinsic&lt;br /&gt;&#13; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2016&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;12,060,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;45,063,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;125,000&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.83&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(9,066,666&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;48,535,969&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(2,500&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,115,905&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.58&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.8&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;11,348,273&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,792,983&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.8&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,141,836&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;322,922&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.57&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;10,206,436&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</txmd:ScheduleOfWarrantRollForwardTableTextBlock>
    <txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years&#13;ended December 31, 2017, 2016 and 2015 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; font: 10pt Times New Roman, Times, Serif"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.67&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.78&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.27&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.47&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.04-1.28&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.02&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;63.24&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;74.10-74.15&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;60.59&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2017, 2016,&#13;and 2015 are set forth in the table below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.82&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.94&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.45&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.84-2.05&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.13-1.90&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.47-1.67&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;61.56-64.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;70.26-73.34&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;58.78-62.94&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2017 is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Number of&lt;br /&gt;&#13; Shares Under&lt;br /&gt;&#13; Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual &lt;br /&gt; Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Aggregate &lt;br /&gt; Intrinsic&lt;br /&gt;&#13; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2016&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;21,767,854&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;60,495,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,271,500&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(102,546&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.07&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;452,287&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(108,375&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.64&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(463,208&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.28&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2017&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,365,225&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.78&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.13&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;64,664,821&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;19,770,142&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.27&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.47&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;63,895,512&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Unvested at December 31, 2017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,595,083&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8.79&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;769,309&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For&#13;financial reporting purposes, income before taxes includes the following components:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 45%; text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;United States&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(76,925,380&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(89,875,459&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(85,077,024&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(76,925,380&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(89,875,459&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(85,077,024&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.4&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.73&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;22.6&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(40.3&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(38.97&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Federal income tax rate change&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(60.8&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;(Provision) benefit for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The components of the net deferred income tax asset as of December 31, 2017, 2016, and 2015 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 45%; text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;99,596,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;111,730,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,499,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;R&amp;#38;D Credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;99,782,668&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;111,916,797&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,685,980&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(99,782,668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(111,916,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(79,685,980&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;10 &amp;#8211; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to&#13;time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements&#13;with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of&#13;our company since July 2015. During the years ended December 31, 2017, 2016 and 2015, we were billed by Catalent approximately&#13;$3,646,000, $3,647,000 and $1,266,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration&#13;batches, stability and validation testing. As of December 31, 2017 and December 31, 2016, there were amounts due to Catalent of&#13;approximately $523,000 and $57,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;11 - BUSINESS CONCENTRATIONS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;purchase our products from several suppliers with approximately 100%, 98%, and 60% of our purchases supplied by one vendor for&#13;the years ended December 31, 2017, 2016 and 2015, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain&#13;drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the years&#13;ended December 31, 2017, 2016 and 2015; four, three, and two customers each, respectively, generated more than 10% of our revenues.&#13;Revenue generated from four major customers combined accounted for approximately 59% of our revenue during the year ended December&#13;31, 2017. Revenue generated from three major customers combined accounted for approximately 41% of our revenue during the year&#13;ended December 31, 2016. Revenue generated from two major customers combined accounted for approximately 67% of our recognized&#13;revenue during the year ended December 31, 2015.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended December 31, 2017, AmerisourceBergen generated approximately $2,667,000 of our revenue; McKesson Corporation generated&#13;approximately $1,959,000 of our revenue; Cardinal Health generated approximately $2,559,000 of our revenue and Pharmacy Innovations&#13;PA generated approximately $2,715,000 of our revenue. During the year ended December 31, 2016, Woodstock Pharmaceutical and Compounding&#13;generated approximately $2,247,000 of our revenue; Medical Center Pharmacy generated approximately $3,700,000 of our revenue and&#13;Pharmacy Innovations PA generated approximately $2,040,000 of our revenue. During the year ended December 31, 2015, Woodstock&#13;Pharmaceutical and Compounding generated approximately $8,848,000 of our revenue and Due West Pharmacy generated approximately&#13;$4,843,000 of our revenue.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of developments in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&amp;#8217;&#13;reliance on third party payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming&#13;longer than in prior years. As a result, during the third quarter of 2016, we centralized the distribution channel for both our&#13;retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies&#13;and minimize business risk exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution&#13;agreements with our retail pharmacy distributors to effectuate this centralization which were effective September 1, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;12 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Operating&#13;Lease&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,&#13;2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to&#13;lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April&#13;26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.&#13;This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.&#13;On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the&#13;same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;rental expense related to our current lease during the years ended December 31, 2017, 2016 and 2015 was $1,029,205, $709,483,&#13;and $446,099, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of December 31, 2017, future minimum rental payments on non-cancelable operating leases are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;951,194&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,094,116&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,113,069&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;943,127&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,101,506&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Legal&#13;Proceedings&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;From&#13;time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved&#13;in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,&#13;or cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Off-Balance&#13;Sheet Arrangements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of December 31, 2017, 2016, and 2015, we had no off-balance sheet arrangements that have had or are reasonably likely to have&#13;current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,&#13;liquidity, capital expenditures or capital resources that are material to investors.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Employment&#13;Agreements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.&#13;Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,&#13;if those circumstances occur during the term of the employment agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of December 31, 2017, future minimum rental payments on non-cancelable operating leases are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;951,194&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,094,116&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,113,069&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;943,127&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,101,506&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;13 &amp;#8211; SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Summarized&#13;quarterly financial data for fiscal years 2017 and 2016 is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4th&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;3,985&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,250&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,418&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,125&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,326&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,568&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,717&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,530&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(21,156&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,677&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(14,665&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(21,427&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.07&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4th&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,930&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,403&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;5,536&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,487&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,822&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,273&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,298&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,778&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(20,929&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(21,094&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(25,016&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(22,836&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.13&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Summarized&#13;quarterly financial data for fiscal years 2017 and 2016 is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2017 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4th&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;3,985&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,250&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,418&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,125&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,326&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,568&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,717&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,530&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(21,156&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,677&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(14,665&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(21,427&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.07&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2016 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4th&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,930&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,403&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;5,536&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif"&gt;4,487&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,822&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,273&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,298&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,778&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(20,929&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(21,094&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(25,016&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(22,836&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.13&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">31421</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-31421</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:PrescriptionProductsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription&#13;Products&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy&#13;distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees,&#13;customer rebates, coupons and estimated returns.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped&#13;to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products&#13;sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.&#13;Our prescription products currently have a shelf life of 24 months from the date of manufacture.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prior&#13;to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the&#13;product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were&#13;known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the&#13;distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader&#13;population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription&#13;products are distributed under the wholesale distributor model described above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer&#13;loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry&#13;averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated&#13;in contracts and estimate chargebacks based on the number of units sold each period.&lt;/font&gt;&lt;/p&gt;</txmd:PrescriptionProductsPolicyTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2018-02-20" unitRef="Shares" decimals="INF">216439483</dei:EntityCommonStockSharesOutstanding>
    <txmd:EntityCommonStockHeldByNonaffiliates contextRef="AsOf2017-06-30" unitRef="Shares" decimals="INF">169430175</txmd:EntityCommonStockHeldByNonaffiliates>
    <dei:EntityPublicFloat contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">892897022</dei:EntityPublicFloat>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">14036</us-gaap:IncreaseDecreaseInRestrictedCash>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-01-01to2017-12-31">Yes</dei:EntityWellKnownSeasonedIssuer>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 9 &amp;#x2013; INCOME TAXES&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For financial reporting purposes, income before taxes includes the following components:&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;        &lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;United States&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(76,925,380&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(89,875,459&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(85,077,024&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(76,925,380&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(89,875,459&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(85,077,024&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;    &lt;/table&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;For the years ended December 31, 2017, 2016, and 2015, there was no provision for income taxes, current or deferred. &lt;/font&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At December 31, 2017, we had a federal net operating loss carry forward of approximately $338,613,987 available to offset future taxable income through 2037. The federal carryforwards will begin to expire in 2031.&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;        &lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Federal statutory tax rate&lt;/td&gt;&#13;            &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.4&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.73&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Adjustment in valuation allowances&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;22.6&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(40.3&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(38.97&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Federal income tax rate change&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(60.8&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Permanent and other differences&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.8&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.9&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.24&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;(Provision) benefit for income taxes&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;    &lt;/table&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;    &#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2017, 2016, and 2015 are as follows:&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;        &lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets:&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-left: 0.25in; width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net operating losses&lt;/td&gt;&#13;            &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;            &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;99,596,321&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;            &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;111,730,450&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;            &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,499,633&lt;/td&gt;&#13;            &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;R&amp;#38;D Credit&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Total deferred income tax asset&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;99,782,668&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;111,916,797&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,685,980&lt;/td&gt;&#13;            &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(99,782,668&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(111,916,797&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(79,685,980&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income tax assets, net&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;            &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;            &lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;    &lt;/table&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on the Company&amp;#x2019;s Balance Sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2017.&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Unrecognized Tax Benefits&lt;/i&gt;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of the period ended December 31, 2017, we have no unrecognized tax benefits.&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, effective January 1, 2018. Consequently, we have recorded a decrease related to deferred tax assets and deferred tax liabilities of approximately $49,500,000 and approximately $2,800,000, respectively, with a corresponding net adjustment to the valuation allowance of approximately $46,700,000 for the year ended December 31, 2017.&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;    &lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Tax Act modifies Section 162(m) of the Internal Revenue Code of 1986, as amended, or the IRC, by (1) expanding which employees&#13;are considered covered employees by including the chief financial officer, (2) providing that if an individual is a covered employee&#13;for a taxable year beginning after December 31, 2016, the individual remains a covered employee for all future years, and (3)&#13;removing the exceptions for compensation stemming from contracts entered into on or before November 2, 2017, unless such contracts&#13;were materially modified on or after the date. Compensation agreements entered into and share-based payment awards granted after&#13;this date will be subject to the revised terms of IRC Section 162(m). In December 2017, the SEC staff issued Staff Accounting&#13;Bulletin No. 118,&amp;#160;&lt;i&gt;Income Tax Accounting Implications of the Tax Cuts and Jobs Act&amp;#160;&lt;/i&gt;(SAB 118), which allows us&#13;to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Since the Tax Act&#13;was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12&#13;months, we consider the accounting for share-based compensation arrangements under the Tax Act to be incomplete due to the forthcoming&#13;guidance and our ongoing analysis of final year-end data and tax positions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We must assess whether our valuation allowance analyses&#13;are affected by various aspects of the Tax Act. Since, as discussed herein, we have recorded provisional amounts related to certain&#13;portions of the Tax Act, any corresponding determination of the need for or change in a valuation allowance is also provisional.&lt;/font&gt;&lt;/p&gt;&#13;    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;        &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&#13;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3115905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12060071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2792983</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>txmd-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\Clients\TherapeuticsMD\XBRL\20171231\txmd_123117.xfr; Date: 2018%2D02%2D23T16:57:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80280002 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaOHKbP9w5dzKelBtm96HTk6by4svag2Jy0XYR6WwbkG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20171231" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20171231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000007 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssets" id="FixedAssets">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000012 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000014 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000016 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000017 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" id="SelectedQuarterlyFinancialData">
	  <link:definition>00000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000022 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000023 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" id="FixedAssetsTables">
	  <link:definition>00000024 - Disclosure - FIXED ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000025 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000026 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000028 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" id="SelectedQuarterlyFinancialDataTables">
	  <link:definition>00000030 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000033 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000034 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
	  <link:definition>00000035 - Disclosure - FIXED ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" id="FixedAssetsDetailsNarrative">
	  <link:definition>00000036 - Disclosure - FIXED ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000037 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000038 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000039 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
	  <link:definition>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
	  <link:definition>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" id="StockholdersEquityDetailsNarrative3">
	  <link:definition>00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000049 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000050 - Disclosure - INCOME TAXES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000051 - Disclosure - INCOME TAXES (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000052 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000054 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000056 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" id="SelectedQuarterlyFinancialDataDetails">
	  <link:definition>00000057 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_PrepaidManufacturingCostsCurrent" name="PrepaidManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidVendorDepositsCurrent" name="PrepaidVendorDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidSalesAndMarketingCostsCurrent" name="PrepaidSalesAndMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalPeriodForPurchaseShare" name="AdditionalPeriodForPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercised" name="NumberOfStockOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OptionExercisePrices" name="OptionExercisePrices" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSharesOfferedInUnderwritingAgreement" name="NumberOfSharesOfferedInUnderwritingAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrelaunchInventoryPolicyTextBlock" name="PrelaunchInventoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OverTheCounterProductsPolicyTextBlock" name="OverTheCounterProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfIntangibleAssetsTableTextBlock" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWarrantRollForwardTableTextBlock" name="ScheduleOfWarrantRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrescriptionProductsPolicyTextBlock" name="PrescriptionProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents1Member" name="Patents1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents2Member" name="Patents2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_GoldmanSachsMember" name="GoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Warrant1Member" name="Warrant1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndividualsMember" name="IndividualsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Warrant2Member" name="Warrant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_JPMorganSecuritiesLLCMember" name="JPMorganSecuritiesLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TwoCustomersMember" name="TwoCustomersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ThreeCustomersMember" name="ThreeCustomersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PharmacyInnovationsTXMember" name="PharmacyInnovationsTXMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PharmacyInnovationsMember" name="PharmacyInnovationsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmerisourceBergenMember" name="AmerisourceBergenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CardinalHealthMember" name="CardinalHealthMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_McKessonCorporationMember" name="McKessonCorporationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WoodstockPharmaceuticalAndCompoundingMember" name="WoodstockPharmaceuticalAndCompoundingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MedicalCenterPharmacyMember" name="MedicalCenterPharmacyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DueWestPharmacyMember" name="DueWestPharmacyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FourCustomersMember" name="FourCustomersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk1Member" name="CustomerConcentrationRisk1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk2Member" name="CustomerConcentrationRisk2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk3Member" name="CustomerConcentrationRisk3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk4Member" name="CustomerConcentrationRisk4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents3Member" name="Patents3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents4Member" name="Patents4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelUnderwritersMember" name="StifelUnderwritersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultantMember" name="OutsideConsultantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredTaxAssetMember" name="DeferredTaxAssetMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredTaxLiabilitiesMember" name="DeferredTaxLiabilitiesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSharesUnderWarrantAbstract" name="NumberOfSharesUnderWarrantAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageRemainingContractualLifeAbstract" name="WeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" name="SummaryOfActivityUnder2009And2012PlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredIncomeTaxAssetsAbstract" name="DeferredIncomeTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>txmd-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\Clients\TherapeuticsMD\XBRL\20171231\txmd_123117.xfr; Date: 2018%2D02%2D23T16:57:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80280002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20171231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20171231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20171231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20171231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20171231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20171231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20171231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20171231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20171231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20171231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20171231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20171231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20171231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20171231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20171231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20171231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20171231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20171231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails2" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20171231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20171231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20171231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000016 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000017 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000022 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000024 - Disclosure - FIXED ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000030 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidManufacturingCostsCurrent" xlink:label="loc_txmdPrepaidManufacturingCostsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidManufacturingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidVendorDepositsCurrent" xlink:label="loc_txmdPrepaidVendorDepositsCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidVendorDepositsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000035 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000036 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000037 - Disclosure - INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000049 - Disclosure - INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000050 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails2" xlink:title="00000051 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000052 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000056 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000057 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>txmd-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\Clients\TherapeuticsMD\XBRL\20171231\txmd_123117.xfr; Date: 2018%2D02%2D23T16:57:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80280002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20171231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20171231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20171231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20171231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20171231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20171231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20171231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20171231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20171231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20171231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20171231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20171231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20171231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20171231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20171231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20171231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20171231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20171231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails2" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20171231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20171231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20171231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000016 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000017 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000022 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000024 - Disclosure - FIXED ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000030 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:label="loc_us-gaapNewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_180" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000035 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000036 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000037 - Disclosure - INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents3Member" xlink:label="loc_txmdPatents3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents4Member" xlink:label="loc_txmdPatents4Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents4Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents2Member" xlink:label="loc_txmdPatents2Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents2Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_120" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_30" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_30" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_JPMorganSecuritiesLLCMember" xlink:label="loc_txmdJPMorganSecuritiesLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdJPMorganSecuritiesLLCMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdGoldmanSachsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdStifelUnderwritersMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmdNumberOfStockOptionsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercised_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfSharesOfferedInUnderwritingAgreement" xlink:label="loc_txmdNumberOfSharesOfferedInUnderwritingAgreement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfSharesOfferedInUnderwritingAgreement_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_170" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedCompensation_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_160" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_160" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_160" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Warrant1Member" xlink:label="loc_txmdWarrant1Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant1Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_150" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Warrant2Member" xlink:label="loc_txmdWarrant2Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant2Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_IndividualsMember" xlink:label="loc_txmdIndividualsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdIndividualsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OptionExercisePrices" xlink:label="loc_txmdOptionExercisePrices_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdOptionExercisePrices_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000049 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000050 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails2" xlink:title="00000051 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000052 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaapScenarioForecastMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_us-gaapScenarioForecastMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaapDeferredTaxAssetDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" xlink:to="loc_us-gaapDeferredTaxAssetDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaapDeferredTaxAssetDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" xlink:to="loc_us-gaapDeferredTaxAssetDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredTaxAssetMember" xlink:label="loc_txmdDeferredTaxAssetMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredTaxAssetDomain" xlink:to="loc_txmdDeferredTaxAssetMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredTaxLiabilitiesMember" xlink:label="loc_txmdDeferredTaxLiabilitiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredTaxAssetDomain" xlink:to="loc_txmdDeferredTaxLiabilitiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_FourCustomersMember" xlink:label="loc_txmdFourCustomersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdFourCustomersMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ThreeCustomersMember" xlink:label="loc_txmdThreeCustomersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdThreeCustomersMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_TwoCustomersMember" xlink:label="loc_txmdTwoCustomersMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdTwoCustomersMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AmerisourceBergenMember" xlink:label="loc_txmdAmerisourceBergenMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdAmerisourceBergenMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_McKessonCorporationMember" xlink:label="loc_txmdMcKessonCorporationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMcKessonCorporationMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CardinalHealthMember" xlink:label="loc_txmdCardinalHealthMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCardinalHealthMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PharmacyInnovationsMember" xlink:label="loc_txmdPharmacyInnovationsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdPharmacyInnovationsMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:label="loc_txmdWoodstockPharmaceuticalAndCompoundingMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdWoodstockPharmaceuticalAndCompoundingMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_MedicalCenterPharmacyMember" xlink:label="loc_txmdMedicalCenterPharmacyMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMedicalCenterPharmacyMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DueWestPharmacyMember" xlink:label="loc_txmdDueWestPharmacyMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdDueWestPharmacyMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet_170" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000056 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000057 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>txmd-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\Clients\TherapeuticsMD\XBRL\20171231\txmd_123117.xfr; Date: 2018%2D02%2D23T16:57:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80280002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Related to Research and Development Activities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer hardware [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Opera Software Patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development Costs Of Corporate Website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents1Member" xlink:label="txmd_Patents1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents1Member_lbl" xml:lang="en-US">Domestic Utility Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Utility Patent Foreign TX-004HR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents2Member" xlink:label="txmd_Patents2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents2Member" xlink:to="txmd_Patents2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents2Member_lbl" xml:lang="en-US">Utility Patent Pipeline Transdermal Patch Technology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_GoldmanSachsMember" xlink:label="txmd_GoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoldmanSachsMember_lbl" xml:lang="en-US">Underwriting Agreement - Goldman and Cowen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultants Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">SCI - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Warrant1Member" xlink:label="txmd_Warrant1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant1Member" xlink:to="txmd_Warrant1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Warrant1Member_lbl" xml:lang="en-US">Warrants - Unaffiliated Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_IndividualsMember" xlink:label="txmd_IndividualsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualsMember" xlink:to="txmd_IndividualsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndividualsMember_lbl" xml:lang="en-US">Individuals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Warrant2Member" xlink:label="txmd_Warrant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Warrant2Member_lbl" xml:lang="en-US">Warrants - Cashless Exercise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_JPMorganSecuritiesLLCMember" xlink:label="txmd_JPMorganSecuritiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JPMorganSecuritiesLLCMember" xlink:to="txmd_JPMorganSecuritiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_JPMorganSecuritiesLLCMember_lbl" xml:lang="en-US">Underwriting Agreement - J.P. Morgan Securities LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Catalent Inc.[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_TwoCustomersMember" xlink:label="txmd_TwoCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoCustomersMember" xlink:to="txmd_TwoCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TwoCustomersMember_lbl" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ThreeCustomersMember" xlink:label="txmd_ThreeCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersMember" xlink:to="txmd_ThreeCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ThreeCustomersMember_lbl" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PharmacyInnovationsMember" xlink:label="txmd_PharmacyInnovationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsMember" xlink:to="txmd_PharmacyInnovationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PharmacyInnovationsMember_lbl" xml:lang="en-US">Pharmacy Innovations PA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AmerisourceBergenMember" xlink:label="txmd_AmerisourceBergenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmerisourceBergenMember" xlink:to="txmd_AmerisourceBergenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmerisourceBergenMember_lbl" xml:lang="en-US">AmerisourceBergen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CardinalHealthMember" xlink:label="txmd_CardinalHealthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CardinalHealthMember" xlink:to="txmd_CardinalHealthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CardinalHealthMember_lbl" xml:lang="en-US">Cardinal Health [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_McKessonCorporationMember" xlink:label="txmd_McKessonCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_McKessonCorporationMember" xlink:to="txmd_McKessonCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_McKessonCorporationMember_lbl" xml:lang="en-US">McKesson Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:label="txmd_WoodstockPharmaceuticalAndCompoundingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:to="txmd_WoodstockPharmaceuticalAndCompoundingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WoodstockPharmaceuticalAndCompoundingMember_lbl" xml:lang="en-US">Woodstock Pharmaceutical and Compounding [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_MedicalCenterPharmacyMember" xlink:label="txmd_MedicalCenterPharmacyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MedicalCenterPharmacyMember" xlink:to="txmd_MedicalCenterPharmacyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MedicalCenterPharmacyMember_lbl" xml:lang="en-US">Medical Center Pharmacy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DueWestPharmacyMember" xlink:label="txmd_DueWestPharmacyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DueWestPharmacyMember" xlink:to="txmd_DueWestPharmacyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DueWestPharmacyMember_lbl" xml:lang="en-US">Due West Pharmacy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_FourCustomersMember" xlink:label="txmd_FourCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersMember" xlink:to="txmd_FourCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FourCustomersMember_lbl" xml:lang="en-US">Four Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="txmd_CustomerConcentrationRisk1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk1Member_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="txmd_CustomerConcentrationRisk2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk2Member_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="txmd_CustomerConcentrationRisk3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk3Member_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">United States [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="txmd_CustomerConcentrationRisk4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk4Member_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents3Member" xlink:label="txmd_Patents3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents3Member" xlink:to="txmd_Patents3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents3Member_lbl" xml:lang="en-US">Foreign Utility Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents4Member" xlink:label="txmd_Patents4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents4Member" xlink:to="txmd_Patents4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents4Member_lbl" xml:lang="en-US">Utility Patent Domestic TX-004HR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_StifelUnderwritersMember" xlink:label="txmd_StifelUnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelUnderwritersMember_lbl" xml:lang="en-US">Stifel Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="txmd_CowenAndCompanyLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CowenAndCompanyLLCMember_lbl" xml:lang="en-US">Cowen and Company, LLC (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OutsideConsultantMember" xlink:label="txmd_OutsideConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultantMember_lbl" xml:lang="en-US">Outside Consultant Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_Warrant2Member_2_lbl" xml:lang="en-US">Warrants Cashless Exercise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US">Subsequent Fiscal Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredTaxAssetMember" xlink:label="txmd_DeferredTaxAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetMember" xlink:to="txmd_DeferredTaxAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredTaxAssetMember_lbl" xml:lang="en-US">Deferred Tax Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredTaxLiabilitiesMember" xlink:label="txmd_DeferredTaxLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxLiabilitiesMember" xlink:to="txmd_DeferredTaxLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredTaxLiabilitiesMember_lbl" xml:lang="en-US">Deferred Tax Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="txmd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DocumentAndEntityInformationAbstract" xlink:to="txmd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xml:lang="en-US">Entity Common Stock, Held by non-affiliates (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $380,580 and $376,374, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 12</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 shares authorized; 216,429,642 and 196,688,222 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US">Accreted interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US">Adoption of ASU 2016-09</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued for exercise of warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued for exercise of warrants, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares issued for exercise of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares issued for exercise of restricted stock units (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">(Decrease) increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrelaunchInventoryPolicyTextBlock" xlink:label="txmd_PrelaunchInventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrelaunchInventoryPolicyTextBlock" xlink:to="txmd_PrelaunchInventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrelaunchInventoryPolicyTextBlock_lbl" xml:lang="en-US">Pre-Launch Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OverTheCounterProductsPolicyTextBlock" xlink:label="txmd_OverTheCounterProductsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OverTheCounterProductsPolicyTextBlock" xlink:to="txmd_OverTheCounterProductsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OverTheCounterProductsPolicyTextBlock_lbl" xml:lang="en-US">Over-the-Counter Products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrescriptionProductsPolicyTextBlock" xlink:label="txmd_PrescriptionProductsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionProductsPolicyTextBlock" xlink:to="txmd_PrescriptionProductsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionProductsPolicyTextBlock_lbl" xml:lang="en-US">Prescription Products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and other Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities in calculation of diluted net loss per share allocable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of 2009 and 2012 Plans activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of components of income before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of the net deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments on non-cancelable operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of summarized quarterly financial data</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal insurance limits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Write-off accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Advance payments - total</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products following product expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_lbl" xml:lang="en-US">Impact from modified retrospective basis adoption of accounting standard</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw material</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidManufacturingCostsCurrent" xlink:label="txmd_PrepaidManufacturingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsCurrent" xlink:to="txmd_PrepaidManufacturingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsCurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidVendorDepositsCurrent" xlink:label="txmd_PrepaidVendorDepositsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDepositsCurrent" xlink:to="txmd_PrepaidVendorDepositsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidVendorDepositsCurrent_lbl" xml:lang="en-US">Prepaid vendor deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Weighted average remaining amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Year Ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSharesUnderWarrantAbstract" xlink:to="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xml:lang="en-US">Number of shares Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Vested and Exercisable at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="txmd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceAbstract" xlink:to="txmd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants outstanding at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Warrants outstanding at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and Exercisable at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants Unvested at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="txmd_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateIntrinsicValueAbstract" xlink:to="txmd_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Warrants outstanding at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xml:lang="en-US">Vested and Exercisable at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_lbl" xml:lang="en-US">Unvested at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:to="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xml:lang="en-US">Summary of Activity under 2009 and 2012 Plans:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Cancelled/Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and Exercisable at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Options, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled/Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and Exercisable at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Options, Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Options outstanding, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and Exercisable at December 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_lbl" xml:lang="en-US">Unvested at December 31, 2017</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_4_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Value of common stock issued during period for stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="txmd_NumberOfStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercised_lbl" xml:lang="en-US">Number of stock options exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfSharesOfferedInUnderwritingAgreement" xlink:label="txmd_NumberOfSharesOfferedInUnderwritingAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSharesOfferedInUnderwritingAgreement" xlink:to="txmd_NumberOfSharesOfferedInUnderwritingAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSharesOfferedInUnderwritingAgreement_lbl" xml:lang="en-US">Number of shares offered in underwriting agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under offering</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="txmd_AdditionalPeriodForPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalPeriodForPurchaseShare_lbl" xml:lang="en-US">Number of days of the option to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Warrants granted (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized estimated compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized estimated compensation expense period recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xml:lang="en-US">Warrants granted to purchase common stock (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Non-cash compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xml:lang="en-US">Forfeited warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested warrants granted to purchase common stock (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Unvested warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OptionExercisePrices" xlink:label="txmd_OptionExercisePrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OptionExercisePrices" xlink:to="txmd_OptionExercisePrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OptionExercisePrices_lbl" xml:lang="en-US">Option exercise prices (in dollars per shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized estimated compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2_lbl" xml:lang="en-US">Recognized weighted-average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Federal income tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">U.S. statutory federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Manufacturing activities billed from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments, year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xml:lang="en-US">Rental income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Loss per common share, basic and diluted (in dollars per shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsCurrent" xlink:to="txmd_PrepaidManufacturingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsCurrent_doc" xml:lang="en-US">It represents amount of prepaid manufacturing costs current during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDepositsCurrent" xlink:to="txmd_PrepaidVendorDepositsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidVendorDepositsCurrent_doc" xml:lang="en-US">It represents amount prepaid vendor deposits current during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents1Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents2Member" xlink:to="txmd_Patents2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents2Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoldmanSachsMember_doc" xml:lang="en-US">Goldman Sachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalPeriodForPurchaseShare_doc" xml:lang="en-US">Refers to additonal period for purchase of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides consutling services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are vesting date in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant1Member" xlink:to="txmd_Warrant1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Warrant1Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xml:lang="en-US">Refer to numbers of shares forfeit during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualsMember" xlink:to="txmd_IndividualsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndividualsMember_doc" xml:lang="en-US">It refers name of the related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Warrant2Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JPMorganSecuritiesLLCMember" xlink:to="txmd_JPMorganSecuritiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_JPMorganSecuritiesLLCMember_doc" xml:lang="en-US">Informatioin related to J.P. Morgan Securities, LLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercised_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersMember" xlink:to="txmd_ThreeCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThreeCustomersMember_doc" xml:lang="en-US">Represent number of major customers.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PharmacyInnovationsTXMember" xlink:label="txmd_PharmacyInnovationsTXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsTXMember" xlink:to="txmd_PharmacyInnovationsTXMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PharmacyInnovationsTXMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PharmacyInnovationsMember" xlink:to="txmd_PharmacyInnovationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PharmacyInnovationsMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmerisourceBergenMember" xlink:to="txmd_AmerisourceBergenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmerisourceBergenMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CardinalHealthMember" xlink:to="txmd_CardinalHealthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CardinalHealthMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_McKessonCorporationMember" xlink:to="txmd_McKessonCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_McKessonCorporationMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:to="txmd_WoodstockPharmaceuticalAndCompoundingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WoodstockPharmaceuticalAndCompoundingMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MedicalCenterPharmacyMember" xlink:to="txmd_MedicalCenterPharmacyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MedicalCenterPharmacyMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DueWestPharmacyMember" xlink:to="txmd_DueWestPharmacyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DueWestPharmacyMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersMember" xlink:to="txmd_FourCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FourCustomersMember_doc" xml:lang="en-US">Represent number of major customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OverTheCounterProductsPolicyTextBlock" xlink:to="txmd_OverTheCounterProductsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OverTheCounterProductsPolicyTextBlock_doc" xml:lang="en-US">Disclosure of policy related to over-the-counter products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionProductsPolicyTextBlock" xlink:to="txmd_PrescriptionProductsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionProductsPolicyTextBlock_doc" xml:lang="en-US">Disclosure of policy related to prescription products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of intangible assets, which may be broken down by major class.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OptionExercisePrices" xlink:to="txmd_OptionExercisePrices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OptionExercisePrices_doc" xml:lang="en-US">The exercise price of the option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk1Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk2Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk3Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The weighted average fair value of awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_doc" xml:lang="en-US">The weighted average fair value at grant date for equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The weighted average exercise price for warrants exercised during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration_doc" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were exercised or put into effect as a result of the occurrence of a terminating event.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">As of the balance sheet date, the weighted-average exercise price for outstanding warrants that are fully vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_doc" xml:lang="en-US">Intrinsic value of unvested equity-based compensation awards outstanding. Excludes stock and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_doc" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk4Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents3Member" xlink:to="txmd_Patents3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents3Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents4Member" xlink:to="txmd_Patents4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents4Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelUnderwritersMember_doc" xml:lang="en-US">Stifel Underwriters</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CowenAndCompanyLLCMember_doc" xml:lang="en-US">Refers to cowen and company llc member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSharesOfferedInUnderwritingAgreement" xlink:to="txmd_NumberOfSharesOfferedInUnderwritingAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSharesOfferedInUnderwritingAgreement_doc" xml:lang="en-US">Number of shares offered in an underwritten public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultantMember_doc" xml:lang="en-US">A person who provides consulting services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetMember" xlink:to="txmd_DeferredTaxAssetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredTaxAssetMember_doc" xml:lang="en-US">Identification of the deferred tax asset for which a valuation reserve exists.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxLiabilitiesMember" xlink:to="txmd_DeferredTaxLiabilitiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredTaxLiabilitiesMember_doc" xml:lang="en-US">Identification of the deferred tax asset for which a valuation reserve exists.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoCustomersMember" xlink:to="txmd_TwoCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TwoCustomersMember_doc" xml:lang="en-US">Represent number of major customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrelaunchInventoryPolicyTextBlock" xlink:to="txmd_PrelaunchInventoryPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrelaunchInventoryPolicyTextBlock_doc" xml:lang="en-US">Disclosure of policy related to pre-launch inventory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2_lbl" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_3_lbl" xml:lang="en-US">SCI - Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>txmd-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\Clients\TherapeuticsMD\XBRL\20171231\txmd_123117.xfr; Date: 2018%2D02%2D23T16:57:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80280002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20171231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20171231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20171231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20171231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20171231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20171231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20171231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20171231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20171231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20171231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20171231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20171231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20171231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20171231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20171231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20171231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20171231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20171231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20171231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20171231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20171231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20171231.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails2" xlink:href="txmd-20171231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20171231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20171231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20171231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20171231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20171231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="loc_txmdEntityCommonStockHeldByNonaffiliates" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_txmdEntityCommonStockHeldByNonaffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000016 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000017 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrelaunchInventoryPolicyTextBlock" xlink:label="loc_txmdPrelaunchInventoryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdPrelaunchInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OverTheCounterProductsPolicyTextBlock" xlink:label="loc_txmdOverTheCounterProductsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdOverTheCounterProductsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrescriptionProductsPolicyTextBlock" xlink:label="loc_txmdPrescriptionProductsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdPrescriptionProductsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000022 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000024 - Disclosure - FIXED ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000025 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000030 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:label="loc_us-gaapNewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidManufacturingCostsCurrent" xlink:label="loc_txmdPrepaidManufacturingCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidVendorDepositsCurrent" xlink:label="loc_txmdPrepaidVendorDepositsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidVendorDepositsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000035 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000036 - Disclosure - FIXED ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000037 - Disclosure - INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents3Member" xlink:label="loc_txmdPatents3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents4Member" xlink:label="loc_txmdPatents4Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Patents2Member" xlink:label="loc_txmdPatents2Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_JPMorganSecuritiesLLCMember" xlink:label="loc_txmdJPMorganSecuritiesLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdJPMorganSecuritiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdStifelUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmdNumberOfStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfSharesOfferedInUnderwritingAgreement" xlink:label="loc_txmdNumberOfSharesOfferedInUnderwritingAgreement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfSharesOfferedInUnderwritingAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Warrant1Member" xlink:label="loc_txmdWarrant1Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_Warrant2Member" xlink:label="loc_txmdWarrant2Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_IndividualsMember" xlink:label="loc_txmdIndividualsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdIndividualsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_OptionExercisePrices" xlink:label="loc_txmdOptionExercisePrices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdOptionExercisePrices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000049 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000050 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails2" xlink:title="00000051 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="loc_txmdDeferredIncomeTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000052 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaapScenarioForecastMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_us-gaapScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaapDeferredTaxAssetDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapValuationAllowanceByDeferredTaxAssetAxis" xlink:to="loc_us-gaapDeferredTaxAssetDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredTaxAssetMember" xlink:label="loc_txmdDeferredTaxAssetMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetDomain" xlink:to="loc_txmdDeferredTaxAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DeferredTaxLiabilitiesMember" xlink:label="loc_txmdDeferredTaxLiabilitiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetDomain" xlink:to="loc_txmdDeferredTaxLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_FourCustomersMember" xlink:label="loc_txmdFourCustomersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdFourCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_ThreeCustomersMember" xlink:label="loc_txmdThreeCustomersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdThreeCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_TwoCustomersMember" xlink:label="loc_txmdTwoCustomersMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_txmdTwoCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_AmerisourceBergenMember" xlink:label="loc_txmdAmerisourceBergenMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdAmerisourceBergenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_McKessonCorporationMember" xlink:label="loc_txmdMcKessonCorporationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMcKessonCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CardinalHealthMember" xlink:label="loc_txmdCardinalHealthMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCardinalHealthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_PharmacyInnovationsMember" xlink:label="loc_txmdPharmacyInnovationsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdPharmacyInnovationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_WoodstockPharmaceuticalAndCompoundingMember" xlink:label="loc_txmdWoodstockPharmaceuticalAndCompoundingMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdWoodstockPharmaceuticalAndCompoundingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_MedicalCenterPharmacyMember" xlink:label="loc_txmdMedicalCenterPharmacyMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMedicalCenterPharmacyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_DueWestPharmacyMember" xlink:label="loc_txmdDueWestPharmacyMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdDueWestPharmacyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000056 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20171231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000057 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>txmd10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd10k001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!+0)8 P$1  (1 0,1 ?_$ -X  0 " P # 0$
M       '" 4&"0$"! ,* 0$  @(# 0$!            !P@%!@,$"0$""A
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M!&S-"'+F2[.610!P1<$6V88H(N%LL<K7M>U[<;4!+6O']@$&_P!ST9_U*1*
MF&@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% :H^GTS8Q9CJ
MD61'0A,EAL= 574\'>YE(JCMYM-Q#)#**NM+*H=$!*$$Y.) 9BBBB96QQQQO
M0%4X ^H5JQLL_<XPC5W/9/?AIOJ3R:S:E>%9I@I0DEBHXZ665'W$^$T,!AX2
MBSTX9:)V,GD*YX(KB;!S&YO 8++,"Z] * 4 H#61'8G!O(JQLB3BNK&VR?=@
M:C@V' (T\$Y.54U'')&7G@G9-4JXA3*H'F EB&\5 P6P%'#!R!!%SP V:@%
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MXT!NE * 4 H!0"@% * 4 H!0"@% * 4!#VP_]@$Y?W/29_4I;H!KQ_8!!O\
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MQ"OU"I0UDFET.IIRP5DN$ =<M(A6XGV>/IEL'K? <L)+CVZG>-T%M23%"^[
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MZXXR>4U-_8^"%R'(Z4U9%?\ *R/+;"4HX9"P@F "BTE.U[$U\9MMU12S)H+
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M9<[217VSG"@O*-W$Z&:\&<[6NO!"%#Q4SAG@;+FRHP(0I;.UP+:T H!0"@%
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MMM)F6*XC=2Z@?10C+1 F(M'4)UV39I33<GC/YMIQE02A;%6>J8+B/SBF%;'
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M8#($O$B1,4H!B,,+@-G0'0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"'MA_[
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MKJ4IO!X;$ N@9@-!JP9+JPZTO"/9(08GE3I-;8+/Q6HAZ'WRXRY-V7<P"59
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M[8VO?[+4!]- * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M<5*,-ACM6*(ZBMAQQF**HJ'E(LV"K)-G;#X6+!YFE@QE8''++//,"S% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(>V'_L G+^YZ3/ZE+= ?S/
M?5$V/>(>O<5PXOPON*#"$2Q5I#* 3YB6 I(=\83/+QR1HB54- <DGM,MFWDY
ME1,D)=Q<D0V-CFY7@K)P-\,0TOFSX&P;"8P,[75NOL,\"S92OJ),;>'3%(T^
MN\S^+?V28; =C;TU4X9CB/6>IJ8#K;[5D)2>;I <B,3+X$U8T:6P5/'.Y<Q8
M #+-5&U_*S?#TU-@ZRL_J/.+ZT^P$326NI[E".; *<))TM;!MU3B]TI7E(9R
MB0HV-0T9$4R*28 LA$" !!6 #P,9A&1 +@;NH&GLW[R1@T-YE"('+J^G:0[
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M^9](_3:@'2YO#\'4??,^D?IM0#I<WA^#J/OF?2/TVH!TN;P_!U'WS/I'Z;4
MZ7-X?@ZC[YGTC]-J =+F\/P=1]\SZ1^FU .ES>'X.H^^9](_3:@'2YO#\'4?
M?,^D?IM0#I<WA^#J/OF?2/TVH!TN;P_!U'WS/I'Z;4 Z7-X?@ZC[YGTC]-J
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M .;&F?\ 3Q6_^)% H#HA0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MHM>_URH!TI/[X;)B]HM>_P!<J =*3^^&R8O:+7O]<J =*3^^&R8O:+7O]<J
M=*;^X\.[;,7'P7X>D>O?'A?CPO\ VY?R\*:K73XCZ_@.E)_?#9,7M%KW^N5
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M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * ]!!
MP0\Q1<\ @@L,A!!!,L< PP\,;Y9YYYY7MCAAAC:][WO?A:U<=UU6/5*^^484
M0BY2E)I1C%+5RDWHDDEJV_!+Q9^H0G9-5UIRLDTDDM6V_!))>;?P12QSN-P;
M+.8U'C".&4J)$8Q@&^GL7QOC=Q"AY<OR*CB9VMB,6$OC;DV\-A+?O1+<U;#
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M?X@]>R&7_<2@'>5B/\0>O9#+_N)0#O*Q'^(/7LAE_P!Q* =Y6(_Q!Z]D,O\
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M!Q[R*!X>'\] =#Z 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M<\<OJN:UXAY"W0)=Y..%Q+\&HW^/)MCRK\+>F/V\*K:_=YVO47-XV\Z):_\
M3T_]R6@7LQ[KN:@LG8]6]/\ J+_^U.DJ6H *Z8G*I6PF)93(E% OB-CC@-B
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M_=T5_",5X)R>B<YZ)R?T148J3N\]KQUS1W[3)OWU3N:0.\]KQUS1W[3)OWU
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M19JW]"=>K^DT%U?4B09 P,,46'FJ;!5<_%!$]Z2$73RX8UN/(R-&A49, 2#
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M,?+&]O\ !G5>Y_ZA.#DRE#9^W7,)RCY/+MV_!B_HU=EUFB^Q2T^LF7;?9_W
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M"+^5D?N* >C;=_ $7\K(_<4 ]&V[^ (OY61^XH!Z-MW\ 1?RLC]Q0#T;;OX
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M^XH!Z-MW\ 1?RLC]Q0#T;;OX B_E9'[B@*Y;B-]!"U'VF%"1$@,4+7*;Q Q
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M5&,8I)126B22\$DO!)>"1^I2E.3G-MS;U;?BVWYMOXMGM7[/R* 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M49$WL V/-M .[+KKU&1-[ -CS;0#NRZZ]1D3>P#8\VT [LNNO49$WL V/-M
M.[+KKU&1-[ -CS;0#NRZZ]1D3>P#8\VT [LNNO49$WL V/-M .[+KKU&1-[
M-CS;0#NRZZ]1D3>P#8\VT [LNNO49$WL V/-M .[+KKU&1-[ -CS;0#NRZZ]
M1D3>P#8\VT [LNNO49$WL V/-M .[+KKU&1-[ -CS;0#NRZZ]1D3>P#8\VT
M[LNNO49$WL V/-M .[+KKU&1-[ -CS;0#NRZZ]1D3>P#8\VT [LNNO49$WL
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MZ,_ZE(E 3#0"@% * 4!SO'_YL:9_T\5O_B10* Z(4 H!0"@% * 4 H!0"@%
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M0/!Q^SC0'0^@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M0"@% * 4 H!0"@% * K?N1_LA[4_[M\X_P"K%T4!M^O']@$&_P!ST9_U*1*
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M7 <L;*&@L!RQDN,'?(,8 <'/'+#+&][98WM>W@H#GP/_ ,V-,_Z>*W_Q)(%
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M#[X4 _AOQU\26_/SO; ^^% /X;\=?$EOS\[VP/OA0#^&_'7Q);\_.]L#[X4
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MU4\]9=)0C%,>H39*IPXAEX/<-F26YA5YT&E0,JB)R:W3UC(@1@4R.4 +WSS
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M.4;MIKA:\:^6V%DAXNF[<)HZW(Y"(XY9:<"@+B\=>DFR$.W'NKHC;!S1PR
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M@YI>.P/%C18[Y=3@@][P4X&_%2$X'59@([T4PCS84T%NE5+Q@$$)1*8%;"C
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MB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'>
M@?KLB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF
M@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(
M9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'> @?KLB/M(9OGF@'3_  /U
MV1'VD,WSS0'GI_@?KLB/M(9OGF@/'3_ ]_LFR(^TAF^>: \]/\$7^R:XD[2&
M=YYH#QT_P/UV1'VD,WSS0#I_@>_V39$?:0S?/- .G^!^NR(^TAF^>: \]/\
M!'77$G:0SO/- >.\! _79$?:0S?/- .\! _79$?:0S?/- .\! _79$?:0S?/
M- .\! _79$?:0S?/- .\! _79$?:0S?/- .\! _79$?:0S?/- .G^!^NR(^T
MAF^>: =X"!^NR(^TAF^>: =/\#]=D1]I#-\\T Z?X'Z[(C[2&;YYH!T_P/UV
M1'VD,WSS0#O 0/UV1'VD,WSS0#O 0/UV1'VD,WSS0#O 0/UV1'VD,WSS0#O
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MO)X?L<W0$W<[OO\ T+4+\TF;S/0#G=]_Z%J%^:3-YGH!SN^_]"U"_-)F\ST
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MDT!7K744;T[7^Z^2^F/Z?\U+GEKHK5)%\J^+=.KDZ;.9\CH_-^)=X7RCY?\
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MK/;IR>;6@Q==PD0,ZQ4)L/U_--MDVY@\WO>PA@PJQN\U127#*GGG;D8A%2X
M =K\H7,3@$!8WRW/_5G#W;D]?_IXH")9]69UR@J:L3L;Q*"3RB61[&QBLV/$
BR9"+79RS8<0N7%@ J$./@%QOAAD*'CEE:UKY8VOQL!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>txmd10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd10k002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!-@)8 P$1  (1 0,1 ?_$ .0  0 " @,! 0$
M       ("08' P0% @$* 0$  @,!  ,!            !P@%!@D$ 0(#"A
M  8" 0$#!P@'! <%! <) @,$!08' 0@ $1(3"2$4%=565Q@Q(I46%Y?7&4&6
MIK8W=YA1,B/887:W.+@Y>7%")"58@5(S)I&A@M(UUB>Q0],T5)1U1R@1  ("
M 00! P(#!00%" 4'#0$"  ,$$1(%!@<A$P@Q(D$R%%%A(Q4)<8%",U(D%A<8
MD6)#TY34)5:A@G.3-/"QX9)35'35<M+B8X.S1#55)E<9_]H # ,!  (1 Q$
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MN.I_[M(7ZEXB/AZH+W'4_P#=I"_4O$1\/5!>XZG_ +M(7ZEXB/AZH+W'4_\
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M 06]8J*)/R688$.43,.(FA*\VJUAMRP9;4U5;%T99=I0'!PIO6\!MB"2^=1
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MB;IOIFVVJ,.\"B/[];</(M6*#UKW/KTIU,JM07)K=L]TNM!/H#*@HZL(R\4
MJ14\CPDA2?!"=N,=59@#Q9\U\W1-PV;O4^0BW[YUD<;@FS7L,;XJVEB"MJZ
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MG7Y>G]G7B)^\1'$1Q$<1'$1Q$<1'$1Q$<1'$33^PO\ KQ_D_9?[EO7$1KU_
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MDOKKB(^&*BO8%+]-27UUQ$?#%1?L"E^FI+ZZXB1P\+L 2M/(<4#'9 5-[?*
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M'$1Q$<1'$1Q$<1*^/"__ -T"(_Z]W%_M5EO$24^PO\ KQ_D_9?[EO7$1KU_
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MC0:$:$!EV_3ZK<PDP^=*I72: V$ID=P19.G;W$U#(H^8I7,99R@T+0N/.*"
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M7<U17:U>T,!LU8A7?3<-RJIT=I9OSO1*0R*NU3DJ<H_#ZM:C<X=K.ES6TC
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MA;BQNR+%W76'_6!>%9&0UUJNP4^'?'-W3[N#PZPW&9;'(&5N1K0S:LEM=VT
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MO8*P66+R9[0>@N#7QU_J"\YX(SJ/&?-ANP>"^+?,HP[5I%7)BAK[+<6Y3;8
M5T(7]+84%5=A"OK4%:['?O!>!W9+.Q89_0=SR14]JEM^-O"*MB$*NNOIK[HU
MW,OJ-&)&'O9+X:])LI6%VC(7[(7&*L#>=(0@*;WT(4J04:&M6*'$9+D6# >]
M(,ZGF=1?+GE</,WF'Y"^3_,O&>2.Q)RW'=PRQCY' 44UWT^SBVO_ *E_+$T#
M6):WTN0.<JPLS%B=HD#J?4^C];ZGD=>XYL:_B*_<3-=VK;?8H_C?J3]%*C_
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MZ::_A-%T!K?%9G%E5@S-O#V9<6\8CD<3EY2-L?;SU:DA*XI@E&A&:>6$'_A
MB[)9100YZ"R+&0\C?A[\'_'OE+H^7YN\K82L_:1G-@<;6OLXW'T77VHF34$9
M2SC0G$4A*Z:=C;'9E-=J/+'F3G.K\W5T[K%I XTTC(R&.^R]U12U;%@0%/\
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MQ$<1'$1Q$<1'$1Q$XSB25!)J=046>0>6,D\@X 323B30Y 84:6/ @&%F %G
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MQ9$(6<8QCRYY@NTX'#\KUGD>+["U:<!DX&15DM8P1%Q[*G2XNS$*J"LL69B
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M5FKKKT+,I+6EG8RJ7D?R1RGD#L"\M8/T^%C:KC5K^:I=P.XN-";&(#,VN@(
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M?2>IT_3^G^W_ +?E_P#V<SN@UU_&>&5\>%__ +H$1_U[N+_:K+>?,24^PO\
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M7)%[;&2)\Y+Q("O,UJD:5Z5]R8 'FC<J+,  LT0PF=QW@LAP(8.QQW\]?/\
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M& P(7*;RM\<./^!W3^.\]^%^RWX_:>*R!C9U'(,33SU.3=O&(*J5VI8B*3L
M"FNDY LIOI#O9[J_D&WS9RN3T?MO&H_&9-9MI>@??@M6FAM+L=2I8_F/J&<5
ME61M!@E6W4DGNP;/+[-4$-V"V]<Q0=*G)#EI9G!S/[E$F5'BZ&Y&<2K.+PI&
M'.1'F [78#@/9B#X[?*WC/-'S/X[R+YUMJP-F#?@<!36@.)AY.39LIKML.C%
M[*KKZOU+J2][U[O:K50FU=[\:9'4_$63U[I"-=K<E^:S'^+=74NKLJCTT4HC
M>V#Z(K:;F)UL^YWQE'(XB5\>%_\ [H$1_P!>[B_VJRWB)*?87^ 5X_R?LO\
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M5XW%8-[6M>T69.0XTTHH+IK6K"RYV6M=BE[:Y6\4>,<OR-S#+8_L\#BE3D6
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MH%U;(>Y6I3RS0DO+[@8A=&1823V?,<D9!_X@\'3!A>0]UV1"%W5]^E_TJ\G
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MS,#)Q>3Y7B+W1[JFK%*XF3C4JMN[V-1^I;:ME96D^XU2^W;'PIXW[]QO!Y/
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M Y25P3%I6508%4(00E)@ R=CY.F BSS 8?P[I3ELLYG+>YP1Q[5Q1L(O6YE
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M3N%*_86Y+3A-)QW7F0,YP#)PNGO3*KLQ%S*Q8:F0,!L<.01J :V4.K?M5E#
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MG=8+VMV#0Z'8M89M3H-!^W7\)["?Q<*T-4IBCZCGR4@U004>J$ZQLX*4@PT
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M2DEA#DLL.!9!G.>N<YSR(.X=NYWN/,CL'.6V-RMV/4+&T%8<HNP.J5A4"E0
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MG8L^[_2)9@N[7L8234T6"OLNLT.3<X*[6(=(,"#DS. =<=&W L"QD7Z/+UY
M_P#Q.<=F#]+;U?M%55WV%Q3HR!_M+C:-P*@[AM^[4>GK+ K\5>3P6&75VSJ=
MMM!WJC7:J[)]P1@QV%6(VG=]NA.OIK-QEZ\;!%%@+Q1MKF8+ $';,BRD1@^S
MC&.T8+)O40Q=.N<_V\ES [SA8&%3@KQG:+EIJ5/<MP+GLLV@#?8Y.K.VFK,?
MJ23Z2'N1\?YO)9]_(-RW4:&OM>SVZ>1IKJKWL6V5(%T1%UVHH^B@#UFSVG1'
M:IS:VYQ;H=$4")>C3K$Z&2R\]JD",M06$WS9Y;AMBD2)P)$+.#"\F#R$6.G7
MFN-ROEOCPN)T_@>,NZRJ*<=\W-R:<LHP#D9-;I8RW*S,KZNWJ-=?P&S_ ,I\
M,\DS9O=NP\K3VMG89*8&#BW80="4!Q;*WK1J6559"$7T.FGXF,=M1:4T--54
M"L1F;DLL]&-CXM"P.X'1N&E<P' 0C"L,3I1".[M)G P]C'9SCY<]>1KSGR#Q
M_&?.9'$]NZX:>W92U9&4</*2RFPE/;J8-8JOJ*JPK @>H)]==3*'!?'&[RKP
M&-R_3>S^]TS$:W&Q%S<1Z[ZP']VY2M3E-#;8S*03]I ]--!LO7O6V:[9DRU9
M I>SPC,&/9$KJ!_PYGA<_K 4Z'(QI<-!8\ $EPTF8'DSY<##T^3/,.O8.R_(
MFRSDO&&=F]8RN,*5Y0?(;9E"X,:6"XP'\2KVW4L_U1E4?EF9?KW5?C137Q7E
M3 P>UXO*;[,0IC)[F(:2@O0MDD_P[?=1PB>@=68^K&;IE'A@;*MJ(@UAGL'F
M"@U5@H] !U?(_E,G[HP?G>53BB.*.Z&A"#NPXP+Y_7KTQGF(YWPE\B_TBIC]
MJLS]SC=7^LRJ=  2&W-]=#H-H_;K^$S'7O//QI&:UF1U*OCMM9VV?H<2_<20
M"FU="-1J=Q]/33\9@@_#5VZ,"(!B>$C /&0B .P#!!$'/RA$'+5G&<9_LYIF
M1X#^1.9COB9>?[N+8I5T?D[F1U/U5E8$,I_$$$&;SC?(KXUX60F7AX'LY=;!
MD=.*H1T8?1E92&5A^!!!$Z>?#JVIA@1R\:.O40(J4=(AK/K62X>; 921N(S\
M(#6,XI:(L*?.<%#"(!F?)G'3.>8+'^-WF'K%Z]DQ1Q^-D8'^L+:F3J]9J!?>
MH]KU8:>@_$^GTF>R?D]X5[50W6,H\CDXW(@8S5/BZ)8+B*]C'W?16W:$_@/6
M1,*O"U1@+-#,E7000##D3-&>O06,"QU_\DSY?+R/%\V^764,.Q\KZC7_ #1_
M^C)(?P1X:5BAZSQ&H)'^3_\ K369ZDU2><I4'"-/4&F'GFBSCM&'&CR88,73
MIC&1#%G/DQC&/T<C;+R;\_+MSLYVNS;K&>RQSN=W8ZLS,?4L2=23)0P\6CC\
M2K P*UIP:*U2NM!M1$4:*JJ/0*H   _"90WS^?-2).W-,\FS6W) 9+2-[9+I
M"WH$I>1B,$6E1(W(E,G+R8,0LX $.,B%G/RYSS)8W8>P85"XN%R&=3BH-%2O
M(N1%&NNBJKA5&I)T 'J29B\KK?7,[(;+SN.X^[+<ZL]F-2[L=--6=D+,= !J
M2?0 3'7MY7OZ[TA)7A>_.?<%)_/Y YJG=P\V)[?<$>>.9ZE5YN3D8NP#M=D/
M7/3&.N>8[.SLGD;_ -1R=UF1E;0-]SM8^T?0;G+-H-3H-=!J=)D^/P,;C<?]
M-Q5%>-B;BVRFM:TW'ZG;6%74Z#4Z:G0:S>5":Q6?L9B4YJI)&5.(@)G"^>F'
MPMF[&7O#B)O\W[*-7YQVL-9W:_N]GICY>O-^\>^*NU^3/U9ZDF*WZ+V_=]RT
M5?YN_9I]K:_Y;:_33T_;(\\D^7>H>+#ACN3Y:?KA;[/M4FW7VMF_=]R[?\Q=
M/KKZ_LFW9EX>>U$+9\/)L(;I0'*Q.B]%P=YS(WO&5&#<X59;@H4G1"1W70TS
MM_,R(/DSU\FY<W\;O+?!X7ZY\"O+&\+[>+;[UOKK]VS8OV#3[FU]-1Z'6:1P
M7R?\.<]G?H$Y"W#/MLWN9=7L5?;I]N_>WWG7[5T]=#Z^DUVUZ<;2.SBB;"*-
MGB0Y>H F+5.S<2U-A Q]>AJYR6J2DB%,'I\XPP00A_3GFLXGA3RSF9->+7P'
M((]C!0UB"M!K^+NS!57]I8@";1F>=O#V%BV9=G8N-=*U+%:W-EAT_!*T4L[?
ML5029L15X=NW21,H5FUF@$4E(.4&!3S>&*E BR"Q&C"0F3O1AZ@X00] %@"(
M8Q=,8QG.>;+;\:_,M-37/Q591%).W*QF.@&OHHM)8_L !)/H!K-7I^47A&^U
M:4Y:P.[!1NQ,I5U)T&K-4 H_:20 /4^DT#G7Z_.QVPT?;N?F=K <UQ+\9SY.
MN,9#EHZXS_H^7D>?[N/(>W<.!YGZ?_<LG_JY)7^\SQMNVGL/"?7_ ._8W_62
MU6#>%/"9)"8?(GZRK'8'Q^BT?>GEB,98\G&RNKHTI%SBTC(6MV%I(VY6>,G(
M#O\ %#D'07SNO+<<!\1>"Y/@L+DN0Y3D\?/R,2FVVHU4@U665JSUD,FX;&)7
M1ON&FA]937L7S,[!Q78,[B^-XGBLGCL;,NJJN%MY%M==C(E@*6;3O4!M5^TZ
MZCTDUH/HOKI&(?'(S)*_CEC.D?;A-@IA+&5"8_NJ8*Y:K2A7"2!)3]$12ON2
M\!#C&"P!_3R=.!\ ^-.*X7&XOE..QN3R\>K8<G(J0W6+N9EW[=!]H;:-!^4"
M0#V'Y$^4N7YS*Y;B>3RN*P\FWW/TV-:XIK;8JMLW:M]Y7>VI_,3)#5]5U>50
MU+&.MX>QPQH<' ;LM;V%&%$F5.0TR=&-:<6'.<"4"2I"@9%_[H,8_1R2.N=3
MZWU#$? ZQA8^#AV6>XR5+M5G*JNXC]NU5&O[ )&'9^X=H[IF5\AVO.R,_-JJ
M]M'N;<RUAF8(#^S<S'3]I,SWFPS6YK^RZL@%PQG,.LF.)I3&A.")URU*E3@D
M*RX-XAB1J>^;%B%5VB!&"Z8[?9SU\N,\USM/4NN]UXO^2]HQER^+]Q;/;9G4
M;TUVMK6R-Z:G\=/VB;-U/N/9>C<M_/>J93X?+>T]?N*J,=CZ;ETL5U]=!^&O
M[#-"I]#=1DIY*DNDX\,P@P)H *724K4XA!SUQ@](L?CTBDO/Z0& $ 7Z<9Y'
MM7Q\\-U6+:O!8Q93J UF0R_WJUQ5A^Y@0?Q$DBWY'^;;JVJ;L&4%8:$K7CHW
M]S+2&4_O4@C\#,@^#/5?W#US]!$__>YDO]R/B3_R_P 9_P"Z$QG^_GS)_P"8
M^5_]\9F.-;]>\8QC%&U'Y,8QCK7<3S\GDQUZM.>O_MYFO]V/CC_^P<-_V/'_
M .KF"/E7R<?7_:'F_P#MN3_UDC%X8&<BU B.19R+.)S< >N<]<]D%I2P  _]
M@ !QC&/T8QTYM^%A8?&XE?'\=571@4H%KKK4(B*/HJ*H"JH_   33,[/SN4S
M;>1Y.ZW(Y"]R]EMC%[+&/U9W8EF8_B229*;87^ 5X_R?LO\ <MZYZIY)#M]W
M+ANL%1Z00]T@UC3Z47?G5>JV\J&Q=V4QB"-EJOU<U478=DSLU#F)1./-#]+D
MI9"0]5Z5>%9@2$28P(5!Z9$\>S/$><*_NZ7Q5!K5.9;K73]OU?0%_;7(9]7K
M9'ZPMNVP5R)A;4-8.+B&<3>'Q(=N1P$I>4O<89QN ^Z3K I%8B$3ZC/B..#[
M?;)"G#6>P(]K5-]@I_J=6^V:V<5ZJ899L%6JF<L[^Q*:H0NAL_C\ =YE6C['
MV:1&X-"N>4(0&I$R52F5&HFP=J]SYU1UB1RGJ-U?F^U]K*:SDUYS:)1*?U_6
MI4'IJ*O;?&SWS#U82]&BDLVE<@7&(X\P)<!RXG(E0E"M"25@T:)H"Q/%C;FM
M$1/Z3UHLJ_:$A- 5!M#LC;C',*_ABBCJ;NZ-NLXB*M!7\I=2Y':$V9Z\9%,B
M?&9N$F]&M&"L@4*%9Y*0:);@D5IEZ5,N1*"5:-:G)5I%2<P)I"E,I+"<0H)-
M!G(#"3BAX$$6,YQG&<9QQ$IMV-V%2ZV^)6;,%437S+ZRZ1UW#T[:WN25J,2G
MG7U;;OY^>I5D*0"3EEMP@B"$/:^=U_1R+N]^2;>G=BX/K&'QMW(<ESE]E=>R
MU:Q7[9JW,^Y6U4+878C\JHWU])+/C[Q?5W?K7/=JS.4IXWC. QZ[;=]36&P6
M"W:J;671BU810==S.H&DP:Z]_P"/6VRHH:Y53)XZJ;G-(YX>DCX!\2"-P3DD
M8$[8F(; *"CP*!=D:C.1%8#\T.!9SG%"_GC@]U\U\,GACKW7K_YSA<Q3>N8U
MV4:&J-;*ME56/2R6FQ;-I&1K['W;2'U,L7X#\=<1PG#U>35['Q8P\S"L6S%N
M]NFVED;^(CV6.S ULGI[:@6@@^HT!UC7]]P*"+5,LD$+D\SDS&:4MA420A2(
M8TZ+2UH,%JI1)##E9S:%"DZF@3EHE(3SPAP+. =>L6>./@!_N+\F8'=.9Q.1
M[C;@\;A96'B8]:IC'EP!^L&9D-Z)C8MP-F'7[;MD@H;B%1UL5>3^-\E=?R./
MNYKBNM<>^9=1D79%CME?I"":7Q<8*#:UJZ)<WN(:CNVC4KIL2$[OI8#-I;.D
M&O[*>9,E[882V-DMPD60UN\U*P_)&Y0I81I'++JO")4()8$(,&9P7_\ #P'(
M;U\'X7ZMXAYA_*GC'H6&WD3GB#R==.8%;$%@]VU<,7+["(UFHNKQEQULL5"0
M4 *PO1S/%=XR,KIO<NXW8G4N-W?H,FW#=TS-C&M#D"IS:A*Z/6UAN*H6UT?T
M:0F?$Q8SY2%0*LY7]03(\:E/:% HWB6CDHW$/969_P#.QLN6/T5@0!%94=]D
MP7:Z=,=G-@<?F>8Y#KO\PNX3+KS['*'!NLQ5MV;MA=V]YJ-I75]IL)*?AJ=L
MC/+X'@L#L?\ *J^=PK>,2H/^NIJRVHW[-XK5?87(+ Z)N]H*'_$*-TJO1S*Q
MD"]X<6F?S%@,.D3T^1@MJDKJE^J_I(T\)(D&$BDDE,KPWF 3&B*QC B08+QG
M(/)RN'BOXPX/2.J\U@A<3C.>Y+*LOPVP"53C7.AKMIV"H"]B$2]J@ON45K3N
M9/23OY$\\==YOM? Y?!\97D];XJA$S4RJ*E;DCH$M2U3[A]H+N>@6DE+G:TJ
M& F9,^PNRA)&$BZ_YZZH$H@8)*],Y.4%+4JH"LLQ2XGE&N*@Q,>#&>P::,.<
M?-'C(/F\WOQ?T7O?%9^3D=F[C9SG%5TVXRU4L2:LDG2QK7?>_NT@G8C,65R"
MPT4"8?RQW_Q]RW'8N-U;I5? \Q;?3E-;>B@6XH!:M::TV(:KR!O=5"N@(4ZL
M3-:R!XED\E>9A84U>9U)TB8EOPXO."<G$)R@B&D3XR2 LL($X#Q""$ 0AP(>
M1?+GF'Z%X*XSBO(E_?N?YW)Y[M^)8H?W:MBUV^PJT,Q+,"]6.5*+7M0%A85W
M'4Y#OGG+*S?'0Z+U7KF)USJ7+*;-U5QL:^M;=MX5=%VI9;64<OJQ5"@)&L\A
M+&41CF8J2M*I2J"+SW)I(3E!11HS!8Z!(*R+L"P+YWE#V<=<=,]?DW3!\,^.
M,#O5G9Z>'M/+^[^M7(:UCCID/8VJ54!P!8IUMT:LHNY2IW: :CR'G'R;R'CZ
MOJU_-4CA_:_0-C)2HRGQDJ72RZ\H2:V!%.JV"QMK!AMU+9Y&ZXF4XD2)DBD/
M6OCZL*5& 2 08+7G%(DXE O-CEN4Q&>Y+ (0L9'U[.,]G&>2!F\!AY'/8_+K
M@<99:0RWWVTJV4%1?X"TN5/T<D-N/VK^3UD<<?V/-QNNY/#/R/+55 JV-CTW
MLF(6=_\ 6&NK##ZH 5V#[G_.=!Z[E3ZC;)KE21&"JY,WY5+$I EBL324C( :
M>  S%AOGYPB4@0BZF#" 0@ ZYQC.<=.9G-IR\BI4Q,FS&L%U;LR!6+HK O40
MX8 6KJA8#<NNY2")@N/R,+%N>S-Q:LNLT6HJNSJ$L="M=P*%26J;1PA.QR-K
M@@S:N- -BD@P*S62'N920P"HUM(F "3G(E./!QK>4:-"0$H:XL&2L"R,'9R/
MKVL=.N/1<K6UM6KM6S C<IT9=?Q4D$:C\-09YJ+%IN2UD2Q58':XU5M/P8 @
MZ'\=")BJ_2_9=8O6JT]2%-J94L4J4[8FE<8&E;TYYXS26\@U1(CE0TZ0H6"@
MB&8(S(0XSD61=<\^[?<""3ZC3ZG7_E^O]_UGYK]I! 'H=?H-/V_3Z:?NTT_#
MZ23#!X;[G)F5M?Y%/S8,^.B4M0Z0\J'H'(B.*^G=#:DKBDF:@E<D38+Q@H[(
MQ&& Z",^?D7/RIJ6BE*$+%$4*"S,[$ :?<S$LQ_:S$DGU))GZWW/D7OD6!19
M8Q8A55%!)U.U$ 55_8J@*!Z  3&9!X;MLFNQ^&F?PAT:4I*1O:ESN!Y:7(UN
M1)P%)@JV]"V.:5,85\X..RH.R(.,9R/.?)C\J,.G'OOR:]WNY#JSZL2-51:P
M%!.B#:H]% !8LQU+$S]LC.OR<?'Q;=OLXR,B:* ='L:UBQ U=BSGU8DA0JC0
M*!-9/GA[[%-3GDIK11B3I1I"!97-TH2H4(#LC.[PD*5\*;5N% ,=.V/N^[%C
M..SG.<9Y]$PV3D;,_P!Z\K92E?M%M:5*,S>XB:>EC[@KMKH51?0'4G]+,Y;.
M,JXWV,</5=99[P32]PZHHJ=]?NJ0J61=-0SOJ2- /3AWAWWD^O)A,M-9H*W%
M-QPR73+D@DZ<]7WZ? $@VQJ=$R@LTPK(Q!.SD00X#D.<?.QGGU? 5^33E#;>
M&KH>H5"QA2=[*WN-5^5K5V[5<^JJS ?6?9.2=.)LX@4XY2S(2TVFM3>-B,OM
MK;^9:FW;W0>C.JD_3UW5'/#*4$OS4HF%DMSQ'4ZD8W- S,:UH=S2!ISBL9;7
M-0X.)"-2$P8<]H1)@1!QD.<>7KC]K\/$R;:;\BJNR_'<O4S*":W*,A9"?RL4
M9E)'KM8B?ACYV;B4WX^+;97CY-8KN56(6U%=; C@?F4.BN ?3<H,WAGPYZ.)
M_P 5MD%GMB\ORIEZ>3-8CTP\_-$,O X]V>T(O.0_]F>>@@$:'U$\P)'J"09X
M>/#3IT/3L3>S09#T[ @+XP'(,X_NY#G$7\F0YQY.?,^/W26:#7VED:)$D.JZ
MOG Y(D2IC5ZR$Q?SI<8G)+*&L58(:B4^5*H0.V9V !!D8L],8QY.(F$'Z;ZS
M*3SU)M3,F#5)YR@W!+C(DY7>GF"-,[I.G>2DY!?;'GL@+"$ ,>0.,8QC'$39
M,*I2JJ\:U#-$(,QM;:I7&.1R8TDUU[2TXD@@PX)SR<X'E8&4G!C(0B"#KCKT
MZYSG*)GR%D9FL9AK8TMC<8:#!9IB% E2#, '/:" P:<HL0P!%GKC&>N,9XB>
MGQ$XS"BC@=@XLLT&<XSD!@ F SG'EQGLBQG'7&>(G7]'-_\ _0H__P"V)_\
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MYA=[LVU<N\*-Q)T4>YZ*-= /P&@F"/&B&I3XYK'9=2[ 4K7&!-/+:G23L+<
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MD2=.'!9>1Y%D ,8#CICR<1.?\JS2#W:3G^H?8_\ %KB(_*LT@]VDY_J'V/\
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M^+7$3@'X46BQJA.K-JN8F*T8%):149L!L4-2D+68*"L E/%:^34X%84Y>#<
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MSR8P@[T:A+)65;.YRG8W]MP8I,186-JG)F0K\%DHD^^(GP886268<<8 HHH
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M2UQM4[2&.8$0VR)4C;\-21_P<E*-&'!8AHDX^(G$:<21@&3C2B<&&EDEY-,
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MTUGP7,P<Z"MY.^Q&MDT'OR<T0<\&QQP;#W9B.=TBM.6:)4C2E.*)Y</I&_[
M3,7APONQ,KJ&UM";9B5OTWL.NKQ@M&1; :+2RO+?IVNUJ91-B!0L5Y0!LF*^
M'2)R<4#H22\,"5Y4-JLIW+*XB3ZTCU#JWPP]=)E4[9:@SZ0CMA32R8[)K3<$
M#2NKN#/Z5DR7%YK/75V"@D*.)'MQI*)T/ VEIF?S1#W& HPFFHF'7)NW:ZVY
M&&FM*JOIW9%X#KAG;!V=I->F8+';"K,Z=N%?LL.HJ1QF%V&P2N>/SPS*LC7.
M2AMC[5WK>%4I[*_!B=$@R=9#Q')BW^.!4UAV//:#M9/":BVMUO=(J<SN]%ZS
M05.*&/+DKA2,][=SK\T]V8/ECK,>QVA'QMU?$)!61-Z0U0B;?J#P@UD3OJB-
MI9CM;)+*L.AK8N20UTT$UQ$X]5A6OUT2BU9NX52J86-P+?I+,\2NR4[V"8NK
MPXA2N+<#S!K2)CC2AHE@>R>YM*:X5U?\J<I=$YG8&OE*3"\I/1D<F\5Q:Q\2
MBC$H>@KE$5.<3'EA8W#NRP"=5:4*),69WHQ9 '.,HE==T.UO[NMYOAK[B(6;
M4Z2;"Q^,7+!;5UHLAXLV'WE3=9RV,2ZSZQJFT9+$*T?:]OR!.&6,]<8-H6DJ
M&!9Z3;<G PK+0(F)LM&W#XA#-%*0V'NMZJ"^=&76XM9MPSHC6L;<UFT-0WK6
MC,PLEFUA(9HG=H_73)LC5:1.O6KTK8YK65:K>FA,%&L1E+242QO6*FZN\-[4
MF)4[++E84M55$OER9IL^U71C@GFT:EE@R*111LG$H?'ST8]2=I02!.UJ7D\X
M@Y[4I_.ADEG'B!A$T+<.^MW-%LWM']<==HOL#7.I==U%:%Y%H[25,ES6-%KC
M8)+,6LW5F%(X6^PZQCV*%1A0L)R[2!E*D3D UJ0#">3DX:)#@N,,U<SASVS<
M[1=]K_#Y\9!Z*A.R#>)K5IXC4Z*[X^SUGIU/HJSH#5#JP0%UK)2VUG/#QFIU
M G94U/)P4N$ZHLE$E!3&CMP,6P.K+S)H!K%2-"^'\W7;"]:TM!2.Q9-/;*K6
MRH=FMX?#+&1S>'QXN!LD;B@BG60$ >Y8.23%M1..#4N"1=ZB2BVBW:KFAZEM
M>705YKVWK+K*5U37+I6+=9C W&Q2>7;:$1J&!8MYQ:RI,[5=$$\HF:=2ZKU;
M::<F;4Z@PI.>8 )0D2 -V,UV^(*[K-&+JEAND6U&NKY%MN8I(*2>5EAP6[&9
M@;I.VT)<-0SJ3,T+?P1>H-B36DZ=QIS8P+L*&Y*AR=E \)EIB)V:S;[3V$[G
M;^J-2]4\[Z$QR1Z(;_1S8R66E#F]@,JX3J<J8Z[=HU K+9)97CS)I43(TXSF
M@)DK@[FW$"<21DE@)1)]:WPBM?#UU UQH.T[OAK<U53!H94*"?6))&2 ,\FD
M:-#W"9GC9<G>@E(T8S@C3LS2%4I4)FXDDC C<E9'E$BU9/B1VI I3LC9"/7E
MDDNG&G=S$TAL?,VRP7DS8Z(810FOYW.;W::5+@AL<>:4KAEL=&K7%8D89 L8
MDBQV2I!EE%)5")%QEU:9Z<?GW4;:.3K]P=(/%F=YO,WJ8N@'-)&8CNK+7IWN
M1\C36=$G0:V"TIL%%&\ISB64KH8%GDL6.++4=\\D"XB35UKU<V)*VDCVT6Q,
M8UIJ-VJW5]\U,AD&U9>YM(8]844=[%A\V12V9+)K!H HB;#!44"2HXI%"2GD
M+,)Y=S!.A@3BR\(FR]A]YHK#8W#&S6Q[I:^K9LG8V*ZKL+89<+2AKJO[4DS!
M,96:7<TIA3?/7R(A:V&"+PE-A;:<ZN3J-(A*++$IR<4B0(M5OV,WV?"7.(R,
MS5K?;PN9+(YFGUT2O/UAK&T;GF[$R&5!,U%IJD4?6334C8"F$DQBQ61,S4Z(
MEC\O\\"2O8!)C43U5U/.FXM7V+L/IQKIJW&1^)53#M56[Z_:8VTVFWH),H4Q
M*:5)8W"$,D5DT7G2JE%"!^97>."'%2G=V1)U07;N_P#%RB6PPY?5^M-?4'1<
MQN&/)7=%$X33]?++-F; RS:V'B'1QGC1(VY*[N*59*Y>\X2EGJ2483SAGG]>
MS\['5$K;5^)7< VEVMU\IZ%U_I[)[^M+4B/W^@G+E-;-U_M.(VQ)]>(K:VS%
M,+XC%X['ZAD]TL $9F&^2K5K&0O;CG(($ZE4<@1(12+P\7=F@I'A!V/:DK?F
M)T;$^U?AQ;5S9E4RLQ@N> %@/V6U\MEM1*&U*\0=_=96Z.@(^:I*+>:VF[RR
M%']60!F$2V/4O72[*_NW8+:O9 J@:\G=R5O2%;O5>ZW.LP<JM&@H8%B*"[:F
M,EGT8@[F[3Q_33_+84#+846R1QE0HQ+%^0]Z6B=J\]W587W72M]-\45?UA;-
M2>V&*%S"1W&8UT0Q$T?"\S>?I'J<5A&+3=W.9&I#"DR!F1(!FYQYTJ/,*)0F
M ,1( SIXO39]^3>(Q28I]#-I_#F(E=(6'X=RE0TJ@/3^&1HI-MK5+[+4@Q(K
M%%>M-)8@]5*^)TJ-%YTWM#CD.,."DA(B8,P^&Y(K:KJY&_4F2T.IT3\1><U)
MMJVS:RFRP&O9C51V/5Q6<K$5$M"5@6,SPA9WAJ&\PEM<W**F5S(W5?T+7%=4
MXD3^@9_M>LHO+6.OG^P(6U6)*6YQ=HE7:Z4L22>RY U$J#W!3%8>I<"9!(2D
MI:4SMB2)S0@[&>UG'3/$2F#XY;GV<I.N&"RH!#=<:0\3ZOWZM=3]E(#-UURK
M:KF=H11V'":ZV-A[K%Z[;8;:<_A^%GH$YI<GEG(E:83*I,\X\T&N1-#KM+)U
M+'*%:(K)009L+X:TNA&ROAS7+=B"02Z ;$Z:ADS&@+H38E7'P(SI#FMY)&&N
M*R89(<.))[-$)22F/.$8G$B6JZC4=+];2]K[VV%>::KE_P!B[9+O>?PJJG]V
M!0E2 CE80NO'%Y(F$Z9(.K?)++T<'P]RF0*FEE*5K3L8RG_P!*5")C-N[O6"
M]V?751Z-0FCMEY!,*(G&S091*+Z^I5;3&M8).X[7!T3J.;0B%6DV2VP7V5/_
M ' U"G*)B8P@*$M4YRJ+ %$@')9U(ULB!XW=6RJR9G59D;CNOFVVF+Y%"R7J
MJ=6JU<I(P7\T/\(2J'LYZV2U9V$<I%)7,179"X19.Y-"0)X3DRE0B9/4WA66
M=7B""4-6DRH-QT;BNY%=[QU%:*Y/.5>W,"2Q:4,UALU-,:O"$^&R9DPE:2(>
MV3%2])UZ&M3\LIC4K[HM0)$MOO/:BG:*B-SO#W+XU()Q2E(V!?3]3$?E4;/M
MQTA%?11TE:]4U0@US ^Y)<D[7DA,I,("ER<8#&3,8SUXB5>V-9]K;JPQBT*V
MYC<4UG0[ZULRS:GKBUXLIUM^%VG5#,MBT^O'75KFT@AM:N, V(,I\2@Y"Y%M
M[FSN#(<L=&X1AK:H2EHGKI8A=VVNE^V_APV_*,H]S=;D,8CT5N62H%1$=ML;
M$ZI+7TIVJ-4)42L@U/+WRO&\$O3HN_/;)4Q/1 "\ "E[Q$M[<YVT5[7:><79
M)H%6Z5H8FE7/9 [RI&S5_'7=00D)<@%RN598B ,H'@_)*4]6%,8<#(.T (Q=
MG")7U<^\MY);BL6O]3: @NR++0U%U)L39R<VXC(I85KP:Z7&QRHDSZK,K="Y
M3$K!?@LE6N2HM4\/+*TN*\Y(W$J "-,5$HD18?+UE'VZQ>+#7]QR6]-0/$1E
MM>Q_8)B(852!JH>#/K+$Z[U(MB/P\DQP<F995+\G,B5H".&!09]8LN"E,GPQ
M#*"B6:4)K].:7V9W3G1;E&5-)[,2ZI+IBS*D.7%RR-7(W5<UT_<9;HA$VA:S
M8Y)&&L(DY(E(%@U(EYS@682 L!(QHG7VHW=JC7*GKWGC*_P>TK"HMJC)LCJ%
MEL>,H)&R.\[E4?A$.'8O<FO+I6\0,?I.E.<G=8WFA0-8#U023\E8*&B0(N]O
MN+?-P7>'+LZ]_!;>\:6PW:N*SS725.5A1*^:WKAP6*(?**1GLPC5?R",2NAM
MDQ0]?,F-T91J,)DZ()!AJ%Z"I3(F6=F\M^M3HDSNC9$ZYWZT=VXIMVL%BE('
MEIK4R]]=IK%GV4N[,X(V5R=15%L;14D6+V!<C3*!IVN5DE#ZGIE!842V*Q;2
MK&H(]];K:L:"5=$_/T;5]9[%E\?A,>]*.(Q%M[;Z:DK@V-OGZXP&0DD][WAN
M<9P'&<\1*S+7\1>V8--]DY=#M>8]8VJFE\VBD)V5D[)93D9L8B;'VJX!<DGN
M&LZ62P9;'I=5U<0.R$*]26=(TCP^(TCB<V)S1)4Y"Y$U7KTT3;1#8N./3[;S
MGL+J_P"*'9<JGQMEHT0QQJH]PK%<'N;5X"(-S<>[%1ZAM@:; W,#?D2E22DE
M472'".P.1C[")/[4K7Z<:ZN^TT?=GN//5869M'8U_P!+DMQSCB0QEFNU&PSF
MS(G*4*A 0VILHKQ<)*M;1HU"@!K8X$X,P4: 0<HDQ.(FG]A?X!7C_)^R_P!R
MWKB(UZ_@%1W\GZT_<MEXB;@XB:MNZY8!KS45BWA:;L>R5[5T3=YE+'%(W+7A
MP+:F=,(\Q.U,[82I<GEX<#< 3HT:<L9ZM4:646'(QXQQ$JZNS>)VMFD+)=HL
MQ; :FRC72X*59=HH#:L7B;%9#3KUL,WF0H^QF5WA\FL6)!01Z*6$9,T:I"\8
M<&MUAIJ5P+2B+-*&B5ZWI76A-#[2L6DDJA:AZ0Q_PO&/75^KK7VO2C]G]J)W
M=5N1YQKN21^(01O+='"5TV=K:\S0^9+1DML0>I.!P5N:3)Y@S42WG7+438^+
M7Q"[SVBV$@]VR&EJ*F^NM52"&5*JK.<3R&V%*ZVEC].-AW(V:RIFD%@A-JMK
M**2L"5H8BUAJ]< @(EA29&B9#?'B/T[K]8-@Q&1U]=LLAU%MT*>-GKKK^%M4
MBJ[69KL-$<\1ERM/O).WS]P0EQHL+R[G1EAD)<>9#BE[IE(F'@>$2JC91NK)
MWH3Q1=E=GW"); 3+7^HK;U0KQILAG@[]!$$'NA\=[PUOLA@=CD939&/K]#]E
M(3'GU\293D*$T+3J3#^TDSD")G=*T/(MB8C:#[HC?12:N+?I& ZL;7SO877Z
M:3J@MLY#$*?0U&OVYUB<EDWKIYF$\;HBC%'75],+7PB;IT:'&!*?1P5AJ);S
M*YK6VAVK$.^L)\WE<2IZ*U!2L/;VQ"5*;0LF2K%43IVKXHSH &-2-ZGM@RIR
M;D)>3#$:/SQ7DT\U.G"8:6B5L;+;*I]O(VBH=(]W=JV-^LQ1IENA3$R8(LT7
M!5K;MQ74E9-?;/*<HZ]3&)OT6DMG,S4TLSU'G]>Q.Z=]<48S\K$IY"9$B/9;
M'IG+-ZMR]3(4RN]6SE4TZ#TW3D&TXK9K/M*M[_I44JO9FW751F.MR>+5K#M?
MV2[8FU#E,A\Q:7%O:U[#WB_J%N,1+DM7=9;T@]S6=LCL[:U7V/<T^JJJJ+#F
MDJO>ZG@Q\$IZ161*&:6R5HDLZL)Y=[%E#U9Z\Q1V%I;:TI %I$A8\=Z>:B;#
M!NA19VYKGH68_+$-\I:,:+X1)3BD9;"\1ITD;]'ET=9G7SPPPZ?1Q*T$NZQJ
M,( =AF<4ZPKO2@J,DHE >S<3K,K0S:^\-HIW$I%LK9=KTGX?<IMNY$<1;&J@
MYW2]ZI*69+>BDS6HFP=:,JUD5 N,W"<](E*=U7G*?H,X&.(DK63520;G0C8G
M&L%EOE3Z#[KVFLF%HUYL%KM+V2?E2CTQ&Y+8.P^E:B02F*NL/BFQ[DB"Y%#E
ML>&4CDP5$G:DW95]TJ1+A-I=C(%J-K[:>R5FIGU?":DC)DC>6R+(DKG*GK)J
MY$U-D>B[8L6MQ+K))"]."9$@2=^6)4K/+*!G(QAQE$@/M(;'-N)9IK%$MI'O
M^F&Z+(WK"T[,WLKM#9Y,JHE-:[<5NQ/.'%'D;M#+RIVM9I'W]J5CR0I0A 7D
MG)G> &B5NP5!KU?&T6V]0ZZO[Y4VQ[!XB)\^UQ4:[U0FFD6U#ENN%"1.@;+N
MW8IC9SX] (/6>R\KC,FBSY'W)<V.D\9CR#D)1IP<.:1$O'U(UPLBGY!L#;UW
MS>!2^[=FYS#II82:H8:]P*I([]GU9Q>JHR@B;%*93-)4X.BQABQ:EU=7%Q&<
MK/, 2642G2DARB:#D7B*5_:!KS4D';KHIM+=KW<&MVKVY4FAL7Q0$WV9BI4N
MAI49ASX"2/[ZV/Z"<QIP+8#)2P,[1+%C,H3M)Z\620'HE5]N/NLD%H73/;2W
M)/"HQ;.X/B(4=LQ8-WV.TM*.=T<YT9%/K]=--0Z6%-YDQ<$<;3T0[UHPQU/W
MRQ9F2B:R$9^3ADFHDQZ0TBGEEPVKVVM)\[57X?*C9*'[AUMKS>FOS_$-K*.?
M*YN8NV6BK*X>W";(4==4?.)^QX>VY ]QS,ICD;=SV8'<%G$E-J)9ALCM7']=
MG&MXDEK.U+QMJWE$NQ75.4PV1%;.)"S5XSI7ZP90-=8,RKV#,L<A[>Y(@J#E
M[PF,4+'%(D2EGJ5!9>42N@$UK'Q$=E:!(4SQVE6L$@84>RL J&:PUO0$E7WJ
M));(I;8*A;GK^5M"=W;Y#$)#?$-?5+*[ -5M,FAOG)(>[+"9A$@=I&75^R"Y
MJ>M')NHK_9BM=H-W;[J^2PVI'6=ZHT%0]P6XO;1:A[-&L3U#HJU-VQK%$FZ8
MXAK"ZD2J.2$1+T%.A"1C"Q$O[T[USD&N4 GJ&;R]BFED7+=EG;"6<XPZ,J89
M7J">6LZ)W)[9*\BK@\R-W:HHV@1E!P->X+5[BM$I7*#,&JA%EHD>GO==EVCI
M7?E@TWECN@V*TRE4Z@:MG6MK2:L=;%J\LR3L86=,(;XC?*UM=UBSA&RG$(,#
M&<G<B,!*5(QX B57WH=HK0+MX93Q*W%C?6J_K+V^W>D]JR&"I9=?5]US=]3S
M]L6T A9(BS.<_O*0VBY;>16,DQU(F=%KC'8V' T^2T.!$HDYM6='KO"9IRX3
MBV5QNL6J+XON/5VNK3JQ;']U(*W2ZH9Q5</U_OVQ2;$DD3<8]3L%LM8W&&HV
M\#R\A0-Y#D=DQ&I4+T2>&TFZ-%:=+:"3W:]JV C8N\&"AXBZ)DI"AO9)+(61
M]=$4EFB@Q4GRPP)&L:$[>M=A8&G0*W1'W_=E&"- B0JLN&1*:;MVXX;7/Y4V
MK#4.MW#;*GJRE<9CDIA2ZM+CJHJKIPM6QYP:Q)G224K-:#DRMK6" <M2I;!-
M3Y'@L\'5$KP\-6."M^K-8;%T(LA!%-C*0UT4Q6W)H_53+;$T3F%86Y8K_<47
MTE?)HPRV$YD=D:E*9_C$?4PMS6@A@"ES4X9[M>:@ B7DT=7T%\._2TICL*P$
MZZ#:_P +M*T[-L/ZM_5YG3)5C_,KFL=U886T'/)L?B3,M?%X&9F(-7'HVPA.
MD":I,!WAB)"6[_$?^LE=2<ACBFP.J5MU.W5ALY(*TN6(0YFE=MZ4YG,>CMW6
M% '.*R>Q8VL1PJ 2A4O<TA3@EDT5>$R +JB1@4E=^B0+OJM]#=6-A=?]-IY&
ML3!L8/#%MBI+#B]5UX0^[.;UNNR$[KV'0MB;X;7B;$KL":F/U'RZ<.3\<+*6
M,OBHAW5.#>$XQ9E$M8UQTWV+8;BI.W-EMAH_<Q&L]1V74U&.R2K5,%NZ9QNX
M#:X.=W?:659G$GC$JFD=:*U;T@RXZW,[<YNW?.IX F9*3%(FQ]@_$0JS7B?S
M:$NE97K9+93,)B5F;*6!4<(:9?$=;:[G*I_)C<NLI&=*&J</:4YOBCFZ*TD3
M9I*Y-C*@-7JTY*?)0S$2LFYE-/R2*>([M9LP\Q'9E%J;0=XQJHHA,V2&S"K9
M!0NS$::MF*5G\4/5(#6E&JE#3*BJZ->DN< <&J+%B./%DHP643JZFTW)K?A2
M66Z%WJV 5DZNT+J!MQ9%YT5,++U(W&?JTJL-:EWE13^5-Z[=[(LJI$+8K8UT
ME1*'&'RMJ4HVXY0K&@*5)$2[NMXC#=/=5X-!5<D7KZ^U?H..1=5+I*H0D.2J
M'TQ7R1L42%[4#&C;$JHUEC@E!^>T4F*SG/3("\>1$KCO79Y@W5T7H/8+7RU)
MS7U!;'2M%1MUKVT#6PV+7$1V:CTOUA6#>R3BW(^'VCK_ '[/H^M4!*4A+3*&
MI1VC#4X@C$B5\WI#-)4N\%ZZ;M$?DD3DK'J-I;K_  "L]/ZY0E[ +[Q9[/D]
M\USLTPQJ(HD+!#&;4=H11UW*F,A$@CZ 3TL;C%)W>Y0'(ESNLNK=_1&]I5LO
MM/;]7VA;RRCH9K8RK:8JUZJ>.OT A$RDT[!/;#:7Z<3LY?8\D?Y.:,*-O.2L
MK"3E04C ;YX:,*)M1YW0HV.[E1#11X>%K=>$[IARNV*$')2,1IV96M^<VE1%
MBG<*K(RIVH;V)R=T[:,D(U+0UK5)8A!3&]E$H3VEAU?J-&]^[TVBE41L38]<
MZP_PWC)[=#1#F9EI&7P^]G:MZGN>)RYQ1M@:O1R.-W/&+4>5*8UM3$+D9:X
MPB 4("))IHUE=MT(CM0Z:;VXXUQIQO.K>8?L'']B-<I6<1/7]?"66)SC;O2W
M#M+(&J:3KBC?<IE"]_95; \O[4&1H23,"-,=42WJ_+\A.JM;1=]D31-9NY2"
M6PFGJOKZ%)&Y[L6TK)EIF6R*0V.^GW>.1T+NX$H5"M4N=7)M;42)(H5*E)))
M0Q81*L[VNZ+;ZN54T<9)++INM+)M"5ZC[<T#84=CK'9E87C'\5_M15\6L5C
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M&2Y7DQ','8R*+EXB#DQ!+F;DA$EIKWH6]5&V1FKGR=!4TUJ]LTHN31@V.JU
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MZZ3*UHTSQ:[ZPFM8/CPQ3*-%O3.@F; N8S7=JRH6FI3%[9E9@\HL\!A!HR\
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MT:B3OJB+Q2I]WV?69@F)=^UG.-<K3M%[0V9F)V;/*3L6I;0JV%"(,G^&@J2
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MHICJ.KJJ\8;,_A3?&#$<JF[MI0^1&*UJ^L,Y9P)E<.D 52_&3#"<9\R,5+!
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ML?Q6\.31%/A8Z)MD6VPI"(N5M:C_ ,J9XTF1NA9QF7UO3@1+//LFJOW:5_\
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81YX45T*U8BBL9ZBP448/ICR!SGR<1/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807113584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 20, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EntityCommonStockHeldByNonaffiliates', window );">Entity Common Stock, Held by non-affiliates (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,430,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 892,897,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,439,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EntityCommonStockHeldByNonaffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EntityCommonStockHeldByNonaffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807435072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 127,135,628<span></span>
</td>
<td class="nump">$ 131,534,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $380,580 and $376,374, respectively</a></td>
<td class="nump">4,328,802<span></span>
</td>
<td class="nump">4,500,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,485,358<span></span>
</td>
<td class="nump">1,076,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,604,284<span></span>
</td>
<td class="nump">2,299,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">139,554,072<span></span>
</td>
<td class="nump">139,410,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">437,055<span></span>
</td>
<td class="nump">516,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,099,747<span></span>
</td>
<td class="nump">2,405,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">139,036<span></span>
</td>
<td class="nump">139,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">3,238,783<span></span>
</td>
<td class="nump">2,545,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,229,910<span></span>
</td>
<td class="nump">142,472,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,097,600<span></span>
</td>
<td class="nump">7,358,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">9,223,595<span></span>
</td>
<td class="nump">7,624,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,321,195<span></span>
</td>
<td class="nump">14,982,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - See Note 12</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 shares authorized; 216,429,642 and 196,688,222 issued and outstanding, respectively</a></td>
<td class="nump">216,430<span></span>
</td>
<td class="nump">196,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">516,351,405<span></span>
</td>
<td class="nump">436,995,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(386,659,120)<span></span>
</td>
<td class="num">(309,702,319)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">129,908,715<span></span>
</td>
<td class="nump">127,489,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 143,229,910<span></span>
</td>
<td class="nump">$ 142,472,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799415360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 380,580<span></span>
</td>
<td class="nump">$ 376,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812869152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
<td class="nump">$ 16,777,713<span></span>
</td>
<td class="nump">$ 19,356,450<span></span>
</td>
<td class="nump">$ 20,142,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">2,636,943<span></span>
</td>
<td class="nump">4,185,708<span></span>
</td>
<td class="nump">4,506,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">14,140,770<span></span>
</td>
<td class="nump">15,170,742<span></span>
</td>
<td class="nump">15,636,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administration</a></td>
<td class="nump">57,703,370<span></span>
</td>
<td class="nump">51,348,414<span></span>
</td>
<td class="nump">28,721,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">33,852,993<span></span>
</td>
<td class="nump">53,943,477<span></span>
</td>
<td class="nump">72,042,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">213,117<span></span>
</td>
<td class="nump">132,451<span></span>
</td>
<td class="nump">62,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">91,769,480<span></span>
</td>
<td class="nump">105,424,342<span></span>
</td>
<td class="nump">100,826,410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(77,628,710)<span></span>
</td>
<td class="num">(90,253,600)<span></span>
</td>
<td class="num">(85,190,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">695,631<span></span>
</td>
<td class="nump">367,317<span></span>
</td>
<td class="nump">95,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accreted interest</a></td>
<td class="nump">7,699<span></span>
</td>
<td class="nump">10,824<span></span>
</td>
<td class="nump">17,442<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">703,330<span></span>
</td>
<td class="nump">378,141<span></span>
</td>
<td class="nump">113,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(76,925,380)<span></span>
</td>
<td class="num">(89,875,459)<span></span>
</td>
<td class="num">(85,077,024)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,925,380)<span></span>
</td>
<td class="num">$ (89,875,459)<span></span>
</td>
<td class="num">$ (85,077,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">205,523,288<span></span>
</td>
<td class="nump">196,088,196<span></span>
</td>
<td class="nump">173,174,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813117920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2014</a></td>
<td class="nump">$ 156,097<span></span>
</td>
<td class="nump">$ 182,982,846<span></span>
</td>
<td class="num">$ (134,749,836)<span></span>
</td>
<td class="nump">$ 48,389,107<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2014</a></td>
<td class="nump">156,097,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 20,040<span></span>
</td>
<td class="nump">91,354,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,374,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">20,040,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,231,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">612,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 1,178<span></span>
</td>
<td class="nump">364,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">1,177,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,777,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,777,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,077,024)<span></span>
</td>
<td class="num">(85,077,024)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2015</a></td>
<td class="nump">$ 177,928<span></span>
</td>
<td class="nump">282,712,078<span></span>
</td>
<td class="num">(219,826,860)<span></span>
</td>
<td class="nump">63,063,146<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">177,928,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 17,424<span></span>
</td>
<td class="nump">134,846,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,863,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">17,424,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">988,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">613,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">1,372,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">722,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,076,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,076,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,875,459)<span></span>
</td>
<td class="num">(89,875,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="nump">$ 196,688<span></span>
</td>
<td class="nump">436,995,052<span></span>
</td>
<td class="num">(309,702,319)<span></span>
</td>
<td class="nump">$ 127,489,421<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">196,688,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of ASU 2016-09 at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,421<span></span>
</td>
<td class="num">(31,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">68,560,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,572,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">212,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">102,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 7,239<span></span>
</td>
<td class="nump">3,791,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,798,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">7,238,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,760,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,760,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,925,380)<span></span>
</td>
<td class="num">(76,925,380)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">$ 516,351,405<span></span>
</td>
<td class="num">$ (386,659,120)<span></span>
</td>
<td class="nump">$ 129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,429,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800578688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,925,380)<span></span>
</td>
<td class="num">$ (89,875,459)<span></span>
</td>
<td class="num">$ (85,077,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">141,601<span></span>
</td>
<td class="nump">77,906<span></span>
</td>
<td class="nump">29,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">71,516<span></span>
</td>
<td class="nump">54,545<span></span>
</td>
<td class="nump">32,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">2,524,909<span></span>
</td>
<td class="nump">22,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">6,889,323<span></span>
</td>
<td class="nump">17,411,021<span></span>
</td>
<td class="nump">7,189,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">167,691<span></span>
</td>
<td class="num">(3,975,893)<span></span>
</td>
<td class="num">(917,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(409,037)<span></span>
</td>
<td class="num">(386,168)<span></span>
</td>
<td class="nump">491,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(4,434,130)<span></span>
</td>
<td class="nump">709,907<span></span>
</td>
<td class="num">(773,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,260,914)<span></span>
</td>
<td class="nump">4,232,340<span></span>
</td>
<td class="num">(3,200,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(522,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">1,599,510<span></span>
</td>
<td class="nump">84,559<span></span>
</td>
<td class="nump">3,698,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(76,155,614)<span></span>
</td>
<td class="num">(69,142,333)<span></span>
</td>
<td class="num">(79,044,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(765,291)<span></span>
</td>
<td class="num">(845,266)<span></span>
</td>
<td class="num">(419,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(61,817)<span></span>
</td>
<td class="num">(396,154)<span></span>
</td>
<td class="num">(165,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Payment of security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(827,108)<span></span>
</td>
<td class="num">(1,255,456)<span></span>
</td>
<td class="num">(584,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">68,572,635<span></span>
</td>
<td class="nump">134,863,475<span></span>
</td>
<td class="nump">91,374,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">212,615<span></span>
</td>
<td class="nump">989,060<span></span>
</td>
<td class="nump">1,232,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">3,798,999<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">72,584,249<span></span>
</td>
<td class="nump">137,225,535<span></span>
</td>
<td class="nump">92,973,228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">(Decrease) increase in cash</a></td>
<td class="num">(4,398,473)<span></span>
</td>
<td class="nump">66,827,746<span></span>
</td>
<td class="nump">13,344,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">131,534,101<span></span>
</td>
<td class="nump">64,706,355<span></span>
</td>
<td class="nump">51,361,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">$ 127,135,628<span></span>
</td>
<td class="nump">$ 131,534,101<span></span>
</td>
<td class="nump">$ 64,706,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803434384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">THE COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
1 &#8211; THE COMPANY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Nature
of Business</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
are a women&#8217;s health care company focused on creating and commercializing products targeted exclusively for women. Currently,
we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our
advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate
the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis
and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone
or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile
compared with competing products. With our SYMBODA&#8482; technology, we are developing advanced hormone therapy pharmaceutical
products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition,
we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, iron supplements,
which we ceased manufacturing in October 2017.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606175152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Principles
of Consolidation</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed,
BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;)
insured limits of $250,000 per bank. We have never experienced any losses related to these funds.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Trade
Accounts Receivable and Allowance for Doubtful Accounts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than
90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual
credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts
previously written off when received as an increase in the allowance for doubtful accounts. <font style="color: #252525">To the
extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be </font>required.
At December 31, 2017, four different customers represented 27%, 23%, 22% and 11%, respectively, of our gross accounts receivable.
At December 31, 2016, two different customers represented 28% and 20%, respectively, of our gross accounts receivable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the third quarter of 2016, we wrote-off accounts receivable balances of approximately $2,200,000 related to two retail pharmacy
distributors. Both pharmacies are relatively small owner-managed pharmacies and share a similar amount of collection risk. Among
the factors that contributed to our decision to write-off these balances were our inability to collect the outstanding balances
and the lack of a continuing communication and business relationship with these parties following the centralization of the distribution
channel for both our retail pharmacy distributors and wholesale distributors, effective September 1, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Inventories</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventories
represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or
net realizable value using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete
or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product
improvements rendering previous versions obsolete.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Pre-Launch
Inventory</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is
probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit
cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research
and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fixed
Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the
useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line
method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are
depreciated over the shorter of their useful life or the term of the lease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
capitalize software and software development costs incurred to create and acquire computer software for internal use, principally
related to software coding and application development. We begin to capitalize software development costs when both the preliminary
project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only
external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized
on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Intangible
Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350,
<i>Intangibles - Goodwill and Other</i>, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside
legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized
patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off
any capitalized patent costs at that time. As of December 31, 2017, we had 18 issued patents (See Note 6). We capitalize external
costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized.
We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not
be recoverable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment
of Long-Lived Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events
or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include,
among others, the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    declines in an asset&#8217;s market price;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    deterioration in an asset&#8217;s physical condition;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    changes in the nature or extent of an asset&#8217;s use or operation;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    adverse changes in the business climate that could impact an asset&#8217;s value, including adverse actions or assessments
    by regulators;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">accumulation
    of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">current-period
    operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated
    with an asset&#8217;s use; and</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">expectations
    that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously
    estimated useful life.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">If
impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset
or asset group&#8217;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level
for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination
of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual
disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values
are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived
from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization,
including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production.
If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217; fair
value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based upon
a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.
There was no impairment of long-lived assets to be held and used during the years ended December 31, 2017, 2016, and 2015.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
perform impairment tests for intangible assets with indefinite useful lives annually, or more frequently if events occur or circumstances
change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test
for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There
was no impairment of indefinite lived intangible assets during the years ended December 31, 2017, 2016, and 2015.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount
of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity
of such instruments, which are considered Level 1 assets under the fair value hierarchy.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in
active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and
liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    1</b></font></td>
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">unadjusted
    quoted prices in active markets for identical assets or liabilities;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    2</b></font></td>
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">quoted prices
    for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
    or indirectly through market corroboration, for substantially the full term of the financial instrument; and</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    3</b></font></td>
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">unobservable
    inputs for the asset or liability.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31,
2017, 2016, and 2015.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Income
Taxes</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable
income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect
on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded
to reduce deferred tax assets to the amount that will more likely than not be realized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions
are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized
uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes
in recognition or measurement are reflected in the period in which those changes in judgment occur.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31,
2017 and 2016, we had no tax positions relating to open tax returns that were considered to be uncertain.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after
2013 are subject to review.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Share-Based
Compensation</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
<i>Compensation-Stock Compensation</i>, to value options. Option valuation models require the input of assumptions, including
the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected
dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds
whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which
our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility
of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available
that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage.
On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose
stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical
stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms
of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid
cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the
input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based
award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based
awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment.
As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different
in the future.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Equity
instruments (&#8220;instruments&#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,
as required by ASC 505, <i>Equity - Based Payments to Non-Employees</i>, or ASC 505<i>. </i>ASC 505 defines the measurement date
and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as
defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The
estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related
to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement
date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular
grant as defined in ASC 505.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant
date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis
over the employee&#8217;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures.
If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly
different from what we have recorded in the current period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price
is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing
support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which we ceased manufacturing in October 2017. The revenue that is generated by us from major customers
is all generated from sales of our prescription prenatal vitamin products, which is disclosed in Note 11. There are no major customers
for our OTC prenatal vitamin or other products.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if
any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC
customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit
card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back
return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC
sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which we ceased manufacturing in October 2017.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy
distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees,
customer rebates, coupons and estimated returns.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Revenue
related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped
to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products
sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.
Our prescription products currently have a shelf life of 24 months from the date of manufacture.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prior
to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the
product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were
known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the
distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader
population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription
products are distributed under the wholesale distributor model described above.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry
averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated
in contracts and estimate chargebacks based on the number of units sold each period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Shipping
and Handling Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated
financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Advertising
Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
expense advertising costs when incurred. Advertising costs were $448,288, $752,611, and $792,574 during the years ended December
31, 2017, 2016, and 2015, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities are capitalized, and were $0 and $228,933 at December 31,
2017 and 2016, respectively, all of which was included in other current assets on the accompanying consolidated balance sheets.
CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,
or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and
FDA submissions. Legal activities that were classified as R&#38;D expenses include professional research and advice regarding
R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing,
and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity
expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance
of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D
activities when the activity has been performed or when the goods have been received rather than when the payment is made. We
review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs
applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such
studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Earnings
Per Share</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and
disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common
stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average
number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the
period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation
of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table
below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common
stockholders for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As
    of December 31,</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 25%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Stock options</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">23,365,225</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">21,767,854</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">20,725,325</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3,115,905</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">12,060,071</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">12,722,431</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">26,481,130</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33,827,925</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33,447,756</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Concentration
of Credit Risk and other Risks and Uncertainties</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable.
Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance
provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Concentration
of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail
pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and
collateral is not required.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Use
of Estimates</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments
that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities.
We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2017, the FASB issued ASU 2017-09, which clarifies when changes to the terms or conditions of a share-based payment award
must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the
terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards
without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will
be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods
within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We
adopted this guidance and it did not have an impact on our consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity
in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for
public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years.
Early adoption is permitted with retrospective application. We adopted this guidance and it did not have an impact on our consolidated
financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
March 2016, the FASB issued ASU 2016-09, Compensation &#8211; Stock Compensation: Improvements to Employee Share-Based Payment
Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both
public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years
beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&#160;ASU&#160;2016-09&#160;effective
January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture
rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of
approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies
in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full
valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to
recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained
earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated
financial statements.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets
but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current
real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting
for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning
after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process
of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing
to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to
the accounting for our operating lease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#8217;s core principle
is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects
the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies
will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance
obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating
the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective
date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for
public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB
issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting
for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical
expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We
have performed a review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition
resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step
model of the new standard to our contracts as well as compared the results to our current accounting practices. We are currently
in the process of drafting disclosures required by the new standard. At this point of our analysis, we do not believe that the
adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures
related to contracts with customers.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803435184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
3 &#8211; INVENTORY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Finished
    product</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,485,358</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,062,285</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Raw material</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">14,036</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">TOTAL INVENTORY</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,485,358</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,076,321</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649228160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
4 &#8211; OTHER CURRENT ASSETS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid sales and marketing costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">5,335,936</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">680,243</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">628,039</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">991,809</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">128,898</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">523,694</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">405,960</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">64,411</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,311</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,035</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,604,284</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,299,052</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803465680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
5 &#8211; FIXED ASSETS, NET</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif">Accounting system</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">301,096</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">301,096</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">273,536</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">215,182</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Computer hardware</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">80,211</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">80,211</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">116,542</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">113,079</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Leasehold improvements</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,888</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,888</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">809,273</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">747,456</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(372,218</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(230,617</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">&#160;TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">437,055</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">516,839</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the years ended December 31, 2017, 2016, and 2015 was $141,601, $77,906, and $29,959, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786708496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
6 &#8211; INTANGIBLE ASSETS, NET</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of December 31, 2017 and 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Gross<br />
 Carrying<br />
 Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Accumulated<br />
 Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Net <br /> Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted- <br />
Average <br /> Remaining <br /> Amortization<br />
 Period (yrs.)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">(8,487</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">23,464</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">11.75</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,293,614</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(171,911</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,121,703</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,721,305</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,721,305</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Multiple trademarks</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">233,275</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">233,275</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,371,888</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(272,141</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,099,747</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Gross<br />
 Carrying<br />
 Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Accumulated<br />
 Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Net <br /> Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted-<br />
 Average <br /> Remaining <br /> Amortization<br />
 Period (yrs.)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">(6,490</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">25,461</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">12.75</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,093,452</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(102,393</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">991,059</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">16</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,203,987</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,203,987</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">185,465</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">185,465</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 0.5in; font: 10pt Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,606,598</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(200,626</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,405,972</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off
any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. <font style="background-color: white">During
the years ended December 31, 2017 and 2016, there was no impairment recognized related to intangible assets.&#160;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
have numerous pending foreign and domestic patent applications. As of December 31, 2017, we had 18 issued domestic, or U.S., patents
and 13 issued foreign patents, including:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">13 domestic and
    three foreign utility patents that relate to our combination progesterone and estradiol product candidates, which are owned
    by us. The domestic utility patents will expire in 2032. In addition, we have pending patent applications with respect to
    our combination progesterone and estradiol product candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel,
    Japan, Mexico, Russia, South Africa, and South Korea;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">three domestic and
    10 foreign patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate. These patents
    establish an important intellectual property foundation for TX-004HR and are owned by us. These domestic patents will expire
    in 2033 or 2032. In addition, we have pending patent applications related to our applicator-free vaginal estradiol softgel
    product candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa,
    and South Korea;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">one domestic utility
    patent that relates to a pipeline transdermal patch technology, which is owned by us and will expire in 2032. We have pending
    patent applications with respect to this technology in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South
    Africa; and</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">one utility patent
    that relates to our OPERA<sup>&#174;</sup> information-technology platform, which is owned by us and is a domestic patent that
    will expire in 2029.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">Amortization
expense was $71,516, $54,545, and $32,441 for the years ended December 31, 2017, 2016, and 2015, respectively. Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Year Ending <br /> December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Estimated <br /> Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2021</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2022</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">761,282</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647615024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
7&#8211; OTHER CURRENT LIABILITIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">366,933</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,281,080</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,240,379</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,531,440</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">945,457</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">665,561</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">600,350</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">176,518</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued sales and marketing costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">420,162</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">665,773</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">602,916</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">224,865</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">172,973</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,510</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">114,480</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">26,507</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,432,846</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">794,816</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">327,099</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">181,015</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,223,595</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,624,085</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780292128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
8 &#8211; STOCKHOLDERS&#8217; EQUITY</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Preferred
Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2017, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares
of preferred stock were issued or outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Common
Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2017, we had 350,000,000 shares of Common Stock authorized for issuance, of which 216,429,642 shares of our Common
Stock were issued and outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Issuances
During 2017</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public
offering of 12,400,000 shares of our Common Stock at a price of $5.55 per share. The net proceeds to us from the offering were
approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017
and we issued 12,400,000 shares of Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2017, certain individuals exercised stock options to purchase 102,546 shares of Common Stock for $212,615
in cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Issuances
During 2016</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
January 6, 2016, we entered into an underwriting agreement with Goldman Sachs &#38; Co. and Cowen and Company, LLC, as the representatives
of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common
Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters
a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full.
The net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions
and other estimated offering expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of
our Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2016, certain individuals exercised stock options to purchase 525,362 shares of Common Stock for $989,060
in cash. Also during the same period, stock options to purchase 127,109 shares of Common Stock were exercised pursuant to the
options&#8217; cashless exercise provisions, wherein 87,833 shares of Common Stock were issued.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Issuances
During 2015</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus &#38; Company, Incorporated and Guggenheim Securities,
LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering
of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement,
we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock,
which option was exercised in full. The net proceeds to us from the offering were approximately $32,257,000, after deducting underwriting
discounts and commissions and other estimated offering expenses payable by us. The offering closed on July 15, 2015 and we issued
4,423,077 shares of our Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative
of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common
Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters
a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full.
The net proceeds from the offering were approximately $59,118,000, after deducting underwriting discounts and commissions and
other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our
Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2015, certain individuals exercised stock options to purchase 612,867 shares of Common Stock for $1,232,579
in cash. Also during the same period, stock options to purchase 417 shares of Common Stock were exercised pursuant to the options&#8217;
cashless exercise provisions, wherein 114 shares of Common Stock were issued.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Warrants
to Purchase Common Stock</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2017, we had warrants outstanding to purchase an aggregate of 3,115,905 shares of our Common Stock with a weighted-average
contractual remaining life of 1.8 years, and exercise prices ranging from $0.24 to $8.20 per share, resulting in a weighted average
exercise price of $2.58 per share.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2017, we granted warrants to purchase 125,000 shares of Common Stock to outside consultants at an
exercise price of $6.83 per share. The fair value for these warrants was determined by using the Black-Scholes Model on the date
of the grant using a term of five years; volatility of 63.24%; risk free rate of 1.47%; and dividend yield of 0%. The grant date
fair value of the warrants was $3.67 per share. The warrants vest ratably over a 12-month period and have an expiration date of
March 15, 2022.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2016, we granted warrants to purchase 245,000 shares of Common Stock to outside consultants at the
weighted average price of $7.90 per share. These warrants vest and have expiration dates as follows: warrants to purchase 75,000
shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares
of Common Stock vest ratably over a 24-month period and have an expiration date of April 21, 2021, and warrants to purchase 120,000
shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an
exercise price of $6.35 vesting ratably over a 12-month period, with an expiration date of April 6, 2020. We recorded share-based
compensation expense related to warrants previously issued of $313,271, $936,974 and $139,142 for the years ended December 31,
2017, 2016, and 2015, respectively, in the accompanying consolidated financial statements. At December 31, 2017, total unrecognized
estimated compensation expense related to the unvested portion of these warrants was approximately $128,000 which is expected
to be recognized over a weighted-average period of 0.2 years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><i>Summary
of our Warrant activity during the year ended December 31, 2017:</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Number of<br />
 Shares Under Warrants</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted <br />
Average<br />
 Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Life in Years</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Aggregate <br /> Intrinsic<br />
 Value</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">12,060,071</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">2.08</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.0</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">45,063,867</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">125,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.83</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(9,066,666</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.98</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">48,535,969</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(2,500</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.64</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,115,905</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.58</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.8</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">11,348,273</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,792,983</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.64</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.8</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,141,836</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">322,922</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.57</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.0</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">10,206,436</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: normal; font-style: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">The&#160;</font><font style="font-weight: normal; font-style: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px">aggregate
intrinsic value of warrants exercised during 2016 and 2015, was $3,988,343 and $7,282,404, respectively.</font> The
weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years
ended December 31, 2017, 2016 and 2015 are set forth in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 35%; font: 10pt Times New Roman, Times, Serif">Weighted average exercise price</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.83</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">7.90</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.35</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted average grant date fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.67</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.78</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.27</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.47</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.04-1.28</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.02</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">63.24</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">74.10-74.15</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">60.59</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period
is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected
to fluctuate each year during the term of the instrument. The estimated volatility is an average of the historical volatility
of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is
based on historical stock prices over a period equal to the term of the instrument as we have insufficient historical information
regarding our stock options to provide a basis for estimate. The expected volatility of warrants was estimated based on a historical
volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, market capitalization,
and financial leverage.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used
in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and
Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and
vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000
shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As
consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01
per share that has vested or will vest, as applicable, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares were
    earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate
    in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares
    did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using
    the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and
    a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013. These shares were exercised
    in 2017 and are included in the warrant exercise details below;</font></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,333 shares vested
    on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date
    of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the
    years ended December 31, 2017, 2016, and 2015, we recorded $0, $77,026, and $154,068, respectively, as non-cash compensation
    in the accompanying consolidated financial statements related to this warrant. As of December 31, 2017 this warrant was fully
    amortized. These shares were exercised in 2017 and are included in the warrant exercise details below; and</font></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">283,334 shares will vest upon the receipt by
    us, prior to the warrant expiration date of April 30,2018, of any final FDA approval of a drug candidate that SCI helped us
    design. It is anticipated that receipt of such an approval may occur in the near future.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over
approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services
in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization
efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing
and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated
therewith; (b) services in support of our efforts to successfully obtain new drug approval; and (c) other consulting services
as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228
on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of
0.74%; and a dividend yield of 0%. During the years ended December 31, 2017, 2016, and 2015, we recorded $128,898, $257,796, and
$257,796, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements.
As of December 31, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized. This warrant was fully exercised, of which
800,000 shares were exercised in 2017 and 500,000 shares were exercised in 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Warrant
exercises</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2017, certain individuals exercised warrants to purchase 2,476,666 shares of Common Stock for $3,798,999
in cash. In addition, during the year ended December 31, 2017, certain individuals exercised warrants to purchase 6,590,000 shares
of Common Stock pursuant to the warrants&#8217; cashless exercise provisions, wherein 4,762,208 shares of Common Stock were issued.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2016, certain individuals exercised warrants to purchase 722,744 shares of Common Stock for $1,373,000
in cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common
Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares
of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions, wherein 232,197 shares of Common
Stock were issued.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Options
to Purchase Common Stock of the Company</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009
Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder.
Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options
may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified
expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the
date the option is issued. As of December 31, 2017, there were non-qualified stock options to purchase 18,575,084 shares of Common
Stock outstanding under the 2009 Plan. As of December 31, 2017, there were 2,173,878 shares available to be issued under 2009
Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option
grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior
to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally
ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder.
As of December 31, 2017, there were non-qualified stock options to purchase 4,790,141 shares of Common Stock outstanding under
the 2012 Plan. As of December 31, 2017, there were 5,128,333 shares available to be issued under 2012 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2017, 2016,
and 2015 are set forth in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 35%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Weighted average exercise price</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.60</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.22</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">8.14</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted average grant date fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.82</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.94</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.45</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.84-2.05</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.13-1.90</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.47-1.67</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">61.56-64.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">70.26-73.34</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">58.78-62.94</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5-6.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5-6.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.27-6.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period
is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is
expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility
of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is
based on historical stock prices over a period equal to the term of the awards as we have insufficient historical information
regarding our stock options to provide a basis for estimate. The expected volatility of share options was estimated based on a
historical volatility analysis of peers that were similar to us with respect to industry, stage of life cycle, market capitalization,
and financial leverage. The average expected life is based on the contractual terms of the stock option using the simplified method.
We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to
pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common
Stock and our estimates of expected volatility and the other relevant assumptions.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2017 is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Number of<br />
 Shares Under<br />
 Options</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted<br />
 Average<br />
 Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Life in Years</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Aggregate <br /> Intrinsic<br />
 Value</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">21,767,854</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">3.56</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">5.8</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">60,495,730</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,271,500</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.60</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(102,546</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.07</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">452,287</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(108,375</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.64</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(463,208</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.28</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,365,225</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.78</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.13</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">64,664,821</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">19,770,142</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.27</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.47</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">63,895,512</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,595,083</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.60</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">8.79</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">769,309</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2017, our outstanding options had exercise prices ranging from $0.10 to $8.92 per share. <font style="font-weight: normal; font-style: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px">The
aggregate intrinsic value of options exercised during 2016 and 2015, was $3,828,358 and $3,186,371,
respectively.</font></font> <font style="font: 10pt Times New Roman, Times, Serif">Share-based
compensation expense related to options recognized in our results of operations for the years ended December 31, 2017, 2016,
and 2015 was approximately $6,447,154, $16,139,225, and $6,621,658, respectively, and it is based on awards vested. At
December 31, 2017, total unrecognized estimated compensation expense related to unvested options was approximately
$10,596,000, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of 2.1 years. No tax benefit was realized due to a continued pattern of operating losses.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784437888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 9 &#x2013; INCOME TAXES</u></b></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">For financial reporting purposes, income before taxes includes the following components:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2017</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2016</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 1pt; width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif">United States</td>
            <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(76,925,380</td>
            <td style="padding-bottom: 1pt; width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
            <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(89,875,459</td>
            <td style="padding-bottom: 1pt; width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
            <td style="padding-bottom: 1pt; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(85,077,024</td>
            <td style="padding-bottom: 1pt; width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">Total</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(76,925,380</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(89,875,459</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,077,024</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="background-color: white; font: 10pt Times New Roman, Times, Serif">For the years ended December 31, 2017, 2016, and 2015, there was no provision for income taxes, current or deferred. </font>
        <font style="font: 10pt Times New Roman, Times, Serif">At December 31, 2017, we had a federal net operating loss carry forward of approximately $338,613,987 available to offset future taxable income through 2037. The federal carryforwards will begin to expire in 2031.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2017</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2016</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif">Federal statutory tax rate</td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">State tax rate, net of federal tax benefit</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.0</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.4</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.73</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Adjustment in valuation allowances</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">22.6</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(40.3</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(38.97</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Federal income tax rate change</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(60.8</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Permanent and other differences</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.8</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.9</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">(Provision) benefit for income taxes</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p>

    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2017, 2016, and 2015 are as follows:</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2017</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2016</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred Income Tax Assets:</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-left: 0.25in; width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif">Net operating losses</td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
            <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">99,596,321</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
            <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">111,730,450</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
            <td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">79,499,633</td>
            <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif">R&#38;D Credit</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif">Total deferred income tax asset</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">99,782,668</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">111,916,797</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">79,685,980</td>
            <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif">Valuation allowance</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(99,782,668</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(111,916,797</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
            <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(79,685,980</td>
            <td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets, net</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
            <td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on the Company&#x2019;s Balance Sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif"><i>Unrecognized Tax Benefits</i></font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">As of the period ended December 31, 2017, we have no unrecognized tax benefits.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, effective January 1, 2018. Consequently, we have recorded a decrease related to deferred tax assets and deferred tax liabilities of approximately $49,500,000 and approximately $2,800,000, respectively, with a corresponding net adjustment to the valuation allowance of approximately $46,700,000 for the year ended December 31, 2017.</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The
Tax Act modifies Section 162(m) of the Internal Revenue Code of 1986, as amended, or the IRC, by (1) expanding which employees
are considered covered employees by including the chief financial officer, (2) providing that if an individual is a covered employee
for a taxable year beginning after December 31, 2016, the individual remains a covered employee for all future years, and (3)
removing the exceptions for compensation stemming from contracts entered into on or before November 2, 2017, unless such contracts
were materially modified on or after the date. Compensation agreements entered into and share-based payment awards granted after
this date will be subject to the revised terms of IRC Section 162(m). In December 2017, the SEC staff issued Staff Accounting
Bulletin No. 118,&#160;<i>Income Tax Accounting Implications of the Tax Cuts and Jobs Act&#160;</i>(SAB 118), which allows us
to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Since the Tax Act
was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12
months, we consider the accounting for share-based compensation arrangements under the Tax Act to be incomplete due to the forthcoming
guidance and our ongoing analysis of final year-end data and tax positions.</font></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">We must assess whether our valuation allowance analyses
are affected by various aspects of the Tax Act. Since, as discussed herein, we have recorded provisional amounts related to certain
portions of the Tax Act, any corresponding determination of the need for or change in a valuation allowance is also provisional.</font></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <font style="font: 10pt Times New Roman, Times, Serif">&#160;</font>
</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803447952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
10 &#8211; RELATED PARTIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of
our company since July 2015. During the years ended December 31, 2017, 2016 and 2015, we were billed by Catalent approximately
$3,646,000, $3,647,000 and $1,266,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration
batches, stability and validation testing. As of December 31, 2017 and December 31, 2016, there were amounts due to Catalent of
approximately $523,000 and $57,000, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784437888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
11 - BUSINESS CONCENTRATIONS</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
purchase our products from several suppliers with approximately 100%, 98%, and 60% of our purchases supplied by one vendor for
the years ended December 31, 2017, 2016 and 2015, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain
drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the years
ended December 31, 2017, 2016 and 2015; four, three, and two customers each, respectively, generated more than 10% of our revenues.
Revenue generated from four major customers combined accounted for approximately 59% of our revenue during the year ended December
31, 2017. Revenue generated from three major customers combined accounted for approximately 41% of our revenue during the year
ended December 31, 2016. Revenue generated from two major customers combined accounted for approximately 67% of our recognized
revenue during the year ended December 31, 2015.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2017, AmerisourceBergen generated approximately $2,667,000 of our revenue; McKesson Corporation generated
approximately $1,959,000 of our revenue; Cardinal Health generated approximately $2,559,000 of our revenue and Pharmacy Innovations
PA generated approximately $2,715,000 of our revenue. During the year ended December 31, 2016, Woodstock Pharmaceutical and Compounding
generated approximately $2,247,000 of our revenue; Medical Center Pharmacy generated approximately $3,700,000 of our revenue and
Pharmacy Innovations PA generated approximately $2,040,000 of our revenue. During the year ended December 31, 2015, Woodstock
Pharmaceutical and Compounding generated approximately $8,848,000 of our revenue and Due West Pharmacy generated approximately
$4,843,000 of our revenue.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of developments in the pharmaceutical industry that negatively affected independent pharmacies, including such pharmacies&#8217;
reliance on third party payors, in 2016, we identified that payment periods for our retail pharmacy distributors were becoming
longer than in prior years. As a result, during the third quarter of 2016, we centralized the distribution channel for both our
retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader population of retail pharmacies
and minimize business risk exposure to any one retail pharmacy. During the third quarter of 2016, we entered into new distribution
agreements with our retail pharmacy distributors to effectuate this centralization which were effective September 1, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803434384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
12 &#8211; COMMITMENTS AND CONTINGENCIES</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Operating
Lease</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to
lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
rental expense related to our current lease during the years ended December 31, 2017, 2016 and 2015 was $1,029,205, $709,483,
and $446,099, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2017, future minimum rental payments on non-cancelable operating leases are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Years Ending December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif">951,194</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,094,116</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,113,069</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2021</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">943,127</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2022</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,101,506</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Legal
Proceedings</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Off-Balance
Sheet Arrangements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2017, 2016, and 2015, we had no off-balance sheet arrangements that have had or are reasonably likely to have
current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that are material to investors.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Employment
Agreements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813137344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
13 &#8211; SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Summarized
quarterly financial data for fiscal years 2017 and 2016 is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">(In thousands, except per share)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4th</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">3,985</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,250</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,418</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,125</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,326</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,568</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,717</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,530</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(21,156</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,677</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(14,665</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(21,427</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.07</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">(In thousands, except per share)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4th</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,930</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,403</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">5,536</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,487</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,822</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,273</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,298</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,778</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(20,929</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(21,094</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(25,016</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(22,836</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.13</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.12</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811095920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Principles
of Consolidation</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed,
BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;)
insured limits of $250,000 per bank. We have never experienced any losses related to these funds.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Trade
Accounts Receivable and Allowance for Doubtful Accounts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than
90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual
credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts
previously written off when received as an increase in the allowance for doubtful accounts. <font style="color: #252525">To the
extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be </font>required.
At December 31, 2017, four different customers represented 27%, 23%, 22% and 11%, respectively, of our gross accounts receivable.
At December 31, 2016, two different customers represented 28% and 20%, respectively, of our gross accounts receivable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the third quarter of 2016, we wrote-off accounts receivable balances of approximately $2,200,000 related to two retail pharmacy
distributors. Both pharmacies are relatively small owner-managed pharmacies and share a similar amount of collection risk. Among
the factors that contributed to our decision to write-off these balances were our inability to collect the outstanding balances
and the lack of a continuing communication and business relationship with these parties following the centralization of the distribution
channel for both our retail pharmacy distributors and wholesale distributors, effective September 1, 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Inventories</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventories
represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or
net realizable value using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete
or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product
improvements rendering previous versions obsolete.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrelaunchInventoryPolicyTextBlock', window );">Pre-Launch Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Pre-Launch
Inventory</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is
probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit
cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research
and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fixed
Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the
useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line
method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are
depreciated over the shorter of their useful life or the term of the lease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
capitalize software and software development costs incurred to create and acquire computer software for internal use, principally
related to software coding and application development. We begin to capitalize software development costs when both the preliminary
project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only
external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized
on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Intangible
Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350,
<i>Intangibles - Goodwill and Other</i>, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside
legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized
patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off
any capitalized patent costs at that time. As of December 31, 2017, we had 18 issued patents (See Note 6). We capitalize external
costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized.
We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not
be recoverable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment
of Long-Lived Assets</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events
or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include,
among others, the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    declines in an asset&#8217;s market price;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    deterioration in an asset&#8217;s physical condition;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    changes in the nature or extent of an asset&#8217;s use or operation;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">significant
    adverse changes in the business climate that could impact an asset&#8217;s value, including adverse actions or assessments
    by regulators;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">accumulation
    of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">current-period
    operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated
    with an asset&#8217;s use; and</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">expectations
    that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously
    estimated useful life.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">If
impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset
or asset group&#8217;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level
for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination
of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual
disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values
are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived
from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization,
including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production.
If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217; fair
value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based upon
a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.
There was no impairment of long-lived assets to be held and used during the years ended December 31, 2017, 2016, and 2015.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
perform impairment tests for intangible assets with indefinite useful lives annually, or more frequently if events occur or circumstances
change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test
for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There
was no impairment of indefinite lived intangible assets during the years ended December 31, 2017, 2016, and 2015.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair
Value of Financial Instruments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount
of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity
of such instruments, which are considered Level 1 assets under the fair value hierarchy.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in
active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and
liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    1</b></font></td>
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">unadjusted
    quoted prices in active markets for identical assets or liabilities;</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    2</b></font></td>
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">quoted prices
    for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
    or indirectly through market corroboration, for substantially the full term of the financial instrument; and</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 8%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level
    3</b></font></td>
    <td style="width: 87%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">unobservable
    inputs for the asset or liability.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2017 and 2016, we had no assets or liabilities that were valued at fair value on a recurring basis.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31,
2017, 2016, and 2015.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Income
Taxes</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable
income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect
on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded
to reduce deferred tax assets to the amount that will more likely than not be realized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions
are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized
uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes
in recognition or measurement are reflected in the period in which those changes in judgment occur.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31,
2017 and 2016, we had no tax positions relating to open tax returns that were considered to be uncertain.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after
2013 are subject to review.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Share-Based
Compensation</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
<i>Compensation-Stock Compensation</i>, to value options. Option valuation models require the input of assumptions, including
the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected
dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds
whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which
our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility
of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available
that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage.
On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose
stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical
stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms
of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid
cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the
input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based
award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based
awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment.
As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different
in the future.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Equity
instruments (&#8220;instruments&#8221;) issued to non-employees are recorded on the basis of the fair value of the instruments,
as required by ASC 505, <i>Equity - Based Payments to Non-Employees</i>, or ASC 505<i>. </i>ASC 505 defines the measurement date
and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as
defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The
estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related
to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement
date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular
grant as defined in ASC 505.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant
date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis
over the employee&#8217;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures.
If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly
different from what we have recorded in the current period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue
Recognition</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
recognize revenue on arrangements in accordance with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price
is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably
assured.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing
support team utilizing similar marketing techniques. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which we ceased manufacturing in October 2017. The revenue that is generated by us from major customers
is all generated from sales of our prescription prenatal vitamin products, which is disclosed in Note 11. There are no major customers
for our OTC prenatal vitamin or other products.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OverTheCounterProductsPolicyTextBlock', window );">Over-the-Counter Products</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Over-the-Counter
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment,
when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees, if
any, in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC
customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit
card sales minimize accounts receivable balances relative to OTC sales (Iron 21/7). We provide an unconditional 30-day money-back
return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC
sales, net of estimated returns and sales discounts. As of January 1, 2017, we ceased manufacturing and distributing our OTC product
lines, except for Iron 21/7, which we ceased manufacturing in October 2017.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrescriptionProductsPolicyTextBlock', window );">Prescription Products</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i><u>Prescription
Products</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacy
distributors. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, wholesaler fees,
customer rebates, coupons and estimated returns.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Revenue
related to prescription products sold through wholesale distributors is recognized when the prescription products are shipped
to the distributors and the control of the products passes to each distributor. We accept returns of unsalable prescription products
sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration.
Our prescription products currently have a shelf life of 24 months from the date of manufacture.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Prior
to September 1, 2016, we recognized revenue related to prescription products sold through retail pharmacy distributors when the
product was dispensed by the retail pharmacy distributor, at which point all revenue and discounts related to such product were
known or determinable and there was no right of return with respect to such product. On September 1, 2016, we centralized the
distribution channel for both our retail pharmacy distributors and wholesale distributors, in order to facilitate sales to a broader
population of retail pharmacies and mitigate exposure to any one retail pharmacy. Beginning on September 1, 2016, all of our prescription
products are distributed under the wholesale distributor model described above.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry
averages, which is reviewed, and adjusted if necessary, on a quarterly basis. We record distributor fees based on amounts stated
in contracts and estimate chargebacks based on the number of units sold each period.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Segment
Reporting</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Shipping
and Handling Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated
financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Advertising
Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
expense advertising costs when incurred. Advertising costs were $448,288, $752,611, and $792,574 during the years ended December
31, 2017, 2016, and 2015, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research
and Development Expenses</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance
payments to be expensed in future research and development activities are capitalized, and were $0 and $228,933 at December 31,
2017 and 2016, respectively, all of which was included in other current assets on the accompanying consolidated balance sheets.
CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various U.S. Food and Drug Administration,
or the FDA, submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and
FDA submissions. Legal activities that were classified as R&#38;D expenses include professional research and advice regarding
R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing,
and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity
expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance
of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D
activities when the activity has been performed or when the goods have been received rather than when the payment is made. We
review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs
applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such
studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Earnings
Per Share</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and
disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common
stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average
number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the
period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation
of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table
below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common
stockholders for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As
    of December 31,</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 25%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Stock options</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">23,365,225</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">21,767,854</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">20,725,325</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3,115,905</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">12,060,071</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">12,722,431</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">26,481,130</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33,827,925</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33,447,756</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Concentration
of Credit Risk and other Risks and Uncertainties</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable.
Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance
provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Concentration
of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail
pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and
collateral is not required.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Use
of Estimates</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments
that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities.
We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2017, the FASB issued ASU 2017-09, which clarifies when changes to the terms or conditions of a share-based payment award
must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the
terms of an award being accounted for as modifications. The new guidance will allow companies to make certain changes to awards
without accounting for them as modifications. This guidance does not change the accounting for modifications. The guidance will
be applied prospectively to awards modified on or after the adoption date and is effective for annual periods, and interim periods
within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including in an interim period. We
adopted this guidance and it did not have an impact on our consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). ASU 2016-15 is intended to reduce the diversity
in practice regarding how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for
public business entities for annual periods beginning after December 15, 2017, including interim periods within those fiscal years.
Early adoption is permitted with retrospective application. We adopted this guidance and it did not have an impact on our consolidated
financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
March 2016, the FASB issued ASU 2016-09, Compensation &#8211; Stock Compensation: Improvements to Employee Share-Based Payment
Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both
public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years
beginning after December 15, 2016, and interim periods within those fiscal years. We adopted&#160;ASU&#160;2016-09&#160;effective
January 1, 2017, electing to account for forfeitures when they occur. The impact from adoption of the provisions related to forfeiture
rates was reflected in our consolidated financial statements on a modified retrospective basis, resulting in an adjustment of
approximately $31,000 to retained earnings. The impact from adoption of the provisions related to excess tax benefits or deficiencies
in the provision for income taxes rather than paid-in capital was adopted on a modified retrospective basis. Since we have a full
valuation allowance on our net deferred tax assets, an amount equal to the cumulative adjustment made to retained earnings to
recognize the previously unrecognized net operating losses from prior periods was made to the valuation allowance through retained
earnings for the first quarter financial statements. Adoption of all other changes did not have an impact on our consolidated
financial statements.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets
but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current
real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting
for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning
after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process
of analyzing the quantitative impact of this guidance on our results of operations and financial position. While we are continuing
to assess all potential impacts of the standard, we currently believe the impact of this standard will be primarily related to
the accounting for our operating lease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#8217;s core principle
is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects
the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies
will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance
obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating
the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective
date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for
public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB
issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting
for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical
expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We
have performed a review of the requirements of the new revenue standard and are monitoring the activity of the FASB and the transition
resource group as it relates to specific interpretive guidance. We have reviewed customer contracts and applied the five-step
model of the new standard to our contracts as well as compared the results to our current accounting practices. We are currently
in the process of drafting disclosures required by the new standard. At this point of our analysis, we do not believe that the
adoption of this standard will have a material effect on our financial statements but will potentially expand our disclosures
related to contracts with customers.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #252525"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OverTheCounterProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy related to over-the-counter products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OverTheCounterProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrelaunchInventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy related to pre-launch inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrelaunchInventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrescriptionProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy related to prescription products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrescriptionProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054294&amp;loc=d3e8384-108330<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159346&amp;loc=d3e8275-108329<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5144-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82851458&amp;loc=d3e221937-122793<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68075638&amp;loc=d3e60635-111653<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68080631&amp;loc=d3e61069-111654<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803569520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities in calculation of diluted net loss per share allocable to common stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">The
table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable
to common stockholders for the periods presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">As
    of December 31,</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 25%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Stock options</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">23,365,225</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">21,767,854</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">20,725,325</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3,115,905</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">12,060,071</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">12,722,431</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">26,481,130</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33,827,925</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33,447,756</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789116256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Finished
    product</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,485,358</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,062,285</font></td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Raw material</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">14,036</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">TOTAL INVENTORY</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,485,358</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1,076,321</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803434384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid sales and marketing costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">5,335,936</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">680,243</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">628,039</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">991,809</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">128,898</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">523,694</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">405,960</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">64,411</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,311</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,035</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,604,284</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,299,052</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777350544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif">Accounting system</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">301,096</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">301,096</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">273,536</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">215,182</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Computer hardware</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">80,211</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">80,211</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">116,542</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">113,079</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Leasehold improvements</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,888</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,888</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;TOTAL</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">809,273</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">747,456</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(372,218</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(230,617</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">&#160;TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">437,055</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">516,839</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813112192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of December 31, 2017 and 2016:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Gross<br />
 Carrying<br />
 Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Accumulated<br />
 Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Net <br /> Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted- <br />
Average <br /> Remaining <br /> Amortization<br />
 Period (yrs.)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">(8,487</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">23,464</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">11.75</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,293,614</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(171,911</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,121,703</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,721,305</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,721,305</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Multiple trademarks</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">233,275</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">233,275</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,371,888</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(272,141</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,099,747</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Gross<br />
 Carrying<br />
 Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Accumulated<br />
 Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Net <br /> Amount</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted-<br />
 Average <br /> Remaining <br /> Amortization<br />
 Period (yrs.)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">(6,490</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">25,461</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">12.75</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,093,452</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(102,393</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">991,059</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">16</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,203,987</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,203,987</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">185,465</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">185,465</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 0.5in; font: 10pt Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,606,598</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(200,626</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,405,972</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Year Ending <br /> December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Estimated <br /> Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2021</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2022</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,777</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">761,282</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of intangible assets, which may be broken down by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786236720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">366,933</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,281,080</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,240,379</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,531,440</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">945,457</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">665,561</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">600,350</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">176,518</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued sales and marketing costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">420,162</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">665,773</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">602,916</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">224,865</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">172,973</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,510</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">114,480</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">26,507</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,432,846</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">794,816</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">327,099</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">181,015</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,223,595</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,624,085</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647687872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><i>Summary
of our Warrant activity during the year ended December 31, 2017:</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Number of<br />
 Shares Under Warrants</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted <br />
Average<br />
 Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Life in Years</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Aggregate <br /> Intrinsic<br />
 Value</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">12,060,071</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">2.08</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.0</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">45,063,867</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">125,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.83</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(9,066,666</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.98</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">48,535,969</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(2,500</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.64</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,115,905</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.58</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.8</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">11,348,273</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,792,983</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.64</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.8</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,141,836</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">322,922</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.57</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.0</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">10,206,436</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of warrants issued</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">The
weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years
ended December 31, 2017, 2016 and 2015 are set forth in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 35%; font: 10pt Times New Roman, Times, Serif">Weighted average exercise price</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.83</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">7.90</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.35</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted average grant date fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.67</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.78</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.27</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.47</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.04-1.28</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.02</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">63.24</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">74.10-74.15</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">60.59</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2017, 2016,
and 2015 are set forth in the table below.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 35%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Weighted average exercise price</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.60</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.22</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">8.14</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted average grant date fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.82</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.94</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.45</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.84-2.05</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.13-1.90</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.47-1.67</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">61.56-64.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">70.26-73.34</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">58.78-62.94</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5-6.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5-6.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.27-6.25</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of 2009 and 2012 Plans activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2017 is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Number of<br />
 Shares Under<br />
 Options</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted<br />
 Average<br />
 Exercise Price</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Life in Years</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Aggregate <br /> Intrinsic<br />
 Value</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">21,767,854</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">3.56</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">5.8</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">60,495,730</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,271,500</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.60</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(102,546</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.07</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">452,287</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Expired</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(108,375</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.64</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Cancelled/Forfeited</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(463,208</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.28</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,365,225</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.78</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.13</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">64,664,821</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">19,770,142</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.27</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.47</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">63,895,512</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,595,083</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.60</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">8.79</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">769,309</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfWarrantRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803401040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of income before taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For
financial reporting purposes, income before taxes includes the following components:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 45%; text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">United States</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(76,925,380</td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(89,875,459</td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,077,024</td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(76,925,380</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(89,875,459</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,077,024</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of tax rate reconciliation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">A
reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif">Federal statutory tax rate</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">State tax rate, net of federal tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.0</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.4</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.73</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Adjustment in valuation allowances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">22.6</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(40.3</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(38.97</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Federal income tax rate change</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(60.8</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#8212;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Permanent and other differences</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.8</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.9</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">(Provision) benefit for income taxes</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the net deferred income tax asset</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The components of the net deferred income tax asset as of December 31, 2017, 2016, and 2015 are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred Income Tax Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 45%; text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Net operating losses</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">99,596,321</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">111,730,450</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">79,499,633</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">R&#38;D Credit</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Total deferred income tax asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">99,782,668</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">111,916,797</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">79,685,980</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Valuation allowance</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(99,782,668</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(111,916,797</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(79,685,980</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets, net</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803563648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments on non-cancelable operating leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2017, future minimum rental payments on non-cancelable operating leases are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Years Ending December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 20%; text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif">951,194</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,094,116</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,113,069</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2021</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">943,127</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2022</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,101,506</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803402640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of summarized quarterly financial data</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Summarized
quarterly financial data for fiscal years 2017 and 2016 is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2017 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">(In thousands, except per share)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4th</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">3,985</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,250</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,418</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,125</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,326</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,568</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,717</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,530</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(21,156</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,677</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(14,665</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(21,427</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.07</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2016 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">(In thousands, except per share)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4th</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,930</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,403</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">5,536</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 12%; font: 10pt Times New Roman, Times, Serif">4,487</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,822</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,273</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,298</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,778</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(20,929</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(21,094</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(25,016</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(22,836</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.13</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.12</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807206896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">26,481,130<span></span>
</td>
<td class="nump">33,827,925<span></span>
</td>
<td class="nump">33,447,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">3,115,905<span></span>
</td>
<td class="nump">12,060,071<span></span>
</td>
<td class="nump">12,722,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">23,365,225<span></span>
</td>
<td class="nump">21,767,854<span></span>
</td>
<td class="nump">20,725,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813487776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal insurance limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-off accounts receivable</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,288<span></span>
</td>
<td class="nump">$ 752,611<span></span>
</td>
<td class="nump">$ 792,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1', window );">Impact from modified retrospective basis adoption of accounting standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member', window );">Customer A [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member', window );">Customer B [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member', window );">Customer C [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member', window );">Customer D [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Related to Research and Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Advance payments - total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 228,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68075217&amp;loc=SL9156395-115594<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791346704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 1,485,358<span></span>
</td>
<td class="nump">$ 1,062,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 1,485,358<span></span>
</td>
<td class="nump">$ 1,076,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6801193808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 5,335,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">680,243<span></span>
</td>
<td class="nump">$ 628,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsCurrent', window );">Prepaid manufacturing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">523,694<span></span>
</td>
<td class="nump">405,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidVendorDepositsCurrent', window );">Prepaid vendor deposits</a></td>
<td class="nump">64,411<span></span>
</td>
<td class="nump">44,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 6,604,284<span></span>
</td>
<td class="nump">$ 2,299,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidConsultingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of prepaid manufacturing costs current during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidVendorDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount prepaid vendor deposits current during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidVendorDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813217040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 809,273<span></span>
</td>
<td class="nump">$ 747,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(372,218)<span></span>
</td>
<td class="num">(230,617)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">437,055<span></span>
</td>
<td class="nump">516,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">273,536<span></span>
</td>
<td class="nump">215,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">116,542<span></span>
</td>
<td class="nump">113,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 37,888<span></span>
</td>
<td class="nump">$ 37,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633862080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 141,601<span></span>
</td>
<td class="nump">$ 77,906<span></span>
</td>
<td class="nump">$ 29,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812962624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,371,888<span></span>
</td>
<td class="nump">$ 2,606,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
<td class="nump">3,099,747<span></span>
</td>
<td class="nump">2,405,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(272,141)<span></span>
</td>
<td class="num">(200,626)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,721,305<span></span>
</td>
<td class="nump">1,203,987<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">1,721,305<span></span>
</td>
<td class="nump">1,203,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">233,275<span></span>
</td>
<td class="nump">185,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">233,275<span></span>
</td>
<td class="nump">185,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Opera Software Patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">31,951<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,487)<span></span>
</td>
<td class="num">(6,490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 23,464<span></span>
</td>
<td class="nump">$ 25,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">11 years 9 months<span></span>
</td>
<td class="text">12 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development Costs Of Corporate Website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 91,743<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(91,743)<span></span>
</td>
<td class="num">(91,743)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,293,614<span></span>
</td>
<td class="nump">1,093,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(171,911)<span></span>
</td>
<td class="num">(102,393)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 1,121,703<span></span>
</td>
<td class="nump">$ 991,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643216976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Year Ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018</a></td>
<td class="nump">$ 76,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">76,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">76,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">76,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">76,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 761,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813004944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense | $</a></td>
<td class="nump">$ 71,516<span></span>
</td>
<td class="nump">$ 54,545<span></span>
</td>
<td class="nump">$ 32,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member', window );">Domestic Utility Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member', window );">Foreign Utility Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member', window );">Utility Patent Domestic TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Utility Patent Foreign TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member', window );">Utility Patent Pipeline Transdermal Patch Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Opera Software Patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800350080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
<td class="nump">$ 366,933<span></span>
</td>
<td class="nump">$ 1,281,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">4,240,379<span></span>
</td>
<td class="nump">3,531,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">945,457<span></span>
</td>
<td class="nump">665,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">600,350<span></span>
</td>
<td class="nump">176,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">420,162<span></span>
</td>
<td class="nump">665,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">602,916<span></span>
</td>
<td class="nump">224,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">172,973<span></span>
</td>
<td class="nump">76,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">114,480<span></span>
</td>
<td class="nump">26,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">1,432,846<span></span>
</td>
<td class="nump">794,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">327,099<span></span>
</td>
<td class="nump">181,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 9,223,595<span></span>
</td>
<td class="nump">$ 7,624,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813622176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesUnderWarrantAbstract', window );"><strong>Number of shares Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding at December 31, 2016</a></td>
<td class="nump">12,060,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="num">(9,066,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,255,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants expired</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding at December 31, 2017</a></td>
<td class="nump">3,115,905<span></span>
</td>
<td class="nump">12,060,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Vested and Exercisable at December 31, 2017</a></td>
<td class="nump">2,792,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at December 31, 2017</a></td>
<td class="nump">322,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue', window );">Warrants outstanding at December 31, 2016</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1', window );">Warrants granted</a></td>
<td class="nump">6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercised</a></td>
<td class="nump">1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration', window );">Warrants expired</a></td>
<td class="nump">2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue', window );">Warrants outstanding at December 31, 2017</a></td>
<td class="nump">2.58<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice', window );">Vested and Exercisable at December 31, 2017</a></td>
<td class="nump">2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Warrants Unvested at December 31, 2017</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Vested and Exercisable</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Warrants Unvested</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrants outstanding at December 31, 2016</a></td>
<td class="nump">$ 45,063,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">48,535,969<span></span>
</td>
<td class="nump">$ 3,988,343<span></span>
</td>
<td class="nump">$ 7,282,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrants outstanding at December 31, 2017</a></td>
<td class="nump">11,348,273<span></span>
</td>
<td class="nump">$ 45,063,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue', window );">Vested and Exercisable at December 31, 2017</a></td>
<td class="nump">1,141,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue', window );">Unvested at December 31, 2017</a></td>
<td class="nump">$ 10,206,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSharesUnderWarrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSharesUnderWarrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price for warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of unvested equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsUnvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding warrants that are fully vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813554640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Weighted average price</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">63.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800648416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) - Stock Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="nump">$ 8.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted grant date fair value</a></td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - minimum</a></td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - maximum</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility - minimum</a></td>
<td class="nump">61.56%<span></span>
</td>
<td class="nump">70.26%<span></span>
</td>
<td class="nump">58.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility - maximum</a></td>
<td class="nump">64.25%<span></span>
</td>
<td class="nump">73.34%<span></span>
</td>
<td class="nump">62.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813601488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 3) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2016</a></td>
<td class="nump">21,767,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">2,271,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(102,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="num">(108,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Cancelled/Forfeited</a></td>
<td class="num">(463,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2017</a></td>
<td class="nump">23,365,225<span></span>
</td>
<td class="nump">21,767,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Exercisable at December 31, 2017</a></td>
<td class="nump">19,770,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested at December 31, 2017</a></td>
<td class="nump">3,595,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at December 31, 2016</a></td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="nump">7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/Forfeited</a></td>
<td class="nump">6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at December 31, 2017</a></td>
<td class="nump">3.78<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Exercisable at December 31, 2017</a></td>
<td class="nump">3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Unvested at December 31, 2017</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Options, Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">5 years 1 month 16 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Exercisable</a></td>
<td class="text">4 years 5 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Unvested</a></td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options outstanding, Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at December 31, 2016</a></td>
<td class="nump">$ 60,495,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">452,287<span></span>
</td>
<td class="nump">$ 3,828,358<span></span>
</td>
<td class="nump">$ 3,186,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at December 31, 2017</a></td>
<td class="nump">64,664,821<span></span>
</td>
<td class="nump">$ 60,495,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and Exercisable at December 31, 2017</a></td>
<td class="nump">63,895,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue', window );">Unvested at December 31, 2017</a></td>
<td class="nump">$ 769,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815592416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2017</div></th>
<th class="th"><div>Sep. 25, 2017</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Jan. 06, 2016</div></th>
<th class="th"><div>Jul. 15, 2015</div></th>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th"><div>Feb. 17, 2015</div></th>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,429,642<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,429,642<span></span>
</td>
<td class="nump">196,688,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,615<span></span>
</td>
<td class="nump">$ 989,060<span></span>
</td>
<td class="nump">$ 1,232,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercised', window );">Number of stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,546<span></span>
</td>
<td class="nump">523,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,572,635<span></span>
</td>
<td class="nump">$ 134,863,475<span></span>
</td>
<td class="nump">91,374,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercised', window );">Number of stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_JPMorganSecuritiesLLCMember', window );">Underwriting Agreement - J.P. Morgan Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesOfferedInUnderwritingAgreement', window );">Number of shares offered in underwriting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember', window );">Underwriting Agreement - Goldman and Cowen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesOfferedInUnderwritingAgreement', window );">Number of shares offered in underwriting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,151,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,424,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_StifelUnderwritersMember', window );">Stifel Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesOfferedInUnderwritingAgreement', window );">Number of shares offered in underwriting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,423,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC (Underwriters) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesOfferedInUnderwritingAgreement', window );">Number of shares offered in underwriting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,580,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,617,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,037,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to additonal period for purchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSharesOfferedInUnderwritingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares offered in an underwritten public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSharesOfferedInUnderwritingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_JPMorganSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_JPMorganSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_StifelUnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_StifelUnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815308144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">$ 6,889,323<span></span>
</td>
<td class="nump">$ 17,411,021<span></span>
</td>
<td class="nump">$ 7,189,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized estimated compensation expense period recognition</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 3,115,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">$ 313,271<span></span>
</td>
<td class="nump">$ 936,974<span></span>
</td>
<td class="nump">$ 139,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized estimated compensation expense</a></td>
<td class="nump">$ 128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized estimated compensation expense period recognition</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of warrants exercised</a></td>
<td class="nump">$ 48,535,969<span></span>
</td>
<td class="nump">$ 3,988,343<span></span>
</td>
<td class="nump">$ 7,282,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">Mar. 15,  2022<span></span>
</td>
<td class="text">Jan. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">63.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">Apr. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">Apr. 21,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">Apr. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">Jan. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember', window );">Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  06,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are expired in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are vesting date in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813968800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>May 11, 2013</div></th>
<th class="th"><div>May 31, 2013</div></th>
<th class="th"><div>May 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,889,323<span></span>
</td>
<td class="nump">$ 17,411,021<span></span>
</td>
<td class="nump">$ 7,189,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights', window );">Forfeited warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
<td class="nump">405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 462,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,026<span></span>
</td>
<td class="nump">154,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">Jun. 30,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">45.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested warrants granted to purchase common stock (shares)</a></td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested warrants</a></td>
<td class="nump">283,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member', window );">Warrants - Unaffiliated Entity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,532,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,898<span></span>
</td>
<td class="nump">$ 257,796<span></span>
</td>
<td class="nump">$ 257,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refer to numbers of shares forfeit during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are vesting date in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6801663088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 6,447,154<span></span>
</td>
<td class="nump">$ 16,139,225<span></span>
</td>
<td class="nump">$ 6,621,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
<td class="nump">$ 10,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 3,798,999<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">23,365,225<span></span>
</td>
<td class="nump">21,767,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 452,287<span></span>
</td>
<td class="nump">$ 3,828,358<span></span>
</td>
<td class="nump">$ 3,186,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OptionExercisePrices', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OptionExercisePrices', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">18,575,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">2,173,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">4,790,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">5,128,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member', window );">Warrants Cashless Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">4,762,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="nump">6,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="nump">9,066,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Individuals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 3,798,999<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">2,476,666<span></span>
</td>
<td class="nump">722,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OptionExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OptionExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_IndividualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_IndividualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800466880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income before taxes</a></td>
<td class="num">$ (76,925,380)<span></span>
</td>
<td class="num">$ (89,875,459)<span></span>
</td>
<td class="num">$ (85,077,024)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income before taxes</a></td>
<td class="num">$ (76,925,380)<span></span>
</td>
<td class="num">$ (89,875,459)<span></span>
</td>
<td class="num">$ (85,077,024)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647750080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances</a></td>
<td class="nump">22.60%<span></span>
</td>
<td class="num">(40.30%)<span></span>
</td>
<td class="num">(38.97%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Federal income tax rate change</a></td>
<td class="num">(60.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.24%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (benefit) for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796059472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred Income Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 99,596,321<span></span>
</td>
<td class="nump">$ 111,730,450<span></span>
</td>
<td class="nump">$ 79,499,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D Credit</a></td>
<td class="nump">186,347<span></span>
</td>
<td class="nump">186,347<span></span>
</td>
<td class="nump">186,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
<td class="nump">99,782,668<span></span>
</td>
<td class="nump">111,916,797<span></span>
</td>
<td class="nump">79,685,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(99,782,668)<span></span>
</td>
<td class="num">(111,916,797)<span></span>
</td>
<td class="num">(79,685,980)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredIncomeTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Assets:</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredIncomeTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795942032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory federal rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=txmd_DeferredTaxAssetMember', window );">Deferred Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=txmd_DeferredTaxLiabilitiesMember', window );">Deferred Tax Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Subsequent Fiscal Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,613,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=txmd_DeferredTaxAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=txmd_DeferredTaxAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=txmd_DeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=txmd_DeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791715424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - Catalent Inc.[Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Manufacturing activities billed from related party</a></td>
<td class="nump">$ 3,646,000<span></span>
</td>
<td class="nump">$ 3,647,000<span></span>
</td>
<td class="nump">$ 1,266,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable - related party</a></td>
<td class="nump">$ 523,000<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813888416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 4,125,000<span></span>
</td>
<td class="nump">$ 4,418,000<span></span>
</td>
<td class="nump">$ 4,250,000<span></span>
</td>
<td class="nump">$ 3,985,000<span></span>
</td>
<td class="nump">$ 4,487,000<span></span>
</td>
<td class="nump">$ 5,536,000<span></span>
</td>
<td class="nump">$ 4,403,000<span></span>
</td>
<td class="nump">$ 4,930,000<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
<td class="nump">$ 19,356,450<span></span>
</td>
<td class="nump">$ 20,142,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | AmerisourceBergen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Cardinal Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Pharmacy Innovations PA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,715,000<span></span>
</td>
<td class="nump">$ 2,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Woodstock Pharmaceutical and Compounding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,247,000<span></span>
</td>
<td class="nump">$ 8,848,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Medical Center Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Due West Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,843,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Four Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_AmerisourceBergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_AmerisourceBergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_PharmacyInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_PharmacyInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_WoodstockPharmaceuticalAndCompoundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_WoodstockPharmaceuticalAndCompoundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_MedicalCenterPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_MedicalCenterPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_DueWestPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_DueWestPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=txmd_FourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=txmd_FourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=txmd_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=txmd_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=txmd_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=txmd_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6623369568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments, year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 951,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">1,094,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">1,113,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">943,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 4,101,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753845696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,029,205<span></span>
</td>
<td class="nump">$ 709,843<span></span>
</td>
<td class="nump">$ 446,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Oct. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813916400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 4,125,000<span></span>
</td>
<td class="nump">$ 4,418,000<span></span>
</td>
<td class="nump">$ 4,250,000<span></span>
</td>
<td class="nump">$ 3,985,000<span></span>
</td>
<td class="nump">$ 4,487,000<span></span>
</td>
<td class="nump">$ 5,536,000<span></span>
</td>
<td class="nump">$ 4,403,000<span></span>
</td>
<td class="nump">$ 4,930,000<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
<td class="nump">$ 19,356,450<span></span>
</td>
<td class="nump">$ 20,142,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,530,000<span></span>
</td>
<td class="nump">3,717,000<span></span>
</td>
<td class="nump">3,568,000<span></span>
</td>
<td class="nump">3,326,000<span></span>
</td>
<td class="nump">3,778,000<span></span>
</td>
<td class="nump">4,298,000<span></span>
</td>
<td class="nump">3,273,000<span></span>
</td>
<td class="nump">3,822,000<span></span>
</td>
<td class="nump">14,140,770<span></span>
</td>
<td class="nump">15,170,742<span></span>
</td>
<td class="nump">15,636,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,427,000)<span></span>
</td>
<td class="num">$ (14,665,000)<span></span>
</td>
<td class="num">$ (19,677,000)<span></span>
</td>
<td class="num">$ (21,156,000)<span></span>
</td>
<td class="num">$ (22,836,000)<span></span>
</td>
<td class="num">$ (25,016,000)<span></span>
</td>
<td class="num">$ (21,094,000)<span></span>
</td>
<td class="num">$ (20,929,000)<span></span>
</td>
<td class="num">$ (76,925,380)<span></span>
</td>
<td class="num">$ (89,875,459)<span></span>
</td>
<td class="num">$ (85,077,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted (in dollars per shares)</a></td>
<td class="num">$ (.10)<span></span>
</td>
<td class="num">$ (.07)<span></span>
</td>
<td class="num">$ (.10)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NR\L3O[CXTO@FT#O^ZB_0)02P,$%     @ -8A73)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M_^[K()^<A#X.73W,OZO#VS!VS=)*L-*47V_/JIV?UZ7]CS ^ )< O > ^M<
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M/F: UQ=PE+G%S!US6FP:SP ]\ PT?F0XHTV*^7-0TRJNG.JUO,0!U3B/-6[
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M#9[M/&:SX<VP_""V?N/J%U!+ P04    "  UB%=,U'XY<K,!  #2 P  &
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M\R\;^U\C.O!2-C=^A%K_P69#0NW"\=:?S3AFH^&PFWX0F[]Q\1M02P,$%
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M/]AL2*A].'["LQW';#2\Z:8?Q.9O7/P!4$L#!!0    ( #6(5TRHZY3(M $
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M"FH?C_?A;,<Q&PV/W?2#V/R-BU]02P,$%     @ -8A73$B#MH*S 0  T@,
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MSW8:L\GPII]_$%N^<?D&4$L#!!0    ( #6(5TP_DL6\U0(  $L,   9
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M3!0K_R*<R%.# S'C[#L1KCC9<S^;(@3C*.(_7[SUT7/.D[N4G8/0A#F,&+[
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M"94/QSV>[3AFH^%--_T@-G_C_!U02P,$%     @ -8A73&FDU#NV 0  T@,
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M+0L&M;93TSY(3DTY+;08YO<&+X]>\1=02P,$%     @ -8A73&:6]"+1 0
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MU5<+&K(XT?_H-$S?!2O<>?INZYX\A07V08&]%]C_T^+C78LAS"%LD@1-DH#
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MT#:M(^>*::/@25LL]. ;-A4[*K,D>BVZ[M]M%&_[R18,XS7[#U!+ P04
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MJ),O=5+@Z>0+G1020DE89Q74605T4F][5PN=#**<8L_.$H9!1G,0MD."=DC
MCG?W=V1YVAC[IO=+%,;STA[,T* 9&C#CWRFZ/ ,  ,K".J;_!GL"""AAORF
MY?7- 8;$/X< $$)*008]4\FL9]E'Y >3UZI5T5%HT_Y<D[H(H;DA!4^FQ-*\
M6U-0\XNVTY69RZ%Y#X$6W?@P)=/KN/T'4$L#!!0    ( #6(5TSW:[L!K@(
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MK=KS<>I&0[+./BAH>M6R?U!+ P04    "  UB%=,[3$(YXD#   B$   &0
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M$C7G"K2E_Z2+;O2;MRP8U,I,4ST7T\V?%HH/\Z.&EY>U^ ]02P,$%     @
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M95N@$^>*Z0K])UW;1;?1]21E)V6&L1Z+LI<L)XH759_LU<WZ\A]02P,$%
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M)T2DO$\4@%%LP#&'6X*MBXCC6\B3"\D]0<1HGO%@'\\I<H([2% 'R> @N7%
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M-?_X+I\1N:+TBUKY3A';?Z2% <L8LV*4KBBEHUZ^[T'#7E:+D#%FQ?B!\OW
M:^;['C1LYB@6PO+/2AA#4)0A:)S--P0(I0DE5S+NR0QE" 8GHT"XFX/!@\_F
MBX0_DN)UMR]G3WE5Y5G[H/,ESRM7#Q@N:MY;EVQ.!ZE[J9J/IOY<= _PNX,J
M/_1?3@2G;TA6_P-02P,$%     @ -8A73"(&!LZ[!   _!@  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&ULE5G9;N,V%/T50Q]@D9>DEL V$-LH6J %
M@BG:/BLVO6 DRY7D>/KWU3:.1!XF2AYB23YWX^4YI.C%/2^^ER>MJ]F/++V4
M2^]45=<GWR]W)YTEY3R_ZDO]S2$OLJ2J;XNC7UX+G>Q;HRSUB;' SY+SQ5LM
MVF<OQ6J1WZKT?-$OQ:R\95E2_+?6:7Y?>MS[^>#;^7BJF@?^:G%-COI/7?UU
M?2GJ.__A97_.]*4\YY=9H0]+[YD_;95J#%K$WV=]+P?7LZ:4USS_WMS\ME]Z
MK,E(IWI7-2Z2^N--;W2:-I[J//[MG7J/F(WA\/JG]U_:XNMB7I-2;_+TG_.^
M.BV]R)OM]2&YI=6W_/ZK[@M2WJRO_G?]IM,:WF12Q]CE:=G^G^UN995GO9<Z
ME2SYT7V>+^WGO?LF"'LS;$"] 3T,2'YH('H#\3#@P8<&LC>0[P;M\/M=*>W8
M;),J62V*_#XKNO9>DV86\2=9C_ZN>=@.=OM=/3QE_?1M)2.^\-\:1SUFW6%H
M@'E'^+7W1PA"(=9DF=,XP,9&"#&&;&U(Z$A"P#I%:R]&=1)V(*$#V3J0(P=&
MDNL.$[282XL)HB@69. V-HZ'DG-&QLAO;6#(HSB(8YRY@IDKD+DT,D<8A8,$
M,$A@.:#(D64('833&Q1!!Q$H(3#*[##18#S9G"2.$L,HL5UG[!@HSC#CV/1*
MN8.T?$*M/6A8;#3G\>C/$17R^)F377O@2ARSD'^!AASSD-M$%+9BV<01G*N8
MN5J%F<,1+4(SE@T2SIHP>;C-'AE%9IS ZB?-E8':0!2+'.E@*O(0I!.;Z70@
M-10Q4HPQ1RA,6@Y8&S,SE$U;,0]"LW(;)>>A,3Y;Z(M"1])8 [@M O9:T(/&
M4U!0R,VT;5PL@CB49N(VCHN82\=,(RP^Q,!XF^SI0:-0%#E;2UBD"(F4N>X@
M4.PJ"<L2V;(D8[,;/6A84KW "56OI>9>Q$:*.(J$M'8D-C"DB"1SK">$)9$$
M2-_E DLBR>FJ2ECI""F=N:+TH"%W@OE@XH\#8:FC"5*W(5O$PKECL2*L831%
MP^A3#>OSL7$DW5I'6.MHBM;1)UHW#H3UB8 ^#38I?2 $"LS"$<B1C,"*(Y#B
MF&L; )&5S">@<3)8DP22&W-6 !"Y&"FP)@E;DY0YJ]8 ))R#ZWBKL<5#,5/.
M 4@XZ\$*(\#;CUT/ KE>TK ,"5N&%',HF< "(X+I8BBP=H@IVB%L30C=DB"P
M) @D"293 4@QA^H*K C"YK%BYEH,08X-L\1DES9%%7-05&**2OZ%-W7,/@EV
M!%;_>M"P?TW['/V3F'\2+=YF_P#(V3_I.'P U+)$%( H=/4/\T\B_CDD26+^
MR2_P3V+^R2G\DVCM_J"!F(!R"@$AR#4JF( 2+:16 ]'A@H,]"A-0(0(ZWOX4
M)J#Z @$5)J!"!#3?Q'K0>#<I'/-58?XIP#]SIFQ[T$2F*\Q A1BHS$@V2#'7
M69WCL YLQ,V)L@4@>Z+X@R/@3!?']GB]G.WRVZ5J3E('3Q]'^,_4'"$;S]?\
M:=L=Q+^[Z7X7^",ICN=+.7O-JRK/VF/D0YY7NLZ1S>L<3SK9/VY2?:B:R["^
M+KKS^.ZFRJ_];PW^XP>/U?]02P,$%     @ -8A73*CTP/G^ P  7!,  !D
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M!KJZ@:IN/Z\FT#R6XDY?16 * KK @2IP/Z](4""O@%8!H%0 C1\%"N45+0!
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MTG\H^^R/G"O00H,[K;34DW,,*!R5V:9Z+_KYT0>*-\-H1.-\SO\#4$L#!!0
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MUO J$CW'.HN+^K>U/A5EEK0J.I0D^MU\'M+Z\]SJ7V@X@;4$=B7HN3\C\);
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M,EE@%.'C^!NXN>B)W"7;QSB"*P"_*-(T>@#;>?T8Y0_H]RT/\S);9DF1H2D
M)Y5\3)?HB?_PX1P_]BY=)W#TJ5EGFPR5+F4GCR1::6CXU,_\XIOH;;Y(?H2O
M;-6;?V3&]MDWM+TXQCE\BO9Y460LQZYAG[(%3,ZN__T:#,2&X?3]3O1U"X9-
M2>L'3K]/O^U9;W] 6B[08U#@:JO!!UE$["86!Q,S"]@X=9%$.-,2K(!]MDF1
M@0HK!$D".XWGV>^^R0^%W2;Z%1RQ_.DAK?X&'K:_@N7(;P]E1W_Y*=D?8!9
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M;I+M8047Z8#<@9P(\$HVAX>C.<CQI7B R?>3+? B.I8+_X"C@ZFA.("OP1$
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MW&P.J!U:&WRNE@]O"UR+NVQG-<P2+W-!EL,J1R)4"V3!R6.>V8"_M9L/OS/
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MHOY]?PRCIB).\))*YG#RK8U-*)E8CX11-0_>039%B@&E:NTY",U>]=PS)LK
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MZA'.&>Y[Y4VC$TT#091G^(VA%71&[G-.F&P])#+)9)2G;$J'.T8;^.&,)\2
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MR? ^G1=T2Y\2#OV883)K6J+#BL(P0VJ[J!4(*T&@4(DX13AN&(:7S/RP]S(
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M&U+0*7'QMHW=(SFM60$ N<EF+3-DI.7:; B,;$FNJ3*/G>%M:*4$0(2URJ6
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M\-0P+NV62NHV_D [H&L+EU:S0IKR0%Z!%M$SUICEU2(PL]J9!6>-XC\I:N
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M__<^RZTK%,-9K/EF$OWQ_]J/)6VM:B@(N@SULBQW.5MTR .\+NC[]H[D#?,
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MS\E&DLRL"\+V41$AEW !MY301L-2DT#4B[T_^ NPR9'(+)[8)5><XE*8C)Q
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M^ O-KX!M9CA\,I%!1<&89R#Z7Q=;4::4#YE%7-E:B_L8$5V5"1^A'[+64.D
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MMB?HQO^Y0RN:+QYQ@6^P@+:[>J=H'G+1+  .6%W-M##D?%[6R8V4_R*U! :
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M^F%>^;T@"JU?AX7V]0_;[>['_P!02P,$%     @ -8A73*Q.*80\ @  @ H
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M-/S;F@G<N;P?T^4SSE._O>&>*%W&55(X/R\.X7GJ1T3X](>4Q[]02P,$%
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MK/J$L@['O#5U]U.29VO7'_/9\/^1Q1M02P$"% ,4    "  UB%=,'R// \
M   3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M"  UB%=,9O,+8((   "Q    $               @ 'I    9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( #6(5TP]AFH#[P   "L"   1
M  "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #6(5TR97)PC
M$ 8  )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ -8A73%:*J)6] @  = H  !@              ( !^ @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #6(5TSWA%R=
MI0,  $ /   8              "  >L+  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  UB%=,;=%NRUD"  !*"   &
M@ '&#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ -8A7
M3)*:J%?B P  N0\  !@              ( !51(  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( #6(5TSU..PS^P0  +T7   8
M      "  6T6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  UB%=,][A#<OL$  #_%0  &               @ &>&P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ -8A73 ^C6+:Q 0  T@,  !@
M             ( !SR   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( #6(5TS2(&@%M $  -(#   8              "  ;8B  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  UB%=,U'XY<K,!  #2
M P  &               @ &@)   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ -8A73#7X)6"U 0  T@,  !D              ( !B28
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  UB%=,.^/!
M9[0!  #2 P  &0              @ %U*   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( #6(5TR*IX]4LP$  -(#   9
M  "  6 J  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M-8A73*:$A*RS 0  T@,  !D              ( !2BP  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  UB%=,,]B7@+,!  #1 P  &0
M            @ $T+@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( #6(5TQP%%]>M@$  -(#   9              "  1XP  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ -8A73#1";5BT 0
MT@,  !D              ( !"S(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  UB%=,T'.P=+4!  #2 P  &0              @ 'V
M,P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #6(5TRH
MZY3(M $  -(#   9              "  >(U  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ -8A73$B#MH*S 0  T@,  !D
M     ( !S3<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M"  UB%=,/Y+%O-4"  !+#   &0              @ &W.0  >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #6(5TS'CN9]LP$  -(#   9
M              "  <,\  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#%     @ -8A73(8Y+"ZU 0  T@,  !D              ( !K3X  'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  UB%=,/_ ;E[8!
M  #2 P  &0              @ &90   >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0    ( #6(5TQII-0[M@$  -(#   9              "
M 89"  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ -8A7
M3!M1#P?$ 0  -P0  !D              ( !<T0  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  UB%=,J);3FK8!  #2 P  &0
M        @ %N1@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( #6(5TR3$ER$X $    %   9              "  5M(  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ -8A73&:6]"+1 0  G 0
M !D              ( !<DH  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  UB%=,GH1M1[@!  #2 P  &0              @ %Z3
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #6(5TPI9ZW7
MN $  -(#   9              "  6E.  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ -8A73*6![$QA @  :@<  !D
M ( !6%   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  U
MB%=,VO+(1C8#  #W#0  &0              @ 'P4@  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #6(5TRC96=.W0$  ,\$   9
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M970S-RYX;6Q02P$"% ,4    "  UB%=,24A8(^D!  !E!0  &0
M    @ '*8P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M #6(5TP+B=)SR0(  +@+   9              "  >IE  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ -8A73#T@_3&Y @  @0D  !D
M             ( !ZF@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  UB%=,B+J@EHD#   G#P  &0              @ '::P  >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #6(5TS]O9UFO0(
M *4*   9              "  9IO  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ -8A73)\YQ8O3 @  < L  !D              ( !
MCG(  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  UB%=,
M,T>P@J8#  #3#P  &0              @ &8=0  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( #6(5TRK6:&H[P0  "T9   9
M      "  75Y  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ -8A73"(&!LZ[!   _!@  !D              ( !FWX  'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  UB%=,J/3 ^?X#  !<$P
M&0              @ &-@P  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( #6(5TS,8M5V'P0  *\2   9              "  <*'  !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ -8A73*R68+D-
M @  JP4  !D              ( !&(P  'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  UB%=,]I->O$P"  #P!P  &0
M@ %<C@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( #6(
M5TQ_ES&P/P(  #4'   9              "  =^0  !X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ -8A73*DNAZQD @  "0@  !D
M         ( !59,  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    "  UB%=,;BOCA @"  !T!0  &0              @ 'PE0  >&PO=V]R
M:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( #6(5TP-'[DU)@0   H5
M   9              "  2^8  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
M4$L! A0#%     @ -8A73'(K>5GM 0  ! 4  !D              ( !C)P
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  UB%=,IML[
MP?D!  !Q!0  &0              @ &PG@  >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;%!+ 0(4 Q0    ( #6(5TQSU\/KE0,  /L.   9
M  "  >"@  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M-8A73#6+:JE0BP  !/@! !0              ( !K*0  'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L! A0#%     @ -8A73*Q.*80\ @  @ H   T
M     ( !+C ! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  UB%=,]>?GK@T$
M   +)0  #P              @ &5,@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ -8A73,VC$6(# @  H"(  !H              ( !SS8! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ -8A73-<FG)W< 0
M1R(  !,              ( !"CD! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $( 0@  $@  %SL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>175</ContextCount>
  <ElementCount>293</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssets</Role>
      <ShortName>FIXED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/InventoryTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - FIXED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetails</Role>
      <ShortName>FIXED ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - FIXED ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative</Role>
      <ShortName>FIXED ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>txmd-20171231.xml</File>
    <File>txmd-20171231.xsd</File>
    <File>txmd-20171231_cal.xml</File>
    <File>txmd-20171231_def.xml</File>
    <File>txmd-20171231_lab.xml</File>
    <File>txmd-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001387131-18-000776-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-18-000776-xbrl.zip
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MR21(_#CZRB;,?;+OO5-I_+2N#Q\?*[2!1,UR>/DFA:MVI(N#-B4#1B<#FV3
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M,YD6&_<,#&/4X/%=!K.V4'/;^&A!UXN1,3('#=Z?CHF<VT9)BP;&C2QSV*"
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M@Z0-&J'W"I5R0R.8FS]),$5'S=$OOWRS@%<^1ZCOO>H'.13DU>W14=^T]"8
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M8*A&ULL"E/^ZN<JPH66,AFH:3L%*-8&I'.H::P;UUMT%,#6JI?2QIJL#IZL
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MOX*TSX'(FN,,L<WVK1(JPQ@WDO9<%9=6$='D8\Y2'673923(1%FRRD+KJA5
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M[3C5U(66GE!0 IA4<28QAMT)'H\]4!0_=U#A 23>K1PE(I]_@@%ILA'I:BD
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MEW]P$G'VDIU-0F0=SA&25))$O17D*8C34_H6M3O)? @\.<N+@JP7B^+,X%+
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M]5>8Y;CBK,RG'"DEB)0,WZ.R@:*T3-Y?A??/T0?MJAC?*B'O:&$_B1T0J77
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M$A"R[11:J V,Y'40UOV(_HB>GEY/J+OI@IY^=.%V%4X>7SH-=' LTDKEF#W
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M@ FV$9NFO6)P/,4#2UL[4PN<O*2*GBE*=S'9!<9^MD-^S,T (]2+XJ3$XS9
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M<?:*#)O.V%\H%_$8=,OHOSGP+WHTSM=%Q^+$^,%<B./?^BBZV/S?C*VBJC(
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M+ 3FX!1SG,MF"(5ALT\;9=G^>1_=P:[&R>*4CI@]FBUJ/<=OSF-EA$H3*7:
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MNK2Q&MWI?"[+25#%2 *NW<G@U*]^ W([P%0@F4./)H)\E7^/C=U=-?=X;LS
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MF-,"H,CK=<RA,M?%H"G@>B5?W_GM!GU,[&FI*V3K3HMW)H<%[;@S1'M](;L
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M-D<=SG7>IXDO0E<#\D]_CMOWB_@6C&+7^9RG*=[^)<X!\.M) BMQ"2#^YO_
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MVW"= 689()ZM*$<IBO_B4"0YV[$:/SAF]U[PS%?X-I],@E& WQMO""),ZR4
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MFEF[MK!BVQ*)+)[O-5&X,\"ZJ)VEWD'V9)L\1J^#\%:0RS$7T:K06K8V?D\
MKS=HN^UV6[$-9'X:4# 0(M8<B8EQ#56;C24?I,X\HTYKR <CX.(TH_Z66!JP
M>7PI21W)/8C3@;DB)0Z)#!Q4C^)H',0ACY]?$CL:E "UUS2>9+<BW$[Z@&CY
M$43N/2J3[GH.CG]4<6^7C17"BH8"@'*B."/."%P;5&?GGSE(]':34</:N5'L
M!B]XT6GBI+">AE)B6C';J/P(TMW' N$+$/F L3P%R#0,Z\K@8BY>HX1.%+ZX
M&; @NAEPIZR7+L>%?D0A7C(>.MW&8 AL",UFA\SF1#ZJU:#L727'$0@?4&%Z
M16GH_/<-YW<>5)]@\1U"@S8=2!B- UA;%$=7(S^= M9G<Q&E3!@^;<8J,E-A
M4F91NF@2!M8HD9Z&PDPJ3+IB4(E*7;( N 7K,>7ZOO6<9B<W]MXX[U%<;(_D
M,C5XVQ;>,2NLK;#>7OB=M[!F$:)!718EU=*HY[FMH99&!G^MECO;R)L"@D?*
MG<X:N=-IL=Q9*V]^UNY+#0.]QME8_^V:Q>Z&Q'H!B'O1[[M-3U[RHM7M@-P:
ME(O>W;5BS)1*9,Z-1NPZ0"!1R\ Z1K(*"V]7FL$7J'& ,2M"^I%TE"!5L@NM
M1ESPRFI*5]$&DA>@D-*S&)C.GV*\490^58228F#%Z!F]S8K1"Q.CQX.W?982
MLZ,YG_)KL1&+W(W\AG.,I.D5Y/ (]NM):['@@/- ^NR4G74-%X8H<H&%@IP@
M6WA![#TD,U?[5<E;6+9NV?.&+KVI".<8AC1,39$"SAK.^XSC;$#UP9RE ]ZD
MH(:GIOEH2H$X]:89&.OQ:)0GBH%'&.F;Y%F>5,54=F(*-M[\0)S!(Y5"MK.I
M]$7C5JE>/:3FN.WFLNNV[)5FMR]J;#HNP/[I!-4<C&=@V)(C:4@$WRCP%R(9
MWLFF.' U(")"/21@=P[[H[].#8^Y=$G0T< 5H'>G@2OE=\JX)"L)%._CV,1+
M_Y4&3,4[EN(51/<R6$(.&AG ,*,*1LRCN!WNC:/;F'1)#!(2$:\^#G\#56N&
M"HJ.+7(C(/4B0#@&B>-D49P4_2,H4LGX:NXG&"HF1Y9^K-34  !]-4<R2U^-
MIF(6</ 3J"2?^*.,5%,=W@3M+TMB4)KT+;2(T,\C.KYC9QZG0)P*-!^538J'
MLRH:PT%.*#,A# 6&\4/<C[E(*'8[=OZ(XONK:7SO<!LIC&*G:3S"I .9  #W
M"PRN_.B\O'E5C>VM@DL1G(6Q=.P1K*RBOQR]DD :[K0268!^.LL1<@SA<VB#
M2&V2Q#,G@V-%[!;_']Y"NC R6OA.O]'<\IA@SB/"T1(ADX)+-@_UV'S1<KMM
MS_6\ 2<BE#UE%,^7U*[,EFBIQ0693M@1\4?#I"E.5X55TVGT6U56#4'0;/0[
M6ULV3[)H6M[ '0Q!,+WPNGVW/^0K"8CB&].X6>^B6P[WL_58=/!ZC,G3($C6
MF#?L@D76M]PFC"V6MEJTQQO.5%HR>JK,H\+R(7%-Z3,$QJ#,AC=82=TMKNR=
M=_K"<5, ]I-O$:@/.7[XG3>>I8#<G)06D.NEZ#O.887GMB4_%Q)0L;'U7&P$
MD@RE2Q 1/P0I838JK%2D/+?3IU'AZQ0GU)A>M(''#=SA<*A4$^1LE'2 5BPG
M0BRU$-PKE#VW.S2YA<J%*T&Z')Y23]+3UD#P(-PA"&-3-(%"EF+:&'!]%.\
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ML(*%259U<S8XV+:-AD@T//-!.YN2^;?.WN<NPS9]_W*3H']5Q4 (PTWB_%
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M'8SEF[%\6QVK#E.X6=L!19VG>$_P))C6@*M=W)[L^F+X56O_\E%<PD)JETQ
MAE7D!*NHM,$;UO?=43N"W60-80UA#6$->1.+S3UY0\68UY]@\L;*GDO*5KMJ
M-9OY)=GPGMAA1(?+Q4ZE:;5R3/-CV1U&=K 4;+8;5F>7<N:%=3%GN?[[?3G7
MGX.W@I"4RL%YC?_*)!6'E:,@)*64XU4>DK7CC6C':WQPKLIQ4DN^0P*C5R!L
M8YPL56I[O;C. U9?I,LVBH.F/\0F&^L'ZP?K!^M'@=)RSB%CYIL2/>5HA==^
M#&4H=(BW?HP\7PE'_X&WT,#7KG"]T/S^K,R],?C%HW(555,*HL% ]S56R%AS
M)8TG? 4C_H^BM)=4#5=,IW'H_A%X!G^;;B;/(@OAF<R<2V\TENYDII>=7P+Q
M03JX 2#NATJ9 ATR (+Z0TO(554!Q5!BOH]RA0I0.70PQ/M2'J5V@W M!8/X
MOJ(Q,,ZSUUU8=)A;<TXK]:9HHX"7-7[XZJ;RM!!B_2%6.!J'3IX]V7$>5EI%
M,DG=:7K<YMD6W[$%ELOU1)06=]J^\)PLII1OW9E$J]5$HBCUKZ7[TK3<]Z,'
M*V67JKPJ5_;146 :I:^&R@V2RZH<]:@#QQAZ^'7DN>"W_*D9]] E8,MH!BZC
M.*7S'UXO$-U^:(G8ME,>1C\TN9KQ'V(D_\#\4-_#N]Q<T[FC7N("@D'BM>9H
M1I+ZGJTL='].A.&0)7I12$[3T2,=NSL@+L+DQ.46^IZ/6:JI.N@F>[56QSF!
M:3KX?K62_&6E;N_ZAW0CS&\ULZ1= K?I!NK/"!YS)K,Y@]/%QWDEP>'UP3L'
M*NV*5SE!'/_<]^FLV.7;Z^H=JU$N6^5RV;CE^5^K5MO\:&%^[M@03P3J< A$
M 77XO><B^RA15LX*_L9<7^7>5]#1M%HQ'8/4M8/LQ',Q&/N,!B8BD3F=C)ZM
M!ZAL]Z@N(/9*L_IN]%/B+JXQ>\V%Z?,%PEDWPH#1)H6H=-J8+PT:/"*A3Z?\
M]9=+F)D3\:[R$UZ *(VR/0]U?R@43'1OHE1 )&".-5Z7IV&"D@UZHO]/'\)6
MIK/=7*XWU&J0R@[W,$96OB7>57\R=U?&CV+4#4KKPONVAF\CK%<:T!28[X0(
M0166T_B:%)GN<'0I[WP '%A2Z::QJZGF?37">'=%'S1%8#8E@3Q=T&ERS=_5
M?B(*X&4@/AZE>NFK,<K"Q,AH'L$PFTD9A&HTP@?)=@'W0A\L.%[W&2JSA8A7
M6;HHC)X:X)+C!J@Q'B%Q")'KJ, $]+,6B(QGO H4Y[@/W(5Y'BN'';=H6$'Q
M/#Q3HL7#E#+YZ"LUHDS\.6)PF,$09'W1 WMHB[&<D+V1YL;,1U^Z=+LBMDU$
MA$.0%':0W*8)E/;^#=J9F"A?/6EL"5X8D9$$E5M0WQ(H;LH73OW@_=4EL% .
M!J -001MW-,?W7X?"Q0 7XF"#Y'C*/@+>%<2E4K;FC<!%.BF$PVG;XMK$+GN
M2R.\> JM]) +1H6:?'??_8#=_63%TX4L<" B(QSR;NA@9K>T@MJ9T@K L,@G
M;14C<#N@9<3C.-BCE29>1QK"5 6&3CRLN>C&JAZ32:$ O66$>Z_1]*><N-$0
MF/%C]%VV<.@Z2[.,''B1#R[F3_"2J"+0I.$Y%7=T'STD[3'2-KD3\EPSGFG4
M%H@^PEB/?)P!Z+Q0[YYBA7.!>%&I$@T0BX3#@-QN8CY,E8E9FSAOTDHW-X>D
M[V.@870U<I/7$XL(G.K%JVP(2V",=J02U8-VPR'\D&C*W)B !]/!2I#-)-"D
M!&BO'.+U!?(?V"MGU2R\0).V++C(>9]B_BFN4UGG(D]K%-_ ]D&O%)J!?7P>
M*BI+BF)=%149$:=\F:1X$;0-_-:3A)D7X5VOJ,ESMH#B89I=Y#]M'?0CFE!X
M$;-V5X23J^9[*JX$#QB"ZR$ZJ%K*@O&A@%RZDX7XSU9H0$$W:5S3ZBEQ"19T
M/!2/XQ1?O>N##M4)O#1Y&[7X!..[V0A^_3D*+AZE'+\WEA\8^Q$DYWAH;!]
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M)"_4F6(O".Q#U3E0%W[^'U!+ P04    "  UB%=,F-;EB6L2   /_0  %0
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M3EX2TJ WNLQ'_(<*JOEKBAZ(M<%+0^4T]1*<=G=]]G.]([D,R!0I$%^#UY?
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M=:"TFC\L6-AU(A__Q9+1M>QN2C',=&M%F"6A /#B\9P!GU:@=FB]6CO+$$!
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M>F/\P_6BA/7\0_Y<@^!^[U9 'MB,,(>%-P9DZE+E'DC/D7\1R*1!YTD,W36
M+N0Q7P]4KAV8KPPV9WB;(_$=?F3/,KG=-5T5%)W#V8><0@YQ+OV47.(Y9%U/
MAG$K/#@#N^BZ1E #))\MY9<+0'APYS$ZOS-_<;VEZY!IM'-YO?+"^Z[AF)9)
M'9+U*PUN$HB\P^BZ7-@3NL*L(KU^Z#MKF>_K7^<>"+>/75 NV-[W"=C(YW$5
M&DR/OUT4OEQ*4"N_6[<F8/:_M6E+I7GH]C3PTM9.TV'X/I/5+<BF\MMI +H;
MJMWL_<+4,TS"4G;XUZ[WU0J,I>7XD_#QT1;<0+-1\@VBZT9:$8P%F$5Z8[TK
M@>B"=E4TT7+NO[BN^6Q%)\CPYDFB_ZS]$?F3GSQ\X+RYWN5@2((]<,SJ73\4
M82YPGEYPMH_LZ=@W/_",.><>6:X_?ASS\(%S:\3A0! +).JI#;T"H$BC&N,,
M]'JPXAD+:XF'KQ1"&!CK(#'G\@JZ2UBU@!O?P^]WD.AN^8*0U)OIA4/YF##9
M48\A$8P6)=[@/)PO..!!8B]F&%**H@ED*CG%2KF28H>LZ(CX7;3].(/PUYL<
M)2]/ZG#7AK<2&/?3#+Y&%,W% IQUY24NVZRSH0J,=! H[\4[N.W6G/ D,VYV
M:^V3@;.?Y -G6VU=,;^"T.6+'#S$XI=1^FLI2Y7+.1O@"!7>IF'@D"J=9T0\
M!IH0XSRX@KE&9&76!"1C"Y;(#V$3K%P <DS!$TVPLF[D,0=+'$BP,K)H2'1'
M3*4%0Y9PM0=@N?XNO\QBLE&-HU(S& %7U7($S:_9EVRD*TI(G:!/-<0!K3_-
M+\>7;*0KCD>=H,_PQ^B(3,*Z77(AU%2B4LW;A30KX"U2.7. 7ZXUV6BFJ?ZD
MNCD09P2\F<&1=:K4=UOXKN*4/]SB'<)^U%P2*G99.%KL2@+&EM]/6^GD/4ZV
M9#B"0,2ZI94I^233NXYXRO-5T=Y%01FH&J$@X +<Q^B\DHIGMA]8QC?+IH,3
M;D:7LV-^>OM!OW/9'_2G_5Z%.>XG@3O_SA*Y$<]?54'@LM#>96$R'77__LMH
M<-4;3_Z]U?OUKC_] T5>FL@HCQ:_L<LQ5A=B;-T_R.2H$?73Z6-ED2:X=.+U
M07/))(?5KC\EE$8]KI,R^1"4;(>[:+LJDH!# C_,%T&9! LK??,ZZ;G@$0M>
M BCD5S>JL<)\):,03\R98=;TBDX2$LTT7:S(S!B73W7%&XW)@^$1_XZZC]Z:
M%$[L;-Q?ASOJ.N//YTSDX 7GCCXB^M*@O@P[8*)+BK&2KL<JFZV*3+PUN35>
MV:\ZSX;':H:.HK*(*[>_[U!6P^A5["@,_(!=WSGW*]%P8IHJ^'KEBI1?)UP]
M0L'I)Y7 _A<F^+>=;25ZN/YFHWU)44B<QAR&SO5>Z-['\BO6NNU7&[W;%0;H
MEQZ>YCU:7C0,+Y=RJ=]MM"\M#C#Z0*U+7MX\8H<QH$.WJIM=_J?KHUF52@2\
MUJ_GXI9V8-D%Q/3!6$O%I_)Y(CYU*DK;8>0EH3Z*J44R8%""VM7O-\*VZ\3L
M/!'/N"<;#^#6L^9$<"0AT[4^AQ+2W$# %'VJJ]HL";5MA]-HLW%E!.3:L+RO
MAAUFW6[MM3;O3Y&6M2*O1J@P8XI$!>FHXL?#Y;$9\>7WUTD2A$QGY:$H%X>\
M!#8:O)?D>!?,]=#H[=Y:FO/*=3H_B8U6[RD[4*\5WSN5Q_C7R'&5YOIMDU^Y
M>A>FM-%R-2($E;WH6;9J95]O%]9LLDI];V<'/#Q4JW)1.GX81=U+0* :ZLVE
M5\'Q0A&7H[K#CX/R-K")#53ZHFD'Y<Z3MIGONJX3B2HTHNC^?$=+HE%J>\HD
MQ1@(W:&>5<>"+R3D-24>MP8J)C(QK&!Y=*ZJQ:RH*,&IH?B4O&R/&G9?\FA\
M%;Y_ 4IKJO28I0GJ?6TN(>ZRO1<\ZIZ7P$;+50D15&[%MQ>=^WN/W%-/N4^)
ML!S?FD?NLL U%?2JCRLJPP@8?(@@!ON;6&&_Y5980"@Q_T3@:6JB2LOJDT.#
M,AQ)G9("]1K+L?MZ'F].&[;795,W,.PD;R4=/LI\NB9:5ZDX0-7"<LB]C92+
M1\:5JU(2G_P15$E6#* *H8M\W3IX5>E/]O=^+.7AR #4G-@I;_6Y.\"<%]D)
MY<].<B6]8#GED3U\3OG=3=H+51.S27O1I+UHTEXT:2]P'$0T:2^:M!=-V@OE
M&(R9,\RW3;$F];%%*;ZP/>N."!2I?J*1'MN2%F2&H)-\H+,=>66-V3;DP /S
MVG]#9;D,ER)0$LUT97S/4G%70"8D]C.]J\Z-\2(E]G@S7?G<)<2>(A,2^[E>
ML6\#!#N^'RZ3SQB@L.9U7V'7V04BETBTQ9?C!D(1P54HAG=:.B+P<I)8*Z7$
M)36<^X2LB3NV_._7'F&G\L0C?C"FO.1;R+)&J)7JY&(*YT8D>TE^)'.JJ5]=
MF\X%FRIY?FRSQZ@]NARV0%<;+;XL$JP8JJSGP6"Y90;TVM$B>&4]629QS.+S
M,S["P2":8@K<&*"\K3W)OJT]S7=;>Z+SMK:P4Y6"7:&;.T!QZ_M6>EC(B ]Q
M(EV0>^]/H+E35J=18#5O17C4XYIZ13?]"O_X?Z<9@H+=JE!R>7SBW(859_V-
M/<>\M0U'IKAS.5_3<X^1#6_.@X ]I(ON4J3^JH3YFD:7NF&^\^DM'VWWE9#(
M[5V=D(DN(L NFN( 2ETA7'G6<5JGF@03E.U)-+$'3>Q!$WN UPX5BCU0#TLI
ML0<\L1=._J4Q]D!3K=>\L0?<8JXUK1^R1]!">=^<M36]^B[O]*ED61U8, 6:
MD(F"5_R-_JH0(,[]C]*IG!5&L+;U%2V\' H:-=Y/<CCWA>7+8.4TZ=3?%06-
M_NXG.9RA+HI=J:Q GVI78"X-C0[O*SN<X3Y52*'2=9A+0Z/%^\I.(K2I3HG#
M1(%Z605HXI(OY9L'JJ4ER@K2RIIF4MX_!K/T3Q^HCI8O,DA58YF-$<6&GF;'
MAI[EBPT];6)#F]C0)C:TB0UM8D.;V% L 7U-;"B2H)7ZJQ+F,)HF-K2)#:U1
M;"B4TC9<+@WO=;3HS .ZI0I>HQ+O)\?'%Y0+VOR$<>(+4OSG&T17QG_UWF5!
MW@\SEB.6,G[LVO:UZ[$_EA>RD?V]PU&N\L544P=8GN%AR+<]RC]5.^V35I+2
ME#(FN ,+I\B,C/KBN7X9YU[PQQJ=W$]T2(,DF,_8]_V0F%>A1V6T(COBT(\Y
ME&]UUCE*EWNL'T:GBDGFP"(2MCQNBI-O9TEY"UG&QWX8I2M)=(@C#/;@EHIS
M0:P@]$@%6IGQL48K]Q/=@448)*J5=AQS&U/ALE]5N#>1I:#1WQ+D"2EUT6JS
MFH.YUB(8NNM"2BM.U]=THMV,^@_^4"I;DO@@#2U:,A;'L@N714\\J6/27U1X
M/BE)2^WTNL*SRSPBY(5H'+YR:]?HVJFQ$FW3HOE\=4=^C@]>I,H\*56E\NJ(
M:-2^>G&#JH_\RD DAE3Q9$W:GXN.9@)HD3@X!Y"_XA1+(G6,J6T6Y**DF0>:
M9 [.!.3W+B)99!R=:IH).2EI9H(FF8,SH=YW/>(S6#T;X_WH:F8)"@3 .?-1
M<<3MGJS>18>ZQ74^"EJMDH8?6K_U2!O4Y:(74"7I,LS3F#"(Z>^[KA-%3H>&
M/; 61!2)KHV@VFDY>'B/0(Z@_B*XGMKC0BZ?5%@:AA.!TU(M,97K.!Y55'LS
M6U3V8(0T@INM/<2Q-F#LZ:ZD.,I('U.<F&9>:)8]."]4OY8K*O-TC=FX:T=V
M=_00MUFQ-GOI@BJZFAF !P9P,B"_%!.@U3'-2)<,^RU!#N]AJJ)=(/>SA^/T
M5R8M4#N17U?)KR5].B<MQ[?F)><L!S]9.ZW,JSREQ=IDR!'45^272GGOF:=N
M8-A5J:[,UQLM+D>DH$(CN!M2LW5(,EW-5G'GFS^B\I8G2%!E45[-$%.XC*J[
M%=C]V(^B>"5+$-2XV 4*HFRB0\-CP3)/;YGO$EE%S_-E%=V.IC6[:& $$8BI
M+4O6 _9T6ZUO\]?DB%)X[K3#DX<3E'WJ?7P6I_5(CMEU0U87X]'P@E>6JHN?
M(S.[M;Y4F=F"=R5H!C'26V"3/(;>_(&NU)U[CT2L[9(O2D"88P@]"2JY>+A%
M>4%Z)U0EH)C31)8!>CDI( &G^+]O;ZB$#&="YJ%'Y4G\P: +9G5D73@]M!5@
MS3V?7'E^P!55\>W3%^KY+2D9QOS!YP*0;C@[KZ'< 38@<9^KONP+K 6QHW2.
MSQ1VZG-SA0XUGUW44/1<9B  +A0#T'6?B=-QHMV=X;R*EAVH^:RMJ_SP/@CP
MN0&7G,(WWC]FQGD9-UHR;3SRVU7TN;Z;M/%(//?ZJQ+F_4"3-K[DM/%M3:YN
MJ6N$;.+X-L]!;A?VD-7 ?$O'(IY'S(CN6\,;>9$!-J-S]UOB1>*!,9?K/VM_
MU*0 LJ>F>?B L-0[89,<1.3ZG3!X<#WK?WF99OG]ZH9<-OTXSU>S*%\EMLV'
MUJI//9&*TX[3B\^B.A:>E ^J6,=ZXI5B '1?-%\D+9>NDW,EY'3"#Y:0> @H
MO3%S*;)%"R#0H88 R2Q]>N._4B1+K7N\7C6$27K%TYP=.3LM?N2^JJD]  ^%
M']6"+$%0*XYQV^:"E<2)=>+V00R().V0Y!4_ED]FX1TMJ+_#8L^VERQ44[;W
M!"(@)(:H"R[2K(#73AC7PA5;0_(<_8D;NR;3'S&8!?@ M\@(#KYE4@6M$FW@
MAV2'5E#LNH\FW#DAIG]-&65:8CAS,EK$?"/>ME?0%3](DBS %[ZJ@QYDIG'6
MFXI5V(!4;\2HY.8"!*;HH00 S%N _(J::]>[74<70,?FK)^H&W(HY,@',2AZ
MWE#$=^X[7<-_L(F__541;SH]"G*$"G$#WU"5 UAL.4W/:ZI3DL2O5@ !K$J_
M51/P2^ 95)'8T0?&%SA;TYA\@O.AX!.<5KMYA-,\PCG<1SBVX=/-_V],W9U@
MY(U9GA/!2QRX"^XX0B&OV.Z,,PD6Q7-Q.VEZ=R,4O 10R(/V5&.%.81.(9Z8
MH^+6](HBX1+-9GJ\19D9X_*I5KT$ CL"=L-FF:1+'5&J@I2"$^Z; JBYKF?V
M.00M)!]4^[)%GD_BVX=6]91XG'S8,]/\^):%J/*]KE@3W%Y6BA=L,5X1@:)%
M/=%(C]>4%F2&H)-\H/.*\LH:L]>3 P_,7LT-E>4R7(I 2333]FHX0\5= 9E(
M+]ENC!<IL<>;S72]FQ2+/44FN #I%3LK0L(B&;BV-=$(MW7-X =;..Z:1-'>
M=Z>9'AN;)<Y,@2,_?2@B<\RV-B<NF.TM\"PM>G)&=S3S!S)RA"Y2CD%FFBZL
MLB>*U+M*D T(TH\HWWK'V)@^N_M#NAUD]JG.D";9@"#]A!Y2^CD%\S0VC*[$
M)(I@W6$$ O9"<8#4^B"(EWF>M=MM-FM_P'R1GTTN)%,4Y^)^QS&CPSBYER*\
M7M6#(Y1YYFDYA_B*CL]3A.Q4IH@5I-@6J6"%,T2S).=P> ';GRN<IY:9Q^")
MPH/;/_KKOV9&B?).U47#X45]?ZY4[Z7++V#$0J2F#X:S#NO:T?$OC,DK:GJN
M#<LK)0WV_A3AU2<4@H%4LJ:%+X;NFO^4?"(!<!\IEO9-O"I8$>N0DB$H1E'*
MW(N8APJY2RV:^P*CFL3#5>%R) 5IO.8GW9E"RJM^-=4%/C"*'V #3N*CY46T
M^$QETFXBX#T5&PPO3/OR!![O(9Q<$BM0],_ZO&RUR(BJ&2GZ"EX-*8U9\ "Q
M@NF_.1+=>^IS!\(+ZC[\@"=?6.[=OKBNR<Z"J$=,-HD;B?=DS8G/SK)]*A,J
M?.8A&*M,CL&#:]+UCLRI,R%3[%K15_"J1VG,@KJC-VI$$:-?79O^UJ8^[)C.
MG]*5*/FY'T6;LK@&U0K+)6,ACL>6__W:(ZQ"'_'HNERJ4F5][-!5"N895"@L
M19/WFD)7UI-E$L>L9)6*?^S0%0KF&50HO8>[O21KV4X^%<&J;F/DROM1G=OX
MW[NN'PS=X \2C,G<O7?XB3A+^R1ZY2J9<U#%]![MEL;U-MG!^E>L'<=SKY:.
M'U<9.>( -;3H4:SJ2]>U_ K6:M_K$C''I_'J5K42 -4I=H",,6/)R9;T1,:2
MCT4SEIPT&4N:C"5-QI(F8PD2<)J,)=E0-1E+FHPE(L_5<.:6;;EO=2@W;A>_
M%*J@&_XL);)<J%X&^6'7;:[4DXUFFMX;Y!1R!M%@@$SSE+?RI[QZ+RR:I[SU
MD#EFT]L\Y2W^E%=3_@?53WFY^2&P7,E6])3WK,Z0)MF (#U##ZGZI[R::MZJ
M?\K+JU][WCR!TU?=6+JF67&V(-Q16ET%SP>^1G=9B7L%K0\_>/3@5SR=<L%Y
M&IHW>F1=R_/QT7.?"+LRW=2C41>4 WZB3OJEA%6<.VY5SX#J V::;G#W=T /
M =#BLP]#X(8 R92JST, M.I1&K?@GN,0=$?S0X ?1)NRV ;O,NJL5@@> ARX
M2L%,0PI5])$R"H5"\!#@P!4*9AI2*,7%KS-]NFWM0#(/6<EGXM-MTH)8=*N^
MC^^;8UC$P*MC#X)8<^'LBLYK])^D(58R+9( 3\L.]:!W^VYA-75U:.0."3^R
M2F:* M1)+$>XRM)O;>NOEJ"&$E\]8,V3YAY4MMCA+\:7(J=;TA,O13X5?2ER
MVKP4:5Z*-"]%FI<B2,!I7HH =Y+-2Y'FI8C4"P5^-=5DHWJ\ DG3C'-!6].9
MKUJPIKIZ^Y8+1EQG;TQL:B[IML +7F/'L?[E:_PO@EJK.<; [1;DEP:V@)@X
MG2*3D]564^W6_'*'@4/N'>R'$&9?H 04*_4)^H[)KIM"P^8_%TVUTU9X%-9Z
M5T0N.#OTKE^WMN$,C:6@NG>R%6Z;DL41MAJD&QI%Z]%N.SW6(E.BV4)';@N*
MR1VS#<B-3:4K_,!U[ED07=^94R:L)Q(_,6=TG1P?7W#7_APCZ'KD!.B^6YP)
M")YSQ6D#AJ[S*S53UL(B)OWK273"OR62$<;%1K:[KI*O8F!R<0"A\E'OCG+U
M4HY^A6_"=YKAMN&9/.$-W ;N 7UNC8&(/<>4-4GE?$V/0Y$-;\Y;UCVDB\XO
MJ;\J8?:1=*D;YEP1VWRJS.*MHA)$1\-@%UV%HDM=(H#TLYF\0QA?:#YK9G(0
M'"6_-<'M$:1XP?84)R)0-(42C30=_:8$F2'H)!_HS&5>66,V3CGPP&Q/;J@L
ME^%2!$JBF2Z[D:7BKH!,<(G7>WQ[8[Q(B3W>C*H16KFGZ03O<8\QOH27B0+=
M/,]8O?\/@P?7XY>@4/ZI6?O3P<;8<EF&E GY[@]B=AVP/@H#/S <TW+N2WM
M 'WJ@%6)SS*X+M53E7;FS9-AV<P;OW:]J$YQ^8O3[A</6+&D. ==;[57 .L'
M"?'\6]!;RJRFB%'BDXSS7GC?M:I@)1A%*Z5<*12T"E.Y%'!>:W3L:' "5,9A
M+\4=GZ-%<OWQZT$>/G >2956,RMV"LHY6ZSD\_CUJ$(Q0&JH-YO,CUI1[X=5
M3(X\P!@*S>\E6=B'[X?$O JIF;Y?<1"9ZNAU.,=G$G7%KP>2+$#0%4T$4RIT
MJZU5,>QB?6L+7HH'\/RZGOL=Q.D+T&M,Z=S#1_;U5+;HGW5^T=7TDDJTN?]7
M#EB90&Y!Y4%PL/I-S.BW5+J9ET?+6P7ZRJ2;4O&)FJB-.E9!G=&:+Z7OT!_)
MU'@A_CJUR9;21'J4B]WT*/UA=W33:TT[O_<FV[0H32J4)A7*P:9"V4Z5]86M
MZ 4TU!YW#!N?2VQ7B6EJ17'%< \]H6X">8O 01XSK@X?S.%Q2C#$'#A'*61>
M\+SKAD[@O8HBN3*;S[)XJ,#?$\X95Y)V$!L,2^# ]?UKRGJ7JJ[EA'3#,J*&
MP5@]M2<+UR-Q3V_-HV@6%AI4UT,Z:1]D7]X@/3C&Y<=OM_\)1_[\6,J1;[7_
M&N.F(HI/LBENRU%\HH'B;1;(;,I/Y"C?CM)LGYKM4[-]:K9/-73/F^T3;GR:
M[9-6& /B.88])D_$"3>Q#/WQ1+21$G34E'PRYXY*@@F<J^-VP9_,B6-XELLW
M6$!SW/:*RR.V/(8;&N\<_Y',HX0HPC0"<!<]!HLO<%>6>*0&2R5"F$V6$A0Q
MFZP-T=>N1^:&+TS)F]U>5PY$\<3)ABB#>G"BZ;5-V])H+ +\F55DOGR](@OB
M><1DEMGWB2!-O_P(N"U87DE@>TZS2ZMHO83:ZS%GN:7O2C&#U+RIP0JS82L%
MSTK3.>Z2P,T.F-U8UU658#:X4G0KOZ82RWE@&=]8S6"+\',D\[K,SFHD\VSJ
M(<F?Z745UO=:SCV[\NH:GO>Z<+WHH02\<,%]T%_O"4B7N+W3\?QHL2!S=@6T
M/5MAQ6W9TQ1G3A5MM2('UX22:MA,%"$EY#71& 93P>#H45?%(\Z3J+15WEVV
MN@\L*K7O=)8L;B&/U\\?"3WPA1B2.-ZJ_@H_EKC?DKUA/MV]81[W!IUI[ZIU
MVQE/^^@NF8%B$"F,I<O)#'!<0,\?B!G:9+20JW8ANJ<N-AR:ZVQ9E%.','M(
ML1YWX#].8:6]L%1??PE//:VF_A+&@YVF_I+V^DN*3N@LC^X#7$\8HIQHI^DB
M75RJ":06_T(74[;;T)L_&#Z) F[C;7);.7"DV0?]$.;P=0JQA_/HHC.?LWV5
M?VN\,B.>W,5T0[H3X^U'97K7#%MIEB3F</6[T,O0I_SY?M>-*LRL(^+E=J-G
MN[O1R[M)?]B;3%K=T;#;&T['G6E_-,2V*TVP.K;\[Q+[45X?C9,Q199@JPFU
M1[.7%&.S6TN:*X%Z;!-3/%R^BFLG<3MIVP@*X!!@E^8;F\>3YH]^45C6G==)
MSV9/1O2BB9;B'-TV3S5:F#=^2A'%O.6;A(^/MD6\%/G"F#5^1TV;0IEYY>;E
M ^GB&?J!NRR G*"CKOB-_-#), )..[W!V!GKRR5QY@]+P_N>VU/9Z5E;=R53
M MC"Z--T;ZC.;0I3/=%X+]E(B #,%@1^/T89@C7S:%2@C-JW,6SBKQ].#3FQ
MC!M/(*LY&FL(S2Y7D@<0([U>S(WQ#]?;&'*?;_JRVM;#V,%<8@NH9W4R1XL$
MO:)5D=-%CT'C2-N5I1RI[5()#V9KM3^$E8;-7[OA&[7<*.Z,EKJ"M\7:[XKI
MAB1\5G09 R0\I7\E<B+.:CH[KX&,0<(A(9^K%O*S*RGB5$-=UXSY!)Q--B3>
M#WI-<4V*.^=RA"2*/.NMC=04><8K:\P.RX]<Y%G3%CEOD6?N+EC%4N^3^4_W
M[M-[DUA,XF?L!R;HLYB@Z:]F W)OV#TG@+-XT5:I1L@7^"R20;^E0F&OZ $W
M2;1)LD7%RSE';"Y 8:FK>3EB1;ERYQ9]I5O*#G52+9_NNN;DDGCWQ.$ZY$#K
MRA^@0<KJRI$*"?>CXHW.S?SOQ/=9;3/OT5TM;%SQ@NUG5=?AD! PGUA(Q)\4
MB[AK>*;E&/8OQ+"#!ZYTLYK.+O )%J03DNF%8IG>/AC>TIB_]AW'?5K%EG(%
M"[:G*QD^\0JHA83</E8LY=]<U_19T;4U05&8KV%WG*B4C1M&A>*Y<L\QPJRM
MWC3NC41N^D%LVJH7;F(R2KJ$I47<* Q_Z89[S-I59]B26;U%](*R/E$LZZN0
M_$;\0$K*F6UG[:I/727DRZ$4E&SA<]:2 A9NZ=Z-_L*X)YPR=;Q>L[:FS 3[
M1Z2GN(!00Q5[(!UU4!]D,@D'IY#.5SG4:"VM(*IC&9DP5K."[COF%K]LV_GY
M[HN<[NCFIC^]Z0VGDU9G>,4>YDS[PR^]8;>?J.-6<BD%,3^"IT8?BC$6?W!4
M,HL38I-Y0,Q?0\.C=M!^O::.-^70L*^,P."B]G&7N4EOT.NRM!Z_WG7&T]YX
M\$?KNC_L4-XZ@]959]K916ZMH>P?5IZ0_N;_ %!+ P04    "  UB%=,HZ@2
MI6EL  !J108 %0   '1X;60M,C Q-S$R,S%?;&%B+GAM;.V]?7/D-I(G_/\3
M<=\!CV_OF>X(R>X7[\S8LWL7U27)KAVUI)'4[?$SN^&@2)3$-8NL(5E2UWSZ
MPPO)(HE7LD@PJSP7<>L>568R$_@AD0 2B7_[/U]6$7K&:18F\;]_]?;K-U\A
M'/M)$,:/__[5I[O3V=U\L?@*9;D7!UZ4Q/C?OXJ3K_[/__X?_P\B_^_?_M_3
M4W01XBCX'ITE_NDB7B9_0E?>"G^/?L Q3KT\2?^$/GO1AOXEN0@CG*)YLEI'
M.,?D!_[A[]&W7[][^X!.3RWD?L9QD*2?;A>5W*<\7W__S3<O+R]?Q\FS]Y*D
MOV9?^XF=N+MDD_JXDG7S_7_.HQ#'>?:?]T]$_S7>Y*&??3S[S[]^N+W\SW=O
MWO[A[;OW;_\S_[(*?J'_>ON'K[\LB8UG7D[8R>]__%_OSMZ\(__GW?O[M[__
M_E__\/V[W___EKKD7K[)*EW>?/GCFW=_?//FS3O._F]1&/_Z/?T_#UZ&$>FY
M./O^2Q;^^U>U%GAY_W62/G[S[LV;M]_\]>/EG?^$5]YI&-,>]/%7)1>5(N-[
M^]UWWWW#?BU)!<HO#VE4?N/]-Z4ZE63R:ZBAKVF2A=]G3+W+Q/=R!D#C9Y"2
M@OZOTY+LE/[I].V[T_=OO_Z2!5^5C<]:,$TB?(N7B)GY?;Y=$U!G(<7D5\7?
MGE*\E"L3I>DWE/^;&#^2'@_HA[ZC'WK[>_JA_UG\^=)[P-%7B%(2I"KM^JXA
MJV#ZQK6R-S@-D^ \[J=UFWLB]<G82?,]#*CS.S?A/LF]J)?R=4[G:E_A?BV^
MXW/?TF3&P?U:NL8YBMJYJ'+GYI6W:T3_>$G^U5 1?\G)5(J#4DDJ0N.!V1?8
MQ%#(KJ0G?D-N1+UYDDIM9R*77O; Y&ZRTT?/6W]#9]5O<)1GY5].Z5].W[PM
MW/?_+/[\RP<OHG/'W1,FEA:3QNQ+F)7?8H;^^U=F\F_:-E#&65H:XJ6^H34*
MBF_\A'Q@G9]&O-TY^S)-5C9:%*V6F&E_B1XJZ;R5B0(*,QID*<Y8@-.ID^NV
M6#9IH> J(@PT=,3QZ:>[K_YW08X8/2H9T-\HRW_]VS>[+TR'J9L4K[TP./^R
MQG&&LUD<7.<D\IMOTI2$@;,LPWGV$:\><*IHDBX"7.*NNV%U)-IS@\%F9Y7;
M:+W%$?7T*$_0+<XP,>,)D74/.L//.$K6*R(%S?P\? [S$&?H;UP8&!PG:YSF
MVQMB4DYL/__[)F0J?]C>DV]KW*05IUOD6IO2A*R1#1!6;75M@[3D/$&,EP&T
MXCY!E!N4?[U+EOF+EV)B9/G/VGB:)YG!O7;@=XG1SF;5D6K-# :O735NH[9D
M N8TJX&CA:! Y1)H"A7K<&J1@ &-7*\V-"HJ8-B@VY2;'*=V&%%2N\2*0>4Z
M9A2D8+"CUZ^-H9(:/7EI -#/7&S2.,PWS']>A%_HO_2SGH[!):+,BM=!I:8&
M@RNCBFUH50PLTEH6+,#P=8F]##\E4;!8K=/D&=,!HP>8EL,EPBQ4KT-,0PX&
M8V8=VR"K.%!88P$&LHN0# 1\&3[C8!'G1/WP(<)\6?UA^]'[[R2=1UZ6:5::
MG20X=7/=36OX/7MV,"#MKK/@&9F$4R8"[60@+@0];!$3@Y@<4&O2,EPH5R6M
M!K *] R\4X1]5N;(@D M(QC$=M&VC=7K-4X]5*U";[P<WH*#V(/3&.=GR<H+
M8YH2H)_"-?0NT6=4NXXX)3$8E)DT;".KOCG,]D'0]9+\(UTG*0$9^@D_9,1+
M#@8UFGAR6J:A,/BP5)39FH4-P8])NDIBS'-7MF?IYG%.PM8P(*IPS,LAU5.&
M"YCM91Z%7B\!D\-Q'ZW;$"W%H$(.*@0A*@E5H@JO""WL7,0!7NX=>G:6XM:%
M]C*QZ5@[B9@<W_OIW4;X3LIII A'AXD_%>YW'[<+T-WV=K.'Y5[W=*N6WO04
MO;K!,<VH?3UV%/!Q$^7A.L+WJ1?@E9?^FETDZ><P]U9AG-UMUN0G]<Y0+PG.
M(-G/M J8W=AAP+.7SFV0ED+03LK8*"R _U:-LC:%,Q3)5:M0TOP9!@JD.@F+
MD(0L4_+01Y_R, KS+=!03C<7*FB<YIVHYC8IP>3PT&G5!D@3%X@X$AP^QNC^
MKZ=OWGS[XZTCE_#.Z!+>3>42WNE=PCL@?:[6R=#C-^$:$T%L'HBS *<K+Z*_
M^4_H'OM/<1(ECUM@[F+VXJ6!(7FM1>/274C5J[N+!L'DT-%I)>P84!IXN63G
MJW64;#&^RQ/_U^LUS276)^ZHZ9VF\)C4;B3SJ(C! ,BDH9#[1>D0)X06D;"-
MA>OE3UY*W&)^G=Z&CT^YQMUHZ)V>^)C4;ISRJ(C!(,JDH9#NPTX4DR4J.%"2
M(L8#REL5RFD]5(O&)8:DZM5QTR  @Q695FU\%#30G,TMT5$7R]1^=PD$0:TZ
M"*H?P0"@K9%PBX/^#LH1? SC<+59:1U!B\9E_TO5JV.@00 &!S*MA-TO3@/,
M#WSTOICQT*1QB@>9>@T\U G@X$&BE8 '3@,,#_-D0Y,.UEZ:;VG"@2[^E)*Z
M3392*]O,+1+IP&!%HYR86KXC974ZQCU)_"&)@I47WWG^D^:81D;E;,=,K6*U
M:R:23-[U>KV$W;,XP.E+&N9A_(AFCREF1RWH%!426#+X/'G!\=A;I]>;/ L#
M/"=KYTV4DZA6LXFJIG4&#I.Z%414A#" 8M!.2"_DY&A'GR&@BY#/]* H?M3,
M,0T*EU.+1+7ZC%+[>7*0J'5J0Z.@ +4@N7OR4OS!RW! <VIQG/$Z#FQCF&#6
M?\+7,=;?RNTBP>F]W.ZF-6[FVK.#P6!WG=L8+<@0H0/FK<RVW;\D>R*U)@$6
M4@73NB&U8C\@I+9U5B&5T!T>4LGG]O6J#1G T"J:UQ&O.P&'A%A!:R5F*>78
MRX4[\JTP"I-9S#3VXFT9AZJ7#68>9\L'6_6K982)87(D==%2.#F=+\B2<_"%
MA (ZQ7<T>7MM"F>PD*M6@:#Y,XPNE^JD/*@Z19]B;[DD&&$5J,[CG.;NP)KA
MBO)8-W0GC&41>3X[TO^PK?^B.]_J(,#I 5AGPQHG9-;<DP.SM\JJ2FF,;MP-
MT44<A,]AL/$BS0PF(7+FFY0*5NY)H)@<"%JU))=K2CI@'HE60#,<F#1)G&83
M2Y1K)!/7?I\<$!JEA )TY'\Y. BY3.+'>YRN%J2AR6SXC.L!.-6!UKU5>X1.
M[,Y\10^C*B_2@7=R./54N TU2H"H&$3EH$H0JDMB=1#'CHVODO@OQ &&RQ '
MY-=W+*>QTH=JH(:B/:\S''8UIP*A+2,,!';45H3?VW>(9Z_NH.<";<6R0'/2
MUZ9PO1)3G>HU?X:! JE.FI78W,N>(IQEZ/P+3OTP&WW/YC]N/A)3O/@.^YN4
MU1:^O)RK^UY+[@P(%DI7J-#0PH"(64'K!('_^/KF:\2EH9TX1.0!"Y[/PA3[
M1+9V1[I-Y#* EBM8#Z&;%)-#2:N6D%?DY5Y$(4.FEJ]A(6.>L-DN9>'5;9C]
M:BPAKN5PFYUF5+V9I*8D!X,FLXYBREJ- U$6>%>YV/WU$*>"=?H#,A.7TR,Q
M.Q,:AV!Z%C"8L]-3.*XHN) $@. ]W <<^T^T/D(W-]=BF]C728TP.+P&#Q@$
M6BIJX?HJ-EC^CTS^V2U^QO$&7QE*3BIHG?HZG;H-#R<C!(,JG7:"-Z.TJ""&
MYK\V69ZLNLZ>1BZGWLO.A(;STK. 09F=GH+K*KC@SYZ\)%NAKJ[HGHS0[4TF
ME:+-ZTQM*C!(4JJF!,^H9S+W+TFEC'I_2D;E;%M*K6*U&R623-[?>KV$A+*7
M!%648V].LJPUFUZ7TKGK=XV:NYZ7$ 'I>[5F0N^S-,+A^[\^-V38__HQ>?XF
MP"&=%KZE_Z#8^+8V&Y __7*)'[V()RM)I@$IA0M$:%2C6)#\/#D*U#J);T40
MJBI#;$QW?_/DI2O/WRYB^JXZRQ!2CW\-L;M:7B:%=V6]5)23 \%*/2$GHZ!'
M-09T,QN]ZCAQ0"$W^P-.'['F$%Q)ZJZ&N%[97:EP.1T,8.B5$\IXM:G'!L3<
M2X,P]J(?L1?E3VHTR.F<04&G9H4#&1$,$&@T$T^9."GBM*,7(/;_C+,LB<OW
M#U0%VDS$[LH*FQ3>51!64<+ A$D]H1)&08]J#*.GM21)D-%TFF*ZPIL\]+VH
MN!21;%B1;$W.2Q=V=PDQW8W:9<O8\\) 67>%A3R;4@)JBB@**E1"1O=4.*"?
MG6-:W*,,GS2^2D?NSEN9E=[Y*S4M#"R9%11\%N= G 550>_(4#G;X)]PEIM!
MHB!T!@^MHA4PI%0P(*%332AYOJ&/*V6Y,QA<$#LM]L&D9,X@H%&R H"$!D;W
MJQ43GAXDE"-O@>UQM)M[.<L&I&\7YULVJ<6T8+?FI,3 X_2HUT;]QI&OCF%R
M9'714O8T>;Y%.UI0*01$K542L_QT_;&O2.?X=4JYFJV7*)M$8'"CTDSR!#FA
MX]<%8.!C%@0A7=9YT8T7!HMX[JW#W(NT6#'P."VO;Z-^H]R^C@$,GFRT%/;Q
M*AY$F5!(ENV<#0;2;G'NA3$.SKTT)FLW_0,O*F*W-[YU"C=O=\LHP:!)JYX
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MZ^F<S\WF(0K]BRCQV@=["AJWCD>B7M/MU @F1XY.*P5*."%BE!/&,CN<WS%
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MM'ZZ6%S-KN8@UT]IXF,<L$?7:/$*>B/T>EF[5JJ*E\Q\CE-_[<QHY?_JF<
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MFI&S2W0VNY^A5Y^N9I_.%H3F-0RD-JH'L!N36XOUF8;%\;K,J'QK/::D!X-
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M:'HU58"+\".9"JG_JKT\!2JR+S2U>7K CF4"T!D?'+"AAP:X+L\,E' #_LQ
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M\]Z^#;R_"^BKP;$,^SWM_^=YL?F K>L*'99J1W;*W"FZ@*07'(<#L%64$0>
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M@N.:() P%@SMA>)*RL&"N&V!!,-O#PW#X?,POK@F"":&VX;VPW IY7 QW+)
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M"PX0/F.V[;H/"+0B#@  -OIW[?QG+I.?G8!!P)W''A)+B',LIJS27,7T;F*
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MFCV]LEZ\VT3+B<6EW(.O9=OJ2]9YV:+8_#3VK*0Z(!C5?BO#KV>[=!V-7O$
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M%+;/"<M)N2<N\;<3=@Z]$4O^0R?G9R^B$[GFPD8G1F!=9J^OK/=8!,/^41-
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M@LT^L%AS4AC# D*DE08*("-IQ;64JA,476L>CSTW,7".5NQI6,>:;,)^M.8
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MV\)L-A,6G5D,B@!51H*>E\)KX)&@G?_8#(TYNX\H*'0GB#FE[!5F'BMZM2T
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M*H@\CL"'<.6^L 7 >?!-T7EP-?BM?TG):2"-[=*[!0!=252:D+\KAM:0T(U
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M_^;_ U!+ 0(4 Q0    ( #6(5TQ%L3[F:@@! "[,#0 1              "
M 0    !T>&UD+3(P,3<Q,C,Q+GAM;%!+ 0(4 Q0    ( #6(5TSEL\?BB!
M %6Z   1              "  9D( 0!T>&UD+3(P,3<Q,C,Q+GAS9%!+ 0(4
M Q0    ( #6(5TR8UN6):Q(   _]   5              "  5 9 0!T>&UD
M+3(P,3<Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  UB%=,O63V:F0M  !F6P,
M%0              @ 'N*P$ ='AM9"TR,#$W,3(S,5]D968N>&UL4$L! A0#
M%     @ -8A73*.H$J5I;   :D4& !4              ( !A5D! '1X;60M
M,C Q-S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #6(5TP(6WQ<.T,  /CF!  5
M              "  2'& 0!T>&UD+3(P,3<Q,C,Q7W!R92YX;6Q02P4&
/  8 !@"* 0  CPD"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
